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ABSTRACT 
Efavirenz and nevirapine are the most widely used agents for treatment of HIV in children. Sources of 
variability in their pharmacokinetics and its association with virological outcome and adverse events 
in African children are poorly characterised, thereby limiting treatment optimisation. To fill this gap 
we studied population pharmacokinetics (PK) of efavirenz and nevirapine in 478 children from 
CHAPAS-3 (aged 0.3-1.5 years) using non-linear mixed effects modelling and identified predictors of 
treatment outcome and PK thresholds most predictive of increased risk of non-suppression using Cox 
proportional hazards regression models and likelihood profiling. 
Efavirenz PK was described by 2-compartment disposition model with 1st-order elimination and 
transit-compartment absorption and nevirapine by 1-compartment model with elimination through a 
well-stirred liver model and transit-compartment absorption. Combined effect of SNPs 516GT and 
983TC was the strongest predictor of between-subject variability in clearance (89% and 68% decrease 
between fastest/slowest CYP2B6 metabolic subgroups for efavirenz and nevirapine, respectively). PK 
was affected by weight, described with allometric scaling. Nevirapine intrinsic clearance displayed 
diurnal variations (oscillations of amplitude 29%, maximum at 12 noon), while age affected pre-
hepatic bioavailability (31.7% lower at birth and increasing exponentially). 
In antiretroviral treatment (ART)-naïve children (n=325) increased exposures were associated with 
decreased risk of non-suppression for both drugs. In efavirenz, risk further increased for children>8 
years and for younger boys; in nevirapine for high pre-ART VL, low pre-ART CD4% and low adherence. 
Thresholds most predictive of non-suppression in efavirenz were: Cmid-dose=1.12 mg/L, Cmin=0.65 mg/L 
and AUC0-24=28 mg∙h/L, while nevirapine had no clear threshold. Adverse events were infrequent in 
efavirenz, whereas in nevirapine transient transaminase elevations >grade 1 were associated with 
Cmin>12.4 mg/L. 
Non-nucleoside reverse transcriptase inhibitors dosage guidelines for African children should take into 
consideration the combined effect of SNPs CYP2B6 516G>T and 983T>C, in particular for efavirenz 
where we observe 10-fold differences in exposures between metabolic subgroups. Moreover the 
target Cmin and AUC0-24 could be lowered in children for efavirenz. 
Treatment initiation at lower pre-ART VL and higher pre-ART CD4%, increased adherence, and 
maintaining average Cmin higher than current target could improve virological suppression of African 
children treated with nevirapine without increasing toxicity. 
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1.1 Context 
Without any doubt, acquired immunodeficiency syndrome (AIDS) caused by the infection with human 
immunodeficiency virus (HIV) is one of the world’s most serious health challenges.1,2  Over the years, 
HIV infection changed its course from being a certain death sentence, reflected in a 1-year AIDS 
mortality of 51% in 1986, to merely a chronic disease nowadays.3,4 This was possible as a result of 
advances in understanding the biology and pathogenesis of the virus, leading to numerous new drugs 
developed for treatment of HIV infection. A major breakthrough was the introduction of combination 
treatment consisting of 3 or more drugs from 2 or more different classes,5 which dramatically 
improved the success of treatment. A more recent milestone was the change in treatment guidelines 
recommending early initiation of ART in all newly diagnosed HIV-infected individuals, regardless of 
CD4 cell count.6 Nonetheless, by the end of 2015 there were 36.7 million people worldwide living with 
HIV with over half of them living in the eastern and southern Africa, where the incidence of new 
infections is the highest.7,8 In 2014 3.2 million of children were globally living with HIV and over 90% 
of them lived in sub-Saharan Africa.9 According to the World Health Organisation (WHO) the actual 
number of children in Africa living with HIV might be higher than most reported statistics10 and an 
effective and optimised treatment for children should be a priority. 
The success of the HIV treatment depends on a number of factors starting with a timely diagnosis and 
start of the therapy, through availability of effective therapeutics and appropriate formulations, drug 
supply, and lastly validated treatment guidelines advising on the most optimal dosage of prescribed 
drugs. In the last years, treatment formularies for HIV-infected adults changed substantially through 
introduction of newer antiretroviral (ARV) agents (such as integrase inhibitors and new generation 
non-nucleoside reverse transcriptase inhibitors [NNRTIs]) which provide reduced number of side 
effects and superior efficacy, and are available as all-in-one fixed dose combination (FDC) tablets.6 At 
the same time, treatment options for HIV-infected children are based on agents no longer 
recommended as first choice in adults and further limited by lack of age appropriate formulations. In 
its 2010 recommendations, WHO highlighted a number of shortcomings of paediatric antiretroviral 
formulations: reduced shelf-life, high alcohol content, poor palatability, and storage difficulties 
(especially in resource limited setting).11 It has been speculated that increased time to viral 
suppression and higher mortality rates, especially among younger children starting ART, could be 
attributed to poor taste of paediatric liquid formulations causing insufficient compliance.12  In 
addition, a widespread approach of treating children with crushed adult tablets or sprinkled capsule 
content could have an unpredictable effect on the pharmacokinetics (PK) of the drugs and in 
consequence significantly contribute towards treatment failure.13,14 Lastly, until recently, it was widely 
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acceptable to derive the paediatric dose by linear scaling of the adult dose based on weight, which led 
to various cases of treatment with sub therapeutic dose or overdosing in children.15–18 
The lack of availability of paediatric formulations and absence of clinical testing in children was 
acknowledged by the International Conference on Harmonisation (ICH), Food and Drug Administration 
(FDA), and European Medicines Agency (EMA) as a major safety concern leading to introduction of 
new paediatric regulations in the USA and the EU.19–24 The new regulations encouraged paediatric 
drug development and drug testing in children on both sides of the Atlantic.25–28 Unfortunately, similar 
regulations have not been approved in any of the African countries, nor did they incentivise 
development of paediatric formulations for established treatments available as generic counterparts. 
The results of trials conducted in children in the US or the European countries cannot be directly 
applied in the African population without prior validation. Numerous publications show that the 
prevalence of various genetic polymorphisms determining the activity of a number of metabolic 
pathways involved in biotransformation of various drugs is different between Caucasians and black 
Africans.29–45 This can lead to differences in systemic drug exposure, which can have an impact on 
treatment efficacy and safety. Differences in pharmacokinetics can be further explained through a 
number of environmental factors, e.g. malnutrition,14,46,47 as well as different prevalence of co-
infections and associated concomitant medications.48–52 Lastly, treatment of African children is often 
conducted in a resource limited setting where the recommended first line options and their 
formulations might be different to the drugs tested and used in the developed countries. 
In order to assist international organisations and governments access to generic antiretroviral drugs 
of acceptable quality and development of age appropriate paediatric formulations, WHO started a 
number of initiatives, the first one being the 2001 prequalification program53 (in collaboration with 
UN agencies), followed by two technical documents in 200454 and 200555 focused solely on children. 
This stimulated development of the first paediatric 3-in-1 solid dispersible FCD containing NNRTI 
nevirapine (NVP) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) stavudine and lamivudine 
(d4T and 3TC) and a number of similar 2-in-1 formulations containing combination of 2 NRTI backbone 
drugs recommended in children – abacavir (ABC), d4T, or zidovudine (ZDV), combined with 3TC. The 
tablets were developed to facilitate paediatric ARV weight band dosing suggested in 2004 
UNICEF/WHO Technical Consultation54 and incorporated in 2006 WHO guidelines.56 More recently, 
following the change in treatment guidelines, Cipla India developed a new paediatric double scored 
efavirenz (EFV) 600 mg tablet.  
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The most recent WHO guidelines6 endorse NNRTI efavirenz combined with two NRTIs (most commonly 
ABC and 3TC) for treatment of HIV in children >3 years old. First line treatment in children <3 years 
should consist of a combination of 2 NRTIs with ritonavir-boosted lopinavir (LPV/r), but nevirapine-
based ART is listed as an alternative regimen.6 Only combinations of the aforementioned NRTIs (ABC, 
d4T, or ZDV with 3TC) and nevirapine are currently available as paediatric solid FDC tablets. Their 
introduction significantly reduced the cost of ART in children and increased treatment feasibility, 
making them the most widely used options for treatment of paediatric HIV in resource-limited setting 
and improving its coverage in this vulnerable population. Despite some concerns how exposure to 
nevirapine for prevention of mother to child transmission of HIV virus (pMTCT) might affect its efficacy 
in later life57 recent reports confirm it is not compromised58–62 and its use in children persists.  
Despite proven efficacy and acceptable tolerability of efavirenz- and nevirapine-based ART, both drugs 
exhibit high levels of variably in individual exposures. This variability in adults was attributed largely 
to single nucleotide polymorphisms (SNPs) in the CYP2B6 gene which encodes the key metabolising 
enzyme for both drugs.43,63–65 A number of SNPs related to functionality of this CYP450 metabolic 
pathway have been studied and documented and it has been shown that the prevalence of those 
polymorphisms varies greatly between Caucasian and black African populations.29,34–36,39,66–68 The key 
identified CYP2B6 polymorphisms are: 516G>T (rs3745274),69 983T>C (rs28399499),43 and 15582C>T 
(rs4803419)70. These SNPs have been reasonably well studied in adults, leading to identification of 
four distinct metaboliser subcategories,71 nonetheless the number of similar investigations in children 
is limited.43,72,73 Until recently, the paediatric investigations into their effect were restricted to 
516G>T,74,75 and even though a recent study in South African adults and children described the 
association between SNP 983T>C and efavirenz concentrations,76 the combined effect of both those 
SNPs was not quantified. The drug exposures obtained under the simplified WHO weight band dosing 
with use of the new paediatric nevirapine FDC tablets were evaluated in African children in CHAPAS-
133,37,77 and in ARROW41 for efavirenz but no prior investigation evaluated the combined effect of 
516G>T|983T>C SNP-vector on exposures across weight bands for neither of the NRTIs. 
Cytochrome 450 (CYP450) enzymes activity is regulated by a number of nuclear receptors. Nuclear 
receptors are ligand-activated transcription factors that control various cell and organism functions 
on a molecular level by up- or down-regulating expression of proteins.78 CYP450 activity is influenced 
mostly by pregnane (steroid) X receptor (PXR) and the constitutive androstane receptor (CAR). 78–80 As 
a consequence, on top of SNPs in genes coding CYP450 enzymes, also polymorphisms in genes coding 
these receptors (NR1|2 for PXR and NR1|3 for CAR) can indirectly impact drug concentrations.81,82 
Publications show that the polymorphisms in NR1|2 and NR1|3 have different frequencies in various 
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ethnic groups. 83,84 Their effect has been evaluated to date in only one study in efavirenz in African 
children76 and never been previously studied in nevirapine.  
The metabolism of nevirapine is mediated to a large extent also through CYP3A4 pathway65 whose 
pharmacogenetics is less studied. Even though not confirmed for nevirapine, systemic exposures of 
CYP3A substrates have been shown to be altered by SNPs rs35599367 (CYP3A4*22)85,86 and rs776746 
(CYP3A5*1).87,88 Furthermore, CYP3A activity exhibits diurnal variation with clearance rates increased 
during the day and reduced at night.89,90 Differences between morning and evening nevirapine trough 
concentrations (Cmin) have been previously reported 91 and may relate to diurnal variation in CYP3A-
mediated effects on its clearance. In addition nevirapine PK is speculated to be affected by 
polymorphisms of ABCC10, a gene coding an efflux transporter.92 Information on the outlined effects 
in children is either scarce or absent. 
The fundamental paradigm of pharmacology is a relationship between drug concentrations (or PK) 
and its effect (or pharmacodynamics - PD).93 It is the drug at the site of action that drives the observed 
effect. In order to achieve optimal treatment effects the drug concentrations should be maintained 
within certain level, usually described by its therapeutic range. Insufficient amounts of a drug can be 
the cause of inadequate treatment effect, or in case of antiretrovirals development of drug resistance.   
On contrary excessive amounts cause unwanted side effects.  
For efavirenz concentration rage of 1 – 4 mg/L has been widely accepted as optimal.94,95 Suboptimal 
efavirenz exposures have been associated with increased risk of treatment failure and high 
concentrations with central nervous system (CNS) side-effects.69,94 A number of studies showed that 
the efavirenz adverse event profile in adults differs from children, indicating lower incidence of the 
unwanted effects in the latter.96–99 The current therapeutic range for efavirenz was derived in a study 
in adults, mostly of European descent, and was based on a random drug concentration measured 14.0 
+/- 2.7 h after dose intake,94 but is customarily applied to mid-dose as well as trough exposures in all 
populations. A few paediatric investigations evaluated the efficacy threshold for efavirenz,32,96,100,101 
but the majority of them was limited to evaluation of pre-defined cut-offs based on exposure 
distribution in the tested population.32,96,100  In addition the results of ENCORE1,102,103 showing that the 
standard 600 mg efavirenz dose in adults can be reduced to 400 mg daily without loss of efficacy, have 
prompted discussions on the validity of the widely accepted efficacy threshold of >1 mg/L and justify 
a new investigation into the most optimal concentration range in children. 
Based on the concentration-response relationship, a therapeutic range of 3–8 mg/L has been 
suggested for nevirapine therapeutic drug monitoring (TDM).95 However, several studies failed to 
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confirm these associations72,104,105 and low incidences of nevirapine-related adverse events (AEs) have 
been reported in low-income settings106 and in African children.107,108 Despite widespread use, few 
studies have investigated the PK determinants of efficacy of nevirapine-based regimens in children. 
The predictive power of the suggested targets has also never been thoroughly investigated in black 
Africans or in children. Whether these pharmacokinetic targets should be universally applied across 
populations was recently questioned.72   
To bridge the existing gap in knowledge and gain clinical proof of efficacy and safety of the treatment 
with nevirapine FDC tablets and new paediatric double scored efavirenz 600mg tablets in black African 
children, a multinational clinical trial was commissioned (CHAPAS-3 – Children with HIV in Africa – 
Pharmacokinetics and Acceptability/Adherence of Simple Antiretroviral Regimens). Presented thesis 
is the first analysis of pharmacokinetic and clinical data for efavirenz and nevirapine from this study, 
which were enriched with previously analysed data from trials CHAPAS-1 and ARROW. The current 
state of knowledge being the context for this thesis is discussed in more detail in Chapter 2. 
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1.2 Hypothesis: 
We hypothesise that single nucleotide polymorphisms in CYP2B6 are the main predictors of variability 
in efavirenz and nevirapine concentrations in HIV-infected African children treated with paediatric 
solid FDC tablets, and that dose adjustment based on individual genotype alone could provide an 
optimal treatment outcome. 
1.3 Key research questions: 
1. Is the inter-individual variability in efavirenz and nevirapine concentrations in African children 
predicted by single nucleotide polymorphisms in CYP2B6 metabolic pathway alone, or in combination 
with selected polymorphisms in additional genes (CYP3A4, CYPCA5, ABCB1, NR1|2, NR1|3), or other 
demographic characteristics? (Publication/study 1 and Publication/study 3) 
2. Do average efavirenz and nevirapine exposures differ between WHO 2010 dosing weight bands and 
different metabolic subgroups, determined by individual CYP2B6 genotype, and could genotype based 
dose adjustment provide more balanced exposures between metabolic subgroups in African children? 
(Publication/study 1 and Publication/study 3) 
3. Are efavirenz and nevirapine concentrations predictive of virological response and adverse events 
in African children treaded with paediatric solid FDC formulations, and what is the contribution of 
other variables to the observed treatment effects? (Publication/study 2 and Publication/study 4) 
4. What thresholds in efavirenz and nevirapine concentrations are most predictive of virological 
suppression and adverse events in African children? (Publication/study 2 and Publication/study 4) 
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1.4 Outline of thesis 
Chapter 2 provides background information on HIV in terms of its epidemiology, disease pathogenesis 
and treatment. It outlines the current guidelines for treatment of HIV-infected children. It describes 
how the knowledge of pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug is 
paramount for treatment optimisation. It summarizes the efavirenz and nevirapine PK and PD, 
including pharmacogenetics, predictors of virological response and safety, with particular focus on the 
paediatric studies into PK and determinants of treatment response. It also gives summary of the 
published population PK models for both drugs. 
Chapter 3 presents details of the clinical studies included in this thesis (study design, objectives, 
population and inclusion/exclusion criteria, chronology of the studies) and elaborates on the statistical 
methods employed with justification of their choice. 
Chapter 4 (Publication/study 1) presents a pharmacokinetic study of efavirenz in African children 
treated with paediatric solid FDC tablets. The analysis is conducted on data from CHAPAS-3 enriched 
with PK sub-study of ARROW. The data is analysed using non-linear mixed effects modelling. The main 
predictors of efavirenz PK are the combined effect of SNP 516T>T and 983T>C and size (weight). 
Pharmacokinetic simulations are implemented on the final model to aid genotype based dose 
optimisation and a new dosing algorithm was suggested. The efavirenz 
pharmacokinetic/pharmacogenetic study is included as a full manuscript with the abstract, 
introduction, methods, results and discussion and its content has not been modified.  
Chapter 5 (Publication/study 2) presents a pharmacokinetic/pharmacodynamic study of efavirenz in 
African children treated with paediatric solid FDC tablets. The analysis is limited to data from CHAPAS-
3. An exploratory analysis is performed using descriptive statistics and a selection of statistical tests, 
while the main analysis is performed using Cox proportional hazards regression. The study presents a 
new statistical method for identification of efavirenz concentration threshold most predictive of 
increased risk of virological non-suppression based on likelihood profiling, describes the 
concentration-response relationship, and identifies predictors of virological response. The efavirenz 
pharmacokinetic/pharmacodynamic study is included as a full manuscript with the abstract, 
introduction, methods, results and discussion and its content has not been modified. 
Chapter 6 (Publication/study 3) presents pharmacokinetic study of nevirapine in African children 
treated with paediatric solid FDC tablets. The analysis is conducted on data from CHAPAS-3 enriched 
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with PK sub-study of CHAPAS-1. Nevirapine PK is described using a semi-mechanistic population 
pharmacokinetic model with elimination through a well-stirred liver model accounting for first-pass 
effect. The main predictors of nevirapine PK are the combined effect of SNP 516T>T and 983T>C, size 
(weight) and diurnal variation in hepatic clearance. Pharmacokinetic simulations are implemented on 
the final model to assess the effect of 516G>T|983T>C determined CYP2B6 metabolic subgroups and 
diurnal oscillation on nevirapine exposures and suggest adjustments to current treatment guidelines. 
The nevirapine pharmacokinetic/pharmacogenetic study is included as a full manuscript with the 
abstract, introduction, methods, results and discussion and its content has not been modified. 
Chapter 7 (Publication/study 4) presents pharmacokinetic/pharmacodynamic study of nevirapine in 
African children treated with paediatric solid FDC tablets. The analysis is limited data from CHAPAS-3 
and is performed using similar statistical methods to Chapter 5. In addition to describing nevirapine 
concentration/response relationship and identifying the predictors of virological response, it suggests 
exposure threshold most predictive of increased risk of non-suppression and liver elevations in African 
children. The nevirapine pharmacokinetic/pharmacodynamic study is included as a full manuscript 
with the abstract, introduction, methods, results and discussion and its content has not been 
modified. 
Chapter 8 summarizes the results of the presented investigations in relation to the thesis’ objectives 
and previously conducted studies. It discusses implications for treatment of paediatric HIV, presents 
limitations of presented research and identifies priorities for future of antiretroviral treatment in 
African children. 
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1.5 Coherence of thesis 
I (Andrzej Bienczak) am the first author on all four papers included I this thesis. All four publications 
described above were prepared during my doctoral research conducted at the University of Cape 
Town under supervision of Doctor Paolo Denti and Professor Helen McIlleron, who jointly supervised 
my work while I was registered as a student at the University of Cape Town, including when I visited 
University of Liverpool as a non-degree seeking student. While at the University of Liverpool I 
conducted genotyping of children from CHAPAS-3 under supervision of Professor Andrew Owen (who 
is a co-author of two of four presented papers). The main data supporting this thesis, previously not 
analysed in terms of efavirenz and nevirapine, originates from CHAPAS-3. For the purpose of 
population pharmacokinetic modelling this data were enriched with data from pharmacokinetic sub-
studies of CHAPAS1 and ARROW, which were conducted in similar populations. In addition to 
completing the genotyping, I conceptualised and conducted all analyses included in presented 
publications. Each publication addresses one or more of the thesis objectives and together with an 
introduction chapter (Chapter 1), a literature review (Chapter 2), justification of the choice of 
methodology (Chapter 3) and the concluding chapter (Chapter 8), form a coherent body of work which 
fully addresses the aims and objectives of my doctoral research. At the time of conceptualising the 
presented analyses, the combination of selected genetic polymorphisms had never been previously 
investigated in African children. The findings from the four presented publications provide data that 
may improve optimisation of dosing and outcome of treatment with efavirenz and nevirapine in this 
vulnerable population. This may ultimately contribute to “personalized medicine” for the HIV-infected 
children worldwide.  
 
Andrzej Bienczak,  
Cape Town, 6th of March, 2017 
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The following chapter gives background information on human immunodeficiency virus (HIV) in terms 
of its epidemiology, disease pathogenesis and treatment. It outlines the current guidelines for 
treatment of HIV-infected children. It describes how the knowledge of pharmacokinetic (PK) and 
pharmacodynamics (PD) properties of a drug is paramount for treatment optimisation. It summarizes 
the efavirenz and nevirapine PK and PD, including pharmacogenetics, predictors of virological 
response and safety, with particular focus on the paediatric studies into PK and determinants of 
treatment response. It also gives summary of the published population pharmacokinetic models for 
both drugs. 
2.1 Human immunodeficiency virus – epidemiology, disease 
and treatment 
2.1.1 Epidemiology of HIV infection 
Since the beginning of the epidemic in early 1980’s, more than 78 million people have been infected 
with HIV and nearly half of them died from HIV related causes.7 The most recent statistics from UNAIDS 
inform that by the end of 2015 there were 36.7 million people worldwide living with HIV, with over 
half of them living in eastern and southern Africa.7 This region also accounts for 46% of new HIV 
infections globally.7 The vast majority of HIV infected children live in sub-Saharan Africa (in 2014 91% 
of 3.2 million worldwide),9 the statistics also consistently highlight this to be the area with the highest 
incidence of paediatric HIV infections.2,7,9  
Figures from South Africa show that, at its peak in 2005, a maximum of 37-39% of child deaths could 
be attributed to acquired immunodeficiency syndrome (AIDS).109 Children were first being diagnosed 
at an advanced stage of the illness with high viral loads, which contributed to a low treatment success 
rate.12 A similar trend was also present in other African countries, with mortality rates particularly high 
within 90 days of treatment initiation.14,47 On account of numerous national intervention programs in 
most of those countries aiming to scale up the prevention of mother-to-child transmission (pMTCT) of 
HIV and increase coverage of antiretroviral treatment (ART), the number of newly infected children is 
constantly decreasing.2,8,109 In the last 5 years the incidence of new paediatric HIV infections 
worldwide declined by 50% (from 290’000 in 2010 to 150’000 in 2015),7 and despite marginal numbers 
in developed countries, in 2015 in eastern and southern Africa 56’000 children were born with HIV 
and another 66’000 in western and central Africa.7 Children with untreated infection rapidly progress 
to disease, especially in resource-limited settings where mortality is greater than 50% by 2 years of 
age.110 Despite substantial increases in the HIV treatment coverage over the last few years,8 in 2014 
less than 25% of children needing ART in sub-Saharan Africa were receiving it.9  
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2.1.2 Pathogenesis of HIV infection 
HIV is a letinovirus belonging to the family of retroviruses that causes a chronic infection in the host 
leading to progressive failure of the immune system called Acquired Immunodeficiency Syndrome 
(AIDS).1 There are 2 types of HIV: HIV-1 and HIV-2, the first one being responsible for majority of 
infections word wide.111 This thesis refers HIV to HIV-1 infection. The virus is transmitted through 
certain contaminated body fluids (such as blood, semen, pre-seminal, rectal and vaginal fluids and 
breast milk) when they come in contact with a mucous membrane or damaged tissue or are directly 
injected into the bloodstream. It can be spread in adults mainly through certain sexual activities or 
injection equipment and in children though mother-to-child transmission (during birth or through 
breast feeding). It infects vital cells of the human immune system such as CD4+ helper subset of 
lymphocytes T, monocytes, macrophages and dendritic cells.1,112,113 As a consequence of the infection 
the number of CD4+ T-cells (crucial to regulating immune response)114 visibly decreases compromising 
the function of immune system and its ability to detect pathogens leading its gradual failure.112,115 
Patients with late stages of AIDS are more susceptible to other opportunistic infections with other 
viruses, bacteria or fungi, as well as cancerous changes and their bodies eventually lose the ability to 
fight them.1 
The lifecycle of HIV virus during the infection can be divided into a number of processes that are 
illustrated on Figure.2.1. After entering the host HIV virus fuses with CD4 lymphocytes through binding 
with CD4 and chemokine receptors (mainly CCR5).116 Its content (including viral genome consisting of 
double stranded ribonucleic acid [RNA] and viral enzymes: reverse trascriptase [RT], integrase, 
ribonuclease and protease) is internalised in the affected cells.117,118 In the next steps RT copies viral 
genome into deoxyribonucleic acid (DNA) creating proviral DNA, which is then integrated (by viral 
integrase) into the cell DNA, creating provirus.116,119,120 At this stage, the infection is in a latent phase 
until the infected cells are activated. Cell activation stimulates the viral replication process through 
transcription and translation using cellular machinery. The proviral DNA is transcribed into messenger 
RNA, which is either spliced to generate RNAs to make viral proteins, or create new viral genome (full-
length RNA), which are then transported to the cell plasma, where the viral proteases assemble them 
into virons.116,119,120 Mature virons kill the T-cells through budding from the cell surfaces. This active 
replication process leads to progressive depletion of CD4 cells resulting in the aforementioned 
weakening of the immune system.1 
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Figure 2.1 HIV lifecycle and the sites of action of antiretroviral drugs (from Apostolova et al.121)A
Note: Explanation of the abbreviations can be found in the List of abbreviations and acronyms section preceding 
Chapter 1. 
2.1.3 Pharmacological approach to HIV treatment 
The primary aim of ART is to disrupt the viral replication process presented in Figure 2.1. The goal of 
treatment is to supress plasma viral load and restore and preserve immunologic function, which in 
consequence would lead to reduction in HIV-associated morbidity and mortality, prolonged survival, 
increased quality of life and reduce the risk of further HIV transmission.122 It has been shown that 
durable suppression of viral replication can be achieved by combining a number of antiretroviral 
agents targeting different phases of HIV lifecycle.123  Depending on their mode of action ARV drugs 
can be divided into 5 different classes:123–125  
1. Entry inhibitors 
There are currently two drugs licensed in this group 
- Co-receptor CCR5 antagonist maraviroc (MRC) preventing the virus from attachment to 
co-receptor and preventing its entry into the host cell 
- Fusion inhibitor efuvirtide (ENF) which binds to viral glycoprotein gp41 preventing 
creation of an entry pore for the capsid of the virus and fusion with the host cell  
2. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 
NRTIs are the oldest and most widely used group of ARVs. Drugs from this group are 
competitive substrate analogues for reverse transcriptase. The active particle has a similar 
                                                          
A Reprinted from the Trends Pharmacol. Sci., 32, 715–725, Apostolova, N. et al., Mitochondrial interference by 
anti-HIV drugs: Mechanisms beyond Pol-γ inhibition. Page No. 716, Copyright (2011) with permission from 
Elsevier. 
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structure to nucleoside/tides present in the cell but they lack 3’-OH group in the ribose ring 
and if they are incorporated during DNA synthesis, they work as chain terminators. Examples 
include: stavudine (d4T), lamivudine (3TC), zidovudine (ZDV), abacavir (ABC), didanosine 
(ddI), and newer generation drugs such as emtricitabine (FTC) or tenofovir (currently 
available in two forms – tenofovir disoproxil fumarate [TDF] and alafenamide [TAF] with a 
more favourable safety profile).126,127 
3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs are non-competitive reverse transcriptase inhibitors that cause steric hindrance by 
binding close to the active sites of the enzyme. They can be divided into 1st generation (with 
rigid structure with lower genetic barrier for developing resistance), e.g. nevirapine (NVP) 
and efavirenz (EFV); and 2nd generation (with more flexible structure and higher barrier for 
resistance), e.g. rilprivirine (RPV), etravirine (ETR). 
4. Integrase inhibitors 
The newest group of ARVs inhibiting the viral integrase (catabolising the integration of viral 
DNA into cell DNA). This group can be characterised by the most favourable safety profile, 
fastest and most durable viral suppression. Currently available drugs from this category are: 
dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL). 
5. Protease inhibitors (PIs) 
PIs are competitive substrate-based inhibitors for viral protease. Despite high potency and 
high genetic barrier for resistance, PIs has been associated with a number of side effects, in 
particular metabolic abnormalities related to mitochondrial toxicity.128,129 The most popular 
agents from this group are: lopinavir (LPV), atazanavir (ATV), amprenavir (APV), darunavir 
(DRV), fosamprenavir (fAPV) and tipranavir (TPV). Due to unfavourable PK properties 
majority of the listed drugs are given in combination with ritonavir (/r = PK boosting), which 
by inhibiting their metabolism enables reduction of dose of the other PI. 
All current treatment guidelines advise that 1st line ART should consist of a combination of 2 NRTIs 
with a 3rd agent form a different class. According to most recent WHO recommendations preferred 
first line NRTI backbone in adults and adolescent should consist of a combination of TDF + FTC/3TC 
(alternative 1st line - ABC+3TC). The preferred companion drug is efavirenz and alternative regimens 
are based on DTG or nevirapine.6 The choice of 1st line WHO regimens is guided not only by their 
efficacy and toxicity but also cost/benefit analyses and availability in all settings. In light of the recent 
results of ENCORE, showing similar efficacy of efavirenz 400mg once daily dose compared with the 
currently licensed 600mg102,130 but improved treatment tolerability and hypothesised cost savings,131 
the WHO guidelines6 were expanded to include both options. 
Over the last few years a number of clinical trials in newer ARV agents stimulated changes in national 
formularies in resource-rich countries.132,133 Due to demonstrated durable virologic efficacy, 
favourable tolerability and toxicity profiles, and ease of use the integrase inhibitor based regimens (in 
particular DTG) are the currently recommended first line option. Other first line or alternative 
recommendations include newer PIs (ATZ/r or DRV/r) and the new NNRTI RPV.132,133 Efavirenz is still 
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listed as a viable treatment option. The preferred NRTI backbone consists of combination of FTC+TDF 
or TAF (ABC+3TC listed as alternative). 
The recommendations in resource-limited countries are in line with the WHO guidelines6 and list 
efavirenz 600mg/400mg+TDF+ETC (or efavirenz 600mg/400mg+ABC+3TC) as preferred first line, 
which is mostly dictated by availability of cheap, generic 3-in-1 formulations consisting of these drugs. 
2.1.4 Treatment of paediatric HIV  
Paediatric HIV treatment guidelines differ considerably from adult recommendations and differ 
further between age groups and geographical regions. Table 2.1 compares most recent paediatric 
recommendations from USA,134 Europe,135,136 South Africa137 and WHO (2015)6, and is complimented 
with WHO 2010 guidelines11 (tested in CHAPAS-3). 
The main reason for differences in HIV treatment guidelines between adults and children is that a 
number of new ARV drugs have never been tested in the paediatric population. For example, the only 
integrase inhibitor currently licensed for use in children is RAL138,139 and although drugs from this group 
are the preferred ART component in resource-rich countries in adults,132,133 their application in 
children in the same setting is limited. Another reason for differences between adult and paediatric 
formularies are the safety concerns for some of the newer drugs. For example TDF is licensed from 2 
years of age but its actual use is limited through its negative effect on bone growth (especially in 
younger children)140–142 and disruption of vitamin D metabolism.143 TDF is currently advised for use 
only in adolescents and adults.6,134,135 TAF is a promising alternative to TDF as it has shown to have a 
more favourable safety profile in adults and adolescent but to date it has not been tested in 
children.126,144  
The choice of treatment in particular age groups is determined primarily by availability of age 
appropriate formulations and clinical evidence. The main change that occurred in the last few years 
was reclassification of nevirapine based regimens from preferred to alternative 1st line in all of the 
paediatric age bands. Results of study P1060 showed consistently that LPV/r based regimens were 
superior in terms of virological outcome, reduced risk of treatment discontinuation and death in 
children <3 years old.62,145,146 Furthermore LPV/r protects better from development of NRTI resistance 
without compromising the efficacy of second-line PI-based regimens.147,148 In the older paediatric age 
groups (>3 years) nevirapine was on the other hand replaced by efavirenz as a favoured 1st line ART 
option.111 Even though the evidence of virological superiority of efavirenz over nevirapine is weak,149–
154 this choice aligns with the new recommended NRTI-backbone (ABC+3TC) allowing once daily 
dosage.111 It has been speculated that once daily regimens might improve treatment compliance and 
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in consequence improve its outcome.155–157 Furthermore co-treatment of tuberculosis infection does 
not require a regimen change or dose adjustment with efavirenz based ART.74  
Despite being an alternative choice for 1st line ART, nevirapine is still widely used in sub-Saharan Africa 
for a number of reasons. Treatment with LPV/r might be challenging in resource-limited setting, as for 
the youngest children the main available formulation is a syrup which requires cold chain environment 
until the point of dispensing. Additionally it has poor palatability which can potentially compromise 
adherence and have unpredictable effect on drug’s bioavailability. Nevirapine is a constituent of the 
first paediatric ART available as an FDC all-in-one tablet targeted to help overcome feasibility issues 
related to treatment with liquid formulations and multiple drugs and to lower treatment cost. This 
treatment option has a high acceptability - a study showed that young children and their caregivers 
preferred paediatric tablets to a syrup-based treatment.158 Currently there is no similar all-in-one 
paediatric solid formulation containing efavirenz. Use of nevirapine was previously discouraged in 
children, who received this drug for prevention of mother to child transmission (pMTCT) but a number 
of studies showed similar treatment outcomes independent of prior exposure.60,61 It has also been 
shown that children who achieved viral suppression on LPV/r based regimen can be safely switched 
to a nevirapine-based ART maintaining positive virological outcomes (maintenance of virological load 
below threshold of detection for the used assay).58,59  
The local variations in the recommended 1st line ART in children are presented in Table 2.1 and show 
similar trends to adult recommendations – the choice of treatment in resource-limited setting is 
determined not only by the supporting clinical evidence but also the drug availability, the cost of 
treatment and its feasibility. WHO guidelines take into consideration all of those aspects and most 
local formularies in resource-limited setting are usually in line with those recommendations. The cost 
of ART is not a significant constraint in resource-rich setting where patients have access to newer, and 
more expensive alternatives. Those treatment options are not available in sub-Saharan Africa making 
optimisation of currently available paediatric regimens a priority.  
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Table 2.1 Comparison of current paediatric treatment guidelines 
Age 
group 
(years) 
WHO 201011 WHO 20156 PENTA 2015135,136 USA 2016134 
South Africa 
2015137 
Standard Alternative Preferred Alternative Preferred Alternative Preferred Alternative Standard 
< 2 
NVPa/ LPV/r  
+ 
3TC  
+  
ABC/d4T/ZDV 
3TC  
+  
ABC 
+ 
d4T/ ZDV 
 
LPV/r  
+ 
3TC 
 +  
ABC/ZDV 
NVP  
+ 
3TC  
+  
ABC/ZDV 
NVP/ LPV/r  
+ 
3TC  
+  
ABCd 
NVP/LPV/r 
+ 
3TC  
+ 
 ZDV 
LPV/r  
+ 
2 NRTIse 
NVP  
+ 
2 NRTIse 
LPV/r  
+ 
3TC  
+ 
ABC 
2 – 3 
NVP  
+ 
3TC  
+  
ABC/d4T/ZDV 
RAL/ LPV/r  
+ 
2 NRTIse 
NVP/RAL/ 
ATV/r  
+ 
2 NRTIse 
 
3 – 6 
NVP/EFV  
+ 
3TC  
+  
ABC/d4T/ZDV 
EFV  
+ 
3TC  
+  
ABC 
NVP/ EFV  
+ 
3TC/ FTCb  
+  
ABC/ZDV/TDF 
EFV/ LPV/r  
+ 
3TC  
+  
ABC 
NVP/DRV/r  
+ 
3TC/FTCb 
 +  
ZDV/TDF 
EFV/RAL/ATV/r 
/DRV/r /LPV/r  
+ 
2 NRTIse 
------ 
EFVg  
+ 
3TC  
+ 
ABC 
6 - 12 
EFV/ ATV/r  
+ 
3TC  
+  
ABC 
NVP/ DRV/r 
/LPV/r  
+ 
3TC/FTCb  
+ 
ZDV/TDF 
> 12 
EFV  
+ 
3TC/3TC 
+ 
TDF 
NVP/EFV/ 
EFV400c/DTG 
+ 
3TC/FTCb  
+  
ABC/ZDV/TDF 
EFV/ATV/r 
/DRV/r  
+ 
3TC/FTCb  
+ 
 ABC/TDF 
NVP/LPV/r 
/RAL/DTG  
+ 
3TC 
+ 
ABC 
DTG/ATV/r / 
DRV/r/EVG/c  
+ 
2 NRTIse 
 
EFV/RPV/RAL  
+ 
2 NRTIse 
 
EFVh  
+ 
3TC  
+  
ABC 
aChildren with no prior or unknown exposure to NVP for pMTCT. bOnly in combination with ABC or TDF. cOnly in combination with TDF+FTC. dPlus ZDV if CNS involvement or high VL.  
gABC+3TC+LPV/r based regiment for children who started it before 3 years. ePreferred NRTI backbone: <3 months - ZDV+3TC/FTC. >3months to <12 years – ABC/ZDV + 3TC/FTC. >12 
years – TDF/TAF+3TC or ABC+3TC/FTC  hIf <40kg align with children, if >40 kg treat as adults (EFV+TDF+FTC)3TC – lamivudine, ABC – abacavir, ATV – atazanavir,  d4T – stravudine, ddI 
– didanosine,  DTG – dolutegravir, DRV – darunavir, EFV – efavirenz, EVG/c – corbicistat boosted elvitegravir, LPV – lopinavir, RAL – raltegravir, RPV – rilprivirine, TAF – tenovir 
alafenamide, TDF – tenofovir disproxil fumarate, ZDV – zidovudine
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2.2 Pharmacological considerations and treatment 
optimisation 
Pharmacokinetics (PK) is the study of how the body affects the drug and can be described through a 
number of processes that take place between when the drug enters and exits the system, those are: 
absorption, distribution, metabolism and excretion.159 The drug can be described in terms of its PK 
parameters (primary and secondary), which characterise its properties, some of them are: clearance 
(CL), volume of distribution (V), absorption rate constant (ka), half-life (t1/2), elimination rate constant 
(kel), maximum concentration and time when it is reached after administration of a dose (Cmax and 
tmax), as well as it’s trough concentration (Cmin – concentration at the end of a dosing interval) and AUC 
(area under the curve – describing drug exposure within a dosing interval).160 
Pharmacodynamics (PD) on the other hand is the study of how the drug affects the body and refers to 
the biochemical, physiologic, and molecular effects of drug interacting with the system. The PD effects 
of the drug can be classified as desirable or unwanted. The desirable effects are measured in terms of 
the drug’s efficacy (in a clinical trial setting) or effectiveness (term more appropriate to real life setting) 
and are both related to its mechanism of action. The unwanted (or undesirable) effects are referred 
to a side effects or adverse effects (AEs) and are often related to off-target interactions of the drug 
with the body. 
The main paradigm of pharmacology is that there is a relationships between drug dose, exposure and 
response, referred to as PK/PD relationship, which can be defined and quantified.93 The response to a 
therapeutic agent can be affected by the variability in drug’s PK but there can be other, independent 
factors affecting the treatment outcome. A drug’s efficacy and safety determine its therapeutic index, 
which is a comparison between the amount of an agent that causes a therapeutic effect to the amount 
that causes toxicity. In practice a term which is more often referred to is the therapeutic target (or 
range), which is the range of drug concentrations (usually measured in the plasma) producing 
therapeutic response without causing any significant AEs in the patients. The lower cut-off for a 
therapeutic range is determined by lowest exposure providing acceptable treatment efficacy and the 
upper cut-off is defined by the drug’s safety profile.  
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Figure 2.2 A rational approach to the design of a dosage regimen (from Rowland and Tozer160)B 
Note: The pharmacokinetics and pharmacodynamics of the drug are first defined. Then, response to the drug, 
coupled with pharmacokinetic information, are used as a feedback (dashed lines) to modify the dosage regimen 
to achieve optimal therapy. 
 
It can be hypothesised that as long as the individual drug exposures remain within the therapeutic 
range the patient should have a successful treatment outcome. The objective of a rational approach 
to the design of dosing regimen (Figure 2.2) is to suggest a dosing strategy providing that individual 
drug concentrations remain within the therapeutic target during the dosing interval. Between subject 
variability is the source of different response to treatment between patients under the same dosing 
regimen. The aim of quantitative pharmacology, or pharmacometrics, is to identify sources of this 
variability affecting the drug response and to quantify them. Those sources could be certain 
demographic characteristics (i.e. weight, age or gender), inherent genetic traits (i.e. single nucleotide 
polymorphisms in genes coding metabolic enzymes affecting individual metabolic capacity), co-
treatments (i.e. drug-drug interactions), environmental factors (i.e. malnutrition), or others. Based on 
that knowledge one could suggest treatment optimisation strategies adjusting the universal dosing 
regimen for known characteristics affecting individual drug response to ensure improvement in 
treatment outcome in the subpopulation containing those characteristics.  
                                                          
B Reprinted from the Clinical Pharmacokinetics and Pharcodynamics, Concenpts and Applications, Chapter 1: 
Therapeutic Relevance, Rowland, M. & Tozer, T. Page No. 4, Copyright (Lippincott, Williams & Wilkins, 2011) 
with permission from Wolters Kluwer Health. 
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2.3 Pharmacology of non-nucleoside reverse transcriptase 
inhibitors 
There are four currently licensed NNRTIs but only two of them (efavirenz and nevirapine) are licensed 
for treatment in children < 12 years. Their pharmacological properties and studies that contributed to 
the current state of knowledge are discussed below.  
 
2.3.1 Efavirenz 
2.3.1.1 Pharmacokinetics 
According to manufacturer’s information after repeated administration of once daily 600mg dose in 
adults efavirenz has a steady state Cmax = 4.07 ± 1.17 mg/L (29%) [mean ± S.D. (% C.V.)], which is 
reached 3 – 5 hours after administration, steady state Cmin = 1.76 ± 1.01 mg/L (57%), and AUC = 58 ± 
23 mg·h/L (40%).63 Efavirenz has lower absorption at higher doses161 (but linear PK within therapeutic 
doses63); the oral bioavailability is 40-45% without food,63 and is 20% lower in liquid formations.40,162 
If taken with food absorption is increased up to 50%.11 Efavirenz is highly protein bound (>99%) – 
mostly to albumin and although penetrates to central nervous system, the fraction that goes through 
blood-brain-barrier is low.63 Population pharmacokinetic analyses (Tables 2.11 to 2.15 in Appendix to 
Chapter 2) have described efavirenz with a 2-compartmental distribution,163–166 although in several 
studies based primarily on sparse data the 2nd compartment could not be identified.66,167–172 High 
volume of distribution (combined Vcent and Vper ranging between 250 and 340L for average weight of 
about 70kg) indicates that despite high protein binding the drug penetrates into tissues (and confirms 
the CNS penetration).170 Efavirenz ka is estimated to range between 0.14 and 0.6 [h-1]66,71,103,167,168,170–
173 and is described as a 1st order process (at dose of 600mg). Delays in drug absorption were previously 
modelled using a combination of a zero and 1st order process170 or through transit compartments.71,165 
Efavirenz is metabolised by the CYP system to inactive hyroxylated metabolites (Figure 2.3) and is a 
drug with relatively low extraction ratio.63,174,175 The primary metabolite is 8-OH EFV (accounting for 
77% of overall metabolism)176 and corresponding principal catalyst is CYP2B6 with lessen contribution 
of CYP1A2, CYP3A5, CYP3A4 and CYP2A6.63,175,177 The secondary metabolite is 7-OH EFV mainly 
produced though CYP2A6, this a minor metabolic pathway and becomes more important in patients 
with impaired function of CYP2B6.174,177–180 Contribution of other 1st phase metabolites is negligible. In 
addition to primary oxidation 17% of 7-OH EFV can be further hydroxylated thought CYP2B6 to 7,8-
dihyroxy EFV. In the 2nd phase efavirenz 
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Figure 2.3  Suggested metabolic pathways for efavirenz with corresponding cytochrome P450 catabolic enzymes for main 
metabolites (based on di Julio et al.174)C 
undergoes glucuronidation (through uridine 5'-diphospho-glucuronosyltransferase - UGT), followed 
by its extretion.63,180,181 By inducing CYP3A4, CYP2B6 and UGT1A1 pathways63 efavirenz alters 
metabolism of other drugs as well as its own (it is an auto-inducer)161,182 which leads to differences in 
clearance rates between single dose and at steady state (up to 150% higher at steady state).164,166 The 
estimated steady state CL ranges between 8 and 11.7 L/h168–170,172 and has also been described as a 1st 
order process, although three studies described it using a semi-mechanistic well-stirred liver model, 
allowing to account for 1st pass metabolism71,172 or auto-induction.166 Efavirenz clearance was shown 
to be increased by 19% during pregnancy.71 The drug has a relatively long half-life (single dose t1/2=52-
76h, steady state t1/2=40-55h),63 which allows once daily administration. Efavirenz is excreted mainly 
in faces (both as metabolite and unchanged drug), approximately 14-34% is excreted really (primarily 
as metabolites).161 
Numerous investigations showed that efavirenz PK exhibits high levels of between-subject variability 
reaching up to 120%94 and coefficient of variation in drug’s clearance up to 40-55%.165,171 It has been 
attributed to a combination of various factors including biologic, exogenous and pharmacogenetic. 
Population pharmacokinetic investigations quantifying their effect on efavirenz PK are presented in 
Tables 2.11 to 2.15 in Appendix to Chapter 2. Efavirenz pharmacogenetic variability attributed to single 
nucleotide polymorphisms (SNPs) in genes coding enzymatic proteins for the drug’s main metabolic 
pathways (Figure 2.3) have been identified as the main contributory factor.171,173 
  
                                                          
C Reprinted from the Pharmacogenet. Genomics, 19, 300–9, di Iulio, J. et al., In vivo analysis of efavirenz 
metabolism in individuals with impaired CYP2A6 function. Page No. 301, Copyright (2009) with permission 
from Wolters Kluwer Health, Inc.  
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2.3.1.2 Pharmacogenetics 
2.3.1.2.1 CYP2B6  
The gene coding CYP2B6, the principal metabolic pathway for efavirenz, is highly polymorphic leading 
to up to 100-fold between-subject variability at enzymatic protein levels.183 The frequencies of those 
polymorphisms vary significantly between populations (Table 2.2).29,69,183–190 The most widely studied 
is the loss-of-function (LOF) polymorphism, 516G>T (rs3745274), which was first described by Lang et 
al.191 and identified to be a point mutation at exon 4 leading to an amino-acid substitution in CYP2B6 
(Gln172His). Haas et al.69,185 showed that this polymorphism was associated with differences in plasma 
exposures and frequency of CNS AEs but not virological outcome, and reported the 516TT variant 
allele to be more common in African-Americans (20%) than in European-Americans (3%).69 A number 
of investigations confirmed those findings showing that this SNP is particularly prevalent in black 
Africans180 with minor differences in recessive allele frequencies between ethnic groups (43% in black 
South Africans,192 42% in Tanzanians,193 31% in Ethiopians,193 48% in Zimbabweans36 and 36% 
Ugandans39) and is associated with increased efavirenz levels observed in this 
population.39,76,176,178,179,194,195 Population pharmacokinetic analyses estimated the 516GT genotype to 
cause a 23-50% reduction in efavirenz clearance and 516TT a drop of 54-75%.36,169,173,185,196,197 
Table 2.2 CYP2B6 loss-of-function allele frequencies in different ethic groups (from Klein et al.35)D 
SNP African-
Americans 
Ghanaians Japanese Taiwanese Koreans Caucasians 
516G>T 
(rs3745274) 
27.8% 48.8% 14.4% 14.1% 15.2% 25.5% 
983T>C 
(rs28399499) 
4.4% 6.6% 0% 0% 0% 0% 
15582C>T 
(rs4803419) 
0% 2.5% 0% 0% 0% ---- 
 
Another polymorphic CYP2B6 variant allele affecting exposure to efavirenz is 983T>C (rs28399499). It 
was first associated with the differences in efavirenz metabolism by Klein et al.,35 who sequenced it 
(g.18799 in exon 6) and reported the mechanism leading to impairment of the enzymatic protein 
(Ile328Thr). Klein et al.35 hypothesised this SNP to be absent in Caucasian and Asian population (Table 
2.2), which was later confirmed by Mehlotra et al.188 The actual combined effect of SNPs 516G>T and 
983T>C on efavirenz PK was first demonstrated by Wang et al.29 and Wyen et al.198 (who was also the 
                                                          
D Reprinted from the Pharmacogenet. Genomics, 15, 861–73, Klein, K. et al., Genetic variability of CYP2B6 in 
populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications 
for anti-HIV therapy with efavirenz. Page No. 865, Copyright (2005) with permission from Wolters Kluwer 
Health, Inc. 
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first to report the effect of 983T>C recessive homozygosity). Ribaudo et al.199 suggested that the 
combined effect of those SNPs on efavirenz PK can be expressed as a composite factor based on the 
combined number of minor allele polymorphisms (0, extensive metabolizer; 1, intermediate 
metabolizer; 2, slow metabolizer). Similarly to 516G>T the frequency of 983T>C recessive allele differs 
among different African ethnic groups, ranging between 5 – 17%.71,76,189,193,195,199,200 It has been shown 
that despite having lower prevalence SNP 983T>C affects efavirenz PK to greater extent than 
516G>T.103,201  
CYP2B6 785A>G is another polymorphism reported in a number of investigations due to its linkage 
with both 516G>T35,191 and 983T>C.29 The effect of this SNP has been previously described on its own, 
as a separate allele (CYP2B6*4), showing to increase the CYP2B6 protein exporession,29 or as a 
haplotype group in combination with 516G>T (CYP2B6*6) 35,191,202 or 983T>C (CYP2B6*16),29 modifying 
their effect.29,191 The described effect of 785A>G is low (in most studies not significant)171 and for that 
reason most current investigations quantify the effects of 516G>T or 983T>C separate and not as 
CYP2B6*6 and CYP2B6*16 haplotype groups.180 
In a recent genome wide association study Holzinger et al.176 identified that the effect of the two 
aforementioned polymorphisms (516G>T and 983T>C) is further modified by SNP 15582C>T 
(rs4803419, Thr168Ile) giving 11 possible combinations of CYP2B6 allele variants in the three genetic 
locations (homozygosity for any one of those three polymorphisms precludes the presence of another 
two). Based on those combinations authors suggested that individuals can be classified into different 
metabolic subgroups for efavirenz (Table 2.3).  
The findings by Holzinger et al.176 were recently replicated in a cohort of South African adults and 
children76 but the effect of SNP 15582C>T on efavirenz PK wasn’t confirmed in others.71,189,195,203 
Admittedly SNP 15582C>T does not improve the ability to predict very high efavirenz concentrations 
(as 15582T cannot be present among individuals who already have two variant alleles at 
CYP2B6 516G>T and/or 983T>C) but only in groups having low exposures,176 and despite proving 
significant in the South African study the investigators concluded this effect was negligible in 
comparison to 516G>T and 983T>C.76 
Alternative classification of metaboliser subgroups based on combination of SNPs 516G>T and 983T>C 
alone was recently proposed by Dooley et al.71 in a study in South African women (Table 2.3). Due to 
significant differences in clearance rates (up to 10-fold differences between the two most extreme 
subgroups) the investigators suggested that individuals having homozygous variant at position 983T>C 
should consist a separate group of ultra-slow metabolisers (USM).   
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Table 2.3 Metabolic subgroups for efavirenz based on CYP2B6 allel variants proposed in different investigations 
MET 
Holzinger et al.176 Dooley et al.71 Dickinson et al.103** 
15582C>T| 516G>T |983T>C 516G>T| 983T>C 
CL* 
[L/h] 
Cmin 
[mg/L] 
516G>T| 983T>C| CYP2A6*9B|*17 
CL 
[L/h] 
Cmin 
[mg/L] 
EM 
Homozygous wildtype at 
516G>T and 983T>C and wild 
type or heterozygote for 
15582C>T (CC|GG|TT or 
CT|GG|TT) 
Homozygous 
wildtype for both 
SNPs 
(516GG|983TT) 
18.6 1.33 
Homozygous wildtype for CYP2B6 SNPs with 
combinations of CYP2A6 alleles (GG/TT/CC/CC, 
GG/TT/CC|CT or TT, GG|TT|CA or AA|CC, 
GG|TT|CA or AA|CT or TT) 
12.4 1.28 
IM 
Homozygous wildtype at 
516G>T and 983T>C with 
homozygous variant at 
15582C>T or one variant allele 
at 516G>T or 983T>C 
(TT|GG|TT or CC|GT|TT or 
CC|GG|CT or CT|GT|TT) 
One variant allele 
at either of the 
positions 
(516GT|983TT or 
516GG|983CT) 
11.0 2.03 
Homozygous wildtype 516G>T and combinations of 
CYP2A6 alleles with heterozygous or homozygous 
variant 983T>C or heterozygous variant 516G>T 
with 983T>C homozygous wildtype and 
combinations of CYP2A6 alleles (GG|TC or 
CC|CC|CC, GT|TT|CC| CC, GT|TT|CC|CT or TT, 
GT|TT|CA or AA|CC, GT|TT|CA or AA|CT) 
8.93 1.94 
SM 
One variant allele at either 
516G>T or 983T>C or 
homozygous variant at 516G>T 
(CC|TT|TT or CC|GT|CT or 
CC|GG|CC) 
One variant allele 
at either of the 
positions or 
homozygous 
variant at 516G>T 
(516GT|983CT or 
516TT|983TT) 
4.79 6.11 
Heterozygous variant 516G>T with heterozygous or 
homozygous variant 983T>C, or homozygous 
variant 516G>T with homozygous wildtype 983T>C 
with combinations of alleles (GG|TC or CC| CC|CT 
or TT, GG|TC or CC|CA or AA|CC, GG|TC or CC| 
CA or AA|CT, GT|TC or CC|CC|CC, GT|TC or 
CC|CC|CT or TT, GT|TC or CC|CA or AA|CC, 
TT|TT|CC|CC, TT|TT| CC|CT or TT, TT|TT|CA or 
AA|CC, TT|TT|CA or AA|CT) 
3.55 6.24 
USM NA 
Homozygous 
variant at 983T>C 
(516GG|983CC) 
1.56 17.42 NA NA NA 
*expressed as apparent hepatic clearance, **values corresponding to efavirenz daily dose of 600mg
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In addition to the listed CYP2B6 polymorphisms two novel SNPs have been recently linked with 
efavirenz concentrations in Thai patients - 18492T>C and 21563C>T.204–206 Sukasem et al.206 suggested 
that the composite effect of SNPs 516G>T, 785A>G and 21563C>T could be defined as a new CYP2B6-
GAC haplotype and reported frequencies of 36.5%, 40.4% and 23.1% for non-GAC, GAC heterozygous 
and GAC homozygous genotypes, respectively, with corresponding average efavirenz concentrations 
of 1.94 mg/L, 2.69 mg/L and 5.54 mg/L. In order to exclude possible confounding effect of other SNPs 
the new associations were evaluated independently in patients who carried CYP2B6*1/*1 
(516GG|983TT) in two separate studies.204,205 They reported consistently that 18492T>C (but not 
21563C >T) was significantly associated with lower efavirenz concentrations and that individuals 
carrying variant allele were at increased risk of virological failure.204,205 Lastly, SNP CYP2B6 136A>G 
(rs35303484) was associated with lower efavirenz clearance (20% reduction) for in Ugandan 
individuals by Mukonzo et al.,39 but this association was not replicated in other studies.  
2.3.1.2.2 Accessory pathways 
Efavirenz accessory metabolic pathways have also been shown to be highly polymorphic180 but due to 
lower contribution to the overall biotransformation they are less studied. A number of investigations 
showed that those polymorphisms become more important in slow CYP2B6 metabolisers where the 
clearance is diverted towards the 7-OH EFV pathway catalysed primarily by CYP2A6.171,174,177–179 Di Iulio 
et al.174 showed in an in vivo analysis that dual slow CYP2B6 and CYP2A6 metabolism can lead to 
extremely high efavirenz concentrations, which was replicated by Arab-Alameddine et al.171 Haas et 
al.185 reported that CYP3A5 6986AA homozygotes had a 10% increased efavirenz clearance. In a study 
in Ghanaian patients CYP2A6*9B (-48T>G) and/or CYP2A6*17 carries had on average 1.8 higher 
efavirenz concentrations comparing to non-carriers178 and the drug exposures were further altered by 
a polymorphism UGT 735A>G  (UGT2B7*1a).179 CYP2A6 -48T>G was predictive of efavirenz 
concentrations in another Ghanaian cohort but only in a univariate analysis and no longer after 
accounting for CYP2B6 516G>T and 983T>C, suggesting that those association might not be 
independent of CYP2B6 polymorphisms.207 None of those findings were confirmed in a genome wide 
association study by Holzinger et al.176 and to verify them Haas et al.207 conducted an investigation in 
a group subjects with slow 516G>T|983T>C genotype. The authors found that CYP2A6 -48T>G and 
UGT2B7 735A>G recessive homozygosities were predictive of further elevations in efavirenz exposers. 
Recently Dickinson et al.103 suggested efavirenz metabolic subgroup classification based on 
combination of SNPs 516G>T and 983T>C in CYP2B6 and CYP2A6*9B/*17 (Table 2.3). 
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2.3.1.2.3 Nuclear receptors 
CYP450 enzymes activity is regulated by a number of nuclear receptors (Figure 2.4). Nuclear receptors 
are ligand-activated transcription factors that control various cell and organism functions on a 
molecular level by up- or down-regulating expression of proteins.78  CYP450 activity is influenced 
mostly by pregnane (steroid) X receptor (PXR) and the constitutive androstane receptor (CAR).78–80 As 
a consequence, additionally to SNPs in genes coding CYP450 enzymes, also polymorphisms in genes 
coding the aforementioned receptors (NR1|2 for PXR and NR1|3 for CAR) are hypothesised to  
indirectly impact efavirenz PK.81,82 SNPs in nuclear receptors are also shown to be prevalent in different 
frequencies in various ethnic groups.83,84 The number of investigations reporting significant effect of 
the polymorphisms in nuclear receptors on efavirenz PK is scarce, and so far they were only confirmed 
for NR1|3 (CAR) in one study in Chilean patients (rs2307424 C>T)208 and in several studies in South 
African individuals (rs3003596T>C).84,189,195 Swart et al.84 showed that the effect of polymorphisms in 
NR1|3 might be more prominent in slow metabolisers for CYP2B6. Those associations were not 
replicated in the majority of other investigations.76,176,207,209   
 
 
Figure 2.4 Schematic illustration of the activation mechanisms and target genes of CAR and PXR (from Tolson et al.210)E 
Note: CAR can be activated by either direct (ligand binding) or indirect mechanisms, while activation of PXR is 
purely ligand dependent. CAR and PXR shared target genes are grouped in a red box, CAR-specific targets in a 
blue box, and PXR-specific targets in a purple box. 
 
                                                          
E Reprinted from the Adv. Drug Deliv. Rev., 62, 1238–49, Tolson, A. H. et al.,  Regulation of drug-metabolizing 
enzymes by xenobiotic receptors: PXR and CAR. Page No. 1240, Copyright (2010) with permission from 
Elsevier. 
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2.3.1.2.4 Transporters 
Variability in efavirenz PK has been previously linked to polymorphisms in ABCB1 (ATP-binding 
cassette transporter gene or multidrug-resistance transporter gene) coding P-glycoprotein (P-gp). P-
gp itself has an important role in transportation of a number of different substrates (including some 
ARVs) at a compartmental and cellular level (Figure 2.5). It is abundant in the intestines (regulating 
drug entry into the body), in cell membranes (regulating drug entry into the cells), and in the apical 
membrane of many other epithelial barriers, e.g. blood-brain barrier (regulating the inter-
compartment drug distribution).211 Decreased expression of P-gp (Figure 2.5b) leads to increased drug 
concentrations in plasma (due to reduced intestinal reverse efflux - E) causing increased intracellular 
concentrations (on Figure 2.5b in CD4+ Lymphocytes). This effect was first reported by Fellay et al.212 
who associated higher efavirenz concentrations leading to significantly larger CD4 increases in 
patients with ABCB1 3435TT genotype. It an be speculated that the disparities in some findings could 
be a consequence of differences in accuracy of intracellular drug concentration measurements and 
reproducibility of assays. The association between ABCB1 3435C>T and exposure to efavirenz was 
replicated in a number studies,39,168 while others related the ABCB1 3435C>T recessive homozygosity 
only to better treatment response (decreased likelihood of virologic failure185 or higher increase in 
CD4-cell count213). Population pharmacokinetic investigations by Csajka et al.168 and Mukonzo et 
al.39 reported that the observed differences in efavirenz plasma exposures for ABCB1 3435TT could be 
attributed to differences in oral bioavailability (20% increase). What makes this finding controversial 
is that it wasn’t confirmed in others studies,189,193–195,199,209,214,215 and in fact a number of in vitro 
investigations found no association between P-gp expression and efavirenz intracellular 
concentrations.216–218 It was hypothesised though that the effect of ABCB1 polymorphisms might be 
more pronounced on the intra-cellular drug concentrations than ones observed in plasma or 
cerebrospinal fluid (CSF).219 
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Figure 2.5 Hypothesis for differential expression of P-glycoprotein (P-gp) and drug concentrations of P-gp substrate in 
plasma (from Saitoh et al.215)F  
Note: (a) Normal expression of P-gp (b) Reduced expression of P-gp 
A recent investigation by Swart et al.220 in South African patients associated differences in efavirenz 
concentrations with two new SNPs in ABCB1: 1236C>T and 4036A>G (only 1236C>T remained 
significant after correction for CYP2B6 516G>T|983T>C and N1|3 8784T > C).195 The finding for ABCB1 
1236C>T hasn’t been replicated since but allele ABCB1 4036G has been associated with increased 
efavirenz levels in studies in South Africans,189 Ethiopians,193 Tanzanians193 and in Ugandans194 (in all 
studies 4036A>G was an significant predictor after correction for CYP2B6 516G>T|983T>C). Mukonzo 
et al.194 estimated that ABCB1 4046A>G variant allele carriers has a 22% increased F1. The mechanism 
for the effect of ABCB1 polymorphisms on the PK of NNRTIs remains uncertain. 
2.3.1.3 Other predictors of variability in the efavirenz pharmacokinetics 
Other covariates identified to effect efavirenz PK are: race, sex, weight, different formations and other 
drugs. Several investigations reported consistently higher efavirenz exposures among black, 
particularly African individuals,66,165,168,172,221,222 none of those studies though looked into the 
pharmacogenetic predictors and it is currently known that the reported differences were due to 
different prevalence of SNPs between populations.69,171 
                                                          
F Reprinted from the AIDS, 19, 371–380, Saitoh, A. et al., An MDR1-3435 variant is associated with higher 
plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. Page No. 377, Copyright 
(2005) with permission from Wolters Kluwer Health, Inc. 
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A population pharmacokinetic meta-analysis by Barrett et al.164 reported 10% lower clearance in 
women relative to men, nonetheless this finding was questioned due to disproportion in distribution 
of sexes in the analysis (the population consisted of only 13% females). In a study by Burger et al.221 
women had 30% higher efavirenz concentrations, however the investigators did not account for the 
effect of CYP2B6 polymorphisms and the majority of women under investigation were of African 
origin. The effect of sex was also detected in analysis by Nyakutira et al.36 (30% reduction in CL for 
women) and Mukonzo et al.39 (twice increased volume of distribution attributed to higher body fat in 
females) but it hasn’t been replicated in other studies making it inconclusive. Weight has been also 
shown to affect efavirenz PK71,167,222,223 but currently it is widely known that size affects the clearance 
and the volume of distribution of most drugs and is accounted for through allometric scaling.224,225 
Efavirenz PK was speculated to be decreased by a concomitant use of rifampicin based TB treatment 
leading to recommendations of dose increase in patients weighing >50kg from 600 to 800mg.226,227 
This was not confirmed in other studies, however some of them showed high variability and 
unpredictability of observed efavirenz concentrations during TB treatment,228,229 others conversely 
that rifampicin decreased efavirenz clearance leading to increases in average drug exposures.222 More 
recent investigations show that the direction of this effect depends on individual CYP2B6 
genotype.52,230 Isoniazid, another component of 1st line TB treatment, was linked with elevated 
efavirenz concentrations through inhibitory effect on its accessory metabolic pathways.74,170,203 This 
effect is concentration dependant and is particularly high for individuals being slow CYP2B6 
metabolisers and slow NAT2 acetylators (who have particularly high isoniazid levels).170 The current 
consensus is that concomitant TB treatment does not require efavirenz dose adjustment.52,170,203,231  
Lastly, zidovudine, a common antiretroviral companion drug, was associated with 25% reduction in 
efavirenz concentrations.222 While an in vivo investigation showed that both drugs share a metabolic 
pathway (UGT)181 giving a possible mechanism for this interaction, it was not confirmed in other 
studies. Furthermore, UGT is an accessory metabolic pathway for efavirenz and the relevance of 
finding is questionable and limited. 
 
2.3.1.4 PK/PD relationship and therapeutic targets 
Literature shows inconclusive information about the concentration – response relationship for 
efavirenz. The PK/PD relationship was first described by Joshi et al.232 who reported that the risk of 
virological failure decreased with increasing efavirenz concentrations and that individuals with trough 
concentrations above 1.1 mg/L were at lower risk of treatment failure comparing to patients with 
exposures below that threshold (Table 2.4). Marzolini et al.94 applied logistic regression to mid-dose 
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efavirenz concentration data obtained from 130 patients followed up for 3 – 18 months (up to 8 
repeated visits per patient every 3 months) identifying that a similar efficacy cut-off (1 mg/L). This 
finding was later confirmed in a larger group of patients by Csajka et al.168 The data from the two latter 
studies was recently pooled together and re-analysed by Siccardi et al.233 and derived logistic 
regression model was applied to predict treatment outcome under different dosage scenarios.  
A number of additional studies aimed to characterise PK/PD relationship for efavirenz, some of them 
suggesting alternative efficacy targets (Table 2.4), but a number of them failed to detect a significant 
association between drug exposures and treatment outcome.103,105,209,234 Van Leth et al.234 showed 
that in treatment adherent patients (on treatment for at least 95% of their follow-up) the 
concentration-effect relationship was very weak and the sensitivity of efficacy cut-offs was very low, 
suggesting that adherence had a more significant effect on treatment outcome than the actual plasma 
exposure levels. In a study in Ugandan patients Mukonzo et al.194 failed to detect a significant 
association between efavirenz mid-dose concentrations and treatment outcome in terms of CD4 
and/or HIV RNA levels but the investigation had a relatively small number of patients. The paediatric 
investigations contribution to the field are discussed in Chapter 2.3.1.7.5.  
A lot of controversy surrounds the current efavirenz efficacy threshold of 1mg/L.94,95 Firstly, the 1 mg/L 
threshold is considerably higher than the in-vitro protein binding–corrected efavirenz 95% inhibitory 
concentration (IC95) of 0.05 mg/L.64 Secondly, recently resurfaced results of the efavirenz phase 2 
dose finding study showed that all tested treatment options (200 mg, 400 mg and 600 mg) had a 
comparable efficacy.235 The maximum effective dose of 600 mg was chosen to avoid the risk of 
emergence of resistance mutations but the results suggest that exposures much lower to current 
therapeutic target could provide adequate virological suppression.130 This hypothesis was recently 
tested in study ENCORE1,102,103 which proved that the standard 600mg efavirenz dose in adults can be 
reduced to 400mg daily without loss of efficacy. The extensive PK/PD analysis of the analysis of 
ENCORE1 data by Dickinson et al.103,167 revealed that even though the correlation between exposure 
to efavirenz and virological suppression was present at 48 weeks of treatment, the confidence 
intervals for the effect were very wide, and the association were no longer present at week 96. The 
authors challenged the validity of the 1 mg/L cut-off suggested by Marzolini et al.94  in prediction of 
virilogical outcome,94 which in fact in a recent South African study was reported to be lower (Table 
2.4).236 Lastly the targed suggested by Marzolini et al. was derived in a very heterogeneous population 
comprising very heterogeneous population (including patients with prior exposure to other ARTs and 
ones who failed on previous treatment regimens) and some combination therapeutics, which are 
currently no longer used in HIV treatment and were replaced by more potenet companion drugs.  
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Table 2.4 Previously published efavirenz therapeutic targets 
Pop Ref (Year) Target Method VL 
[copies/mL] 
n 
A
d
u
lt
s 
Joshi et al.232 
(1999)  
Cmin > 1.1 mg/L 
 
No 
information 
No 
information 
---- 
Marzolini et al.94 
(2000)  
CTDM = 1 – 4mg/La  Logistic 
regression 
400 130 
Csajka et al.168 
(2003)  
CTDM = 1 – 4mg/La logistic 
regression 
400 235 
Gonzalez de 
Requena et al.237 
(2004)  
 
Cmin >3mg/Lb No 
information 
50 48 
Stahle et al.238 
(2004)  
CTDM = 2.2 – 4.1mg/L Cumulative 
distribution of 
concentrations 
50 68 
Van Leth et al.234 
(2006)  
Cmin > 1.1 mg/L 
AUC > 40 mg*h/L 
Cox model 50 800 
Orrell et al.236 
(2016)  
CTDM > 0.7 mg/L Cox model + 
likelihood 
profiling 
400 (at week 
16)/ 40 
(week 48) 
180 
C
h
ild
re
n
 
Starr et al. 96,239 
(1999, 2002)  
AUC = 60 – 120 
mg*h/mLc 
Exposure 
target 
extrapolated 
from adults 
50, 400 57 
Brundage et al.101 
(2003)  
AUC > 59 mg*h/mLd Pre-defined + 
Cox model 
400 50 
Hirt et al.32 
(2003)  
Cmin > 1.1 mg/L 
AUC > 51 mg*h/L 
Pre-defined  + 
Fisher’s exact 
test 
300 48 
Fletcher et al.100 
(2007)  
AUC > 49 mg*h/mLd Pre-defined  + 
Chi-square 
400 50 
Bouzza et al.240 
(2013) 
Cmin > 3.3 mg/L 
 
HIV dynamic 
model 
300 49 
aMid-dose concentration (8-20h post-dose, TDM). bAdults who failed on NVP. c Cut-off chosen to match adult 
exposures observed in Phase II study. dMost predictive lower cut-off. 
 
Similar to other ARVs, efavirenz treatment efficacy has been shown to be affected by treatment 
adherence (in particular so called drug holidays - ≥48h periods of unplanned drug cessation), 
depression, younger age and baseline mutations,241,242 but none of those predictors was as strongly 
associated with increased risk of treatment failure as suboptimal drug concentrations.94,168,232,234,238 
2.3.1.5 Safety 
As outlined in Chapter 2.3.1.4 the therapeutic target for a drug is defined by the lowest exposure 
providing acceptable treatment efficacy and upper cut-off is defined by drug’s safety profile. For 
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efavirenz the sub-therapeutic concentration have been associated with increased risk of virological 
failure (discussed in previous chapter) and higher exposures with central nervous system (CNS) 
toxicities.69,94,168  
Early studies in efavirenz showed that 20-40% of patients developed CNS toxicities with variable 
severity and duration, which led to treatment discontinuation in some of the individuals.243,244 CNS 
disturbances ranged from dizziness to hallucinations, including headaches, problems with 
concentrations, depression, nightmares and insomnia.63,245  Marzolini et al.94 showed that severity of 
those side effects was concentration dependant and that they were 3 times more frequent in patients 
with efavirenz concentrations > 4mg/L. The concentration-dependant association with CNS AEs has 
been replicated in a number of investigations, which showed an increased incidence in slow CYP2B6 
metabolisers69,186,192,199 and black Africans,246–248 with particularly high dug concentrations. It has been 
shown that the incidence of neuropsychiatric adverse events decreases with time, which has been 
associated with building of tolerance.69 This could also explain less clear association with efavirenz 
concentrations and CNS AEs in some of the studies.168 The severity of reported symptoms differs 
between studies between mild CNS manifestations such as insomnia, fatigue69,186,192 to severe such as 
confusion, seizures and severe psychosis.248,249  
The differences in prevalence of neuropsychiatric AEs between reports could result from 
underreporting in studies not utilising neuropsychological examinations. A recent study in 
predominantly Italian patients showed a high prevalence of HIV-associated neurocognitive disorders 
in apparently asymptomatic HIV+ individuals treated with efavirenz.250 This has been confirmed in a 
systematic review speculating that efavirenz intake is associated with worsening of cognitive 
functions.251 Despite the constrains related to detecting and reporting efavirenz associated 
neurological side effects studies consistently report average drug concentrations in individuals not 
experiencing similar AEs to range between 2.4 and 3.7 mg/L.245 Conversely neurological side effects 
(resulting from high efavirenz exposures) were the cause of treatment discontinuation in 54% of 
patients in a Scandinavian cohort (half of them changing treatment after 12 months indicating 
persistence of symptoms).252 In 90% of them after efavirenz discontinuation the unwanted symptoms 
subsided.252  
High efavirenz concentrations related to slow CYP2B6 metaboliser genotype have also been associated 
with high bilirubin levels253 and increased risk of liver injury in case reports254 and cohort studies.255,256 
The mechanisms underlying the efavirenz-related hepatotoxicity is currently not known. 
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2.3.1.6 Optimisation of efavirenz dosage 
The aim of efavirenz dosage optimisation is to ensure individual patient exposures fall within the 
therapeutic range of 1-4mg/L in order to reduce the risk of sub-therapeutic concentrations associated 
with virological failure and prevent supra-therapeutic concentrations putting patients at risk of 
developing CNS AEs. The first treatment personalisation strategy was suggested by Csajka et al.168 All 
variability in Csajka’s pharmacokinetic model was allocated to bioavailability following an assumption 
that no matter what its true source is, it would lead to change in the individual value of bioavailability 
(Find). The average predicted efavirenz trough concentration (at steady state after daily administration 
of 600mg and population average bioavailability value assumed to be Fpop=1) was 1.87 mg/L. 
Calculating the ratio of model estimated Find and Fpop would allow adjustment of dose to provide more 
optimal exposure, i.e. for an individual with Find=1.4 the dose should be reduced by 1/1.4 (he should 
receive 0.7x standard dose). Such dose optimisation strategy has several limitations. It assumes the 
variability is constant over time, whereas a number of publications show that it’s highly occasion 
dependant, which could lead to wrong conclusions if optimisation would be based on a single efavirenz 
sample. Furthermore, it does not allow a priori optimisation of dose before the start of treatment and 
it has been shown that the CNS AEs are particularly severe in the first weeks after treatment start.  
An approach that would allow a priori prediction of individual efavirenz concentrations and dose 
adjustment before treatment start is based on individual patient CYP2B6 genotype. First such 
approach was suggested by Nayakutira et al.36 advising that efavirenz dose for poor metabolisers 
(516GG) could be reduced to 400mg and an even greater dose reduction (down to 200mg) was 
proposed by Arab-Alameddine et al.171 Cabrera et al.169 suggested the efavirenz dose should be 
reduced by 33% for each dysfunctional 516GT allele (516GT – 400mg, 516TT – 200mg), a dosing 
recommendation also suggested by Sanchez at al.173 and Siccardi et al.233 Recently a new dosing 
algorithm was derived in Chinese patients suggesting most optimal daily doses of 550 mg, 350 mg, 
and 100 mg for the 516GG, 516GT, and 5146TT populations, respectively.257 This dosing algorithm was 
based on simulations in population pharmacokinetic studies and data on its implementation in a 
clinical setting and effect on treatment effectiveness and safety is limited. Of note is that none of the 
previously genotype based dose optimisation strategies accounted for the effect of SNP 983TC. 
In a Japanese study Gatanaga et al.258 successfully implemented dose reduction from 600 mg to 400 
mg daily in 11 patients slow CYP2B6 metabolisers (516GG) with persistently high efavirenz 
concentrations (>6 mg/L), and in 7 of them the dose was subsequently reduced to 200 mg while 
maintaining virological suppression < 50 copies/ml. There are also case reports of similar successful 
dose reductions in patients with CYP2B6 516GG genotype.259,260 A successful dose reduction guided by 
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efavirenz TDM concentrations was implemented in a small Swiss cohort of 13 patients.261 Patients with 
efavirenz mid-dose concentrations between 75th and 95th percentile had the dose reduced to 400 mg 
and one with concentrations >95th percentile 200mg. All patients maintained virologic suppression 
<50 copies/ml and subsequent genotyping showed that all but one had CYP2B6 516TT genotype (one 
had CYP2B6 516GT). Similar TDM guided dose reduction strategy was also implemented in a small 
cohort of Italian patients.262 In addition a recent modelling and simulation analysis showed average 
lifetime efavirenz treatment cost with a current standard dose of 600mg is 18500 USD higher than a 
genotype guided dosage, leading to incremental cost–effectiveness ratio >100,000 USD/QALY when 
comparing both treatment options.263 
Re-analysis of the initial phase 2 efavirenz dose-ranging study showed no difference in efficacy 
between 400mg and 600mg doses.264 Reduction of adult efavirenz dose from 600mg to 400mg could 
lower the cost of treatment by 30% and was estimated to bring savings of US$16 per person in a 
resource-limited setting, leading to an overall saving of US$192 million per year,265 which could 
contribute towards increasing treatment coverage in low-income countries. This led to design and roll 
out of ENCORE1 study, which showed that such efavirenz dose reduction in adults, when combined 
with tenofovir and emtricitabine, could provide reduced incidence of side effects without 
compromising treatment efficacy. Such universal dose reduction has been widely discussed and it was 
highlighted that it might be not appropriate in all populations considering limited information in 
pregnant women and during TB co-treatment.266 It was also questioned that two thirds of ENCORE1 
participants were of African or Asian origin, where the prevalence of LOF CYP2B6 polymorphisms is 
particularly high.267 Recently, pharmacokinetic simulations showed that reduction of efavirenz dose 
to 400mg in individuals 516GG might lead to underdosing in a larger proportion of patients than under 
current dose of 600mg and a dose of 500mg was suggested as most optimal in this subgroup.267 
2.3.1.7 Paediatric investigations  
The number of paediatric investigations describing efavirenz PK and sources of its variability is 
unsurprisingly limited what results from constraints of conducting clinical research in children outlined 
in Chapter 3.2.1. The majority of these studies include small numbers of patients and are based on 
predominantly sparse data. The number of PK/PD investigations (exploring association between 
efavirenz concentrations and treatment outcome) is even scarcer. The paediatric literature on 
efavirenz is further complimented by (predominantly comparative) studies evaluating treatment 
effect in terms of efficacy and safety (Tables 2.6 and 2.7). The overview of the paediatric studies in 
efavirenz is presented below (paediatric population pharmacokinetic analyses are additionally 
summarised in Tables 2.11 and 2.12 in Appendix to Chapter 2). 
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The product label for Sustiva (efavirenz originator drug) was recently extended in the USA268 and 
Europe269 to children as young as 3 months (weighing at least 3.5kg, Table 2.5), nonetheless WHO 
guidelines still recommend efavirenz should not be used in children < 3 years of age (Table 2.8).6  
2.3.1.7.1 Early studies 
The data leading to paediatric approval of efavirenz was provided by Pediatric AIDS Clinical Trials 
Group (PACTG) 382 study published by Starr et al. in 199996 (for solid formulations) and 2002239 (for 
liquid formulation). Both studies proved high efficacy of efavirenz in combination with nelfinavir and 
one or two NRTI’s (61% of children reached HIV RNA levels of <400 copies/ml, and 53% had <50 
copies/ml in an intent-to-treat analysis in the first study and in the second 58% and 53%, respectively). 
Studies showed that efavirenz based treatment in children was well tolerated and that the CNS AEs 
previously observed in adults were less severe and less frequent. The first study in solid formulations 
reported high prevalence of skin rashes (occurring predominantly within 2 weeks of start of 
treatment), a finding which was not replicated in other trials. In those paediatric dose finding studies 
the initial efavirenz dose was derived to match adult exposures (Table 2.4) and calculated through 
allometric scaling (600 𝑚𝑔 • (
weight [kg]
70 kg
)
0.7
 [scaling of 720 mg dose used for liquid formulation due 
to lower bioavailability]).96,239 The final average efavirenz dose used in the study using solid 
formulations was 14.2mg/kg/day.96 Effectiveness and safety of efavirenz-based ART in a clinical setting 
was confirmed in a number of small studies (8 - 33 participants), where efavirenz dose ranged between 
10.0 – 16.7 mg/kg, in children with prior exposure to ARVs in combination with NRTIs270,271 or PIs,272 
and in treatment-naïve individuals.273 An alternative, simplified weight band dosing was shown to 
provide similar virological outcome in a study by Scherpbier et al.274 and has been used since. 
2.3.1.7.2 Paediatric underdosing 
Despite favourable virologic outcomes of efavirenz treatment a number of pharmacokinetic 
investigations reported underdosing in children. Van Henting et al.275 showed that 63% of children 
receiving the recommended bodyweight adjusted dose of 10 -15mg/kg did not achieve the target 
exposure range of 60 – 120 mg*h/mL.96 Suboptimal exposures were also highlighted in a number of 
studies with weight band dosing56 leading to modification of guidelines in 201011 (Table 2.5). In a small 
study in South Africa Ren et al.97 showed that 40% of children had efavirenz concentrations <1mg/L, 
19% of children (44% weighing <15 kg) were reported to have similar low exposures in a study in 
Burkina Faso.32 Sub-therapeutic (<1mg/L94) efavirenz concentrations following WHO 2006 
recommendations56  were also reported in high proportion of children in other South African 
cohorts,34,74 in 20% of children in a study in Rwanda,99 in 34% of trough measurements in ARROW,41 
and in 15% of trough measurements in a Thai children.98 CHAPAS-3 was the first trial aiming to describe 
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and evaluate the pharmacokinetic exposure in children under new WHO 201011 efavirenz dosing 
schedule (with one modification - following previous reports the dose in the weight band 20 - 25kg 
was increased to 400mg – Table 2.5). 
Table 2.5 Comparison of efavirenz paediatric dosing recommendations and dosing tested in CHAPAS-3 
Weight band WHO 2006 WHO 2010 CHAPAS-3 
10 - 13.9 kg 200* 200 200 
14 - 19.9 kg 250* 300 300 
20 - 24.9 kg 300 300 400 
25 - 29.9 kg 350 400 400 
30 - 34.9 kg 400** 400 400 
35 - 39.9 kg 400 400 400 
> 40 kg 600 600 600 
Note: Dosage presented in mg 
*WHO 2006 weight bands 10 - <15 kg and 15 - <20kg; **Sustiva Summary Product Characteristics (2004/2008) 
in weight band 25 - 32.5 kg recommended efavirenz dose 350mg, 32.5 - 40 kg - 400mg 
 
2.3.1.7.3 Paediatric pharmacokinetics of efavirenz 
Until recently use of efavirenz was limited to children >3 year old, where all metabolic pathways of 
drug clearance are expected to be fully mature.276 The differences between PK in adults and children 
are caused mainly by differences in size and are commonly accounted for using allometric scaling of 
body weight.224,225 Following theory of allometry (also see Chapter 2.3.2.8.3) the weight effect on 
volume of distribution and clearance can be described as follows: 𝑉𝑤𝑒𝑖𝑔ℎ𝑡 = (
𝑤𝑒𝑖𝑔ℎ𝑡
70𝑘𝑔
)
1
and 𝐶𝐿𝑤𝑒𝑖𝑔ℎ𝑡 =
(
𝑤𝑒𝑖𝑔ℎ𝑡
70𝑘𝑔
)
0.75
 what has been implemented in majority of paediatric pharmacokinetic models for this 
drug (Table 2.11 and 2.12 in Appendix to Chapter 2). In addition clearance rates in children were shown 
to be increased beyond adult values around 4-5 years of age,277 which explains higher clearance 
reported in paediatric investigations (11.2 – 14.5 mg/L in children32,34,40,215 vs 8 - 11.7 L/h in adults168–
170,172 at steady state scaled to 70kg). In an investigation by Saitoh et al.278 clearance in younger 
children (3-5 years) was 47% higher than in the older group (>5 years), an effect also confirmed in 
studies from Burkina Faso32 and South Africa.97 The maturation of efavirenz metabolism was recently 
described by Salem et al.162 using a sigmoid Emax model (90% of adult values by 9 months of age) 
confirming this effect should not present children >3 years of age. In addition the authors reported 
that efavirenz bioavailability of liquid formulations increases with age (90% of “full” bioavailability 
observed in older children in achieved by 8 years of age. 
 38 
 
CHAPTER 2: Background and Literature Review 
                                                   Doctoral Thesis by A.M. Bienczak, March 2017 
Nonetheless, similarly to adults, the high variability in efavirenz PK observed in children has been 
attributed predominantly to pharmacogenetic factors. Other variables previously confirmed to affect 
efavirenz PK in children include compliance, formulation effect (in particular liquid formulations) and 
drug-drug interactions. 
2.3.1.7.4 Pharmacogenetics of efavirenz in children 
The effect of SNP 516G>T on efavirenz PK in children was first described by Saitoh et al.278 who 
reported an 18.5% drop in clearance for CYP2B6 516GT and 57% for 516TT. Similar effect was shown 
in population pharmacokinetic investigations by ter Heine et al.40 and Viljoen et al.97 (29.7-37.2% 
decrease in clearance for 516GT and 59.4-66.4% for 516TT) but not in a recent investigation by Salem 
et al.,162 where children 516GG and 516GT had comparable clearance rates and 516TT had 51% lower 
values. It could be speculated that those differences originate partly due to much younger age of 
children in the study by Salem et al. (included 2 months to 3 years of age) and related age driven 
differences in efavirenz clearance and bioavailability, and use of liquid formulation. In addition, ter 
Heine et al.40 and McIlleron et al.74 found that the subtherapeutic efavirenz concentrations were 
particularly prevalent in children with 516GG genotype (having highest clearance rates). 
The data on the effect of SNP 983TC in children is scarce. Mutwa et al.99 reported that Rwandan 
children with a variant allele had average efavirenz concentrations higher than wild type (3.1 mg/L in 
983TC and 1.8 mg/L in 98TT). Mixed effects linear regression was recently used in a South African 
study,76  which included a small proportion of children, to confirm associations of the combined 
CYP2B6 15582C>T|516G>T|983T>C genotype and efavirenz concentrations. The effect of those SNPs 
on efavirenz clearance in children has however never been previously estimated. 
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Table 2.6 Predictors of increased risk of virological failure for efavirenz and nevirapine (part 1) 
Drug Reference (year) PK Covariates Population n Method 
VL Target 
[copies/mL] 
EF
V
 
Starr et al.96 
(1999)  
Not analysed 
Uni: (A)°°° log2 bCD4% , ↓WAZ, ↑bVL / (B)°°° ↓WAZ, ↑bVL 
Multi: (A)°°° ↓WAZ, ↑bVL / (B)°°° ↑bVL 
PACTG 382 
study 
57 Cox 
400 (A)† 
50 (B)† 
Brundage et al.101 
(2004)  
↓AUC 
Uni: ↓IPAM, ↑bVL, ↓bCD4%, ↓WAZ 
Multi: ↓IPAM, ↑bVL, ↓AUC 
PACTG 382 
study 
50 Cox, TSSA 400 
Hirt et al.32 (2009)  ↓Cmin, ↓AUC Not analysed 
Burkina 
Faso 
48 
Fisher’s exact 
test 
300 
Fletcher et al.100 
(2008)  
↓AUC Not analysed 
PACTG 382 
study 
50 
Chi-square, 
logistic 
regression 
400 
EF
V
/N
V
P
 
Janssens et al.279 
(2007)  
Not analysed 
Uni: ↑orphan status, ↑male gender 
Multi: ↑orphan status 
Cambodian 212 
logistic 
regression 
400 
Kamaya et al.150 
(2007)  
Not analysed 
Uni: ↑male gender, ↑ bCD4%<5%, ↑NVP 
Multi: ↑male gender, ↑bCD4%<5%, ↑NVP 
Uganda 250 
logistic 
regression 
400 
Jittamala et al.149 
(2009)  
 
Not analysed 
Uni: ↑NVP (vs other treatments), ↑male gender, ↑age, 
↑adherence (<95%) 
Multi: ↑NVP (vs other treatments) 
Thailand 202 Cox 50 
Emmett et al.280 
(2010)  
Not analysed 
Chi2: ↑NVP (vs other treatments), ↓age, ↑maladherence, 
↑bCD4% <25% 
Multi: ↑maladherence, ↑bCD4% <25% 
Tanzania 206 
Chi-square, 
logistic 
regression 
400 
Lowenthan et 
al.151 (2013)  
Not analysed Multi: ↑NVP (vs other treatments) Botswana 804 Cox 400 
Bunupuradah et 
al.154 (2015)  
Not analysed 
Multi: ↑NVP (vs other treatments), age (↑<3 years & 10–
16 years) 
Thailand 840 Cox 1000 
Note: ↑indicates increased risk of virological failure (with increasing values of the covariate if continuous, or presence of covariate if categorical), ↓indicates reduced risk of 
virological failure (with increasing values of the covariate if continuous, or presence of covariate if categorical) 
†two efficacy cut-offs used: (A) 400 copies/mL, (B) 50 copies/mL; bCD4% - baseline CD4 percentage, bVL – baseline viral load, Cox – Cox proportional hazards regression, EFV 
– efavirenz, IPAM – integrated pharmacokinetic adherence measure, Multi – multivariate analysis, NVP – nevirapine, TSSA - tree-structured survival analysis, Uni – univariate 
analysis, WAZ – weight-for-age-adjusted z-score   
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Table 2.7 Predictors of increased risk of virological failure for efavirenz and nevirapine (part 2) 
Drug Reference (year) PK Covariates Population n Method 
VL Target 
[copies/mL] 
N
V
P
 
Musoke et al.61 
(2015)  
Not analysed 
Multi: ↑male gender, ↓adherence, ↑bVL, ↑syrup 
formulation 
Uganda/ 
Zimbabwe 
367 
logistic 
regression 
80 
EF
V
/N
V
P
/P
I 
Duong et al.153 
(2014)  
Not analyses 
Multi: ↑NVP (vs other treatments), ↑age, ↑pMTCT, 
↑ART start <2004, ↑bVL* 
UK 997 
Poisson mixed 
models 
400 
Mgelea et al.281 
(2014)  
Not analyses Multi: ↑NVP (vs other treatments) Tanzania 218 
Logistic 
regression 
400 
N
V
P
/P
I Violari et al.
145 
(2012)  
Not analysed Multi: ↑NVP (vs other treatments), ↑bVL 
Study 
P1060 
288 Cox 
drop >1 
log10 from 
baseline 
Lindsay et al.282 
(2014)  
Not analysed Multi: ↑NVP (vs other treatments), ↓bCD4%, ↑bVL 
Study 
P1060 
120 Cox 400** 
Note: ↑indicates increased risk of virological failure (with increasing values of the covariate if continuous, or presence of covariate if categorical), ↓indicates reduced risk of 
virological failure (with increasing values of the covariate if continuous, or presence of covariate if categorical) 
*at 12 months only, **composite end point: drop >1 log10 from baseline at 12 months or VL>400 copies/mL at month 24; ART – antiretroviral treatment, bCD4% - baseline 
CD4 percentage, bVL – baseline viral load, Cox – Cox proportional hazards regression, EFV – efavirenz, Multi – multivariate analysis, NVP – nevirapine, PI – protease inhibitor, 
pMTCT – prevention of mother to child transmission 
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2.3.1.7.5 Paediatric PK/PD relationship and therapeutic targets 
The PK/PD relationship in children has been little studied and the adult efficacy cut-off of 1mg/L94 is 
customarily used, even though it was recently questioned whether this cut-off can be universally 
extrapolated between populations and age groups.72 The first target exposure range suggested in 
children was based on AUCs observed in the adult phase 2 study (efavirenz dosed 600 mg once daily) 
and was derived based on 50th to twice 50th percentile of those values (60 - 120 mg•h/mL).96 The 
PK/PD analysis of data from PACTG 382 conducted by Brundage et al.101 showed that children with 
efavirenz AUC <60 mg•h/mL were at higher risk of treatment failure. The risk was further modified by 
baseline VL and treatment adherence expressed as integrated pharmacokinetic adherence measure 
(IPAM) calculated based on the intra-individual variability between PK measurements. The data from 
PACTG 382 was re-analysed by Fletcher et al.100 providing a more thorough investigation into the 
relationship between systemic exposures to efavirenz and virological outcome in children suggesting 
a new efficacy threshold of AUC > 49 mg•h/mL based (cut-off relating to 1st quartile of observed AUC). 
An alternative threshold (of 1.1 mg/L) was suggested by Hirt et al.32 (Table 2.4). Both those cut-offs 
were derived from small cohorts of children using simplistic methods based on comparison of a priori 
defined break points and none of them attempted to identify predictors of virological outcome other 
than the observed drug exposures. No association between efavirenz mid-dose concentrations and 
virological response was detected in a study in Rwandan children by Mutwa et al.,99 which can be 
attributed to a sample size. A novel approach to PK/PD data analysis and establishing therapeutic 
targets was recently suggested by Bouzza et al.,240 who by applying an HIV dynamics model derived an 
EC90 of 3.3 mg/L for efavirenz and suggested that if used in a triple combination with lamivudine and 
didanosine it contributes towards 65% of observed total treatment antiretroviral effect.  
All other paediatric investigations evaluating the effectiveness of efavirenz treatment explored 
associations between a selection of factors independently of drug concentrations and showed 
inconclusive findings across studies (Tables 2.6 and 2.7).99,100,149–151,279 Virological failure was 
associated with factors previously found in adults - lower adherence,101,149 higher baseline VL,96,101 
lower baseline CD4%,101,150 and male sex,149,150 as well as variables specific to this population - orphan 
status,279 type of caregiver,283 and lower weight-for-age Z-score (WAZ).96 Noteworthy is that that the 
suppression rates seen in children are lower than previously reported adults (24-52% vs 80-90% 
achieve VL<50 copies/ml at week 48, respectively).283 
2.3.1.7.6 Paediatric safety 
Literature indicates similar differences in the safety profile of efavirenz between children and adults, 
maily in terms of severity and incidence of adverse events. Majority of the early clinical studies showed 
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that the adverse events in children were rare, transient and mostly occurring within first weeks after 
treatment initialisation. The incidence of neurotoxicities observed in children varied between 
investigations: a study in a French cohort reported CNS toxicity in 37% of participants,271 20% in a small 
German study,273 and 16% in a large study in Ugandan children. Efavirenz associated persistent CNS 
side effects resulted in treatment discontinuation in 18.2% of children in a study by Wintergerst et 
al.284 Nonetheless, more recent investigations imply that more severe and complex cases might have 
been previously underreported. A significant association between efavirenz concentrations >4mg/L 
and psychiatric side effects was reported in a Thai study,67 and persistent high concentrations have 
been linked to cases of psychosis in children.285 Severe central nervous system manifestations such as 
seizures, cerebellar dysfunction as well as aggressive behaviour, anti-social behaviour and poor school 
performance were recently associated with extremely high efavirenz concentrations (>20mg/L) in 
children in South Africa.286 All of those individuals had impaired efavirenz metabolism due to CYP2B6 
polymorphisms and authors postulated that dosage optimisation based on both CYP2B6 516G>T and 
983T>C genotype could help prevent similar neurobehavioral or CNS abnormalities in African children. 
A lot remains unknown about the efavirenz CNS toxicity and its effect on brain development in children 
and the knowledge gaps were recently highlighted in a review by Van der Wijer et al.287  
2.3.1.7.7 Paediatric dose optimisation 
In addition to dose increases in certain paediatric weight bands following the aforementioned reports 
of under-dosing,32,275,288 it has been documented that treatment with liquid formulations requires 
further dose adjustment, due to reduced bioavailability.40,162,239 To date there have been two 
investigations suggesting genotype based dose optimisation in children, and neither of them 
accounted for the effect of SNP 983TC. 
In order to prevent sub-optimal exposures in children with CYP2B6 516GG genotype ter Heine and co 
workers40 suggested dose increases in that group - for patients >25kg carrying two variant alleles 
efavirenz dose should be matched with adults (600mg), 20-25kg should receive 500mg, 15-20kg – 
450mg, and 13-15kg – 400mg (current guidelines advise 400mg,  300mg, 300mg and 200mg, 
respectively). This algorithm was never evaluated in real life. 
The results of the population pharmacokinetic/pharmacogenetic analysis by Salem et al.162 and the 
preliminary results of genotype guided dose decreases in the 1st cohort of patients in study P1070289 
stimulated development of the new guidelines for children <3 years by the Panel on Antiretroviral 
Therapy and Medical Management of HIV-Infected Children at the United States Department of Health 
and Human Services (DHHS), which account for the individual metabolic status.134 Unlike in other 
investigations (Table 2.3), children were classified as extensive metabolisers (EM), if they had either 
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516GG or 516GT genotype, or as poor metabolisers (PM), if they had two 516TT variant alleles (Table 
2.8). Additionally, the developed dosing algorithm accounted for age driven differences in efavirenz 
clearance detected by Salem et al.162 leading to dose increases in EM. The proposed guidelines are 
currently tested in study P1070290 and should give answers to feasibility and efficacy of genotype 
based dose adjustment strategies in children. Their application is nevertheless limited – firstly they 
should not be extrapolated to children > 3 years of age, secondly, not only they don’t account for 
differences in clearance rates between individuals carrying two version of common allele for 516G>T 
and individuals carrying one variant allele, but also don’t take into consideration the effect of SNP 
983T>C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Table 2.8 Proposed American efavirenz treatment guidelines for children <3 years accounting for CYP2B6 516G>T genotype 
P1070* 
Modified FDA/EMA  
guidelines** 
Weight band EM PM Weight band No genotype 
3 - 5 200 mg 50 mg 3.5 - 5 100 mg 
5 - 7 300 mg 50 mg 5 - 7.5 150 mg 
7 - 14 400 mg 100 mg 7.5 - 15 200 mg 
14 - 17 500 mg 150 mg 15 - 20 250 mg 
>17 600 mg 150 mg 20 - 25 300 mg 
 
25 - 32.5 350 mg 
32.5 - 40 400 mg 
> 40 600 mg 
*genotype guided dosage currently tested in the study P1070.290  **The Sustiva product label was recently 
extended in USA268 and Europe. EM – extensive metaboliser = 516GG or 516GT, PM poor metaboliser = 516TT 
 
On the contrary, the recently published population pharmacokinetic analysis that supported efavirenz 
label extension to children < 3 years (Table 2.8) presented conflicting results. The model by Luo et 
al.291 showed that individuals with CYP2B6 516GT genotype had 24% reduced clearance and 516TT 
had 61% lower clearance rate, nonetheless the authors concluded that due to large variability 
between genotypic groups the CYP2B6 genetic status was not predictive of exposure and was not 
informative in guiding paediatric dosing. The conclusions drawn by authors are discussed in Chapter 
8.4. 
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2.3.2 Nevirapine 
2.3.2.1 Pharmacokinetics 
According to manufacturer’s information after repeated administration of twice daily 200mg dose in 
adults nevirapine has a steady state Cmax = 5.74 mg/L (5.00 – 7.44), which is reached 4 hours after 
administration, Cmin = 3.73 mg/L (3.20 – 5.08), and AUC = 108 mg·h/L (96.0 – 143.5).292 Nevirapine 
concentrations increase linearly with dose in the licensed range of 200 - 400 mg. Oral bioavailability is 
approximately 90% and is comparable for solid and liquid formulations.293  Manufacturer advises that 
food does not affect nevirapine pharmacokinetics, nonetheless one study reported increased 
bioavailability when the drug was ingested with food, and another that food increased its absorption 
time.294  Nevirapine is lipophilic (it is essentially non-ionized at physiologic pH), in plasma it is 
approximately 60% protein bound, it crosses the placenta, the blood-brain barrier (concentration in 
cerebrospinal fluid is approx. 55% lower than in plasma) and is found in breast milk.292 Population 
pharmacokinetic analyses (Tables 2.16 to 2.18 in Appendix to Chapter 2) show that nevirapine has a 
1-compartmental distribution, with volume of distribution ranging between 84.5 L and 153 L66,72,73,294–
297 for average weight of 70kg (although an investigation by Chou et al.298 reported 223 L for average 
weight of 55kg). Nevirapine ka has been estimated to range between 1.25 h-1 and 1.67 h-1 66,73,294,296–
298 (with exception of Dickinson et al.72 – 0.578 h-1), and oral clearance between 2.95 L/h and 3.49 
L/h66,72,294–298 (both processes were described using 1st order kinetics). Similar to efavirenz delays in 
nevirapine absorption were described through transit compartments.294 
 
Figure 2.6 Suggested metabolic pathways for nevirapine with corresponding cytochrome P450 catabolic enzymes and main 
metabolites (from Fan-Havard et al.65)G 
                                                          
G Reprinted from the AAC, 57, 2154–2160, Fan-Havard, P. et al., Pharmacokinetics of phase I nevirapine 
metabolites following a single dose and at steady state. Page No. 2155, Copyright (2013) with permission from 
American Society for Microbiology. 
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Biotransformation of nevirapine is mediated though cytochrome P450 (CYP450) system and includes 
first step hydroxylation catabolised though an number of pathways including primarily CYP3A4, 
CYP2B6, CYP2D6, followed by UGT catabolised glucuronidation (Figure 2.6).65,292,299 Similar to 
efavirenz, nevirapine clearance rate increases after repeated dosing (by 23% - 39%66,300) leading to 
significant reduction of its half-life (from 45h to 25-30h).292 Recent investigation identified different 
contribution of metabolic pathways after single dose and at steady state.65 The main metabolite 
identified after administration of a single nevirapine dose is 12-OH-NVP with the corresponding 
metabolic pathway being CYP3A4.301 The metabolic index (ratio of the metabolite AUC to the 
nevirapine AUC) for 12-OH-NVP after repeated dosing remains unchanged, but decreasing 2-OH-NVP 
concentrations suggest nevirapine marginally inactivates CYP3A enzymes (Figure 2.6).65 On the 
contrary, repeated dosing causes substantial induction of CYP2B6 pathway (and increased 
concentrations of the corresponding metabolite - 3-OH-NVP). CYP2B6 activation is the main 
mechanism for the observed auto-induction in nevirapine clearance.65 In addition, nevirapine has 
been shown to significantly induce the P-gp expression.216  
Low apparent nevirapine clearance suggests that biotransformation occurs mainly in the liver and that 
the intestinal first-pass effect is negligible.65 Nevirapine is excreted primarily in form of glucuronide 
conjugates of hydroxylated metabolites in the urine.292 Study in rats showed that nevirapine 
undergoes enterohepatic recycling,302 and although a second peak was seen in some of the early 
studies in adults,91,295 it is an effect not observed in all of the patients.50 Despite a long half-life allowing 
for a once daily dosage nevirapine in adults is administered twice a day (200 mg) due to concerns 
about high peak and low trough concentrations observed under once daily administration (Chapters 
2.3.2.5 - 2.3.2.7).303 
2.3.2.2 Pharmacogenetics 
2.3.2.2.1 CYP2B6 
Similarly to efavirenz nevirapine PK exhibits high levels of between subject variability, which has been 
similarly associated with highly polymorphic CYP2B6 metabolic pathway.43,186,278,304 Due to a higher 
contribution of CYP3A to biotransformation of nevirapine (Figure 2.6) the effect of CYP2B6 
polymorphisms on its pharmacokinetics is not as strong as observed for efavirenz.186,278 Rotger et al.186 
showed that the mean plasma efavirenz AUC for individuals with 516GG genotype were 3-fold higher 
than in individuals homozygous for common allele, whereas the difference was 1.7-fold for nevirapine. 
Similar association were replicated in a small cohort of 23 Ugandan patients, where the mean ratio of 
trough concentrations for 516TT vs. 516GG individuals was 1.51.304 Population pharmacokinetic 
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studies estimated that the average steady state clearance of nevirapine is reduced by 9-19.4%, if one 
variant allele is present, and 23-37% for two variant alleles.72,73,298,300,305   
In addition to SNP 516G>T nevirapine pharmacokinetics is further modified by the effect of 983T>C. 
This association was first detected by Wayne et al.198 in patients from the German Competence 
Network for HIV/AIDS. Noteworthy, the effect of SNP 983T>C on nevirapine clearance is more 
prominent than previously detected for efavirenz. A population pharmacokinetic investigation by 
Schipani et al.73 showed that in the presence of one variant allele for 516G>T nevirapine clearance is 
reduced by 14%, 37% for two variant alleles, whereas in individuals wild type homozygous for 516G>T 
but with one variant allele for 983T>C the observed reduction was 40%. This associating was replicated 
in a large Malawian study where the apparent  nevirapine clearance was reduced by 23% in patients 
with CYP2B6 983TT|516TT, and by 36% 983TC|516GG or GT, compared to the reference 
983TT|516GG.72 These associations were recently also replicated in study in Zimbabwean patients.306 
A large pharmacogenetic investigation by Haas et al.64 evaluating associations between single dose 
nevirapine PK and 51 different CYP2B6, ABCB1, CYP3A4, and CYP3A5 polymorphisms did not show any 
significant effect of combined 516G>T|983T>C genotype. This surprising lack of effect could be linked 
to the aforementioned differences in the contribution of CYP2B6 pathway to its total clearance under 
single- and multiple-dose conditions.65 This also is the only study that evaluated the composite effect 
of those SNPs in terms of a metabolic subgroups (proposed as “extensive metabolizer” [EM] denoted 
no variant allele at either position 516 or 983; “intermediate metabolizer” [IM], a single variant allele 
at either position 516 or 983, but not both; “slow metabolizer” [SM], 2 variant alleles [i.e., either 
516TT, 983 CC, or 516 GT with 983 TC]).64 
2.3.2.2.2 CYP3A4/5 
CYP3A is known to be less polymorphic than CYP2B6, but it has been shown to be affected by SNP 
CYP3A5 6986 G>A.307 The CYP3A5*3 allele (G at position 6986) creates a cryptic splice site, linked to 
aberrant mRNA with a premature stop codon. Individuals with at least one A allele (CYP3A5*1) 
produce high levels of full-length CYP3A5 mRNA and express an active CYP3A5 enzyme, while those 
carrying the CYP3A5 6986GG (CYP3A5*3) genotype have very low (or even undetectable) hepatic 
CYP3A5 protein content.308 Due to substantial contribution of CYP3A5 pathways to nevirapine 
biotransformation it has been speculated that its PK could be affected by SNP CYP3A5 6986 G>A, which 
has been shown to alter clearance of other CYP3A5 substrates.87,88 The frequency of CYP3A5 6986G 
allele differs between populations and has been reported to range from 0.87 – 0.94 in Caucasians,69,309 
0.65 in Cambodians,298 0.74 – 0.78 in Asians,309 and 0.36 in black Africans.69 Despite having been tested 
in a number of pharmacogenetic nevirapine investigations this association was reported to be 
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significant only in one study in Malawian patients  (CYP3A5*3 decreased navirapine AUC by 31%310). 
All other studies revealed no association.72,300,304,311,312 Some focus has been contributed to SNP 
CYP3A4*1B (329A>G) but this association has similarly not been confirmed in any of the 
studies.300,304,310–312 Moreover, reports in other CYP3A4/5 substrates revealed haplotype CYP3A4*22 
as a promising new target.85,307,308 
In addition, nevirapine clearance has been reported to be affected by SNP CYP2C19 8402G>A (26.8% 
reduction reported in re-analysed data from 2NN study),300 however significance of this association 
has not been replicated and nevirapine is not known to by metabolised by CYP2C19 pathway. A recent 
analysis in a Cambodian cohort did not confirm this finding but revealed two two novel SNPs in CYP2B6 
(rs7251950 and rs2279343) which were highly correlated with nevirapine concentrations.311 312 
2.3.2.2.3 Nuclear receptors 
The information on the effect of polymorphisms in genes coding nuclear receptors for nevirapine is 
scarce, but a study by Faucette et al.313 showed that nevirapine was a CAR inducer which was 
hypothesised to be linked with the auto-induction of its clearance.314 To date two studies explored the 
associations between polymorphisms in NR1|2 and NR1|3 but both did not find any significant 
associations.310,311  
2.3.2.2.4 Transporters  
The effect of polymorphisms in genes coding membrane transporters for nevirapine remains unclear 
and controversial. Störmer et al.216 in an in vivo experiment showed that neither efavirenz, nor 
nevirapine were substrates for P-gp, but nevirapine caused an up to 3.5-fold concentration-dependant 
induction of P-gp expression.216 The inducing effect of nevirapine on P-gp activity was confirmed in 
another study.315 An association between nevirapine intracellular concentrations and P-gp expression 
was shown in a small study by Almond et al.316 SNP ABCB1 3435C>T has been associated with the risk 
of hepatotoxicity in patients on nevirapine in a study by Ritchie et al.317 In another investigation Saitoh 
et al.278 found that recessive ABCB1 3435C>T hetero- or homo-zygosity were linked to increased ratio 
of nevirapine CNF/plasma concentrations (0.62 vs 0.43 for wild type). All other investigations did not 
find any significant association for any of the ABCB1 polymorphisms with nevirapine 
PK.278,298,304,311,312,318 
2.3.2.3 Circadian variation 
The extensive pharmacokinetic investigation by van Heeswijk et al.91 reported differences between 
morning and evening nevirapine PK parameters in a cohort of 20 adults (dosed 200 mg twice a day). 
The reported differences were of small magnitude and mostly not statistically significant, which could 
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be attributed to the small sample size in the study. Similar diurnal variability in pharmacokinetics 
(although of greater magnitude) was previously reported in another group of ARV agents, protease 
inhibitors (PIs).319–322 The differences in morning and evening trough concentrations vary depending 
on the drug and the investigation, and range between 57% and 2.5-fold, which led to suggestions of 
adjustment of dosing interval for some PIs (shortening of the day-time interval) to ensure more 
balanced exposures over the 24h cycle.321,322 The observed variation was linked to differences in 
hepatic blood flow over the 24h cycle.323  
The diurnal pattern for nevirapine pharmacokinetics was characterised in a population 
pharmacokinetic analysis by Elsherbiny et al.50 The variability was described using a step function 
related to the day-night cycle (day was defined as the time between sunrise and sunset, while night 
was the time between sunset and sunrise) included in the model on ka and CL. Nevirapine CL was 27% 
higher during the night and ka was 10-fold lower. The observed differences in absorption were 
explained though faster gastric emptying and a higher perfusion of the gastrointestinal tract in the 
mornings leading to rapid absorption by passive diffusion observed in other drugs.324 It was 
hypothesised that the rapid absorption in the morning may decrease the time of contact between 
nevirapine and the metabolizing enzymes in the gut, thus resulting in decreased first-pass metabolism 
and increased bioavailability of nevirapine, leading in consequence to the observed lower CL/F1 in the 
morning (modelled as higher clearance during the night). Despite a theoretical plausibility of this 
hypothesis it is not in line with more recent findings characterising a different pattern of circadian 
oscillation in CYP4A4 activity.325 
This effect was extensively studied in a CYP3A4 probe – midazolam. Population pharmacokinetic 
investigation by Tomalik-Scharte et al.89 characterised the observed daily oscillation in CYP3A4 activity 
using a cosine function with peak clearance values around 3pm and nadir around 3am. Van Rongen et 
al.90 presented similar findings (peak oscillation in clearance around 7pm), additionally reporting 
circadian pattern in oral bioavailability with a peak around midday and ka with a peak at 2pm. It could 
be speculated that due to a high contribution of CYP3A4/5 enzymes to nevirapine metabolism a similar 
circadian oscillation could be observed in its clearance. 
The molecular mechanism for the observed rhythmicity in CYP3A4 has been linked to the oscillation 
in the expression of CYP3A4 mRNA in human hepatic cells, which is regulated by a circadian expression 
of two transcriptional factors (D-site-binding protein and E4 promoter-binding protein 4).325 The 
expression of those factors is directly controlled by a particular gene referred to as the CLOCK gene 
(Circadian Locomotor Output Cycles Kaput) generating circadian oscillations contribution to the 
observed pattern.326  
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2.3.2.4 Other predictors of variability in the nevirapine pharmacokinetics 
In addition to the above mentioned factors the pharmacokinetics of nevirapine has been previously 
shown to be affected by a sex, race, hepatitis B co-infection, selection of laboratory markers and 
interactions with other drugs. The clearance of nevirapine was reported to be lower in females in 2 
studies - it was 23% lower in an investigation by Zhou et al.295 and 14% lower in 2NN study.66 Similar 
to efavirenz, the race effect on nevirapine clearance detected in some studies66,296  was related to the 
differences in the distribution of CYP2B6 polymorphisms between populations. Additionally, De Maat 
et al.296 reported that nevirapine clearance was reduced by over 50% in patients with hepatitis C co-
infection. Clearance was also lower in patients with increased ASAT levels,296 and linearly correlated 
with increasing plasma albumin levels.50 
The interaction between nevirapine and rifampicin is hypothesised to have a dual mechanism. Firstly, 
rifampicin is a potent inducer of CYP3A family in the liver and intestinal wall, secondly, it also induces 
the expression of transporter proteins such as P-gp.327 It is currently known that both of those 
pathways are linked to rifampicin-induced up-regulation of nuclear receptors.328–330 Several 
investigations showed that rifampicin co-treatment significantly reduced the nevirapine levels (up to 
55% lower) exposing patients to increased risk of sub-therapeutic concentrations,331,332 and modelling 
analyses identified this effect as changes in nevirapine clearance (37% increase during co-treatment50) 
or bioavailability (39% reduction294). It was previously suggested that during rifampicin co-treatment 
dose of nevirapine should be increased from 200mg to 300mg to prevent the risk of virological failure 
related to sub-optimal drug exposures.50  The current guidelines suggest that HIV-infected patients 
who contract TB should be switched from nevirapine based regiment to efavirenz.6  
Other important interactions include protease inhibitors, in particular ritonavir (casing increase of 
nevirapine concentrations through inhibition of CYP3A pathway),301 and zidovudine (nevirapine was 
also shown to reduce the bioavailability of zidovudine by 23% with no effect of zidovudine on 
nevirapine PK).295 
2.3.2.5 PK/PD relationship and therapeutic targets 
The current therapeutic target for nevirapine was set to 3 – 8 mg/L95,333 and similarly to other ARVs is 
defined by lowest concentration providing optimal virologic response and highest concentration not 
causing any safety signals. The associations of the concentration thresholds for nevirapine are weaker 
than for efavirenz and their application has been previously questioned234 (in particular the upper 
therapeutic target105). Furthermore, the predictive power of those targets was never previously 
evaluated in children, or in black African patients in a resource limited setting, which raised doubts 
about their universal application across populations.72  
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The results of the initial single-rising-dose study in nevirapine concluded that a daily dose of 12.5mg 
would be sufficient to inhibit replication of wild-type HIV-1 in human T-cells, but that it was well 
tolerated in doses up to 400mg.334 Results of further investigations indicated that only a dose of 400mg 
would provide a sustained virological suppression,335,336 and additionally, in order to prevent 
emergence of resistant HIV strains the drug should be administered in combination with 2 NRTIs, and 
not as a stand alone treatment.335,337,338 Paradoxally however, based on the results of those studies,  it 
was believed that a relationship between pharmacological exposure and virological effect for 
nevirapine did not exist (because the plasma concentrations necessarily for achieving positive 
treatment effect were several fold higher than the in vitro concentrations giving 90% inhibition [IC90] 
for wild type virus).339  
Table 2.9 Previously published nevirapine therapeutic targets 
Pop Ref (Year) Target Method VL 
[copies/mL] 
n 
A
d
u
lt
s 
Veldkamp et 
al.340 (2001)  
 
CTDM > 3.5 mg/L Pre-defined - median 
concentration plus 
logistic regression 
20 51 
de Vries-Sluijs 
et al.341 (2003)  
 
CTDM= 3.0 – 8 mg/L Pre-defined -
selected based on 
study by van 
Heeswijk et al.91 plus 
Cox multivariate 
models 
 
500 189 
Gonzalez de 
Requena et 
al.342 (2005)* 
 
CTDM > 4.3 mg/L Receiver operator 
curve (ROC) 
50 178 
Duong et al.343 
(2005) ** 
CTDM > 3.4 mg/L Logistic regression 
applied to cut-off by 
Veldkamp et al.340 
20 74 
*patients ART-naïve, experienced and switching from PI-based regiment; **patients switching from PI-based 
regiment.  
 
The efficacy targets for nevirapine suggested in the literature are presented in Table 2.9. The first 
target was derived in the PK/PD investigation of INCAS trial, where individuals with higher nevirapine 
concentrations had better virological outcome and shorter time to initial virological suppression.340 
Average nevirapine TDM plasma concentrations above population median at multiple time points 
(3.45 mg/L at week 12, 3.69mg/L at week 24, 3.84 mg/L at week 36 and 3.79 mg/L at week 52) were 
predictive of virological suppression at week 52 and Veldkamp et al. suggested a cut-off of 3.5 mg/L 
as a potential efficacy threshold. De Vries-Sluijs et al.341 verified the association between the high 
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nevirapine exposures and the virological suppression and proposed a new cut-off of 3 mg/L. The 
authors detected that the risk of virological failure was further increased by younger age, Black race, 
high initial HIV-RNA levels and a low CD4+ cell count and the calendar year of ART start (all significant 
at p<0.1). Those association were not confirmed in the 2NN study by Van Leth et al.,234 where the 
analysis was limited to treatment adherent patients only (>95% adherence) and no significant 
predictors of virological outcome could be found, or in fact any concentration-response relationship 
for nevirapine. 
The presented studies were conducted in patients with no prior exposure to ART at the time of 
enrolment. A study by Gonzalez de Requena et al.342 included a mixture of ART-naïve and experienced 
individuals and found a threshold of 4.3 mg/L as most predictive of virological failure. The risk was 
significantly higher in ARV-experienced patients (in particular ones with detectable VL at baseline). 
Lastly, the 3.4 mg/L (suggested by Veldkamp et al.340) was validated by Duong et al.343 on data in ART-
experienced patients switching to nevirapine from a PI-based regimen. In that study patients who 
retained virological suppression had significantly higher nevirapine concentrations than ones who 
experienced virological failure (4.6 mg/L vs. 2.6 mg/L, respectively). 
2.3.2.6 Safety 
Treatment with nevirapine has been associated with development of hypersensitivity reactions and 
hepatotoxicity with frequency of those events differing between studies and populations. An early 
open-label phase I/II study by Havlir et al.336 reported that 48% of patients developed rash shortly 
after treatment initiation. Nevirapine in this study was dosed once daily as 400mg with no 200mg lead 
in period. A safety review by Pollard et al.344 of early nevirapine studies (including 906 adult and 468 
paediatric patients) revealed that rash was the most common adverse event (16% of patients, vast 
majority developed it within the first 6 week since treatment start) and suggested dose escalation as 
a preventative measure. Effectiveness of this approach was confirmed in a study by de Barreiro et 
al.,345 where incidence of rash under standard treatment approach (no dose escalation) was halved 
after implementation of alternative approaches (from 18.7% to 11.2% on dose escalation and 7.7% on 
dose escalation plus oral during the first 2 weeks of treatment). In contrast, a 2-fold higher incidence 
of rash was associated by de Maat et al.346 with nevirapine plasma concentrations > 5.3 mg/L. 
Contradictory findings were presented in the analysis of 2NN study by Kappelhoff et al.105 who 
reported no significant association between nevirapine concentrations and adverse events, although 
the incidence was higher in females, patients with a higher CD4 cell count at baseline, patients from 
Thailand and ones with hepatitis co-infection. No association between nevirapine exposures and 
hypersensitivity was similarly found by Dickinson et al.72 in Malawian patients. A review by Cooper et 
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al.303 showed that despite those contradictory reports the incidence of rash was higher among 
individuals dosed with nevirapine 400mg once a day and to prevent the excess toxicities its daily dose 
is currently split (2 x 200mg). Recent studies showed that the mechanism for the nevirapine induced 
hypersensitivity reactions is idiosyncratic and immune-mediated347 and was associated with the 12-
OH metabolite.348 Most recent investigations indicate that higher susceptibility to developing 
nevirapine related hypersensitivity has a genetic background.349,350 
The safety review by Pollard et al.344 showed additionally that 1% of patients in nevirapine trials 
developed hepatitis. Gonzalez de Raquena et al.351 reported that high nevirapine concentrations (> 
6mg/L) and hepatitis C co-infection were risk factors for developing of liver toxicity. Another study by 
the same group indicated that nevirapine concentrations were associated with transaminase 
elevations in both HEP-C+ and HEP-C- patients.352 In addition, Sanne et al.353 identified body-mass 
index (BMI) <18.5, female sex, serum albumin level <35 g/L, mean corpuscular volume >85 fL, plasma 
HIV-1 RNA load <20,000 copies/mL, aspartate aminotransferase level <75 IU/L, and lactate 
dehydrogenase level <164 IU/L as independent risk factors for development of severe hepatotoxicity 
in patients treated with nevirapine, but did not evaluate the association with actual drug 
concentrations. The authors concluded that the use of nevirapine in female patients with a low BMI 
should be discouraged. No association between nevirapine and hepatotoxic events was found in a 
number of other studies,104,105,354–358 including a large meta-analysis by Stern et al.355 (based 8711 
patients). However, it has been hypothesised that development of skin rash after start of nevirapine 
treatment might frequently prevent developing hepatotoxicity,354 as it often triggers ART switch. The 
mechanism for the nevirapine induced hepatotoxicity is speculated to similar to hypersensitivity. It’s 
similarly idosynchractic and related to formation of quinone methide by sulfation of 12-OH metabolite 
followed by loss of sulphate by P450 in the liver; increased susceptibility to hepatotoxicity was also 
associated with certain genetic polymorphisms.106,299,317,347–349,359,360  
Of note is that the side effects associated with nevirapine treatment are reported to be less common 
in resource limited setting.72,361 
2.3.2.7 Optimisation of nevirapine dosage 
The treatment optimisation strategies for nevirapine are limited in comparison to efavirenz. Despite 
comparable pharmacokinetics and treatment efficacy under daily and twice daily dosing regiments, 
the aforementioned review by Cooper et al.303 showed that once a day dosing with 400 mg was 
associated with a less favourable safety profile, leading to the current twice a day dosing schedule for 
nevirapine. Of concern are also reports of sub-therapeutic concentrations during rifampicin-based TB 
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treatment,331,332 and it is recommended that in that period nevirapine is either substituted by a 
different drug, or its dose is increased. 50 
No previous investigation suggested genotype-guided dose optimisation strategy for nevirapine. 
2.3.2.8 Paediatric investigations  
To date there are few investigations describing the PK of nevirapine in children and no prior paediatric 
investigation explored the association between the systemic exposure to nevirapine and the 
virological outcome or side effects. The vast majority of paediatric investigations focus on treatment 
efficacy and/or safety and tolerability, primarily in comparison with efavirenz (Tables 2.6 and 2.7). The 
overview of the paediatric studies in nevirapine is presented below (paediatric population 
pharmacokinetic analyses are additionally summarised in Table 2.16 in Appendix to Chapter 2). 
2.3.2.8.1 Early studies 
Initial information on nevirapine pharmacokinetics, efficacy and safety in children was generated in 
trails ACTG 241 and 245.362–364 The early studies were conducted before introduction of triple therapy, 
when only limited options were available for treatment of HIV in children (zidovudine, didanosine and 
lamivudine). Those studies showed that nevirapine mono- and bi-therapy (in combination with 
zidovudine), despite providing initial reduction in viral load, did not ensure lasting virological 
suppression, which led to resistant viral strains and loss of antiviral activity.362 Much better virological 
outcome and durable suppression was obtained through treatment in triple combination with 
zidovudine and didanosine.363 Following reports in adults, treatment in children was initiated with 
dose escalation, and following reports of higher clearance rates in young children, the dose in 
individuals ≤8 years was higher than in older children.362 The ACTG studies utilised a mg/body surface 
area (BSA) dosage algorithm (120 mg/m2 lead-in phase followed by 200 mg/m2 every 12h in children 
≤8 years and 120 mg/m2 every 12h in children >8 years thereafter).362 A simplified mg/kg dosing was 
suggested by the FDA: 4 mg/kg once daily for 2 weeks in all children followed by 7 mg/kg twice daily 
thereafter in children 3 months to 8 years and 4 mg/kg twice daily in children ≥8 years.365  
The early paediatric pharmacokinetic studies, while limited to small numbers of patients, reported 
that the paediatric mg/m2 (or kg) dosage provided nevirapine exposures similar to observed in adults 
(after administration of 200 mg twice a day).365 Unlike efavirenz, the liquid formulations of nevirapine 
had similar bioavailability to its solid ones and did not require a dose adjustment.365 In addition 
nevirapine was the recommended drug used in prevention of HIV mother to child transmission.365 
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2.3.2.8.2 Paediatric underdosing 
Prior to availability of the paediatric nevirapine solid formulations, in order to reduce the cost of ART, 
increase its convenience, feasibility and coverage a number of national formularies in resource-limited 
countries introduced the option of treating children with adult FDC tablets. The first paediatric PK 
study evaluating nevirapine concentrations obtained under administration of divided adult FDC 
tablets reported adequate drug exposures in 34 Thai children.366 Based on the satisfactory virological 
response in this study it was concluded it was an acceptable treatment option while waiting for the 
development of paediatric solid forumations.366 However, similar studies in Malawian and Zambian 
children found that even though the exposures were adequate in older children, a high proportion of 
youngest children (treated with a quarter of the adult tablet) had sub-therapeutic 
concentrations.77,367–370 Those studies postulated increase of the mg/m2 dosage in the 
youngest/lightest children. 
Anticipating the development of the paediatric all-in-one FDC tablet containing nevirapine WHO 
suggested in 200656 a new simplified weight band dosage recommendations adjusted for more 
aggressive dosing in the younger age groups (Table 2.10). Alternative, recommendations were 
proposed in a number of national formularies.305,366,370,371 
Table 2.10 Nevirapine paediatric dosage recommendations 
Weight band 
WHO 
200656/201011 
3 – 5.9 kg 50 
6 – 9.9 kg 75 
10 - 13.9 kg 100 
14 - 19.9 kg 125 
20 - 24.9 kg 150 
25 - 40 kg 200 
Note: Dosage presented in mg under twice a day administration following a 2 week once a day lead-in phase. 
Children in each weight band anticipated to have a target dose of 160 – 200 mg/m2. 
 
The first study evaluating nevirapine exposures under the new paediatric nevirapine FDC (Triomune 
Baby/Junior) and WHO 2006 weight-bands was CHAPAS-1. The PK investigation in 65 Zambian children 
showed that even though the overall observed drug exposures were higher than in adults and above 
therapeutic target of 3mg/L in majority of patients, the concentrations were much more variable and 
sub-optimal in 6% of paticipants.33 The proportion of individuals with low nevirapine concentrations 
did not differ between the higher weight bands, but was noticibly higher in children weighing < 6kg 
(5% vs 27%, respectively). A subsequent analysis by Filekes et al.37 (after recruiting additional patients 
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≤ 6kg) showed that the nevirapine concentrations were on average 20% lower in that weight band 
(with a significantly higher proportion of sub-therapeutic exposures) compared to children weighing 
≥6kg. Similar results were found in a small Indian study, where a substantial proportion of participants 
(35%) had subtherapeutic nevirapine trough levels (<3 mg/L), and this was more pronounced in young 
and stunted children.372 Filekes et al.37 concluded that the new WHO simplified weight-band dosing 
provides on average adequate exposures and the subtherapeutic nevirapine concentrations observed 
in the youngest children can be attributed to the high intra-individual variability. The given fast growth 
rates after starting ART (such that most infants spend only a short time in the lowest weight band) 
limiting the exposure to low nevirapine concentrations observed in some patients the dose in the 
lowest weight band should not be further increased.  
Similar investigations were conducted with an alternative FDC formulation developed and used in 
Thailand (GPO-VIR S7),371,373 and showed that the new paediatric tablets dosed according to 
alternative Thai weight-band dosing provided adequate exposures in children. In order to account for 
the differences in dosing schedules and formulations used in different trials a pooled population 
pharmacokinetic analysis including majority of previous nevirapine PK studies was conducted (PACTG 
studies: 245, 356, 366, 377, 403, 1056, and 1069 and CHAPAS-1 - total of 639 children).305 Its main 
objective was to assess WHO simplified weight-band dosing recommendations and showed that it 
provided adequate drug exposures. In contrast, a much smaller analysis (95 children) by Foissac et 
al.374 reported that while patients weighing more than 10 kg had less than 6% probability of nevirapine 
concentrations <3 mg/L, the probabilities were 19% and 11% in the 3–6 and 6–10 kg weight ranges, 
respectively. Authors suggested the doses for the 3–6 and 6–10 kg weight ranges should be increased 
to 75 and 100 mg twice daily, respectively. 
2.3.2.8.3 Paediatric pharmacokinetics of nevirapine 
Similar to efavirenz the increased clearance levels observed in nevirapine studies in younger children 
could be explained through the theory of allometry (Chapter 2.3.1.7.3).224,225 Figure 2.7 presents the 
differences in relative clearance compared to when it’s scaled linearly and in an allometric manner. It 
shows that actual clearance values in younger children (modelled best using an allometric power or a 
BSA model) exceed the values predicted through linear extrapolation. The clearance values reported 
in paediatric studies range between 3.93 and 5.67 L/h278,305,366,374 in contrast to 2.95 - 3.49 L/h66,72,294–
298 reported in adults. This explains why children ≤8 years require a higher mg/kg dose than older 
children and adults to ensure comparable nevirapine exposures. 
 
 56 
 
CHAPTER 2: Background and Literature Review 
 
                                          Doctoral Thesis by A.M. Bienczak, March 2017 
 
Figure 2.7 Comparison of models describing changes in relative clearance over the rage of human weight (from Anderson et 
al.225)H 
Note: A 70-kg person has a normalized clearance of 1 for each model. 
Additional changes in clearance values observed in very young children can be attributed to the 
maturation of metabolic pathways. Nikanjam et al.305 described maturation of nevirapine clearance in 
children using an inverse exponential function with an intercept (the clearance at birth was 39% of 
“mature” clearance, the “half-life” of the maturation process was 3.2 months and 100% was reached 
by the age of 4 years). Foissac et al.374 contributed those changes to age-driven differences in oral 
bioavailability expressed through an Emax model with 50% of F1 (PMA50) reached by about 6 months 
of life and 90% of “full bioavailability” by 4 years.  
Similarly to efavirenz and presented adult nevirapine investigations, the variability in nevirapine PK in 
children has been primarily attributed to differences in clearance rates determined by patient’s 
CYP2B6 genotype. Nevirapine PK in children has been previously reported to be further affected by 
nutritional status (stunting and wasting) and effect of different formulations. 
The effect of malnutrition was first reported in a study in Malawian children by Ellis et al.77 who 
associated lower nevirapine exposures with stunting (lower height-for-age score) and lack of wasting 
(here higher BMI-for-age scores). The authors hypothesised that malnourished children have a weight 
lower than normal with values otherwise corresponding to higher clearance (higher clearance in 
younger/lighter children). Those associations were not replicated in another study in a similar 
population by Pollock et al.368 On the contrary, Swaminathan et al.372 reported that in stunted Indian 
children nevirapine 2h concentrations were significantly lower compared with non-stunted children, 
                                                          
H Reprinted from the Annu. Rev. Pharmacol. Toxicol., 48, 303–32, Anderson, B. J. et al., Mechanism-based 
concepts of size and maturity in pharmacokinetics. Page No. 310, Copyright (2008) with permission from 
Annual Reviews. 
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but there were no significant differences in trough concentrations between different nutritional 
groups. Furthermore, neither WAZ nor HAZ was significant in a multivariate regression after 
accounting for other factors. 
The pooled analysis by Nikanjam et al.305 reported lower bioavailability for Trioumune formulations (- 
42%) but the authors concluded that this effect was completely confounded by the population, as this 
was the only African study included in this analysis, and the detected effect could also be related to 
race, study design, diet, or other factors. Kashuba et al.369 in a cross-over study in Malawian children 
reported that use of FDC tablets lead to significantly lower nevirapine exposures than liquid 
formulations and Vanprapar et al.371 in a similar study in Thai children the opposite effect (higher 
exposures after administration of FDCs). In both studies this effect was small and not clinically 
relevant.  
2.3.2.7.4 Pharmacogenetics of nevirapine in children 
The information on pharmacogenetics of nevirapine in children is limited. The association between 
CYP2B6 516G>T polymorphism and nevirapine PK in children was first described by Saitoh et al.,278 
who reported that the clearance was reduced by 9% in the presence of one recessive allele and 31.5% 
if both alleles were affected. In addition, SNP ABCB1 3435C>T while not associated with nevirapine 
plasma concentrations, was predictive of concentrations in CSF. Similar associations for SNP 516G>T 
were replicated in a small Thai study,373 where children with 516GT genotype had 11% higher and 
516TT genotype 59% higher AUCs than wild type.  
Indian children with 516TT genotype had significantly higher nevirapine exposures than 516GT or 
516GG in a study by Swaminathan et al.372 and the authors hypothesises that 516GT or 516GG 
genotype could increase the risk of developing sub-therapeutic exposures in younger and stunted 
children. Nikanjam et al.305 reported that the clearance in poor metabolisers (516TT genotype) was 
36% lower than in all other patients (combined 516GT, 516GG and missing genotype), which was 
comparable to a 47% reduction reported by Brown et al.310 in a group of Malawian adults and children. 
The latter investigation also reported that the AUC was decreased by 31% in CYP3A5*3 carriers. The 
effect of SNP 983T>C was never previously investigated in nevirapine in children. 
2.3.2.7.5 Paediatric PK/PD relationship and therapeutic targets 
Based on the conducted literature review the therapeutic target for nevirapine was never previously 
evaluated in children. Moreover, no previous paediatric investigation described the concentration – 
response relationship for nevirapine (although Filekes et al.37 reported no association between viral 
load values and nevirapine PK parameters in their study). The predictors of virological outcome in 
children on nevirapine were studied only in comparative investigations alongside other treatments, 
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mainly efavirenz-based ART but also PIs (Tables 2.6 and 2.7). An investigation in Thai children by 
Lapphra et al.375 and Cambodian children by Janssens et al.279  showed similar efficacy of nevirapine 
and efavirez based treatment in a clinical setting, but all other studies reported that nevirapine was 
inferior to other regiments.145,149–151,153,154,280,281 In addition, replicating general findings from studies 
in other drugs, Kamaya et al.150 reported that Ugandan children were almost twice as likely to have 
virological failure compared with adults on efavirenz or nevirapine based ART (26% vs. 14%; p< 0.01). 
The predictors of virological failure in children on nevirapine (and efavirenz) based ART are presented 
in Tables 2.6 and 2.7. The majority of the studies report that the risk of virological failure increased 
with age at treatment initiation, for non-compliant patients and for boys. Worse virological outcome 
was also associated with higher baseline viral load145,153  and lower CD4%.150,280 A pharmacogenetic 
investigation by Saitoh et al.278 showed that children with 516TT genotype had higher increases in 
CD4+ from baseline comparing to others. It could be speculated that this effect was mediated by 
increased nevirapine concentrations in consequence to impaired clearance in that group. 
Inconclusive information exists on consequence of use of nevirapine for pMTCT on its efficacy in future 
life. A study in women from Botswana, who received a single dose nevirapine (sdNVP) or placebo 
before initiation of ART reported an increased risk of virological failure in case of prior exposure.57 The 
same study followed a limited number of infants with/without sdNVP exposure reporting similar 
findings. A large observational study of 997 children in the UK found an increased risk of treatment 
failure among children with prior exposure to nevirapine for pMTCT.153 In contrast a number of 
nevirapine re-use studies showed a comparable virlologic response between children who switched 
back to nevirapine after achieving initial suppression on a PI-based regiment and ones who stayed on 
the same treatment.58,59 No effect of sdNVP exposure on the effect of nevirapine treatment was also 
shown in small Ugandan study,60 as well as recently published analysis of studies P1060145,282 and 
ARROW.61   
2.3.2.7.6 Paediatric safety 
Studies ACTG 241 and 245362–364 reported that side effects related to nevirapine treatment were less 
common than previously observed in adults. This might be due to the fact that following previous 
information from adults335,336 the paediatric patients were not started on full dose of the drug but only 
half dose for the first 2 weeks before up-titration. More favourable safety profile in children was 
confirmed in reviews of the early nevirapine studies conducted by Pollard et al.344 and Bardsley-Elltiot 
et al.365 A similar safety profile for nevirapine in children as in adults, but with a lower frequency of 
adverse events, was also confirmed in a study by Lepphra et al.375 Treatment initiation with half-dose 
nevirapine was recently confirmed to be a safe tool in prevention of drug related rash in CHAPAS-1 
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study.107 Nevirpaine PK was never previously associated with incidence of safety signals in children 
and L’homme et al.33 concluded that their data suggested no effect of drug concentrations on the rate 
of adverse events. 
2.3.2.7.7 Paediatric dose optimisation 
Paediatric underdosing is of great concern for a long term success of ART, as the lack of potency in 
suppressing replication of the virus could lead to development of resistance mutations, in particular 
for drugs with a low genetic barrier to resistance such as nevirapine. In addition the data on 
relationship between systemic exposure to nevirapine and adverse events is inconclusive, indicating 
no clear relationship between concentrations and treatment safety. As a consequence a number of 
paediatric studies highlighted that the aim of optimisation of nevirapine treatment in children should 
be prevention of sub-optimal drug exposures, rather than concern about high concentrations.33,37  
The results of studies presented in Chapter 2.3.2.8.2 contributed to the increase of recommended 
standard nevirapine dose with the current daily target being 300 – 400 mg/m2 split into two parts. 
While it has been speculated that nevirapine pharmacokinetics exhibits diurnal variation, this effect 
has not been thoroughly studied. It can be assumed that due to long half-life this phenomenon is of 
limited significance in adults, but might be of more importance in children, where the dose cannot 
always be split to equal parts during the day. In addition, the studies in efavirenz show that individuals 
with a higher metabolic capacity determined by their CYP2B6 516G>T|983T>C genotype are at greater 
risk of developing subtherapeutic concentrations. The PK in youngest children is further modified by 
age-driven developmental changes and maturation. To date only two quantitative investigations 
aimed to characterise nevirapine paediatric PK but neither of them considered all of the 
aforementioned factors. Lastly, the therapeutic targets for nevirapine were never previously 
evaluated in children, preventing treatment optimisation in this population.  
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2.4 APPENDIX TO CHAPTER 2 
2.4.1 Review of published population pharmacokinetic models 
for efavirenz and nevirapine 
Table 2.11 Review of population pharmacokinetic models for efavirenz in children (part 1) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Ter Heine 
et al.40 
(2008) 
POP-PK(/PGx); NONMEM VI; 1-
comp with 2 transit comp for 
absorption and 1st order 
elimination 
CL: ↑ weighta, 
CYP2B6 516G>T (GT 
↓29.7%, TT ↓59.4%), 
auto-induction (↑21% at 
week 2) 
F1: formulation (solution 
↓45.6%) 
BSV: CL, V, MAT 
BOV: F1 
332 samples, 
intensive (1st 
dose) + sparse 
(week 2+6) 
33 
Black, 
Nonblack 
Hirt et al.32 
(2009) 
POP-PK; NONMEM VI; 1-comp 
model with 1st order absorption 
and elimination 
CL: ↑ weight (linear 
model), ↓ age, 
F1: formulation (solution 
↓45.6%) 
BSV: CL, V 
200 samples, 
sparse (all at 
day 15) + 
intensive (9 
children at 
month 2 and 5) 
48 African 
Viljoen et 
al.34 (2012) 
POP-PK(/PGx); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: ↑ weighta, ↓ age, 
CYP2B6 516G>T (GT 
↓37.2%, TT ↓66.4%), 
V: ↑ weighta, ↓ age 
BSV: CL, V 
BOV: CL 
649 samples, 
sparse, multiple 
OCC 
60 African 
Salem et 
al.162 
(2014) 
POP-PK(/PGx); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: ↑ weighta, CYP2B6 
516TT (↓51%),↑ age – 
maturation ( 90% of Emaxb 
at 9 months) 
F1: formulation + age 
(liquid form 90% of Emax-solc 
at 8 years + Emax-sol=0.79 
F1caps/tabs), formulation 
(solution ↓) 
BSV: CL, V, F1 
BOV: CL 
3172 samples, 
intensive (at 
weeks 2, 6, 10, 
56 and 112) + 
sparse 
96 
Cauc., 
Black, 
Hisp., 
Native 
Amer. 
aAllometric scaling, bSigmoid Emax model, cEmax model 
CL – clearance, V – volume of distribution, MAT – mean absorption time, F1 – bioavailability, OCC – PK sampling 
visit (relates to all samples taken within one dosing interval), Cauc. -Caucasian, Hisp. – Hispanic 
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Table 2.12 Review of population pharmacokinetic models for efavirenz in children (part 2) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Luo et al.291 
(2016) 
POP-PK(/PGx); NONMEM VI; 2-
comp model with 1st -order 
absorption and elimination 
CL: age group (↑children), 
↑ weighta, ↑ PART, 
CYP2B6 516G>T (GT↓ 
24.4%, TT↓ 61.3%)† 
Vcent: age group 
(↑children),  ↑ weighta 
ka: ↑weighta 
F1: formulation (solution 
↓ 35-75% depending on 
study) 
BSV: CL, Vcent, Q, Vper, ka 
RUV: different variance 
terms depending on 
formulation and age 
group*  
4521 samples 
(3289 in 168 
children and 
1232 in 24 
adults) – 
intensive and 
sparse, multiple 
OCC 
192 
Cauc., 
Black, 
Other 
aPower model, *age group = adults vs children, †despite significance not included in the final model 
CL – clearance, PART – prior exposure to antiretroviral therapy in study PACTG1021, Vcent – volume of central 
compartment, ka – absorption rate constant, F1 – bioavailability, OCC – PK sampling visit (relates to all samples 
taken within one dosing interval), Cauc. -Caucasian, Q – intercompartmental clearance, Vper volume of peripheral 
compartment, RUV – residual unexplained variability  
  
 62 
                                           Doctoral Thesis by A.M. Bienczak, March 2017 
APPENDIX to CHAPTER 2 
 Table 2.13 Review of population pharmacokinetic models for efavirenz in adults (part 1) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Villani et 
al.163 (1999) 
POP-PK; P-Pharm; 2-comp open 
model 
None 
115 samples, 
intensive (1 
OCC) 
22 NI 
Barrett et 
al.164 (2002) 
POP-PK; NONMEM; 2-comp 
model with 1st order absorption 
and elimination 
CL: ↑ at steady state, race 
(↓Asian +Black), sex 
(females ↓11%) 
BSV: CL, V 
meta-analysis – 
60% of 9342 
samples 
334 
Asian, 
Black, 
Cauc., 
Other 
Pfister et 
at.172 
(2003) 
POP-PK/PD;NONMEM; 1-comp 
model with 1st-order absorption 
and elimination through well-
stirred liver model (accounting 
for 1st pass metabolism) 
CLint: race (↓28% Black 
American and Hispanic) 
Fgut: adherence (↑4.3% for 
100% adherence) 
531 samples, 
intensive and 
sparse (multiple 
OCC) 
139 
Cauc, 
Black, 
Hisp, 
Asian 
Csajka et 
al.168 (2003) 
POP-PK/PD(/PG); NONEMEM V; 
1-comp model with 1st order 
absorption and elimination 
No significant and clinically 
relevant covariates 
identified* 
BSV: F1 
719 samples, 
intensive (7 
individuals) + 
sparse (multiple 
OCC) 
235 
Cauc, Afr- 
Am, Hisp, 
Asian 
Haas et 
al.69 (2004) 
POP-PK/PD(/PG); NMLE 3.2; 1-
comp model with 1st order 
absorption and elimination 
CL: CYP2B6 516G>T (GT 
↓23%, TT ↓54%), CYP3A5 
6986 A>G (AG ↑10%, GG 
↑27%) 
 
sparse at 
weeks: 1, 4, 12, 
24 
157 
Cauc, Afr- 
Am, Hisp, 
Other 
Haas et 
al.185 (2005) 
POP-PK/PD(/PG); NMLE 3.2; 1-
comp model with 1st order 
absorption and elimination 
None evaluated – explored 
the effect of covariates on 
model estimated AUC 
(affected by 
CYP2B6 516G>T) 
sparse at 
weeks: 4 and 32 
340 
Cauc, 
Black, 
Hisp 
Kappelhoff 
et al.165 
(2005) 
POP-PK; NONEMEM V; 2-comp 
model with 3 transit comp for 
absortption, 1st order 
absorption into central comp 
and elimination 
F1: race (↑56% for Asian, 
↓10% for missing), 
baseline total bilirubin 
(↑57% if > 1.5-fold ULN) 
BSV: CL, Vcent, ktr, Q 
BOV: F1 
1009 samples, 
intensive (40 
individuals – 
694 samples) + 
sparse (315 
samples) 
172 
Cauc, 
Black, 
Latino, 
Asian 
Kappelhoff, 
van Leth et 
al.66 (2005) 
POP-PK; NONMEM, 1-comp 
model with 1st-order absorption 
and elimination 
CL: steady state (↑10%), 
geographic location 
(Western countries ↑76%, 
South America + South 
Africa ↑53), nevirapine 
(↑43%) 
BSV: CL, V (both 
correlated) 
1694 samples, 
intensive + 
sparse 
376 
South 
American, 
African, 
Asian, 
Cauc 
Ribaudo et 
al.376 (2006) 
POP-PK(/PG); S-PLUS; 1-comp 
model with 1st -order 
absorption and elimination 
CL: CYP2B6 516G>T (t1/2 
GG=23h, t1/2 GT=27h, t1/2 
TT=48h) 
No information 152 
Cauc, Afr- 
Am, Hisp 
*significant effect of ABCB1 (MDR1-C3435T) on CL evaluated in 33 patients only 
CL – clearance, V – volume of distribution, F1 – bioavailability, OCC – PK sampling visit (relates to all samples 
taken within one dosing interval), CLint – clearance intrinsic, Fgut – pre-hepatic bioavailability, ktr – transit rate 
constant, Q – inter-compartmental clearance, Vcent – central volume, ULN – upper limit of normal, Cauc. -
Caucasian, Afr Am - African American, Hisp. – Hispanic, NI – not indicated  
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Table 2.14 Review of population pharmacokinetic models for efavirenz in adults (part 2 - continuation) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Nyakutira et 
al.36 (2008) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st order 
absorption 
CL: CYP2B6 516G>T (GT 
↓23%, TT ↓57%) 
BSV: CL 
64 samples 
sparse only (12 
individuals 2 
OCC) 
58 African 
Arab-
Alameddine 
et al.171 
(2009) 
POP-PK(/PG); NONMEM VI; 1-
comp 
model with 1st order 
absorption and elimination 
CL: CYP2B6, CYP2A6, 
CYP3A4 rs4646437 (all 
SNPs included using 
square root models), 
weight (power 0.7) 
BSV: CL 
393 samples all 
sparse (multiple 
OCC) 
169 
Cauc, 
Afr- 
Am, 
Hisp, 
Asian 
Zhu et al.166 
(2009) 
POP-PK; NONMEM; 2 comp 
with 1st order absorption and 
elimination using a well 
stirred liver model with auto-
induction and interaction 
models 
CL: auto-induction (CL↑ 
60% at day 14, CL↑ 150% 
at day 35) and interaction 
with carbamzazepine at 
steady state (CL↑ 190%) 
920 samples, 
intensive and 
sparse 
37 No info 
Cabrera et 
al.377 (2009) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: CYP2B6 516G>T (GT 
↓50%, TT ↓75%) 
BSV: CL, V 
sparse only (2 – 
7 per patient) 
131 
Cauc, 
Black 
Mukonzo et 
al.39 (2009) 
POP-PK(/PG); NONMEM VI; 2-
comp model with zero- 
followed by  1st -order 
absorption 
CL: CYP2B6*6 (↓21%), 
CYP2B6*11 (↓20%) 
F1: ABCB1 rs3842 (↑26%) 
Vper: sex (females  ↑108%) 
BSV: CL, Vcent, Vper, Q, ka, 
F1, D1 
402 samples – 
intensive (32 
individuals), 
sparse (89 
individuals) 
121 African 
Sánchez et 
al.173 (2011) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: CYP2B6 516G>T (GT 
↓39.8%, TT ↓64.6%), 
MPR4 1497C>T (↓20.7%), 
GGT (↓CL for ↑ GGT – 
cantered linear model) 
BSV: CL, V 
869 samples 128 Cauc 
Siccardi et 
al.233 (2012) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: CYP2B6 516G>T (GT 
↓39.8%, TT ↓64.6%) 
BSV: CL, V 
202 - intensive 
(9 healthy 
volunteers) + 
sparse (148 
patients) 
157 No info 
CL – clearance, V – volume of distribution, F1 – bioavailability, OCC – PK sampling visit (relates to all samples 
taken within one dosing interval), Q – inter-compartmental clearance, GGT - gamma-glutamyltranspeptidase, 
Vper – peripheral volume, Vcent – central volume, ka – absorption rate constant, D1 – duration of zero-order 
absorption phase, Cauc. -Caucasian, Afr Am - African American, Hisp. – Hispanic, NI – not indicated 
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APPENDIX to CHAPTER 2 
 Table 2.15 Review of population pharmacokinetic models for efavirenz in adults (part 3 - continuation) 
Reference Model (type, software, PK) Covariates Data n Race 
Bertrand et 
al.170 (2013) 
POP-PK(/PG); NONMEM VI; 1-
comp model with zero-order 
delayed absorption and 1st -
order elimination 
CL: CYP2B6 516G>T – 
effect modified by TB 
treatment and NAT2 
metaboliser type, CYP2B6 
485-18T (↓ 30%), weight 
(linear centred) 
BSV: CL 
BOV: CL 
1111 samples - 
intensive (10 
individuals at 
week 50) and 
sparse (week 2, 
6, 22 and 50) 
307 Cambodian 
Mukonzo et 
al.194 (2014) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st -order 
absorption and elimination 
CL: CYP2B6*6/*1 (↓21%), 
CYP2B6*6/*6 (↓54%) 
F1: ABCB1 rs3842 (↑22%) 
BSV: CL 
556 samples 
sparse 
99 African 
Dooley et 
al.71 (2014) 
POP-PK(/PG); NONMEM VII; 1-
comp model with 1st -order 
absorption and elimination 
through well stirred liver model 
CLint: composite CYP2B6 
516GT|983TCb (IM ↓41%, 
SM ↓74%, USM ↓914%), 
pregnancy (↑19%), 
isoniazid and slow NAT2 
metaboliser type (↓21%), 
weighta 
V: weighta 
BSV: CL 
BOV: Fgut 
468 samples - 
sparse (up to 4 
per sampling 
OCC) 
87 
African 
(pregnant 
women) 
Dickinson 
et al.103 
(2015) 
POP-PK(/PG); NONMEM VII; 1-
comp model with 1st -order 
absorption and elimination 
CL: metaboliser status 
based on composite 
CYP2B6 516GT|983TC and 
CYP2A6*9B/*1, weighta 
V: weighta 
BSV: CL 
BOV: CL 
1491 samples - 
sparse + 
intensive (46 
individuals) 
606 
African, 
Asian, 
Cauc, Hisp 
Hui et al.223 
(2016) 
POP-PK(/PG); NONMEM VII; 1-
comp model with 1st -order 
absorption and elimination 
CL: CYP2B6 516G>T (GT 
↓29%, TT ↓77%), weight 
BSV: CL, V 
266 samples 
sparse + 
intensive (9 
individuals) 
163 Chinese 
aAllometric scaling, bcomposite 516GT|983TC metaboliser classification: EM (extensive metabolisers) - 
516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (slow metabolisers) - 
516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 516GG|983CC.  
CL – clearance, V – volume of distribution, F1 – bioavailability, Fgut – pre-hepatic bioavailability, OCC – PK 
sampling visit (relates to all samples taken within one dosing interval), CLint – clearance intrinsic, NAT2 – N-acetyl 
transferase type 2, Cauc. -Caucasian, Afr Am - African American, Hisp. – Hispanic, NI – not indicated 
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Table 2.16 Review of population pharmacokinetic models for nevirapine in children 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Chokephaibulkit 
et al.366 (2005) 
POP-PK; NONMEM ; 1-
comp model with 1st-order 
absorption and elimination 
No information No information 34 Thai 
Foissac et al.374 
(2012) 
POP-PK; MONOLIX 4.0; 1-
comp model with 1st-order 
absorption and elimination 
CL: ↑ weighta 
V: ↑ weighta 
F1: ↑ ageb (90% 
maturation at 4 years) 
BSV: CL 
360 samples 
sparse and 
intensive 
94 NI 
Nikanjam et 
al.305 (2012) 
POP-PK(/PG); NONMEM VI;  
1-comp model with 1st-
order absorption and 
elimination 
CL: ↑ weighta, ↑ ageb 
(39% at birth, 100% 
maturation at 4 years), 
CYP2B6 516G>T (516TT 
↓36%), ritonavir (↓ 25%) 
F1: Triomune formulation 
(↓ 42%) 
V: ↑ weighta 
BSV: CL, V (correlated) 
BOV: CL 
3759 samples 
(sparse and 
intensive) 
639 
African, 
Asian, 
Cauc, 
Hisp 
 
aAllometric scaling, bSigmoid Emax model 
CL – clearance, V – volume of distribution, F1 – bioavailability, OCC – PK sampling visit (relates to all samples 
taken within one dosing interval), Cauc. -Caucasian, Hisp. – Hispanic, NI – not indicated 
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 Table 2.17 Review of population pharmacokinetic models for nevirapine in adults (part 1) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Zhou et 
al.295 (1999) 
POP-PK; NONMEM V, 1-comp 
model with zero-order 
absorption and 1st-order 
elimination 
CL: sex (male ↑1.31) 
BSV: CL 
 
273 samples 
(sparse but 
measured at 
different time at 
each visit, 
multiple OCC) 
82 Cauc, 
Black, 
Hisp 
de Maat et 
al.296 (2002) 
POP-PK; NONMEM V, 1-comp 
model with 1st-order absorption 
and elimination 
CL: HEP-C (↓52%), 
ASAT>1.5x ULN (↓34%), 
race (black ↓27%), ↑ 
weight (0.21 L/h for 10kg) 
BSV: CL, kel 
BOV: CL, V 
1329 samples 
(intensive – 13 
patients + 757 
sparse samples, 
multiple OCC) 
173 Cauc, 
Black, 
Asian 
Kappelhoff, 
van Leth et 
al.66 (2005) 
POP-PK; NONMEM, 1-comp 
model with 1st-order absorption 
and elimination 
CL: steady state (↑39%), 
geographic location 
(Western countries ↑28%, 
South America ↑11), sex 
(females ↓13.8%), HEP-B 
(↓ 19.5%) 
BSV: CL, V (correlated) 
3024 samples 
(intensive and 
sparse, multiple 
OCC) 
701 South 
American, 
African, 
Asian, 
Cauc 
Capparelli 
et al.378 
(2008) 
POP-PK; NONMEM V, 1-comp 
model with 1st-order 
absorption and elimination 
No covariates 
BSV: CL, ka 
 
intensive 
sampling 
26 Cauc, 
Black, 
Hisp 
Moltó et 
al.297 (2008) 
POP-PK; NONMEM V, 1-comp 
model with 1st-order absorption 
and elimination 
CL: ↑ weight (linear) 
V: ↑ weight (linear) 
BSV: CL, V, ka 
319 (intensive, 
1 OCC) 
40 Cauc 
Elsherbiny 
et al.50 
(2009) 
POP-PK; NONMEM VI, 1-comp 
model with 1st-order absorption 
and elimination 
CL: rifampicin (↑37.4%), 
circadian variation (night 
↑27%), ↑ age (1.56% per 
year), ↑ albumin (2.84% 
per 1 g/L), ↑ vit B (11.8%) 
ka: rifampicin (↓6x), 
circadian variation (night 
↓10x) 
LAG: circadian variation 
(day – no LAG, night - 
0.73h) 
V: ↑ weight (1.42% per 1 
kg) 
BSV: CL, ka 
(sparse and 
intensive in 8 
patients) 
53 African 
CL – clearance, V – volume of distribution, F1 – bioavailability, HEP-C – hepatitis C, HEP-B – hepatitis B, ULN – 
upper limit of normal, ASAT - aspartate transaminase, kel – elimination rate constant, ka – absorption rate 
constant, OCC – PK sampling visit (relates to all samples taken within one dosing interval), LAG – delay in 
absorption, Cauc. -Caucasian, Hisp. – Hispanic, NI – not indicated  
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Table 2.18 Review of population pharmacokinetic models for nevirapine in adults (part 2 - continuation) 
Reference 
(year) 
Model (type, software, PK) Covariates Data n Race 
Chou et 
al.298 (2010) 
POP-PK(/PG); MONOLIX 2.4; 1-
comp model with 1st-order 
absorption and elimination 
CL: CYP2B6 516G>T 
(516GT ↓11%, 516TT 
↓37%), ↑ creatinine 
clearance (power model) 
BSV: CL 
BOV: CL 
sparse and 
intensive data 
(10 patients), 2 
OCC 
170 Cambodian 
Schipani et 
al.73 (2011) 
POP-PK(/PG); NONMEM VI;  1-
comp model with 1st-order 
absorption and elimination 
CL: CYP2B6 516G>T 
(516GT ↓14%, 516TT 
↓37%, 983TC↓40%), 
weight (5%↓ for 10kg) 
BSV: CL 
403 samples 
(sparse + 9 
patients 
intensive, 1 
OCC + 11 
patients 2 OCC) 
270 Cauc, Black 
Lehr et 
al.300 (2011) 
POP-PK(/PG); NONMEM VI; 1-
comp model with 1st-order 
absorption and elimination 
CL: CYP2B6 516G>T 
(516GT↓19.4%, 
516TT↓30.6%), CYP2C19 
(HOM ↓26.8%), race 
(Black/Asian ↓19.4%), 
BSV: CL, V (correlated) 
1260 samples 
(sparse and 
intensive) 
271 South 
Amer, 
African, 
Asian, Cauc 
Svennson 
et al.294 
(2012) 
POP-PK(/PG); NONMEM VII;  1-
comp model with absorption 
through 2 transit comp and 
elimination 
CL: weight (fat free mass)a, 
mixture model (slow + 
extensive metabolisers) 
F1: TB treatment (↓ 39%) 
V: weighta 
MTT: food (2.5h fed, 0.6h 
fasted) 
BSV: CL, F1 
BOV: F1, MTT 
1270 samples 
(sparse and 
intensive) 
115 African 
Dickson et 
al.72 (2014) 
POP-PK; NONMEM V, 1-comp 
model with 1st-order 
absorption and elimination 
CL: 
CYP2B6 516G>T|983T>C 
(516TT|983TT ↓23%, 
516GT/GG|983TC ↓36%) 
BOV: CL 
BSV: CL 
sparse and 
intensive – 40 
patients, 
multiple OCC 
180 Malawi 
aAllometric scaling 
CL – clearance, V – volume of distribution, F1 – bioavailability, HOM – homozygote, MTT – mean transit time, TB 
– tuberculosis, OCC – PK sampling visit (relates to all samples taken within one dosing interval), LAG – delay in 
absorption, Cauc. -Caucasian, Hisp. – Hispanic, NI – not indicated
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This thesis is supported by four peer reviewed publications (Chapter 4 - 7), the content of each one is 
included in its unchanged version with the abstract, introduction, methods, results and discussion 
sections in full. The methods sections in each of the publications present following information: 
Chapter 4 (Publication/study 1) presents information relevant to the data on efavirenz 
pharmacokinetics in studies CHAPAS-3 and ARROW. This includes: efavirenz dosage, formulations, PK 
sampling schedule, transport and storage of samples, details of assays used for quantification of 
efavirenz plasma concentrations, details of procedure and assays used for genotyping, details of 
population pharmacokinetic modelling used for data analysis (structural model building and 
diagnostic, covariate analysis and simulations). 
Chapter 5 (Publication/study 2) presents information relevant to the data on outcome of treatment 
with efavirenz in CHAPAS-3. This includes: study overview and viral load sampling schedule, details of 
statistical analysis (inclusion criteria for data, statistical tests used for between group comparisons, 
details of Cox proportional hazards regression modelling used for detection of associations with main 
outcome [VL > 100 copies/mL], details of likelihood profiling method developed for identification of 
drug exposure most predictive of increased risk of non-suppression, details of multivariate analysis). 
Chapter 6 (Publication/study 3) presents information relevant to the data on nevirapine 
pharmacokinetics in studies CHAPAS-3 and CHAPAS-1. This includes: nevirapine dosage, formulations, 
PK sampling schedule, transport and storage of samples, details of assays used for quantification of 
nevirapine plasma concentrations, details of procedure and assays used for genotyping, details of 
population pharmacokinetic modelling used for data analysis (structural model building and 
diagnostic, covariate analysis and simulations). 
Chapter 7 (Publication/study 4) presents information relevant to the data on outcome of treatment 
with nevirapine in CHAPAS-3. This includes: study overview and viral load sampling schedule, details 
of statistical analysis (inclusion criteria for data, statistical tests used for between group comparisons, 
details of Cox proportional hazards regression modelling used for detection of associations with main 
outcomes [VL > 100 copies/mL and >1 transaminase elevations], modifications to procedure for 
identification of drug exposure most predictive of increased risk of developing main outcomes, details 
of multivariate analysis). 
 
Non-linear mixed effects modelling was conducted with the software NONMEM VII (version 7.3), and 
facilitated using Perl Speaks NONMEM (PSN) 4.4.0.379 Data exploration, plotting, processing of model 
run results, statistical tests and Cox proportional hazards regression modelling were conducted with 
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R.380 Additionally, fractional polynomials in STATA 13 or 14 (StataCorp. 2013/2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP) were used to explored non-linearities in 
effects of continuous covariates in Cox modelling. 
 
Chapter 3 presents further details of the clinical studies included in this thesis (study design, 
objectives, population and inclusion/exclusion criteria, chronology of the studies) and elaborates on 
the statistical methods employed with justification of their choice. 
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3.1 Clinical StudiesI 
 
The main clinical study supporting this thesis is CHAPAS-3 (data previously not analysed in relation to 
nevirapine and efavirenz). In order to increase statistical power in the population pharmacokinetic 
analysis the data from CHAPAS-3 was enriched with the data from pharmacokinetic sub-studies of 
CHAPAS-1 (to describe nevirapine PK) and ARROW (to describe efavirenz PK). The studies are 
presented in chronological order.  
3.1.1 CHAPAS-1 
CHAPAS-1 (Children with HIV in Africa – Pharmacokinetics and Adherence of Simple Antiretroviral 
Regimens) was an open-label, controlled phase I/II trial randomising 212 HIV-infected African children 
to start nevirapine treatment with either dose escalation schedule of once-daily administration for 14 
days (followed by full dose twice a day) or full dose twice a day without escalation (randomisation 
ratio 1:1).33  All children were treated with new paediatric FDC tablets (Triomune Baby/Junior). The 
CHAPAS-1 trial diagram is presented in Figure 3.1  
The overall aim of the CHAPAS-1 was to evaluate the appropriate dosing of, and adherence to, the 
new formulation combining stavudine (d4T), lamivudine (3TC), and nevirapine (NVP) in a dispersible 
FDC tablet specifically developed for children (Triomune Baby/Junior). The specific objectives were to 
describe the toxicity related to nevirapine, in order to investigate the necessity of dose escalation in 
African children treated with new FDC tablets and to determine the pharmacokinetics of the new 
formulation, as well as to describe possible interactions with common concomitant medications, such 
as rifampicin. Further objectives were to describe mortality, disease progression, hospital admission 
rates and laboratory markers after initiation of ART and to estimate the budget impact and cost-
effectiveness of effective ART in HIV infected children in Zambia. 
The study was conducted at a single site in Zambia (University Teaching Hospital, Lusaka) between 
February 2006 and October 2008. All children were treated with the new paediatric FDC tablets 
Triomune Baby/Junior and dosed according to WHO 2006 recommendations.56 
The study enrolled children aged 3 months to 14 years inclusive (<30 kg in weight), previously 
untreated with ARVs and fulfilling one of the WHO 2006 criteria for treatment initiation (related to 
HIV disease stage and CD4%).56 Prior exposure to nevirapine for prevention of mother to child 
transmission (pMTCT) was an exclusion criterion. After enrolment, children were followed up for at 
                                                          
I Studies presented in chronological order. 
 72 
 
CHAPTER 3: Methods 
 
                                            Doctoral Thesis by A.M. Bienczak, March 2017 
least 48 weeks. 64 children (16 per age group, i.e. <3 years, 3-6 years, 7-10 years, 11-14 years) were 
also enrolled in a 12 hour PK sub-study with 7 blood draws at least 4 weeks after starting ART.77 An 
additional 14 children, weighing 3-6 kg were enrolled into a separate 12 hour PK sub-study involving 
only 4 blood draws on account of their size.37 The objective of the intensive PK sub-study was to 
describe nevirapine exposures in the dosing weight bands suggested in WHO 2006 guidelines.56  
The data used in this thesis was limited to the PK sub-study of CHAPAS-1, the details of the sampling 
schedule are presented in Chapter 6.  
 
Figure 3.1 CHAPAS-1 trial diagram (reproduced from the CHAPAS-1 trial protocol with permission authors’ permission). 
Pedimune = Triomune Baby/Junior (lamivudine + stavudine + nevirapine), Lamivir-S = (lamivudine + stavudine). 
 
3.1.2 ARROW 
ARROW (Antiretroviral Research for WatotoJ) was an open-label, parallel group, multicentre 
randomised controlled clinical trial in 1200 symptomatic HIV infected African infants.381 The trial had 
a complicated design with a number of randomisation stages and its main objective was primarily to 
evaluate two strategic approaches for management of ART in children: the first strategy compared 
clinically driven monitoring (CDM) with laboratory plus clinical monitoring (LCM); the second approach 
                                                          
J Watoto means "Children" in Swahili language. 
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compared a continuous first line ART three drug/two class regimen (2 nucleoside reverse transcriptase 
inhibitor [NRTIs] +1 non-nucleoside reverse transcriptase inhibitor [NNRTI]) with a four drugs/two 
classes induction (3 NRTIs +1 NNRTI) followed by maintenance with three drugs. Additionally, after at 
least 36 and 96 weeks on ART respectively, two further randomisations assessed simplification 
strategies hypothesised to improve long-term ART adherence: (i) once versus twice daily abacavir 
(ABC) + 3TC, (ii) stopping versus continuing daily co-trimoxazole prophylaxis. The ARROW trial diagram 
visualising primary (first stage) and secondary (second stage) randomisations are presented in Figures 
3.2 and 3.3 (respectively).  
The study was run at four sites in Africa: 3 in Uganda (Medical Research Council/Uganda Virus 
Research Institute, Entebbe; Joint Clinical Research Centre, Kampala; Paediatric Infectious Disease 
Clinic/Mulago, Kampala) and 1 in Zimbabwe (University of Zimbabwe-Clinical Research Centre, 
Harare) between March 2007 and March 2012. All children were dosed according to WHO 2006 
recommendations56 and where available they were treated with paediatric FDC tablets (3-in-1 or 2-in-
1). 
The study enrolled children aged 3 months to 17 years inclusive (13-17 years were capped at 10%), 
previously untreated with ARVs and fulfilling one of the WHO 2006 criteria for treatment initiation 
(related to HIV disease stage and CD4%),56 with or without prior exposure to nevirapine for pMTCT.61 
After enrolment children were followed up for 3½-5 years. 41 children from the main study (aged 3–
12 years) treated with a combination of EFV+3TC+ABC took part in the intensive PK sub-study. The 
objective of the sub-study was to describe abacavir exposures in the dosing weight bands suggested 
in WHO 2006 guidelines56 under once a day and twice a day dosing and included children limited to 2 
Ugandan sites (Kampala and Mulango). Children were sampled for abacavir on two separate occasions 
(at week 36 and 4 weeks later). The companion drugs to abacavir used in individual children were 
additionally measured in the same blood samples, this included efavirenz concentrations.  
The data used in this thesis was limited to the efavirenz concentrations from the PK sub-study of 
ARROW, the details of the sampling schedule are presented in Chapter 4.  
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Figure 3.2 ARROW trial diagram part 1 depicting the primay randomisation (reproduced from the ARROW trial protocol 
with permission authors’ permission). ART- antiretroviral treatment, AE – adverse event, NRRTI – non-nucleoside reverse 
transcriptase inhibitor, 3TC - lamivudine, ABC – abacavir, ZDV - zidovudine. 
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Figure 3.3 ARROW trial diagram part 2 depicting the secondary randomisation (reproduced from the ARROW trial protocol 
with permission authors’ permission). BD – twice daily, OD – once daily, ART – antiretroviral treatment 
 
 
3.1.3 CHAPAS-3 
CHAPAS-3 (Children with HIV in Africa – Pharmacokinetics and Adherence of Simple Antiretroviral 
Regimens) was an open-label, multicentre, randomised, controlled phase II/III trial in 478 African 
infants and children.382 The main objectives of the study were to compare the pharmacokinetics, 
toxicity, acceptability, adherence, virological efficacy and cost-effectiveness of the three first-line two 
drug ART (NNRTI + 2 NRTIs) - combinations of NVP or efavirenz (EFV) with 3TC and ABC, or d4T, or 
zidovudine (ZDV). The aim of the trial was to provide the evidence for the FDA and WHO review of 
these new formulations and endorse the WHO recommendations for simplified dosing.11 In addition 
the study aimed to describe the pharmacokinetics of efavirenz in the new paediatric dispersible 
double scored 600 mg tablets (allowing tablets to be split to 400 mg, 300 mg or 200 mg doses). The 
trial diagram is presented in Figurfe 3.4.  
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The study was run at four sites in Africa: 3 in Uganda (Joint Clinical Research Centre, Kampala; Bristol 
Myers Squibb Children’s Clinical Centre of Excellence, Baylor College of Medicine, Kampala; Joint 
Clinical Research Centre, Gulu) and 1 in Zambia (University Teaching Hospital, Lusaka) between 
November 2010 and December 2013. All children were dosed according to WHO 2010 
recommendations56 exclusively with paediatric dispersible (3-in-1 or 2-in-1) FDC tablets and/or double 
scored paediatric efavirenz tablets. 
The study enrolled children aged 3 months to 13 years inclusive (3  – 13 years for efavirenz), either 
previously untreated (ART-naïve) or treated with d4T-based regimens (NNRTI + 2 NRTIs) for at least 2 
years and virologically suppressed (viral load < 50 copies/mL) at screening. The protocol allowed 
inclusion of children with or without prior exposure to nevirapine for pMTCT (children aged 3 -12 
months included only if not exposed to pMTCT). ART-naïve children had to meet one of the WHO 2010 
criteria for treatment initiation (related to HIV disease stage and CD4%).56 After enrolment all children 
were followed up for at least 2 years. All children in the study took part in sparse PK sampling (2 PK 
samples taken about 2h apart at each visit at weeks 6, 36, and every 24 weeks thereafter until the end 
of follow up). Additional intensive PK-sampling was conducted in the first patients enrolled in each 
WHO weight-band at week 6 and in all patients who acquired tuberculosis during the study (4-10 
weeks after tuberculosis treatment initiation and again 4-10 weeks after tuberculosis treatment 
cessation). Viral loads were measured at baseline, week 48, week 96 and week 132 (or 144).  
The details of the formulations, dosage, sampling schedules and essays can be found in Chapters 4 – 
7. 
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Figure 3.4 CHAPAS-3 trial diagram (reproduced from the CHAPAS-3 trial protocol with permission authors’ permission). d4T 
- stavudine, BD – twice a day, 3TC - lamivudine, NNRTI – non-nucleoside reverse transcriptase inhibitor, ZDV - zidovudine, 
ABC - abacavir, NVP - nevirapine, EFV - efavirenz, OD –once a day. 
 
3.2 Data Analysis – choice of methods 
3.2.1 Population pharmacokinetic modelling 
Drug testing in children cannot be conducted in the same way as in adults. There are several practical 
and ethical constraints, for example the number of venipunctures per patient or amount of blood that 
can be drawn from a child. In order to overcome them, International Conference on Harmonisation 
(ICH) urged development and implementation of novel approaches to drug testing.19,383 Population 
pharmacokinetic/pharmacodynamic (POP-PK/PD) analysis is one of them. POP-PK/PD analysis is a 
model-based approach allowing the description of the relationship between drug dose, concentration, 
and response a mathematical language. The model-based approach assumes that the human body is 
a structural entity creating a system of pathways linked together, which can be expressed through 
mathematical functions. In this approach, data from all individual patients is combined and analysed 
simultaneously to obtain PK or/and PD parameter estimates characterising the whole population.  
 78 
 
CHAPTER 3: Methods 
 
                                            Doctoral Thesis by A.M. Bienczak, March 2017 
POP-PK/PD analysis is also known as nonlinear mixed-effects modelling. Nonlinear refers to the fact 
that the relationship between the model parameters and the response is generally nonlinear384, while 
mixed-effects refers to the fact that the model is constituted of both fixed and random effects. This 
technique enables not only to calculate values of population and individual pharmacokinetic 
parameters but also to identify and quantify various sources of variability in drug response: between 
subject-variability (BSV), between-occasion variability (BOV) and residual unexplained variability 
(RUV).384–386 Additionally, it allows to characterise factors (covariates) explaining those differences, 
detect what PK parameters they influence, and quantify their effect. This facilitates to estimate the 
typical concentration-time profiles for the whole population, sub-groups within the population and in 
the individual patients. It is also a more mechanistic approach based on compartmental distribution 
of the drug in the body. In addition, this method is superior to classical regression analysis by allowing 
for the aforementioned non-linearity in associations between variables.384  
A POP-PK model comprises of three building blocks. The first one is a “structural model”, which 
contains basic equations describing the “mechanism” underpinning the PK and/or PD of the drug. The 
second one is a statistical component that models the variability in drug response around population 
values, which is explained by BSV/BOV and measurement error. The third one is a covariate sub-
model, which incorporates influence of various factors, such as demographic, patho-physiological or 
genetic characteristics on the structural model. As the name “mixed effects” implies there are two 
kinds of effects incorporated in the model: fixed effects and random effects. Fixed effects are 
deterministic parameters that characterise the whole population, while random effects are stochastic 
in nature, and describe the differences between patients, occasions, or the measurement error 
affecting the observed data. Fixed effects are generally denoted with THETA (Θ) (Equations 3.2 and 
3.4). Those are population parameter values, e.g. the typical values of clearance or volume of 
distribution, as well as the covariate effects explaining the variability in drug response - known, 
observed properties that vary across population (e.g. weight, Equation 3.4). Random effects are the 
variables that describe the aforementioned different levels of variability (BSV and BOV), and are 
generally denoted ETAs (Equations 3.5 and 3.6, respectively) or EPSILON for RUV (Equation 3.2). 
Combination of all those parameters enables to describe the population trends as well as individual 
patient response (Figure 3.5).  
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Figure 3.5 Graphical illustration of the statistical model used in NONMEM for the special case of a one-compartment model 
with first order absorption. Black: serum concentration curve resulting from the average population parameters; grey: 
serum concention curves of 2 subjects with different pharmacokinetic parameters (from Vozeh et al.387)K  
Note: THETAS here presented as: 𝒌𝒂̅̅ ̅̅ , population value of absorption rate constant; 𝑪𝒍̅̅ ̅, population value of 
clearance:  𝑽𝒅̅̅ ̅̅ , population value of volume of distribution. Figure 3.5 presents only 2 levels of variability: η, 
inter-individual variability, ε – intra-individual variability (which in fact depicts residual unexplained variability). 
The true residual error should include three levels of variability: BOV, BSV and RUV. 
 
 
 
The structural (parameter) model, comprising the first building block, can be simplified though 
following mathematical function: 
𝑦 = 𝑓(𝛩, 𝑥) 
Equation 3.1 
where 𝑦 is the observation, which is a function of parameter values (𝛩) and known quantities  𝑥 (being 
time, dose, dosing schedule, etc).  
                                                          
K Reprinted from the Eur J Clin Pharmacol., 23, 445–451, Vozeh, S. et al., Population pharmacokinetic 
parameters in patients treated with oral mexiletine. Page No. 447, Copyright (1982) with permission from 
Springer Verlag. 
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As outlined above nonlinear mixed-effects modelling accounts for different level of variability and as 
a consequence the basic model is expanded as follows: 
𝑦 = 𝑓(𝛩, 𝑥) + 𝑔(𝜙, 𝑧, 𝛩, 𝑥) + 𝜀 
Equation 3.2 
where 𝑓(. ) is the structural model function, 𝑔(. ) is the variance function that relates the vector of 
known quantities 𝑥, the covariates 𝑧, the structural model parameters 𝛩, and residual variance model 
parameters 𝜙 to the variance of y, whereas 𝜀 indicates the residual error model.388 
Equation 3.2 can be broken down to particular sub-models describing relations for individual 
predictions, covariate effect and variability. Model for estimating individual PK parameters can be 
summarised as: 
𝑦𝑗 = 𝑓(𝜙𝑗 , 𝑥𝑗) • (1 + 𝜀𝑗(1)) + 𝜀𝑗(2) 
Equation 3.3 
where 𝑦𝑗 is the observed dependent variable (observation) in the j
th individual when the PK parameters 
take the value 𝜙𝑗 (i.e. individual parameter prediction) under the vector of knows relations 𝑥𝑗. The 
RUV (𝜀, EPSILON) is assumed to be normally distributed with a mean of zero and a variance of 
𝜎2 (SIGMA), ε=(N, 𝜎2).389 In Equation 3.3 RUV has a combined error structure comprising of 
proportional error (𝜀𝑗(1)) and additive error (𝜀𝑗(2)).
388 
Each PK parameter can be described using a general model for fixed effects to account for covariate 
effect: 
𝜙𝑗 = ℎ(𝛩, 𝑧𝑗) 
Equation 3.4 
where 𝜙𝑗is a PK parameter for j
th individual patient, which is a function of the true (but unknown) 
population mean value (𝛩) and a specific covariate (𝑧𝑗), which could be either categorical (e.g. sex) or 
continuous (e.g. age) – the covariate model. Equation 3.4 represents the base parameter model. 
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The model in Equation 3.3 can then be expanded in terms of the aforementioned BSV, and so deviation 
of parameters 𝜙𝑗for a particular individual from the population value can be expressed as follows: 
𝜙𝑗 = ℎ(𝛩, 𝑧𝑗) • 𝑒𝑥𝑝
𝜂𝑗   
Equation 3.5 
where 𝜂𝑗 is the BSV for the j
th individual and is assumed to be normally distributed with a mean of 
zero and a variance of 𝝎𝟐 (OMEGA), η=(N, 𝝎𝟐). BSV is usually modelled with an exponential function 
(what prevents implausible negative values of PK parameters), but depending on the character of the 
variability it can be modelled using another transformation approximating normal distribution (e.g. 
log-normal or logit). Equation 3.5 is the mathematical function describing the graphical illustration of 
model presented on Figure 3.1, where the individual pharmacokinetic parameters (𝜙𝑗) are 𝑘𝑎̅̅̅̅ , 𝐶?̅? and 
𝑉𝑑̅̅̅̅ , and BSV is 𝜂𝑗. 
In addition model parameters can change between sampling occasions, which be described in terms 
of BOV,390 and so Equation 3.5 can be further expanded as follows: 
𝜙𝑗𝑘 = ℎ(𝛩, 𝑧𝑗𝑘)  • 𝑒𝑥𝑝
𝜂𝑗+κ𝑗𝑘   
Equation 3.6 
where κ𝑗𝑘  describes the inter-occasion variability for j
th individual and kth occasion, which is similarly 
assumed to be normally distributed with a mean of zero and a variance of 𝜋2, κ=N(0, 𝜋2). The 
temporal differences between Equation 3.5 and Equation 3.6 are indicated by the k subscript and can 
be quantified in longitudinal data with repeated sampling visits (relating to different dosing intervals). 
An additional advantage of POP-PK modelling over classical analysis methods is that it enables analysis 
of sparse and unbalanced data 391 - by use of POP-PK models we can obtain full drug concentration 
curves by collecting as little as two samples per patient.392 In addition, it enables combining data from 
various sources, such as: in vitro, in vivo, literature information, different studies or populations.393 In 
contrast using a classical “two stage” analysis would not allow to combine pharmacokinetic data from 
various studies independent of their sampling schedules.384 In a “two stage” method each individual’s 
data is analysed individually and then averaged for the population and it requires identidal samplinch 
schedules for all analysed individuals. Another advantage is that it allows for graphical display of the 
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data and results, which makes decision-making easier and information understandable also to clinical 
audience with limited understanding of mathematics or statistics.393 
Validated models can also be used for simulations of drug response under different dosing conditions 
or in other sub-populations and to allow testing of various “what-if” scenarios not feasible or ethical 
to test in real life.384,394,395 Such simulations can facilitate treatment optimisation18 and can be used to 
optimise trial design, minimising the numbers of individuals needed in a study.385,396,397  
The outlined characteristics are particularly advantageous in drug testing in children, as they result in 
increased safety and feasibility of studies and reduction of burden related to drug testing.384,393,398 
The most popular software used to conduct non-linear mixed effects modelling (also in the presented 
thesis) is NONMEM (Beal, S., Sheiner, L.B., Boeckmann, A., & Bauer, R.J., NONMEM User's Guides. 
[1989-2009], Icon Development Solutions, Ellicott City, MD, USA, 2009.) The presented nomenclature 
(THETA, ETA, SIGMA, OMEGA etc.) is utilized by users of this software and other programmes might 
use a different nomenclature.  
 
3.2.2 Cox proportional hazards regression model 
The most basic analysis method describing a relationship between one (or more) explanatory 
variable(s) and a response variable is linear regression for continuous outcomes, or logistic regression 
for binary outcomes (describing an association in a probabilistic manner). Simple regression analysis 
is based on a number of assumptions, one of them being that the relationship between a predictor 
and outcome is constant over the range of predictor variable, another is independence of data (each 
observation in the model should come from a different individual). Analysis of longitudinal data 
including repeated measurements and non-linear effects requires a more advanced approach.  
One such approach is Cox proportional hazards regression model,399 where probability of an effect is 
estimated in terms of hazard expressed through following function: 
ℎ(𝑡, 𝑋) =  ℎ0(𝑡)exp (∑ 𝛽𝑖𝑋𝑖
𝑝
𝑖=1
) 
Equation 3.7 
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Where the hazard is a function of baseline hazard ℎ0 at a time 𝑡 and sum of individual effects 𝛽𝑖 of 
covariate 𝑋 (𝑋𝑖 indicates covariate value for individual 𝑖). 
The differences in risk related to a specific covariate in this approach are estimated in terms of hazard 
ratio as follows: 
𝐻𝑅 =  
ℎ̂(𝑡, 𝑋∗)
ℎ̂(𝑡, 𝑋)
 
Equation 3.8 
where 𝑋∗ is the group with larger hazard and 𝑋 is the group with smaller hazard for a specific covariate.  
With one variable of interest (𝑋∗ = 1, 𝑋 = 0) hazard ratio can be simplified to:399  
𝐻𝑅 =  
ℎ0̂(𝑡) exp (∑ 𝛽?̂?𝑋𝑖
∗𝑝
𝑖=1 )
ℎ0̂(𝑡) exp (∑ 𝛽?̂?𝑋𝑖
𝑝
𝑖=1 )
=  exp (∑ 𝛽?̂?(𝑋𝑖
∗ − 𝑋𝑖)
𝑝
𝑖=1
) =  𝑒𝛽?̂? 
Equation 3.9 
Cox proportional hazards regression modelling has a number of advantages over logistic regression 
modelling or simple survival analysis. It does not have limitations of logistic models, which ignore 
survival times and censoring information, but unlike some of other maximum likelihood based 
approaches it does not make assumptions about the underlying baseline hazard or its distribution (it 
has a semi-parametric character).400 It estimates the effect of a covariate in terms of change in hazard 
(hazard ratio) but because of the model form (baseline hazard multiplied by exponential of the effect) 
the estimated hazards are always non-negative. Hazard ratio itself is easily understandable and 
changes in hazard ratio are easy to interpret. It also allows for the non-linearity in the effect of 
continuous covariates, which can be explored graphically using splines or thought automated methods 
based on fractional polynomials.401 A further advantage is that the model fit can be measured in terms 
of log likelihood or Akaike Information Criterion (AIC). 
Efron approximation and Anderson-Gill repeated outcomes framework used in our analyses introduce 
further modifications to the basic Cox proportional hazards regression model allowing for recurrent 
events and reformulating of the problem as a counting process (taking place within specified time 
intervals).380,402–404 
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4.1 Abstract 
Aim: To characterise the efavirenz steady-state pharmacokinetics in African children using model-
based approach, quantifying demographic and genotypic effects on the drug’s disposition, and 
conduct simulations allowing prediction of optimised doses of efavirenz in this population.  
Methods: We modelled the steady-state population pharmacokinetics of efavirenz in Ugandan and 
Zambian children using nonlinear mixed-effects modelling. Individual mid-dose efavirenz 
concentrations were derived and simulations explored genotype-based dose optimisation strategies.  
Results: A 2-compartment model with absorption through transit compartments well described 2086 
concentration-time points in 169 children. The combined effect of SNPs 516GT and 983TC explained 
44.5% and 14.7% of the variability in efavirenz clearance and bioavailability, respectively. The detected 
frequencies of composite CYP2B6 genotype were 0.33 for 516GG|983TT, 0.35 for 516GT|983TT, 0.06 
for 516GG|983TC, 0.18 for 516TT|983TT, 0.07 516GT|983TC and 0.01 for 516GG|983CC. The 
corresponding estimated clearance rates were 6.94, 4.90, 3.93, 1.92, 1.36, and 0.74 L/h for a 15.4 kg 
child and median (95% CI) observed mid-dose concentrations 1.55 (0.51-2.94), 2.20 (0.97-4.40), 2.03 
(1.19-4.53), 7.55 (2.40-14.74), 7.79 (3.66-24.59) and 18.22 (11.84-22.76) mg/L, respectively. 
Simulations showed that wild-type individuals had exposures at the bottom of therapeutic range, 
while slower metabolisers were over-exposed. 
Conclusions: Dosage guidelines for African children should take into consideration the combined 
effect of SNPs CYP2B6 516G>T and 983T>C. 
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4.1.1 ‘What is known about this subject’  
 High variability in efavirenz pharmacokinetics is largely contributed by SNPs in 
CYP2B6: 516G<T and 983T<C. 
 SNP 983T<C is virtually absent in individuals of European ancestry. 
 No previous studies quantified the effect of 983T<C on efavirenz clearance in children using 
model-based approach or recommended dose optimisation strategies accounting for this 
SNP. 
 4.1.2 ‘What this study adds’ 
 We propose a model concomitantly accounting for effect of weight and CYP2B6 
516G<T|983T<C variants in African children. 
 Using the model we simulated and compared exposures in weight-bands between CYP2B6 
metabolic subgroups and suggested a dose optimisation strategy adjusting for effect of both 
516G>T and 983T>C. 
 
  
 87 
 
CHAPTER 4: The impact of genetic polymorphisms on PK of efavirenz in African children 
 
Doctoral Thesis by A.M. Bienczak, March 2017 
4.2 Introduction 
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used within first-line 
antiretroviral treatment (ART) for HIV-1 infected adults and children over 3 years.11,63 Due to its ease 
of dosing (the long half-life allows once daily administration), proven efficacy, ability to be used with 
anti-TB drugs, and availability of cheap generic formulations, it is especially widely used in Africa.  
Suboptimal efavirenz exposures have been previously related to treatment failure and high 
concentrations to central nervous system (CNS) side-effects.69,94 Numerous studies reported very large 
between-subject variability (BSV) in efavirenz pharmacokinetics (PK).74,94,168,221 This variability is 
attributed largely to single nucleotide polymorphisms (SNPs) in the CYP2B6 gene which encodes the 
key metabolising enzyme. The loss-of-function polymorphism, 516G>T (rs3745274),69,74,176,198 alters 
drug metabolism to the extent that dose adjustment based on CYP2B6 516G>T genotype is currently 
under investigation in children.122,290 The proportion of slow metabolizers varies among different 
populations and is relatively high among black Africans.69,76,176,198,221 In addition, efavirenz 
concentrations are affected by the functional polymorphisms CYP2B6 983T>C (rs28399499),176,198 
785A>G (rs2279343)39,203 and 15582C>T (rs4803419),76,176 which are reported predominantly in black 
African and African-American patients; by polymorphisms involving its accessory pathways, including 
CYP2A6, CYP3A4 and UGT;103,171,177 and in genes coding nuclear receptors CAR (NR1|3) and PXR 
(NR1|2), which regulate enzyme expression.78,81 PK variability has also been linked to several 
physiological and environmental factors, such as sex,36,39,221 ethnicity,172,221,222 formulation type,63,162 
concomitant food63 or co-medication (e.g. zidovudine222, rifampicin and isoniazid74,170,222), and 
adherence164. However, reports on these effects have been to some extent contradictory and vary 
between adults and children.  
Several investigators have reported a high proportion of sub-therapeutic efavirenz concentrations in 
children, highlighting the need for optimisation of paediatric dosing guidelines.32,40,41 The aim of this 
analysis was therefore to characterise the steady-state PK of efavirenz in the largest cohort of African 
children reported so far, quantifying demographic and genotypic effects on efavirenz disposition, and 
thus allowing prediction of optimised doses of efavirenz in this population.  
4.3 Methods 
PK and other data from two studies in African children from Uganda and Zambia were pooled 
together: CHAPAS-3382 (Children with HIV in Africa – Pharmacokinetics and Adherence/Acceptability 
of Simple antiretroviral regimens) and ARROW41,381 (Anti-Retroviral Research for Watoto). 
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4.3.1 CHAPAS-3 
Efavirenz was dosed once daily, mane or nocte, following modified WHO 2010 guidelines (Table 4.5), 
using a new paediatric double-scored 600 mg efavirenz tablet (provided by Cipla Pharmaceuticals, 
India) that can be split into 2 or 3 parts enabling administration of doses of 200, 300, 400, or 600 mg. 
All included patients took part in sparse PK-sampling on clinic visits at week 6, 36, and every 24 weeks 
thereafter until the end of the study. The self-reported time of the last dose was recorded. Additional 
intensive PK-sampling was conducted in the first patients enrolled in each WHO weight-band at week 
6 and in all patients who acquired tuberculosis during the study (4-10 weeks after tuberculosis 
treatment initiation and again 4-10 weeks after tuberculosis treatment cessation). Children in this 
intensive PK sub-study were advised to take efavirenz in the morning for 6 weeks prior to sampling 
and the drug intake on the PK day was observed. Plasma was separated and stored at −80°C until 
transportation on dry ice for drug concentration assay.  
Plasma efavirenz concentrations from the intensive PK were assayed using ultra high-performance 
liquid chromatography at the Department of Clinical Pharmacy of Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands. The method produced linear results over the range of 
0.0517 to 15.51 mg/L. The lower limit of quantification was 0.05 mg/L. The intraassay and interassay 
coefficients of variation (CV) were 1.01% to 5.31% and 0.1% to 1.63%, respectively. Relative error of 
the method ranged from 97.7% to 104.5%.405 Plasma efavirenz concentrations from sparse PK were 
determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) in the Division of 
Clinical Pharmacology, University of Cape Town, South Africa. The method was accurate over the 
range of 0.0195 to 20 mg/L. The lower limit of quantification was 0.0195 mg/L. The interassay 
coefficient of variation (CV) and residual error (RE) were 3.59%–5.78% and −2.57% to 0.92%, 
respectively, and the intraassay CV and RE were 1.50% to 9.67% and −6.00% to 4.28%, respectively.71 
Both laboratories participate in international quality assurance and proficiency testing schemes and 
are expected to have comparable standards, although no cross-validation was performed for the 
assays. Systematic differences between the labs and assays were tested as covariates in the PK model 
(see Population Pharmacokinetic Analysis/Covariates).  
4.3.2 ARROW 
Efavirenz was dosed once-daily, mane or nocte, according to modified WHO 2006 paediatric 
recommendations. The tested formulations included 50, 100, and 200 mg capsules; and half or whole 
600 mg tablets (provided by the national ART programme in Uganda).  
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Children in a PK sub-study41 were sampled on 2 occasions: 36 and 40 weeks after starting ART. Eligible 
children were advised to take efavirenz in the morning for 4 weeks prior to sampling and drug intake 
on the PK day was observed. Samples were stored and assayed at the Department of Clinical Pharmacy 
of Radboud University Nijmegen Medical Centre, Nijmegen using the same methods as described 
above. 
4.3.3 Genotyping 
Genotyping was performed by allelic discrimination real-time PCR assay on a DNA Engine Chromo4 
system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The PCR protocol involved an initial 
denaturation step at 95°C for 15 min, followed by 50 cycles of amplification at 95°C for 15 s and final 
annealing at 60°C for 1 min. TaqMan® Genotyping Master Mix and assays for CYP2B6-516G>T 
(rs3745274, C_7817765_60), CYP2B6-983T>C (rs28399499, C_60732328_20), CYP2B6-c.485-18C>T 
(rs4803419; C_7817764_10), CYP2B6-499C>G (rs3826711, C__27522377_10; ARROW patients only), 
CYP3A4*22 (rs35599367, C__59013445_10), CYP3A5-6986G>A (rs776746, C__59013445_10), NR1I3 
(rs3003596, C__16194070_10; rs2307424, C__25746794_20), NR1I2-63396C>T (rs2472677, 
C__26079845_10) were obtained from Life Technologies Ltd (Paisley, Renfrewshire, UK). CYP2B6*4 
(785A>G, rs2279343) and CYP2B6*29 copy number assay were performed on samples from ARROW 
study only using previously described custom TaqMan assays.406,407 Opticon Monitor® version 3.1 (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) was used to obtain allelic discrimination plots and make 
allele calls. The assays were performed at the Department of Molecular and Clinical Pharmacology, 
University of Liverpool, Liverpool, UK. 
The distribution of the genotypes was evaluated for compliance with Hardy-Weinberg equilibrium 
using the exact test conducted using R-package “genetics”.380 
4.3.4 Population pharmacokinetic analysis 
4.3.4.1 Model building 
The steady-state efavirenz PK was analysed using nonlinear mixed-effects modelling with software 
NONMEM VII (version 7.3)408 and the first-order conditional estimation method with interaction. PsN 
4.4.0, Pirana, and Xpose were used to facilitate modelling and for model diagnostics.379 The model was 
developed and validated in accordance with standard methods described in the literature.409 For the 
structural model, 1- , 2-, and 3-compartment models with first-order absorption and elimination were 
tested, as well as time lag or transit-compartment absorption410 and hepatic first-pass model.411 
Between-subject and -occasion variability (BSV, BOV) were tested on PK parameters assuming 
lognormal distribution. Residual unexplained variability (RUV) was tested using a combined 
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proportional and additive error. Data below level of quantification (BLQ) were included in the analysis 
by imputing half of the LLOQ of the corresponding assay as suggested in Beal (M6 method).412 
Implausible samples and PK-profiles were identified using extreme values of CWRESI and their 
exclusion was evaluated based on visual checks. 
Model development and covariate selection was guided by the NONMEM objective function value 
(OFV), inspection of goodness-of-fit (GOF) plots and visual predictive checks (VPCs), biological 
plausibility, and clinical relevance. OFV (proportional to -2 log-likelihood of the data) was assumed to 
be χ2-distributed and a drop of 3.84 or more between two hierarchical models after inclusion of one 
additional parameter (df=1) was considered a significant improvement (p=0.05). Stability and 
robustness of the final model, together with precision of its parameter estimates, was evaluated 
through a nonparametric bootstrap (n=200).  
Intensive and sparse data were included in the model development process in a stepwise manner as 
suggested in Svensson et al.,294 starting with intensive PK data from CHAPAS-3, followed by the 
intensive data from ARROW, and finally the sparse PK data from CHAPAS-3. 
The model-derived Empirical Bayesian Estimates for the individual parameters were used to predict 
steady-state mid-dose concentrations (measures 12h after dose) for each sampling occasion and 
patient. 
4.3.4.2 Covariates 
Allometric scaling was added to the model at an early development stage as previously suggested.225 
The effect of maturation of metabolic pathways on PK parameters was tested using post-menstrual 
age (gestation-adjusted age) as a predictor.  Both a power function or a sigmoidal model with and 
without Hill coefficient were tested.225 Besides weight and age, the other covariates tested were: 
tuberculosis co-treatment, study site, nucleoside reverse transcriptase inhibitor (NRTI) backbone, sex, 
weight-for-age Z-score (WAZ) and height-for-age Z-score (HAZ), drug formulation, the effect of 
splitting tablets used in CHAPAS-3 (inferred from total daily dose), and genotyping information (SNPs 
listed above). The potential difference between assays and lab procedures for the quantification of 
drug concentrations was tested in the model as proportionality and correction factors on RUV. 
Missing genotype values were imputed using mixture modelling with frequencies fixed to those 
observed in the rest of the cohort as previously suggested by Keizer et al.413  
4.3.4.3 Simulations 
The final model was used to simulate exposures after administration of efavirenz with the formulation 
given in CHAPAS-3 and using a dataset of subjects with a uniform distribution of weights ranging from 
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10 to 40 kg, in 0.1 kg steps (300 individuals simulated 100 times). Several dosing strategies were 
explored. To avoid generating implausibly extreme values, the maximum variability for each random 
effect was limited to 3 standard deviations. Data were analysed and plots generated using R.380 
4.4 Results 
4.4.1 Demographic results and samples 
This analysis included data from 128 children from CHAPAS-3, and 41 children from ARROW. Relevant 
subject characteristics including the genotype frequencies for the tested SNPs are presented in Tables 
4.1 and 4.2. All tested genotypes were in Hardy-Weinberg equilibrium (HWE). For SNPs rs35599367, 
rs3826711 and CYP2B6*29 all patients were homozygous for the common allele and HWE was not 
calculated. The genotype information was missing for 5 children from ARROW and 2 from CHAPAS-3, 
who were assigned by the mixture model as follows: 2 as 516GG|983TT, 4 as 516GT|983TT, and one 
as 516TT|983TT. 
Table 4.1 Demographic characteristics of children in ARROW and CHAPAS-3 treated with efavirenz (part 1) 
Characteristics ARROW 
iPK 
CHAPAS-3 Combined 
iPK sPK 
No. of children* 41 51 128 169 
No. of samples 611 474 1002 2087 
Sampling 
schedule 
0h, 1h, 2h, 4h, 6h, 8h, 
12h, 24h 
2 samples 2 h 
apart 
 
No. of samples 
excluded 
9 8 5 22 
Age [years]** 
7.6 (4.0-12.5) 4.5 (2.1-13.8) 
4.7 (2.1-
13.8) 
Weight [kg] ** 20.0 
(14.0-30.0) 
15.0 
(7.8-29.9) 
15.5 
(7.8-30.0) 
Sex [M/F] 17/24 63/65 80/89 
Race  Black African 
CYP2B6 516GT (rs3745274; HWE p=1)† 
GG 16 (44%) 49 (39%) 65 (40%) 
GT 14 (39%) 53 (42%) 67 (41%) 
TT 6 (17%) 24 (19%) 30 (19%) 
MAF 0.36 0.40 0.39 
CYP2B6 983T>C (rs28399499; HWE p=0.6)† 
TT 33 (92%) 106 (84%) 139 (86%) 
TC 3 (8%) 19 (15%) 22 (14%) 
CC 0 (0%) 1 (1%) 1 (1%) 
MAF 0.04 0.08 0.07 
Note: explenations below Table 4.2 
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Table 4.2 Demographic characteristics of children in ARROW and CHAPAS-3 treated with efavirenz (part 2) 
Characteristics ARROW CHAPAS-3 Combined 
CYP2B6 15582C>T (rs4803419; HWE p=1)† 
CC 32 (89%) 113 (90%) 145 (90%) 
TC 4 (11%) 13 (10%) 17 (10%) 
MAF 0.06 0.05 0.05 
CYP3A4*22 (rs35599367)† 
GG 36 (100%) 126 (100%) 162 (100%) 
CYP3A5 6986G>A (rs776746; HWE p=0.57)† 
GG 1 (3%) 2 (2%) 3 (2%) 
GA 7 (19%) 41 (33%) 48 (30%) 
AA 28 (78%) 83 (66%) 111 (69%) 
MAF 0.12 0.18 0.17 
NR1I3 (rs3003596; HWE p=0.34)† 
AA 7 (19%) 30 (24%) 37 (23%) 
AG 18 (50%) 55 (44%) 73 (45%) 
GG 11 (31%) 41 (33%) 52 (32%) 
MAF 0.46 0.46 0.46 
NR1I3 540 C>T (rs2307424; HWE p=1)† 
TT 0 1 (1%) 1 (1%) 
CT 3 (8%) 23 (18%) 26 (16%) 
CC 33 (92%) 102 (81%) 135 (83%) 
MAF 0.04 0.10 0.09 
NR1I2 63396C>T (rs2472677; HWE p=0.07)† 
CC 13 (36%) 43 (34%) 56 (35%) 
CT 16 (44%) 72 (57%) 88 (54%) 
TT 7 (19%) 11 (9%) 18 (11%) 
MAF 0.42 0.37 0.38 
CYP2B6*4 785A>G (rs2279343; HWE p=0.47)‡ 
AA 16 (44%) 
not tested AG 14 (39%) 
GG 6 (17%) 
MAF 0.36  
CYP2B6 499C>G (rs3826711)‡ 
CC 36 (100%) not tested 
CYP2B6*29‡ 
*1/*1 36 (100%) not tested 
Note: Data are median (range) or no. (%) of subjects; *51 children in the CHAPAS-3 study who underwent both 
intensive and sparse sampling are counted in both categories; **Baseline values; †162 pts from both CHAPAS-3 
and ARROW studies; ‡36 pts from ARROW study; iPK – intensive sampling; sPK – sparse sampling; HWE - Hardy-
Weinberg equilibrium, MAF – minor allele frequency 
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From CHAPAS-3, 61 intensively sampled PK-profiles (a total of 474 samples) and 510 sparse PK-profiles 
(1002 samples, 1-2 per occasion) were available. The PK data were collected from 6 weeks after 
starting efavirenz up to a maximum of 132 weeks. There were up to 7 PK-sampling visits per child. Of 
14 children who acquired tuberculosis, 9 had at least one intensively sampled PK-profile on efavirenz 
with tuberculosis treatment. The only BLQ measurement from intensive PK sub-study was a pre-dose 
measurement and all 8 samples from that PK visit for that patient were excluded from the analysis as 
it was deemed likely not to be in steady-state due to poor adherence. Within the sparse data, 15 
samples were BLQ and were included by imputing half LLOQ, i.e. 0.00975 mg/L. From the ARROW 
study, 611 intensive PK samples from 82 PK visits (2 visits per patient) were available. Data from one 
visit were discarded due to an implausible PK profile, possibly caused by mismatch of samples. No 
samples were BLQ. 
4.4.2 Population pharmacokinetics 
The data were best described using a 2-compartment model with first-order elimination and transit 
compartment absorption.410 Final parameter estimates, their precision (obtained through a bootstrap) 
and statistical significance for the inclusion of the covariate and random effects (based on drop in OFV) 
are presented in Table 4.3. The PK parameters were estimated relative to oral bioavailability whose 
typical value was fixed to 1 due to lack of intravenous data. Adequate fit of the model was confirmed 
by a GOF plots and VPC (Figures 4.4 and 4.5 in Appendix to Chapter 4).  
The effect of body size on all clearance and volume parameters was accounted for using allometric 
scaling, which significantly improved model fit (18 points drop in OFV).225 No effect of age on the 
maturation of clearance could be detected. After adjusting for body size, the main predictor of 
clearance was the effect of CYP2B6 genotype, categorised into 6 subgroups based on the combined 
effect of 516G>T and 983T>C SNP-variants present in our population (Table 4.3 and 4.4). CYP2B6 
genotype explained 44.5% and 14.7% of BSV in clearance and oral bioavailability respectively. 
Exclusion of individuals with missing genotype did not have a significant effect on final results.   
The absorption rate constant (ka) and the absorption mean transit time (MTT) were 1.6-fold larger and 
1.4-times longer in ARROW compared with CHAPAS-3. Splitting of the new double-scored efavirenz 
tablets used in the CHAPAS-3 was not found to affect efavirenz bioavailability. No other covariate (see 
Methods) was found to significantly improve the model fit. We did not detect any systematic 
differences between the assays and labs employed in the analysis.  
The model fit was markedly improved by inclusion of a correction parameter to allow for larger 
residual unexplained variability for all samples obtained after self-recorded efavirenz intake. This  
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Note: Final parameter estimates are typical population values estimated by the model. All clearance and volume parameters scaled allometrically to median weight of 15.4kg. *Estimated 
from nonparametric bootstrap (n=200) of the final model; **Expressed as approximate %CV on SD scale (√𝐸𝑇𝐴*100). †Change in the objective function value after elimination of the 
parameter from the final model (dOFV > 10.83 corresponds to p < 0.001).  F – bioavailability; NN – number of transit compartments; MTT – mean transit time; Ka – absorption rate constant; 
CL – clearance; Q – inter-compartmental clearance; Vc – volume of central compartment; Vp – volume of peripheral compartment; BSVBIO – between subject variability in bioavailability; 
BOVBIO - between occasion variability in bioavailability; BOVMTT - between occasion variability in medium transit time; BOVKA - between occasion variability in absorption rate constant; 
BSVCL - between subject variability in clearance; BOVCL - between occasion variability in clearance.  
. Fixed Effects (THETA) p-value† Random Effects (ETA)** p-value† 
F 1 (FIXED) 
 
BSVBIO 42.2% (31.3%-50.8%) p<0.001  (dOFV=19.7, df=1) 
BOVBIO 50.5% (42.3%-55.9%) p<0.001 (dOFV=304.3, df=1) 
NN [number] 25.0 (17.7-35.1) 
  
MTT [h] 
CHAPAS-3 0.82 (0.69-0.96) 
p<0.001 (dOFV=21.4, df=1) BOVMTT 78.0% (71.5%-96.1%) p<0.001 (dOFV=443.3, df=1) 
ARROW 1.17 (1.02-1.37) 
Ka [1/h] 
CHAPAS-3 0.79 (0.37-0.95) 
p<0.001 (dOFV=37.9, df=1) BOVKA 57.7% (45.5%-69.0%) p<0.001 (dOFV=96.7, df=1) 
ARROW 1.27 (0.90-1.62) 
CL [L/h] 
516GG|983TT 6.94 (6.47-7.61) 
p<0.001 (dOFV= 154.7, 
df=5) 
BSVCL 36.9% (24.9%-45.6%) p<0.001 (dOFV=64.2, df=1) 
516GG|983TC 3.93 (2.61-5.65) 
516GG|983CC 0.74 (0.72-0.75) 
BOVCL 26.6% (18.9%-35.4%) p<0.001 (dOFV=26.9, df=1) 
516GT|983TT 4.90 (4.40-5.46) 
516GT|983TC 1.36 (0.97-1.76)  
516TT|983TT 1.92 (1.52-2.33) Error Model 
Vc [L] 64.1 (49.1-73.3) 
 
Additive error [mg/L] 0.101 (0.067-0.131) p<0.001 (dOFV=199.2, df=1) 
Q [L/h] 17.1 (14.1-20.9) Proportional error [%] 0.0672 (0.052-0.079) p<0.001 (dOFV=678.5, df=1) 
Vp [L] 92.2 (80.1-112.7) 
Increased error for sparse 
data 
2x (1.7x -2.5x) p<0.001 (dOFV=17.7, df=1) 
Table 4.3 Final efavirenz population parameter estimates (5th and 95th percentile)* 
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includes all pre-dose intensive PK-samples and all the sparse PK-samples from CHAPAS-3. The residual 
variability for those samples was twice as large as in the rest of the data  
4.4.3 Simulations 
Simulations were performed to predict exposures in African children based on their weight and 
genotype, when dosed according to the regimen used in CHAPAS-3. Median mid-dose concentrations 
were comparable across weight-bands but noticeable differences were observed between the CYP2B6 
genotype subgroups (Figure 4.1, Table 4.4). 
Note: Individual mid-dose concentrations estimated by the population pharmacokinetic model (black dots) are 
plotted on top of the mid-dose concentrations (percentile plots) simulated across weight-bands (left) and by 
different CYP2B6 516GT|983TC subgroups (right). Red horizontal lines correspond to efavirenz concentrations 
of 1mg/L and 4mg/L.3 Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers 
correspond to 5th and 95th percentile of the simulated data. 
A dose optimisation strategy for African children was devised by categorising subjects into four 
phenotypic subgroups based on their composite genotype vector 516G>T|986T>C, similarly to Dooley 
et al.71 (presented in Table 4.4). The proposed dose-adjustment between metabolic subgroups is 
based on optimal ratios of 1:0.66:0.33:0.1 for EM:IM:SM:USM (extensive, intermediate, slow and 
ultra-slow metabolisers), respectively, and is outlined in Table 4.5. 
The predicted exposures based on the suggested dose-optimisation algorithm are presented in Figure 
4.2 and Table 4.6 (in the Appendix to Chapter 4). The suggested dosing approach ensured adequate 
drug exposure in all simulated weight-bands (Figure 4.2, left panel), and reduced the differences due 
to metabolic status (Figure 4.2, right panel). 
Figure 4.1 Individual efavirenz mid-dose concentrations estimated by the population pharmacokinetic model and the simulated mid-dose 
concentrations across weight-bands and by different CYP2B6 516GT|983TC subgroups 
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Table 4.4 Efavirenz PK exposures of different metabolic subgroups determined by 516GT|983TC SNP vector 
SNP Vector MET Pts* CL [L/h]* C12h [mg/L]**† 
C12h < 1 
[mg/L]** 
1> C12h <4 
[mg/L]** 
C12h > 4  
[mg/L]** 
C24h [mg/L]**† 
AUC  
[mg∙h/L] **† 
516GG|983TT EM 
56 
(33.1%) 
6.94 
1.55  
(0.51-2.94) 
40 
(22%) 
132  
(74%) 
6 
(3%) 
0.86  
(0.26-2.02) 
37.53  
(14.26-75.12) 
516GG|983TC IM 10 (5.9%) 3.93 
2.03  
(1.19-4.53) 
7 
(16%) 
28 
(62%) 
10 
(22%) 
1.33  
(0.65-3.66) 
46.30  
(30.65-118.08) 
516GG|983CC USM 
1 
 (0.6%) 
0.74 
18.22 (11.84-
22.76) 
0 
(0%) 
0 
(0%) 
6 
(100%) 
17.28  
(11.20-21.63) 
438.94  
(286.10-548.20) 
516GT|983TT IM 
59 
(34.9%) 
4.90 
2.20  
(0.97-4.40) 
19 
(10%) 
132 
(69%) 
40 
(21%) 
1.54  
(0.58-3.54) 
56.05  
(25.16-105.47) 
516GT|983TC SM 12 (7.1%) 1.36 
7.79  
(3.66-24.59) 
0 
(0%) 
6 
(17%) 
29 
(83%) 
6.97  
(3.24-23.07) 
258.42  
(64.81-548.77) 
516TT|983TT SM 
31 
(18.4%) 
1.92 
7.55  
(2.40-14.74) 
7 
(6%) 
20 
(18%) 
82 
(75%) 
6.61  
(1.93-13.35) 
175.98  
(49.61-356.44) 
 
Note: Data are population median (5th-95th percentile) or number (percentage).  Based on all patients from ARROW and CHAPAS-3 trials (missing genotype estimated by 
mixture model). *CL refers to typical population value estimated by the model for a patient with median weight of 15.4 kg (combined ARROW and CHAPAS-3 data). **CHAPAS-
3 data only (due to differences in dosing between studies, see Methods). Value for each PK visit estimated by the model, multiple measurements used to calculate geometric 
mean for every patient which were then used to calculate median and percentiles for each subgroup. MET – metabolic subgroup:71  EM (extensive metabolisers) - 
516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 
516GG|983CC. The light grey shading indicates groups of patients who would be significantly overexposed if dose optimisation would be conducted based only on SNP 
516G>T. 
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4.5 Discussion 
 
Efavirenz pharmacokinetics in Africans has been previously shown to be affected by the combined 
effect of SNPs 516G>T and 983T>C.71,76,103,176,203 The current investigation confirms those findings and 
is the first analysis to quantify the effect of the CYP2B6 516G>T|983T>C SNP-vector on efavirenz 
clearance in African children using nonlinear mixed-effects modelling. The use of modelling provides 
a tool to concomitantly account for multiple effects such as genotype and weight, and a platform to 
derive a dose adjustment strategy based on these effects.  
Numerous studies in adults and children have reported a significant effect of CYP2B6 516G>T on 
efavirenz clearance. Our analysis shows that presence of one variant allele in 516G>T causes clearance 
to drop by 34%, while the reduction reaches 72% for homozygous mutants, which is in line with 
previously reported reductions of 20-47% and 58%-80%, respectively.34,36,39,40,169,170,173 Our findings 
also show that the effect of SNP 516G>T is significantly modified by the 983T>C (i.e. in wild type 
516G>T individuals presence of a single variant allele in 983T>C causes a 43% drop in clearance and 
89% if no functional allele is present), confirming associations found by Holzinger et al.176 and in a 
number of African studies.71,76,203 This polymorphism is virtually absent in individuals of European 
ancestry176,198 and was not detected in a study of Cambodian patients.170 The combined effect of the 
CYP2B6 516G>T|983T>C SNP-vector on efavirenz clearance has been previously reported 
distinguishing 4 phenotypic subgroups.71,103 In our study, we were able to further characterise this 
effect using six CYP2B6 516G>T|983T>C variant subgroups. Similarly to previous reports we show that, 
despite its low prevalence, SNP 983T>C is not only a significant predictor of efavirenz clearance, but it 
is responsible for a larger drop in metabolic rate than 516G>T (i.e. 29% drop in clearance in 516G>T 
heterozygote vs 43% drop in 983T>C heterozygote, when no other polymorphisms were present).76,176 
No further significant genetic associations were detected. 
A genome-wide association study by Holzinger et al. identified rs4803419 as another significant 
polymorphism in CYP2B6 affecting efavirenz clearance.176 The effect of SNP rs4803419 becomes 
significant only for homozygous mutants who are wild type for 516G>T and 983T>C and no such 
variants were present in our population. Although this finding was recently replicated in South African 
patients, the investigators concluded this effect was negligible in comparison to 516G>T and 983T>C.76 
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Figure 4.2 Simulated efevirenz mid-dose concentrations across weight-bands and by different 516GT|983TC genotypes 
based on suggested most optimal dosing. 
Note: The left plot shows the simulated efevirenz mid-dose concentrations across weight-bands and the right 
one by different 516GT|983TC genotypes based on suggested most optimal dosing. Red horizontal lines 
correspond to efavirenz concentrations of 1mg/L and 4mg/L.94  Breaks in the percentile plot correspond to 25th, 
median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data 
 
Results from the simulations (Figure 4.1) showed that, even though the dosage guidelines tested in 
CHAPAS-3 result in average mid-dose concentrations within target range of 1.0-4.0 mg/L,94 the effect 
of CYP2B6 genotype leads to large differences within each weight-band. In particular, children with 
slower CYP2B6 genotypes (516GG|983CC, 516GT|983TC, and 516TT|983TT) were over-exposed, 
while the fastest metabolisers (516GG|983TT) achieved exposures at the bottom of the therapeutic 
range. Over 20% of children in the study with the 516GG|983TT genotype had efavirenz 
concentrations below the proposed minimum target concentration of 1.0 mg/L (Table 4.4). Moreover, 
our model indicates that disregarding the effect of the 983T>C SNP and basing dose optimisation only 
on 516G>T could lead to exposures significantly higher than the therapeutic range94 in  ~14% of African 
patients with 983TC or 983CC genotypes (Table 4.4 in grey). This suggests that genotype-based dose 
optimisation in African children should take into account both 516G>T and 983T>C SNPs.  
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Figure 4.3 Simulated efavirenz mid-dose concentrations across weight-bands and by different 516GT|983TC genotypes 
based on dose recommendations tested in IMPACT study P1070 applied to our population.  
Note: The left plot shows the simulated efavirenz mid-dose concentrations across weight-bands and the right 
one by different 516GT|983TC genotypes based on dose recommendations tested in IMPACT study P1070 
applied to our population. Red horizontal lines correspond to efavirenz concentrations of 1mg/L and 4mg/L.94 
Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th 
and 95th percentile of the simulated data. 
 
The only available guidelines on genotype-adjusted paediatric dosage were recently formulated for 
patients under 3 years by the Panel on Antiretroviral Guidelines for Adults and Adolescents at the 
Department of Health and Human Services (dHHS) and are currently being tested in the IMPAACT 
study P1070.122,290 The dose adjusted strategy was developed based on results of an analysis by Salem 
et al.162 and preliminary results of IMPAACT P1070289 and proposed different dosing for individuals 
with 516GG or 516GT genotype versus 516TT. In contrast to previous paediatric studies,34,75 Salem et 
al. did not detect significant differences in clearance rate between patients with 516GG and 516GT 
genotypes, and the effect of 983T>C was not evaluated. Their findings might differ from the current 
investigation for several reasons: the study by Salem et al. included a smaller number of patients, the 
lowest age of participants was only 2 months, the tested population comprised patients of various 
races and the formulations included capsules and liquid. According to simulations from the current 
model, direct application of that strategy in African children could result in result in exposures above 
the therapeutic range94 in a large proportion of patients who are either heterozygous for 516G>T or 
wild type with 983TC or 983CC genotypes (Figure 4.3). 
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Table 4.5 Efavirenz dosage tested in CHAPAS-3 vs. proposed genotype adjusted dose optimisation 
CHAPAS-3 Based on 516GT|986TC 
Weight 
[kg] 
Dose 
Weight 
[kg] 
EM IM SM USM 
1 0.66 0.33 0.1 
10 – 13.9 200 10 – 13.9 300 200 100 50 
14 – 19.9 300 14 – 19.9 400 300 150 50 
20 – 24.9 400 20 – 24.9 600 400 200 100 
25 – 29.9 400 25 – 29.9 600 400 200 100 
30 – 39.9 400 30 – 39.9 600 400 200 100 
Note: EM (extensive metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 
516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 
516GG|983CC.71 The dose recommendations were rounded to the nearest full entity of currently available 
formulations (50 mg capsule, 100 mg capsule and 600 mg double scored tablets allowing dose of 200 mg, 300 
mg, 400 mg and 600 mg) 
Our recommendations were simplified to previously described 4 metabolic subgroups determined by 
the composite 516G>T|983T>C vector outlined in Table 4.4.71 The clearance between EM:IM:SM:USM 
drops as follows: 1:0.6:0.24:0.1, which is remarkably similar to the ratios detected by Dooley et al. in 
African adults (1:0.6:0.26:0.08, respectively).71 Our dosage algorithm presented in Table 4.5 
(1:0.66:0.33:0.1) was adjusted to maximise the use of currently available solid formulations and 
conducted simulations show it would provide optimal drug exposures across all weight bands 
acounting adequately for individual CYP2B6516G>T|983T>C genotype (Figure 4.2). A similar dose 
adjustment pattern (1:0.66:0.33) was previously successfully implemented based of phenotypic 
differences in an adult study by Mello et al.261 
The results of the few dose reduction studies guided by CYP2B6 genotype conducted in developed 
countries highlighted improved treatment tolerability and cost-effectiveness in adults.258,259,261,414 
These results were confirmed by recent cost-effectiveness analysis of this practice in American 
adults.263 It could be speculated that in a resource-limited settings, cost and logistical challenges would 
make implementation of such practice difficult. Nonetheless, decreasing price and broader availability 
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of genotyping technology and economic development open future scenarios in which genotype-based 
dosing approaches may be economically viable and beneficial even in developing countries. The 
IMPAACT P1070 study, which is currently being conducted in HIV-infected infants and children, should 
hopefully give more insight into practical implications of genotyping in low- and middle-income 
countries. 
Similarly to previous paediatric studies, the average clearance value (before inclusion of genotype 
effect) was higher than findings in adults - 14.34 L/h versus 7.5 to 11.7 L/h (both after scaling with 
allometry up to 70 kg).34,168–170,172 This is consistent with reports that efavirenz clearance in children 1-
4 years exceeds adult values.32,34,277 In keeping with previously published paediatric models, the effect 
of size on clearance and volume was explained through allometric scaling.34,162,225 Unlike Salem et al. 
we did not observe age-related maturation of clearance, but the previous analysis showed that 90% 
of maturation was reached by the age of 9 months162 and the majority of patients in the current study 
were >3 years. 
We detected significant differences in absorption parameters between CHAPAS-3 and ARROW, 
possibly related to the use of different formulations (tablets in former and mostly capsules in latter). 
The formulations were assumed to be bioequivalent and indeed no formulation effect on 
bioavailability was detected. 
Due to the availability of data from multiple sampling occasions within the same patient, it was 
possible to characterise both BSV and BOV in the PK parameters. Large BOV was identified for 
absorption parameters and bioavailability. Drug absorption is widely known to be a variable 
phenomenon, depending on occasion-specific factors, such as food intake, gastric emptying times, 
and GI-tract pH. In the current study, other factors may have contributed to inflating BOV (in particular 
on bioavailability), including differences between actual and self-reported intake times for the sparse 
data, lack of accurate intake history before the last dose, lack of information on accompanying food 
consumption. The fact that the information about intensively sampled occasions was more accurate 
was accounted for with the introduction of a scaling factor on residual unexplained variability (2-fold 
larger for sparse data).  
The current study had several limitations. As mentioned, the dosage timing and food co-
administration was not recorded beyond the last intake. Previous studies showed that efavirenz PK 
was affected by adherence and food effects.63,164,172 Polymorphisms in accessory pathways including 
CYP2A6 and CYP3A4 or UGT were not assessed and the effect of CYP2B6 785A>G was only evaluated 
in patients from the ARROW study. Despite several reports suggesting that efavirenz metabolism is 
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affected by polymorphisms in those pathways, the genome-wide association study by Holzinger et al. 
showed that their effect was significantly less dramatic than for 516G>T and 983T>C.176 
Furthermore, no PK/PD relationship was explored in this analysis for either efficacy or toxicity, but 
currently accepted therapeutic ranges were used as cut-offs guiding dose optimisation. These targets 
were generated in an adult cohort and have recently been brought into question suggesting that lower 
efavirenz concentrations might be sufficient to provide viral suppression,103 however no alternative 
has been suggested to date. 
Lastly our study was underpowered to determine the effect of tuberculosis treatment on efavirenz 
concentrations, but recent findings suggest that the inducing effect of rifampicin on clearance is 
counterbalanced by a concentration-dependent inhibitory effect of isoniazid that could explain 
contradictory conclusions from previous studies.71,74,170  
4.6 Conclusions 
Our study suggests that genotype-adjusted efavirenz dosage in African children should be based on 
the composite 516G>T|983T>C SNP-vector, due to significant modification of clearance rates caused 
by SNP 983T>C genotype, whose prevalence in Africans is much higher than other populations. Using 
nonlinear mixed-effects modelling we quantified this effect and suggest that a dose optimisation 
algorithm 1:0.66:0.33:0.1 (EM:IM:SM:USM, respectively) would provide more balanced drug 
exposures between individuals with a different metabolic status while maximising the potential of 
using the new double-scored efavirenz tablets tested in the CHAPAS-3 study. The findings warrant 
further studies evaluating the genotype-based dosing approach and the feasibility of genotyping in 
resource-limited settings. 
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4.10 APPENDIX TO CHAPTER 4 
4.10.1 Supplementary figures 
 
Figure 4.4 Goodness of fit plots for the final efavirenz population pharmacokinetic model 
Note: Top left – observations vs population predictions; top right – observations vs individual predictions; 
bottom left – conditional weighted residuals vs time after dose; bottom right – absolute values of individual 
weighted residuals vs individual predictions 
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Figure 4.5 Visual Predictive Check of the final efavirenz population pharmacokinetic model by 516G>T|983T>C SNP vector in 
semi-log scale.  
Note: Hollow points – observations, red solid line – median of observed data, red line with breaks – 5th and 95th 
percentile of observed data, orange fill area – 95% confidence interval of simulated median, blue fill area - 95% 
confidence interval of simulated 5th and 95th percentile 
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4.10.2 Supplementary tables 
Table 4.6 Simulated values of efavirenz mid-dose concentrations obtained under various dosage scenarios and proportions 
of patients <1mg/L, 1mg/L>&<4mg/L and >4mg/L 
Weight 
Band 
[kg] 
Metabolic 
group 
FM IM SM USM 
SNP Vector 
516GG| 
983TT 
516GG| 
983TC 
516GT| 
983TT 
516GT| 
983TC 
516TT| 
983TT 
516GG| 
983CC 
10-13.9 
Dose [mg] 300 200 100 50 
C12h [mg/L] 
2.02 
(0.47-8.04) 
2.49 
(0.64-9.11) 
1.93 
(0.50-7.42) 
3.71 
(1.08-14.01) 
2.63 
(0.67-10.04) 
3.57 
(0.83-12.43) 
>4 [mg/L] 21% 29% 20% 46% 30% 45% 
1> & <4 
[mg/L] 60% 58% 59% 50% 57% 49% 
<1 [mg/L] 20% 13% 21% 4% 12% 7% 
14-19.9 
Dose [mg] 400 300 150 50 
C12h [mg/L] 
2.11  
(0.52-7.86) 
2.98  
(0.79-10.90) 
2.22  
(0.57-8.68) 
4.30  
(1.10-15.77) 
3.04  
(0.79-11.12) 
2.70  
(0.79-9.99) 
>4 [mg/L] 22% 36% 24% 53% 37% 30% 
1> & <4 
[mg/L] 
60% 55% 59% 43% 54% 60% 
<1 [mg/L] 19% 9% 16% 4% 9% 10% 
20-24.9 
Dose [mg] 600 400 200 100 
C12h [mg/L] 
2.55  
(0.63-9.98) 
3.11  
(0.76-12.07) 
2.47  
(0.62-8.98) 
4.6  
(1.27-16.79) 
3.31  
(0.87-12.68) 
3.84  
(1.13-14.30) 
>4 [mg/L] 29% 38% 28% 57% 41% 47% 
1> & <4 
[mg/L] 
58% 54% 58% 40% 52% 48% 
<1 [mg/L] 13% 8% 14% 3% 7% 4% 
25-29.9 
Dose [mg] 600 400 200 100 
C12h [mg/L] 
2.10  
(0.52-8.12) 
2.80  
(0.67-10.20) 
2.14  
(0.54-8.14) 
3.92  
(1.04-14.74) 
2.84  
(0.73-10.42) 
3.31  
(0.93-12.77) 
>4 [mg/L] 22% 34% 22% 49% 34% 42% 
1> & <4 
[mg/L] 
58% 55% 60% 47% 56% 53% 
<1 [mg/L] 19% 12% 18% 5% 10% 6% 
30-39.9 
Dose [mg] 600 400 200 100 
C12h [mg/L] 
1.80  
(0.43-7.11) 
2.27  
(0.57-8.42) 
1.76  
(0.45-6.75) 
3.30  
(0.87-12.59) 
2.32 
 (0.61-8.87) 
3.06  
(0.77-12.74) 
>4 [mg/L] 16% 24% 16% 40% 26% 36% 
1> & <4 
[mg/L] 
60% 60% 60% 53% 59% 55% 
<1 [mg/L] 24% 16% 25% 7% 15% 9% 
Note: Data presented as median (5th-95th percentile) or percentage. EM (extensive metabolisers) - 
516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (slow metabolisers) - 
516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 516GG|983CC.  
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4.10.3 NONMEM control stream 
; Model descr: FINAL EFV model 
 
$SIZES      LVR=50 
$PROBLEM    EFV PK PGx 
;----------------------------------------------------------------------------------------------------------------------------------- 
$INPUT      ID EVENT=DROP SPK STUDY IND WHAT=DROP DAT1=DROP TIME OCC 
                    OCC_CL OBS AMT DV MDV EVID NRTI TB SITE AGE SEX WT HT WAZ 
                    HAZ DOSE TRAD_MED TRAD_MED_CODE G516T T983C rs480349 A785G 
                    rs35599367 rs776746 rs3003596 rs2307424 rs2472677 PGX3 MET 
                    wghtband FLAG COMMENTS=DROP 
;---------------------------------- ------------------------------------------------------------------------------------------------ 
$DATA      EFV_NONMEM_BOTH_14Apr2015v2.csv IGNORE=@ IGNORE=(FLAG.EQ.1) 
 
;---------------------------------- ------------------------------------------------------------------------------------------------ 
$ABBREVIATED COMRES=2 
$SUBROUTINE ADVAN13 TRANS1 TOL=9 
;---------------------------------- ------------------------------------------------------------------------------------------------ 
$MODEL      NCOMP=3 COMP=(DEPOT DEFDOSE) COMP=(CENTRAL DEFOBS) 
            COMP=(PERI) 
;----------------------------------------------------------------------------------------------------------------------------------- 
 
;; Initial estimates Theta and Omega 
$THETA (0,6.853900,15)        ; 1 516GG 983TT TVCL  [L/h] 
$THETA (0,62.42090,200)      ; 2 TVV2 [L] 
$THETA (0,0.729018,5)           ; 3 TVKA [1/h] 
$THETA (0,0.098377,5)           ; 4 ADD error 
$THETA (0,0.067533,1)           ; 5 PROP error [] 
$THETA (0,17.35440,30)         ; 6 TVQ [L/h] 
$THETA (0,92.86670,400)       ; 7 TVV3 [L] 
$THETA (0,0.803833,8)           ; 8 TVMTT [h] 
$THETA (0.1,3.213450,8)        ; 9 LOG NN[] 
$THETA (0,2.009010,5)           ; 10 SPK ERROR [] 
$THETA (0,3.931,10)               ; 11 516GG 983TC TVCL  [L/h] 
$THETA (0,0.738663,10)         ; 12 516GG 983CC TVCL  [L/h] 
$THETA (0,4.81844,10)           ; 13 516GT 983TT  TVCL  [L/h] 
$THETA (0,1.35335,10)           ; 14 516GT 983TC TVCL  [L/h] 
$THETA (0,1.94779,10)           ; 15 516TT 983TT TVCL  [L/h] 
$THETA (-0.99,0.67467,3)       ; 16 KA ARROW [% change] 
$THETA (-0.99,0.578425,3)     ; 17 MTT ARROW [% change] 
 
$OMEGA  0.156951          ; 1 BSVCL 
$OMEGA  0  FIX                 ; 2 BSVV2 
$OMEGA  0  FIX                 ; 3 BSVKA 
$OMEGA  0  FIX                 ; 4 BSVQ 
$OMEGA  0  FIX                 ; 5 BSVMTT 
$OMEGA  0.174540          ; 6 BSVBI0 
$OMEGA  0  FIX                 ; 7 BSVV3 
$OMEGA  BLOCK(1) 
 0.229487                           ; BOVBIO OCC 1 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.763071                         ; BOVMTT OCC 1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.332270                          ; BOVKA OCC 1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.080154                         ; BOVCL OCC 1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
;------------------------------------------------------------------------------------------------------------------------------------ 
$PK                  
;----- Allometric Scaling ------------------------------------------------------------------------------------------------------ 
   TVWT = 15.4                ; Median weight in kg 
   ALLMCL=(WT/TVWT)**0.75  
   ALLMV=WT/TVWT  
    
;----- DEFINE VARIABILITY  -------------------------------------------------------------------------------------------------- 
;----- BSV ------------------------------------------------------------------------------------------------------------------------ 
   BSVCL     = ETA(1) 
   BSVV2    = ETA(2) 
   BSVKA    = ETA(3) 
   BSVQ      = ETA(4) 
   BSVMTT = ETA(5) 
   BSVBIO   = ETA(6) 
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    BSVV3     = ETA(7) 
    
;----- BOV ------------------------------------------------------------------------------------------------------------------------ 
   BOVBIO =ETA(8)                                      ;OCC=1 lag doses and pre-dose are treated as same occasion  
   IF (OCC.GT.1.5.AND.OCC.LE.2.5) BOVBIO = ETA(9)  ;OCC=2 
   IF (OCC.GT.2.5.AND.OCC.LE.3.5) BOVBIO = ETA(10) ;OCC=3 
   IF (OCC.GT.3.5.AND.OCC.LE.4.5) BOVBIO = ETA(11) ;OCC=4 
   IF (OCC.GT.4.5.AND.OCC.LE.5.5) BOVBIO = ETA(12) ;OCC=5 
   IF (OCC.GT.5.5.AND.OCC.LE.6.5) BOVBIO = ETA(13) ;OCC=6 
   IF (OCC.GT.6.5.AND.OCC.LE.7.5) BOVBIO = ETA(14) ;OCC=7 
   IF (OCC.GT.7.5.AND.OCC.LE.8.5) BOVBIO = ETA(15) ;OCC=8 
   IF (OCC.GT.8.5.AND.OCC.LE.9.5) BOVBIO = ETA(16) ;OCC=9 
    
   BOVMTT = ETA(17)                                                           ;OCC=1 
   IF (OCC.GT.1.5.AND.OCC.LE.2.5) BOVMTT = ETA(18) ;OCC=2 
   IF (OCC.GT.2.5.AND.OCC.LE.3.5) BOVMTT = ETA(19) ;OCC=3 
   IF (OCC.GT.3.5.AND.OCC.LE.4.5) BOVMTT = ETA(20) ;OCC=4 
   IF (OCC.GT.4.5.AND.OCC.LE.5.5) BOVMTT = ETA(21) ;OCC=5 
   IF (OCC.GT.5.5.AND.OCC.LE.6.5) BOVMTT = ETA(22) ;OCC=6 
   IF (OCC.GT.6.5.AND.OCC.LE.7.5) BOVMTT = ETA(23) ;OCC=7 
   IF (OCC.GT.7.5.AND.OCC.LE.8.5) BOVMTT = ETA(24) ;OCC=8 
   IF (OCC.GT.8.5.AND.OCC.LE.9.5) BOVMTT = ETA(25) ;OCC=9 
    
   BOVKA = ETA(26)                                                           ;OCC=1 
   IF (OCC.GT.1.5.AND.OCC.LE.2.5) BOVKA = ETA(27) ;OCC=2 
   IF (OCC.GT.2.5.AND.OCC.LE.3.5) BOVKA = ETA(28) ;OCC=3 
   IF (OCC.GT.3.5.AND.OCC.LE.4.5) BOVKA = ETA(29) ;OCC=4 
   IF (OCC.GT.4.5.AND.OCC.LE.5.5) BOVKA = ETA(30) ;OCC=5 
   IF (OCC.GT.5.5.AND.OCC.LE.6.5) BOVKA = ETA(31) ;OCC=6 
   IF (OCC.GT.6.5.AND.OCC.LE.7.5) BOVKA = ETA(32) ;OCC=7 
   IF (OCC.GT.7.5.AND.OCC.LE.8.5) BOVKA = ETA(33) ;OCC=8 
   IF (OCC.GT.8.5.AND.OCC.LE.9.5) BOVKA = ETA(34) ;OCC=9 
    
   BOVCL = ETA(35)                                                                        ;OCC=1 
   IF (OCC_CL.GT.1.5.AND.OCC_CL.LE.2.5) BOVCL = ETA(36) ;OCC=2 
   IF (OCC_CL.GT.2.5.AND.OCC_CL.LE.3.5) BOVCL = ETA(37) ;OCC=3 
   IF (OCC_CL.GT.3.5.AND.OCC_CL.LE.4.5) BOVCL = ETA(38) ;OCC=4 
   IF (OCC_CL.GT.4.5.AND.OCC_CL.LE.5.5) BOVCL = ETA(39) ;OCC=5 
   IF (OCC_CL.GT.5.5.AND.OCC_CL.LE.6.5) BOVCL = ETA(40) ;OCC=6 
   IF (OCC_CL.GT.6.5.AND.OCC_CL.LE.7.5) BOVCL = ETA(41) ;OCC=7 
 
    
;----- DEFINE POPULATION PARAMETERS -------------------------------------------------------------------------------  
;----  CL BASED ON MIXTURE MODEL ------------------------------------------------------------------------------------ 
EST=MIXEST 
 
PGX_EST=PGX3                                                                      ; patients with available genotype 
 
IF (PGX_EST.EQ.99.AND.MIXNUM.EQ.1)  PGX_EST=1      ; 516GG 983TT - from mixture model 
IF (PGX _EST.EQ.99.AND.MIXNUM.EQ.2) PGX_EST=2      ; 516GG 983TC - from mixture model 
IF (PGX _EST.EQ.99.AND.MIXNUM.EQ.3) PGX_EST=3      ; 516GG 983CC - from mixture model 
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IF (PGX _EST.EQ.99.AND.MIXNUM.EQ.4) PGX_EST=4      ; 516GT 983TT- from mixture model 
IF (PGX _EST.EQ.99.AND.MIXNUM.EQ.5) PGX_EST=5      ; 516GT 983TC - from mixture model 
IF (PGX _EST.EQ.99.AND.MIXNUM.EQ.6) PGX_EST=6      ; 516TT 983TT- from mixture model 
 
IF (PGX _EST.EQ.1) THEN           CLPGX = THETA(1)      ; 516GG 983TT 
ELSEIF (PGX _EST.EQ.2) THEN   CLPGX = THETA(11)    ; 516GG 983TC 
ELSEIF (PGX _EST.EQ.3) THEN   CLPGX = THETA(12)    ; 516GG 983CC 
ELSEIF (PGX _EST.EQ.4) THEN   CLPGX = THETA(13)    ; 516GT 983TT 
ELSEIF (PGX _EST.EQ.5) THEN   CLPGX = THETA(14)    ; 516GT 983TC 
ELSEIF (PGX _EST.EQ.6) THEN   CLPGX = THETA(15)    ; 516TT 983TT 
    ENDIF 
;---------------------------------------------------------------------------------------------------------------------------------- 
  
   TVCL   = CLPGX * ALLMCL   ; typical value of CL 
   TVV2  = THETA(2) *ALLMV          ; typical value of V 
   TVQ    = THETA(6) *ALLMCL        ; typical value for Q 
   TVV3  = THETA(7) *ALLMV          ; typical value for V3 
   TVNN = EXP(THETA(9))                 ; typical number of transit compartments 
   TVBIO= 1 
    
   COVKA=0 
   IF(STUDY.EQ.1) COVKA=THETA(16)    ; % increase in ka for ARROW 
   TVKA = THETA(3) *(1+COVKA)             ; typical value of KA 
     
   COVMTT=0 
   IF(STUDY.EQ.1) COVMTT=THETA(17) ; % increase in MTT for ARROW 
   TVMTT= THETA(8)*(1+COVMTT)        ; typical mean transit time 
     
 
;----- DEFINE INDIVIDUAL PARAMETERS -------------------------------------------------------------------------------- 
  CL     = TVCL *EXP(BSVCL+BOVCL)             ; individual value of CL 
  V2    = TVV2 *EXP(BSVV2)                           ; individual value of V2 
  KA    = TVKA *EXP(BSVKA+BOVKA)            ; individual value of KA 
  Q      = TVQ   *EXP(BSVQ)                             ; individual value of Q 
  V3    = TVV3  *EXP(BSVV3)                           ; individual value of V3 
  MTT = TVMTT*EXP(BSVMTT+BOVMTT)    ; individual value of MTT 
  NN   = TVNN                                                    ; individual value of NN 
  BIO   = TVBIO *EXP(BSVBIO+BOVBIO)        ; individual value of BIO 
   
;------------------ TRANSFER RATE CONSTANTS ------------------------------------------------------------------------- 
  K    = CL/V2 
  K23  = Q/V2 
  K32  = Q/V3 
 
 ; RESET code for Cmax Tmax 
IF (NEWIND/=2.OR.EVID>=3) THEN  
 COM(1)=0 
 COM(2)=0 
 TIMEDOSE = TIME 
 AMOUNTDOSE = AMT 
ENDIF  
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 ;----------------------  TRANSIT  --------------------------------------------------------------------------------------------- 
  
F1=0                              ; I need to set bioavailability in compartment 1 to 0 
 
KTR = (NN+1)/MTT 
  
IF (NEWIND/=2.OR.EVID>=3) THEN ; new individual, or reset event 
    ; The values read here will be stored in TDOS and PD in this very PK call 
 TNXD=TIME ; Time of the dose 
 PNXD=AMT ; Amount. If it's zero, the DE is deactivated. 
ENDIF 
 
TDOS=TNXD ; This will either save here the temporary values if it's a new individual... 
PD=PNXD ; ...or the values which were read one record ahead during the execution of the previous 
record. 
 
IF(AMT.GT.0) THEN ; This reads one record ahead and stores the data to be used when running the 
following record 
 TNXD=TIME 
 PNXD=AMT 
ENDIF 
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
; approximation of log of gamma(n), 0.572364942 is LOG(PI)/2 
; To speed up the computation, I calculate here all the non-time-varying quantities used in $DES 
PIZZA=LOG(BIO*PD*KTR+0.00001)-LNGAM ; without +0.00001, it won't work with ETAs in 
bioavailability 
 
;---------------- Initialisation for DES solver  ------------------------------------------------------------------------------ 
; SS option causes model to crash due to some low concentrations 
; Instead initialise the compartments with approximated SS Cmin (see below) 
; Based on individual parameter values  
; 2 CMT model - CALCULATE ALPHA AND BETA 
 
  K20=K 
  TMP0 = K20*K32                                                 ; ALPHA * BETA 
  TMP1 = K20+K23+K32                                        ; ALPHA + BETA 
  TMPDELTA = SQRT(TMP1*TMP1 - 4* TMP0) ; SQ ROOT FROM EQUATION 
  SOL1 = (TMP1 + TMPDELTA) / 2                       ; ALPHA  
  SOL2 = (TMP1 - TMPDELTA) / 2                        ; BETA  
   
  ALFA  = SOL1 
  BBETA = SOL2 
  VBETA = CL / SOL2                                               ; VBETA=CL/BETA – approx of volume in terminal phase 
 
; SEQUENCE FOR INITIATION OF $DES 
  TAU_EQ=MTT+1/KA 
  KA_EQ=1/TAU_EQ                                              ; because we’re using TRANSIT absoprtion 
   
 ; treat both compartments as one single compartment at steady state  
 ; Cmin cent = approx Cmin per (should be approx at equilibrium) 
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; SUBSTITUTE V BY VBETA AND K BY SOL2 (BETA) – just an approximation 
; Followed with additional 5 days of dosing to make sure patient is at steady state 
 
  CMIN = ( (BIO*DOSE * KA_EQ) /(VBETA*(KA_EQ - SOL2)))*( (1 / (1- EXP(-SOL2 * 24)))-(1 / (1- EXP(-
KA_EQ*24))) ) 
   
  A_0(1)= 0.0001                           ; initialise absorption CMT 
  A_0(2)= V2 * CMIN                    ; initialise central CMT 
  A_0(3)= V3 * CMIN                    ; initialise peri CMT 
  
$DES                       
TEMPO=T-TDOS                        ; this is time after dose, it should always be >= 0 
KTT=0 
 
DADT(1)=0 
;incorporated code to switch off depot compartment after 16hr to speed up model runs 
IF(PD.GT.0.AND.TEMPO.GT.0.AND.TEMPO.LT.16) THEN ; This happens only id PD>0, so only if a dose 
has been detected 
                   KTT=KTR*(TEMPO) 
                   DADT(1)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KA*A(1) 
                   DADT(2)= KA*A(1)- K23*A(2) + K32*A(3) - K*A(2) 
                ELSE 
                   DADT(1)=0 
                   DADT(2)= - K23*A(2) + K32*A(3) - K*A(2) 
ENDIF 
 
   DADT(3)= K23*A(2) - K32*A(3)   
    
; For Cmax Tmax 
CP = A(2)/V2                                           ; plasma concentration    
TIMEAFTERDOSE=T-TIMEDOSE 
 IF (CP.GE.COM(1)) THEN 
 COM(1) = CP                             ; CMAX 
 COM(2) = TIMEAFTERDOSE     ; time of CMAX 
ENDIF    
 
;------------------------------------- MIXTURE MODEL  ----------------------------------------------------------------------  
$MIX       NSPOP=6  
; proportions set to ones observed in patients 
P(1) = 0.33     ; prop of 516GG 983TT 
P(2) = 0.06     ; prop of 516GG 983TC 
P(3) = 0.01     ; prop of 516GG 983CC 
P(4) = 0.34      ; prop of 516GT 983TT 
P(5) = 0.07     ; prop of 516GT 983TC 
P(6) = 0.19      ; prop of 516TT 983TT 
;------------------------------------------------------------------------------------------------------------------------------------ 
$ERROR                 
  IPRED = A(2)/V2                             ; Individual prediction PK (CMT=2) 
  IRES     = DV - IPRED                       ; Individual residual 
 
  WA    = THETA(4)                            ; Additive error 
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   WP    = IPRED * THETA(5)                  ; Prop error 
  W     = SQRT(WA**2 + WP**2)         ; Weighting factor for residuals 
  IF(W.LE.0.0001) W = 0.0001              ; Protection against division with 0 
 
  IF(SPK.GT.0.5.AND.SPK.LT.1.5) W = W*(THETA(10))     ; Additional error term for sparse data 
   
  IWRES = IRES / W 
  Y     = IPRED + W*EPS(1)      ; Model prediction of observed PK value with additive + proportional error 
 
 AA1 = A(1)                             ; abs CMT 
 AA2 = A(2)                             ; central CMT 
 AA3 = A(3)                             ; peri CMT 
 CMAX = COM(1)                   ; CMAX 
 TMAX = COM(2)                   ; TIME OF CMAX 
 AUC_INF =  DOSE*BIO/CL  ; because no temporal effects 
 VAR_AUC = (BSVBIO + BOVBIO) - (BSVCL + BOVCL) 
 
 TVPC=TIME-120                    ; approx for plotting VPC/ (time - 5x 24h ->imputed 5 days of dosing) 
 TAD =TIME-TIMEDOSE  
 
IF(AMT.GT.0) THEN 
 TIMEDOSE = TIME 
 AMOUNTDOSE = AMT 
; Reset CMAX code when a new dose is given  
 COM(1)=0 
 COM(2)=0 
ENDIF 
   
  IF (ICALL==4.AND.Y.LE.0.1) Y=0.05 ; prevents negative simulated values for VPC 
;------------------------------------------------------------------------------------------------------------------------------------ 
$SIGMA  1  FIX  ; Scaled RUV variance - all error is going to the thetas and it makes SD 
$ESTIMATION MSFO=msf910 MAXEVAL=0 PRINT=1 METHOD=1 INTER MCETA=1000 
            RANMETHOD=4P ETASTYPE=1 NONINFETA=1 NOABORT NSIG=3 SIGL=9 
            ATOL=9  
$ESTIMATION MSFO=msf910 MAXEVAL=9999 PRINT=1 METHOD=1 INTER MCETA=5 
            RANMETHOD=4P ETASTYPE=1 NONINFETA=1 NOABORT NSIG=3 SIGL=9 
            ATOL=9  
 
$COVARIANCE PRINT=E SIGL=12 TOL=10 ATOL=12; values for high precision 
 
$TABLE      WRESCHOL ID DV OCC OCC_CL EVID MDV TAD TVPC TIME PRED 
            IPRED DOSE AA1 AA2 AA3 IWRES WRES CWRES NPDE OBJI 
            ESAMPLE=100 NOPRINT ONEHEADER FILE=sdtab910 
$TABLE      ID CL V2 KA BIO K Q V3 AUC_INF VAR_AUC NN MTT BSVCL BSVV2 
            BSVKA BSVQ BSVV3 BSVBIO BSVMTT BOVBIO BOVKA BOVMTT WA WP 
            NOPRINT NOAPPEND ONEHEADER FILE=patab910 
$TABLE      ID AGE HT WT WAZ HAZ NOPRINT NOAPPEND ONEHEADER 
            FILE=cotab910 
$TABLE      ID SPK STUDY IND SEX SITE DOSE NRTI TB TRAD_MED 
            TRAD_MED_CODE PGX3 wghtband G516T T983C rs480349 A785G 
            rs35599367 rs776746 rs3003596 rs2307424 rs2472677 MET PGX_EST 
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            NOPRINT NOAPPEND ONEHEADER FILE=catab910 
$TABLE      ID DV CP OCC SPK STUDY IND FLAG OCC_CL EVID MDV TAD TVPC 
            TIME AA1 AA2 AA3 CL V2 KA BIO K Q V3 NN MTT BSVCL BSVV2 
            BSVKA BSVQ BSVV3 BSVBIO BSVMTT BOVBIO BOVKA BOVMTT AUC_INF 
            VAR_AUC TMAX CMAX CMIN WA WP AGE HT WT WAZ HAZ HT WT WAZ 
            HAZ SEX SITE DOSE NRTI TB TRAD_MED TRAD_MED_CODE PGX3 PGX_EST MET  
            wghtband G516T T983C rs480349 A785G rs35599367 rs776746 
            rs3003596 rs2307424 rs2472677 NOPRINT NOAPPEND ONEHEADER 
            FILE=mytab910.csv FORMAT=, 
; Xpose can read these tables 
 
; there must be one empty line after the last command line 
 
;-------------------------------- 
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5.1 Abstract: 
Background: Due to insufficient evidence in children, target plasma concentrations of efavirenz are 
based on studies in adults. Our analysis aimed to evaluate the paediatric therapeutic thresholds and 
characterise the determinants of virological suppression in African children. 
Methods: We analysed data from 128 African children (aged 1.7-13.5 years) treated with efavirenz, 
lamivudine, and either abacavir, stavudine, or zidovudine, and followed up to 36 months. Individual 
pharmacokinetic measures (C12h, C24h and AUC0-24) were estimated using population-
pharmacokinetic modelling. Cox multiple failure regression and multivariable fractional polynomials 
were used to investigate the risks of unsuppressed viral load associated with efavirenz exposure and 
other factors amongst 106 initially treatment-naïve children, and likelihood profiling used to identify 
the most predictive pharmacokinetic thresholds. 
Results: The risk of viral load >100 copies/mL decreased by 42% for every 2-fold increase in efavirenz 
mid-dose concentration (95% CI:  23-57%; p<0.001). The most predictive PK thresholds for increased 
risk of unsuppressed viral load were: C12h 1.12 mg/L (HR=6.14; 95% CI: 2.64-14.27), C24h 0.65 mg/L 
(HR=6.57; 95% CI: 2.86-15.10), and AUC0-24 28 mg∙h/L (HR=5.77; 95% CI: 2.28-14.58). Children over 8 
years old had a more than 10-fold increased risk of virological non-suppression (p=0.005); among 
children under 8 years old boys had a 5.31 times higher risk than girls (p=0.007). Central nervous 
system AEs were infrequently reported. 
Conclusions: Our analysis suggests the minimum target C24h and AUC0-24 could be lowered in children. 
Our findings should be confirmed in a prospective paediatric trial. 
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5.2 Introduction 
The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is recommended by the World 
Health Organization (WHO) as part of first-line treatment for HIV-infected children aged over 3 years.11 
Due to its high potency, long half-life, and availability of low cost generic formulations, efavirenz 
continues to be one of the most widely used antiretrovirals in Africa and worldwide.155 The mid-dose 
plasma concentration target of 1.0-4.0mg/L derived from adult clinical monitoring data is customarily 
also applied to trough concentrations.93,94 In adults, systemic exposure below that range is associated 
with virological failure and higher exposures with central nervous system (CNS) toxicities.69,94,168 The 
same target range is used in children, however rigorous analyses have not confirmed the optimal 
therapeutic range for this age group.32,99,100,105,284 
The main objective of a pharmacokinetic/pharmacodynamic (PK/PD) analysis is to quantify the 
relationships between drug dose, exposure and response, identifying factors affecting drug disposition 
and efficacy.93 While the high variability in efavirenz PK in children has been thoroughly 
studied,34,74,75,162 analyses successfully relating observed drug exposures to treatment response and 
detecting other determinants of treatment failure are limited.32,100,101 Factors affecting efavirenz 
effectiveness have often been investigated independently of drug concentrations with inconclusive 
findings across studies, 99,100,149–151,279 similarly the effect of high efavirenz exposure on increased risk 
of CNS AEs is unconfirmed in children.96–99  
The recent results of ENCORE1,102,103 showing that the standard 600mg efavirenz dose can be reduced 
to 400mg daily without loss of efficacy in non-pregnant adults, have prompted discussions on the 
validity of the widely accepted efficacy thresholds of >1 mg/L, for a mid-dose interval or trough 
concentration,103 and suggest that the target range used for children should also be re-evaluated. Our 
analysis therefore aimed to characterise associations between systemic exposure to efavirenz and risk 
of virological non-suppression and CNS AEs over the longer-term, to identify factors affecting 
virological non-suppression independently of systemic exposure and to validate the lower boundary 
of the therapeutic range for efavirenz in African children.   
5.3 Methods 
5.3.1 Population and Study Design 
As described previously,382 the CHAPAS-3 study enrolled HIV-infected antiretroviral therapy (ART) 
naïve and experienced children 13 years or younger in four sites in Uganda and Zambia. Of 478 
participants, 128 received efavirenz and lamivudine combined with either abacavir, stavudine or 
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zidovudine. Children switched to boosted protease inhibitor-based second-line ART for clinical or 
immunological failure following WHO 2010 guidelines. Samples for PK analysis were taken at week 6, 
week 36, and every 24 weeks thereafter. Efavirenz pharmacokinetics were described previously.415 
Viral load (VL) was measured retrospectively in stored plasma samples taken at enrolment and weeks 
48, 96, and 144; and at weeks 36, 60, 84, 108, and 132 when PK samples were taken. An undetectable 
VL was defined as <100 copies/mL, the lower limit of detection as many samples had to be diluted due 
to low volumes. 
5.3.2 Statistical analysis 
Empirical Bayesian Estimates for the individual parameters from the previously developed population 
PK (POP-PK) model were used to estimate steady-state mid-dose efavirenz concentrations (C12h, 
defined as plasma concentration 12 h after dose), trough concentrations (C24h, 24 h after dose), and 
AUC0-24 (area under the curve) for each child at each included timepoint.415  
Children followed for <48 weeks were excluded from all analyses. For a preliminary analysis, VL 
response was categorized as: suppressed (<100 copies/ml achieved within 48 weeks of treatment 
initiation and maintained throughout the study), single rebound (<100 copies/ml within 48 weeks and 
a single viral rebound >100 copies/ml), multiple rebounds (<100 copies/ml within 48 weeks and 
multiple viral rebounds) and never suppressed <100 copies/mL. Treatment-experienced children who 
were virologically suppressed at study enrolment were analysed separately. Since multiple PK 
exposures were available for each child, the geometric-mean exposure value (derived from all PK 
visits) for each child were compared between groups using Kruskal-Wallis and ranksum tests. 
Categorical factors were compared between groups using Fisher’s exact test.  
The effects of PK on virological non-suppression (>100 copies/ml) were then estimated using Cox 
proportional hazards regression models (Andersen-Gill repeated outcomes framework) with Efron 
approximation in R (survival package),380,402–404 including only VLs measured on PK sampling days from 
week 36 onwards in children treatment-naïve at enrolment. Samples taken before initial viral 
suppression were excluded, unless children never suppressed during the study. Each time interval ran 
from the preceding to current VL (classified as suppressed vs non-suppressed “event”), and the 
estimated PK parameters at the current VL were applied to the whole time interval. Non-linearity in 
effect of PK exposures was explored visually using smoothed splines, and tested using fractional 
polynomials (using Stata 14.0 mfp).401 The best-fitting (lowest Akaike Information Criterion [AIC]) 
dichotomous threshold was identified by profile likelihood. Because PK parameters were estimated 
and not observed, we used a re-simulation approach to assess the impact of unobserved variability on 
selection of the dichotomised threshold. The original data set was re-simulated 500 times introducing 
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a normally distributed random error on each of the exposure parameters, set to the unexplained 
residual variability from the POP-PK model (additive error 0.101 mg/L, proportional error 0.0672).415 
The results were used to derive 95% confidence interval (CI) for the threshold (2.5th and 97.5th 
percentile of distribution of most predictive cut-offs from 500 runs). 
For each PK exposure threshold identified in this study and the previously proposed efficacy 
thresholds, we calculated sensitivity (proportion of samples correctly predicted as not-suppressed), 
specificity (proportion of samples correctly predicted as suppressed), accuracy (overall proportion of 
correctly predicted samples), positive predictive value (proportion of samples with exposure below 
the threshold not suppressed), and negative predictive value (proportion of samples with exposure 
above the threshold that were suppressed).  
Finally, we used backwards elimination (exit p=0.05, retaining all levels of categorical factors where 
any were p<0.05) to consider the additional independent effects of covariates on non-suppression 
with associations (p<0.2) in univariable models. Categorical covariates included nucleoside reverse 
transcriptase inhibitor (NRTI) backbone (abacavir, zidovudine, stavudine), sex, clinical site, mother as 
primary carer, self-reported missing doses in previous 4 weeks. Continuous variables included pre-ART 
viral load, CD4% pre-ART and at time of PK/VL measurement, age, weight-for-age Z-score (WAZ),416 
height-for-age Z-score (HAZ)416 and MEMS-adherence (proportion of days without drug intake based 
on MEMS-cap container openings in the interval between previous and current measurement 
[truncated at a lower limit of 0.5]. The only covariate with incomplete information was adherence; 
where no data was available for current interval the previous MEMS-adherence was carried forward. 
If no MEMS-adherence data were available for the child (N=19) we imputed the median of all 
treatment-naïve patients). Only one child had concurrent co-administration of anti-TB drugs, so this 
factor was not considered. Non-linear effects in continuous variables were included using fractional 
polynomials (Stata mfp). Interactions between factors included in the final model were investigated 
and included if p<0.05. How much of the PK exposure effect could be explained by metabolic status 
based on 516GT|983TC single nucleotide polymorphisms (SNP)71 was then investigated by adding this 
factor into the final model. 
5.3.3 CNS adverse events 
Specific CNS toxicities relating to cognitive or motoric functions were solicited at every follow up visit 
(concentration, vivid dreams/nightmares, sleepiness/sleepwalking, waking at night, difficulty waking 
in the morning, dizziness) and graded between 1-3 (mild-severe). Incidence of CNS AEs was compared 
between groups using Fisher’s exact test.   
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Table 5.1 Demographic characteristics and model-derived PK parameters in different suppression groups of children in 
CHAPAS-3 treated with efavirenz 
 
 
Treatment-naïve at enrolment 
Treatment –
experienced at 
enrolment Suppressed 
Single 
Rebound 
Multiple 
Rebound 
Never 
Suppressed 
 
p* 
Number of children 73 19 10 7 14 p** 
Baseline  
Age [years] 
4.3 
(3.5-4.7) 
3.9 
(3.6-4.5) 
3.5 
(3.3-3.8) 
3.5 
(3.2-8.5) 
0.208 
7.3 
(5.7-8.5) 
 
<0.001 
Weight 
[kg] 
14.0 
(12.4-16.0) 
14.5 
(13.5-16.0) 
13.4 
(12.8-15.7) 
12.3 
(12.0-17.5) 
 
0.513 
20.1 
(19.3-22.6) 
 
<0.001 
CD4% 
[%] 
18.5 
(11.0-24.0) 
17.2 
(7.3-22.1) 
19.5 
(15.5-24.5) 
19.5 
(10.3-19.5) 
 
0.565 
35.6 
(31.4-37.8) 
 
<0.001 
CD4 
[cells/mL] 
707 
 (497-977) 
648  
(204-904) 
684  
(477-1047) 
618 (201-
913) 
0.429 
 
915  
(807-1249) 
<0.001 
Viral Load 
[copies/mL] 
172165 
(63250- 
338685) 
93160 
(23415- 
218830) 
175390 
(130080- 
606275) 
149080 
(69065- 
354885) 
 
0.268 
< 100 
 
<0.001 
Sex 
(M/F) 
29/44 10/9 8/2 4/3 0.133 9/5 0.091 
Metabolic 
Subgroup† 
 
FM 24 7 1 2 
 
0.073 
5 
0.173 
IM 28 6 8 3 6 
SM 21 6 -- 2 3 
USM -- -- 1 -- -- 
NRTI 
 
Stavudine 23 7 5 1 
0.738 
5 
0.908 
 
Zidovudine 26 6 2 4 4 
Abacavir 24 6 3 2 5 
PK  
measure 
AUC0-24 
[mg∙h/L] 
57.1  
(37.1-
101.4) 
57.8  
(45.9-
121.8) 
46.6  
(42.8-78.0) 
36.8  
(13.6-74.0) 
0.360 
77.7  
(58.5-
114.2) 
0.142 
C12h [mg/L] 
2.25  
(1.43-4.11) 
2.22  
(1.77-4.96) 
1.93  
(1.65-3.08) 
1.40  
(0.5-2.83) 
0.367 
3.12  
(2.38-4.43) 
0.155 
C24h [mg/L] 
1.54  
(0.95-3.15) 
1.43  
(1.19-3.69) 
1.24  
(1.01-1.77) 
0.76  
(0.31-1.82) 
0.223 
2.27 
(1.630-
3.53) 
0.123 
Cmax [mg/L] 
4.20  
(3.03-6.28) 
4.42 (3.22-
6.59) 
3.81 (3.24-
6.99) 
3.50  
(1.07-5.62) 
0.606 
 
5.33 (4.70-
6.66) 
0.159 
CL 
[L/h] 
5.6  
(3.2-7.7) 
5.6  
(2.4-7.3) 
6.2  
(5.2-7.6) 
9.1 
(5.9-9.2) 
0.382 
6.5 (4.3-
8.3) 
0.479 
Adherence  
(MEMScaps)‡ 
1.00 
(0.97-1.00) 
0.98 
(0.95-1.00) 
0.98 
(0.91-0.99) 
0.87 
(0.69-0.95) 
0.010 
0.97  
(0.91-1.00) 
<0.001 
Note: Presented values are number or median (IQR) 
*Kruskal Wallis or Fisher’s Exact test comparing 4 groups of originally treatment-naïve children only. **Kruskal 
Wallis or Fisher’s Exact test comparing 5 groups including children who were treatment-experienced at 
enrolment. †EM (extensive metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 
516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 
516GG|983CC; ‡Data from 104 patients (91 treatment-naïve and 13 treatment-experience at enrolment) 
 
 121 
 
CHAPTER 5: Plasma efavirenz exposure, sex, and age predict virological response in 
HIV-infected Afrcan children 
Doctoral Thesis by A.M. Bienczak, March 2017 
5.4 Results  
 
In total 128 children (14 treatment-experienced) received efavirenz in CHAPAS-3 and contributed a 
total of 1482 PK measurements from 570 PK visits, 345 with paired VL measurements. Five children 
with <48 week follow-up were excluded from all analyses and a further 3 children with no paired PK-
VL measurements were excluded from the Cox model. Table 5.1 shows child characteristics and 
model-derived PK parameters in each suppression group. 67% of children (n=73) who were treatment-
naïve at enrolment achieved and maintained viral suppression <100 copies/ml, 17% (n=19) had a 
single episode of viral rebound while 15% (n=17) had multiple viral rebounds or never suppressed. 
There were no statistically significant differences in baseline (pre-ART) demographic characteristics or 
geometric-mean PK parameters across study follow-up between these four groups. However, there 
was a trend to lower average exposures and higher average clearance among treatment-naïve 
children who never suppressed, compared to children who achieved and sustained viral suppression 
(pairwise ranksum: C12h p=0.11, C24h p=0.07, AUC p=0.12, CL p=0.08). Average adherence was also 
significantly lower in those who never suppressed (p=0.004 vs sustained suppression), whereas there 
was no difference in demographics between these two groups. 
Of 14 children who were treatment-experienced (and virologically suppressed) at enrolment, one had 
a single episode of viral rebound, the rest remained suppressed throughout follow-up. Children 
treatment-experienced at enrolment differed significantly from the treatment-naïve children in 
baseline characteristics, and had higher geometric-mean efavirenz exposures (all p<0.05 vs naïve 
children combined) but no difference in average clearance (p=0.63). Average adherence was 
marginally lower in treatment-experienced compared to the naïve patients (0.97 vs 1.00, p=0.006). 
 
 
5.4.1 Hazard of virological non-suppression 
Repeated measures Cox proportional hazards regression models fitted to 345 matched PK-VL samples 
from 106 treatment-naïve children indicated that the risk of virological non-suppression increased 
approximately uniformly with each fold-change in PK exposures (i.e. a log transform of PK exposure) 
(Table 5.2).  
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Table 5.2 Univariable Cox proportional hazards regression models for efavirenz C12h, C24h and AUC 
PK Par 
Change in risk per unit 
increase in absolute 
exposure 
Change in risk per 
doubling of exposure 
(per unit increase in log 
transformed exposure) 
Change in risk change at 
threshold for 
dichotomized exposure 
variables (Supplement 1) 
C12h 
[mg/L] 
HR (95% CI) 
0.87  
(0.69-1.10) 
0.58 
(0.43-0.77) 
6.14 
(2.64-14.27) 
(vs C12h>1.12mg/L) 
p-value 0.241 < 0.0001 < 0.0001 
AIC 324.11 305.76 304.55 
C24h 
[mg/L] 
HR (95% CI) 
0.86  
(0.67-1.11) 
0.60 
(0.46-0.78) 
6.57 
(2.86-15.10) 
(vs. C24h>0.65mg/L) 
p-value 0.246 < 0.0001 < 0.0001 
AIC 324.67 304.18 302.82 
AUC 
[mg∙h/L] 
HR  (95% CI) 
0.9941 
(0.9843-1.0040) 
0.57 
(0.42-0.76) 
5.77 
(2.28-14.58) 
(vs. AUC>28mg∙h/L) 
p-value 0.247 < 0.0001 < 0.0001 
AIC 324.04 305.70 307.74 
HR=Hazard ratio.  
Note: Lowest AIC values indicates the models best describing the association with viral non-suppression. Log 
transform was the best fitting fractional polynomial for C24h; for C12h and AUC the best fitting transform was 
inverse square root. However, the difference in AIC compared to log-transform was very small in both cases 
(+0.47 and +0.97) and so the log transform is presented above for comparability with C24h and ease of 
interpretation. 
 
 
Profile likelihood identified thresholds of 1.12 mg/L (95% CI from re-simulations 0.47-1.56 mg/L) for 
C12h, 0.65 mg/L (95% CI 0.25-1.27) for C24h and 28 mg∙h/L (95% CI 20.47-32.22) for AUC0-24 as the 
best dichotomised thresholds for predicting virological suppression (Figure 5.1 in the Appendix to 
Chapter 5). For AUC, the model including log exposure was superior, whereas for C12h and C24h, a 
dichotomised threshold provided a better model fit, but these margins were relatively small (Table 
5.2). 
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5.4.2 Multivariate analysis 
 
The three PK exposures were highly correlated (spearman rho >0.98), which could be expected since 
they were derived from the same population-PK model. We therefore only considered C12 in 
multivariable models. The only other factors associated (p<0.2) with virological non-suppression in 
univariate analyses were sex, site, current age and current WAZ. However only C12h, sex, site and 
current age were independent predictors (selected using backwards elimination). There was a 
significant interaction between sex and age (p=0.01), i.e. age was an effect modifier for sex. To 
represent this interaction we dichotomised age at 8 years (based on univariate profile likelihood as 
Table 5.3 Univariate and multivariate predictors of virological suppression for children in CHAPAS-3 treated with efavirenz 
Factor 
Univariate 
 
Final Multivariate Model 
 
HR (95% CI) p HR (95% CI) p 
C12h 
(per doubling) 
0.58 
(0.43-0.77) 
<0.001 0.61 (0.50-0.76) <0.001 
Sex: male vs 
female 
2.77 
(1.01-7.64) 
0.048 (see interaction below)  
Current age 
(ref. <8 years) 
 
5.45 (1.85-16.06) 0.002 (see interaction below)  
Sex and age (ref 
girl <8y) 
 
Boy <8y: 6.14 (2.01-18.77) 
Girl >8y: 16.63 (4.05-68.37) 
Boy >8y: 25.50 (3.37-193.13) 
0.001 
<0.001 
0.002 
Boy <8y: 5.31 (1.58-17.82) 
Girl >8y: 15.82 (2.97-84.27) 
Boy >8y: 12.47 (1.31-119.08) 
0.007 
0.001 
0.028 
Site 
(ref. S1) 
S2: 0.22 (0.06-0.77) 
S3: 0.39 (0.11-1.38) 
S4: 2.48 (0.69-8.99) 
0.018 
0.146 
0.166 
S2: 0.73 (0.18-2.88) 
S3: 1.04 (0.23-4.82) 
S4: 4.96 (1.38-17.79) 
0.653 
0.956 
0.014 
WAZ (per unit 
higher) 
0.66 (0.49-0.88) 0.005 -  
Note: as the final multivariable model identified a significant interaction between age and sex, this interaction 
is also presented unadjusted for other factors in the univariable column. Final model selected using backwards 
elimination, see methods. Interaction between continuous age and sex (p=0.01) dichotomised at the optimal 
age threshold for presentation. HR – hazard ratio; CI – confidence interval; 
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for PK-exposures). Adjusting for other factors, the hazard of virological non-suppression for boys <8 
years was six times greater than girls of similar age (Table 5.3). Older children had increased risk of 
virological non-suppression compared to younger children, but there was no evidence of a difference 
between boys and girls >8 years (p=0.76). The hazard of virological non-suppression was significantly 
higher in the smallest site, which contributed only 5 children. There was marginal evidence that poorer 
MEMS-adherence independently increased the hazard of virological non-suppression (p=0.065; 
effects of other factors, including C12h, were similar to Table 5.3). The remaining factors, including 
metabolizer status (p=0.27) did not have an effect on viral non-suppression (p>0.1). 
5.4.3 CNS adverse events 
Despite being solicited at every follow-up visit, only 18 CNS AEs were reported in 11 children (3 
problems with concentration, 4 vivid dreams, 2 sleep walking, 2 difficulties waking up in the mornings, 
3 waking up at night, 4 dizziness; all but one graded mild). These 11 children were 5 slow, 4 
intermediate and 2 extensive metabolisers (exact p=0.41). Nine children reported one of these AEs 
<24 weeks after treatment initiation. Only 2 children reported AEs on repeated occasions (both slow 
metabolisers), of which only 1 had a paired PK-sample: plasma efavirenz 4h after dose was 45 mg/L, 
but the child was incorrectly receiving 600mg instead of a 400mg dose.  
 
5.5 Discussion 
We observed that efavirenz concentrations were related to virological non-suppression in African 
children in a non-linear manner, a 2-fold increase in efavirenz exposure decreased the risk of 
virological non-suppression by over 40%. Some previous studies failed to detect a similar 
association,99,167,284 which could be due to a number of reasons: their follow-up time was short, they 
had only a single outcome at one time point, they were underpowered to characterise the PK/PD 
relationship or tried to simplify it by a linearisation.96,99,284 To avoid such limitations our study analysed 
a unique set of matched PK/VL longitudinal data using Cox multiple failure regression, allowing for 
repeated within-child measurements, similar to Van Leth234 and Brundage.101 This approach enabled 
us to identify the most predictive dichotomous threshold related to increased risk of VL >100 
copies/mL for each PK parameter using profile likelihood, allowing for uncertainty in estimated PK 
exposures by a resampling approach.  
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Table 5.4 Comparison of previously published treatment targets for efavirenz concentrations and AUC and most predictive 
thresholds derived in this analysis. 
 C12h [mg/L] C24h [mg/L] AUC [mg∙h/L] 
Threshold 1.0 94 1.12 1.0 94 0.65 49100 6096 28 
HR 6.36 6.14 3.96 6.57 3.16 3.84 5.77 
95% CI 2.53-15.96 2.64-14.27 1.73-9.03 2.86-15.10 1.39-7.16 1.56-9.44 2.28-14.58 
AIC 305.35 304.55 315.07 302.82 319.86 318.12 307.74 
Samples 
not-sup/sup 
(n) 
< T > T < T > T < T > T < T > T < T > T < T > T < T > T 
17/
27 
21/
281 
19/
34 
19/
274 
21/ 
66 
17/ 
242 
19/ 
32 
19/ 
276 
24/ 
101 
14/ 
207 
30/ 
153 
8/ 
155 
18/ 
32 
20/ 
276 
Sensitivity 44.7% 50.0% 55.3% 50.0% 63.2% 78.0% 44.7% 
Specificity 91.2% 88.9% 78.5% 89.6% 67.1% 50.2% 90.23% 
Accuracy 86.1% 84.7% 76.0% 85.3% 66.8% 53.5% 85.2% 
Positive 
Predictive 
Value 
38.6% 35.8 % 24.1% 37.3% 19.2% 16.4% 36.2% 
Negative 
Predictive 
Value 
93.0% 93.5% 93.4 % 93.5% 95.1 % 95.1% 92.9% 
HR –hazard ratio, 95% CI – 95% confidence interval, AIC – Akaike information criterion, PK – pharmacokinetic, T 
– cut-off target. In grey – cut-offs proposed by this analysis, in white – previously published cut-offs. 
 
 
Comparing our findings with previously proposed cut-offs (Table 5.4), the 1.12 mg/L threshold we 
obtained for C12h does not differ markedly in sensitivity, specificity, or negative predictive power from 
the 1.0 mg/L value proposed by Marzolini.94 However, our cut-offs for C24h and AUC0-24 (0.65 mg/L 
and 28 mg∙h/L, respectively) are lower than previously derived targets,32,94,100,101,234 and substantially 
improved specificity, accuracy and positive predictive power, while maintaining a negative predictive 
power comparable with previously suggested therapeutic thresholds. Whilst our revised cut-offs 
require independent validation in a prospective paediatric trial, they were determined from the PK/PD 
relationship rather than using arbitrary percentiles of PK-exposure distribution.   
The results of the ENCORE1 study question the validity of a 1 mg/L efficacy threshold in adults103 but 
due to low failure rates in the study the authors failed to detect a significant relationship between  
efavirenz exposure and the virological outcome.167 Due to design, analytical and population 
differences, our study was able to define efavirenz exposure thresholds associated with increased risks 
of virological non-suppression. Our findings should not be extrapolated to adults. Efavirenz clearance 
in children is relatively higher than in adults, which could affect the suggested cut-offs, especially for 
C24h and AUC. Furthermore, other differences in PK or pathophysiology between those populations
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Table 5.5 Comparison of efavirenz exposure targets and predictors of virological outcome in paediatric studies 
 
† target derived based on adult data, ‡ patients treated with nevirapine or efavirenz – presented results relate to efavirenz only, *two efficacy cut-offs used: (A) 400 
copies/mL, (B) 50 copies/mL; bCD4% - baseline (pre-ART) CD4 percentage, bVL – baseline (pre-ART) viral load, Cox – Cox proportional hazards regression,  IPAM – integrated 
pharmacokinetic adherence measure, Multi – multivariate analysis, TSSA - tree-structured survival analysis, Uni – univariate analysis, VL – viral load, WAZ – weight-for-age z-
score 
Reference Derived PK Targets 
Predictors of virologic failure 
n Method 
VL Target 
[copies/mL] PK Covariates 
Starr et al.96† 
AUC = 60 – 120 
mg∙h/mL 
Not analysed 
Uni: (A)* log2 bCD4% , WAZ, bVL / (B)* WAZ, bVL 
Multi: (A)* WAZ, bVL / (B)* bVL 
57 Cox 
400 (A)* 
50 (B)* 
Brundage et al.101 AUC > 59 mg∙h/mL AUC 
Uni: IPAM, bVL, bCD4%, WAZ 
Multi: IPAM, bVL, AUC 
50 Cox, TSSA 400 
Hirt et al.32 
Cmin > 1.1 mg/L 
AUC > 51 mg∙h/L 
Cmin, AUC Not analysed 48 
Fisher’s exact 
test 
300 
Fletcher et al.100 AUC > 49 mg∙h/mL AUC Not analysed 50 
logistic 
regression 
400 
Janssens et al.279  Not analysed 
Uni: Orphan status, male gender 
Multi: Orphan status 
212 
logistic 
regression 
400 
Kamaya et al.150‡ Not analysed 
Uni: male gender, bCD4%<5% 
Multi: male gender, bCD4%<5% 
250 
logistic 
regression 
400 
Jittamala et al.149‡ 
 
Not analysed 
Uni: male gender, age, adherence 
Multi: none 
202 Cox 50 
Bienczak et al. 
(this analysis) 
C12h > 1.12 mg/L 
Cmin > 0.65 mg/L 
AUC > 28 mg∙h/L 
C12h, Cmin, AUC 
Uni: male gender, age < 8 years, site, WAZ 
Multi: male gender, age < 8 years  
118 Cox 100 
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cannot be excluded and the companion drugs used in the paediatric antiretroviral regimens are 
different to those used in adults. While the threshold we identified for C12h is not markedly different 
from 1 mg/mL, our findings do not support dose reduction in children. In our previous analysis we 
reported that the average exposures across paediatric weight bands dosed according to the current 
WHO recommendations were above that cut-off.415 However, the average exposures were 
significantly affected by CYP2B6 516G>T|983T>C genotype and individuals wild type for those 
polymorphisms are at risk of sub-therapeutic exposures. The results of the current analysis support 
modifications of the paediatric dosing recommendations based on individual metabolic status. 
Among younger children (< 8 years), we found a higher risk of virological non-suppression in boys. 
Older children (>8 years) has similarly high risk of viral non-suppression in both girls and boys. This 
phenomenon could arise from differences in treatment adherence by age, as similar effects were 
observed after adjusting for MEMS adherence. Although the latter is an imperfect measure of 
adherence, numerous studies have showed that treatment adherence declines with decreasing levels 
of parental supervision over daily drug intake in older children and adolescents.417,418 It is less likely 
that different treatment adherence explains differences between younger boys and girls, in whom 
caregivers supervise medication intake. Similar effects of male sex were detected in paediatric studies 
by Janssens279, Kamaya150 and Jittamala149 (Table 5.5).  
Adherence measures are cumulative over time since the last visit, whereas PK exposures may be 
influenced by enhanced pill-taking immediately before clinic visits. In our analysis children who never 
suppressed had lower average adherence scores and a trend to lower systemic exposures than those 
who suppressed, a similar trend was identified in the multivariate analysis. In keeping with our 
findings, Brundage75 showed that the effect of adherence on the hazard of virological failure was 
independent of efavirenz exposure.  
Children who were treatment-experienced at enrolment were excluded from our main analysis for 
several reasons. Inclusion criteria required these children to have been on effective antiretroviral 
treatment for >2 years and have suppressed viral load. It is possible that they therefore had better 
adherence or were infected with HIV strains free of NNRTI resistance mutations (no pre-ART 
genotypes were available). They also differed significantly from treatment-naïve children by being 
older and healthier. Interestingly their PK exposures tended to be higher, supporting a selection effect 
whereby those with optimal viral suppression are more likely to have higher exposure. All the matched 
PK/VL samples for this group of children were suppressed and so we could not estimate the 
subsequent hazard of virological non-suppression. 
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Our study has several limitations. Most important is the risk of over-fitting the current data when 
estimating a dichotomised efficacy threshold, with lower external generalisability, which we were 
unable to test in a validation dataset. The proposed thresholds should also be interpreted in terms of 
treatment effectiveness in the clinical setting of our study population; their value may be lower in a 
setting of complete treatment adherence. Adherence in our study was measured only in certain time 
periods and participants did not use MEMS caps throughout the trial. This intermittent assessment 
could introduce error into adherence measurement, subsequently affecting the estimated effect of 
adherence on the risk of non-suppression. Moreover, the wide confidence intervals for efavirenz 
exposure thresholds predicting a detectable viral load show that larger studies are needed to define 
thresholds more precisely. We had no viral load data between treatment start and week 36 and 
therefore could not examine factors affecting time to first suppression, or the impact of PK parameters 
on VL decline. Furthermore, viral load was measured on average only every 24 weeks so our analysis 
assumes that no viral rebounds occurred between scheduled measurements.  
Despite major concerns, very little CNS toxicity was reported in these predominantly younger children, 
although this may be more important in adolescents.419 The relationship between high efavirenz 
exposures and CNS side effects detected in adults still remains unclear in children.96–99 
Lastly, antiretroviral therapy consists of a combination of drugs and its efficacy depends on all the 
components of the tested regimen. Children in CHAPAS-3 were treated with efavirenz and an NRTI 
backbone consisting of lamivudine combined with either abacavir, stavudine, or zidovudine.382 Our 
findings might not be generalisable to different drug combinations, for example, those including more 
effective companion drugs such as tenofovir, although this is still rarely used in children due to 
concerns about its impact on growth.  
5.6 Conclusions 
Efavirenz exposure predicts virological non-suppression, independently of other factors, including 
adherence, with every two-fold increase in efavirenz concentration reducing the hazard of non-
suppression by about 40%. The widely accepted lower therapeutic threshold of 1mg/L for mid-dose 
concentrations derived in adults is applicable in children, but the cut-offs for trough concentration 
and AUC0-24 could be lowered to 0.65mg/L and 28mg∙h/L, respectively. Our findings should be 
confirmed in a prospective paediatric trial. 
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5.9 APPENDIX TO CHAPTER 5 
5.9.1 Supplementary figures 
 
Figure 5.1 Profile likelihoods for virological non-suppression for the range of tested efavirenz exposures and distribution of 
identified cut-offs 
Note: In the left panels the results from the likelihood profiling procedure: the black dots are Akaike Information 
Criterion (AIC) values for dichotomised cut-offs in tested exposure parameter based on the original data, the 
blue line and shaded area are the mean and 95% confidence interval of AIC for cut-offs in the tested exposure 
parameter from 500 re-simulation runs. In the right panels the distribution of the most predictive cut-offs in 
each of the 500 re-simulation runs. From top to bottom, the results are presented for efavirenz mid-dose 
concentrations (C12h), trough concentrations (C24h) and AUC – (a) and (b), (c) and (d), (e) and (f), respectively.
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6.1 Abstract 
Objective: We aimed to characterise the effects of CYP2B6 polymorphisms, diurnal variation, and 
demographic factors on nevirapine pharmacokinetics in African children. 
Methods: Nonlinear mixed-effects modelling conducted in NONMEM 7.3 described nevirapine plasma 
concentration-time data from 414 children aged 0.3–15 years.  
Results: Nevirapine pharmacokinetics was best described using a 1-compartmental disposition model 
with elimination through a well-stirred liver model accounting for first-pass effect and transit-
compartment absorption. Intrinsic clearance was affected by diurnal variation (characterised using a 
cosine function with peak amplitude 29% at 12 noon) and CYP2B6 metaboliser status (extensive [EM] 
516GG|983TT,  reference; intermediate [IM] 516GT|983TT or 516GG|983TC, 17% lower; slow [SM]  
516TT|983TT or 516GT|983TC, 50% lower; ultra-slow [USM] 516GG|983CC, 68% lower). Age was 
found to affect pre-hepatic bioavailability: 31.7% lower at birth and increasing exponentially. Median 
(90% CI) evening Cmin in the different metaboliser groups were 5.01 (3.01-7.47), 6.55 (3.65-13.32), 
11.59 (5.44-22.71), and 12.32 (12.32-27.25) mg/L, respectively.  Evening Cmin were <3mg/L in 43% of 
EM <6kg and 26% of IM <6kg, while 73% of SM and 88% USM in all weight-bands had evening Cmin >8 
mg/L. Cmin was not markedly affected by administration time but by unequal splitting of the daily dose. 
Conclusions: Diurnal variation does not greatly affect nevirapine exposure. However, when daily doses 
cannot be split equally, the larger dose should be given in the morning. To achieve homogeneous 
exposures, nevirapine doses for SM and USM should be reduced by 50%, and children <6kg with EM 
or IM metabolizer status should receive the same dose as children weighing 6-10 kg. 
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6.2 Introduction  
Nevirapine was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) available in low-
income countries in a generic paediatric fixed-dose combination (FDC) tablet. This contributed to 
substantial cost reductions and improved feasibility of treating HIV-infected children and is still used 
in resource-limited settings.33,180,367,371 Nevirapine has several advantageous characteristics: it has 
fewer drug interactions than protease inhibitors, it does not cause central nervous system (CNS) 
adverse events when compared to efavirenz, and its bioavailability is not affected by food.420 
Despite high potency, nevirapine has a low genetic barrier for mutations and suboptimal drug 
exposures increase risks of developing drug resistance and treatment failure.341,421 Several studies 
have reported highly variable nevirapine concentrations, with levels <3 mg/L among children in the 
lower paediatric weight-bands when dosed according to WHO guidelines increasing their risk of 
virological failure.33,37,77,305,367,368,372 Nevirapine concentrations >8mg/L on the other hand were 
associated with an increased risk of treatment discontinuation due to adverse events among adults.341 
However, paediatric studies quantifying nevirapine pharmacokinetic variability due to different 
sources and suggesting  optimisation of current dosing remain limited.278,305,374  
Nevirapine has complex metabolism mediated mainly by CYP3A4 and CYP2B6 coded enzymes.301 
Single nucleotide polymorphisms (SNPs) present in CYP2B6 - 516G>T and 983T>C were identified as 
the main source of nevirapine variability in adults,72,73,198 as for efavirenz.64,180,198 The prevalence of 
516G>T loss of function (LOF) polymorphisms differs between populations and is particularly high in 
black Africans, whereas 983T>C variants are not observed among Caucasians.64,180,198 In our previous 
investigation of efavirenz pharmacokinetics (PK) in African children, we showed that extensive 
metabolisers (CYP2B6 516GG|983TT genotype), are at higher risk of developing sub-therapeutic 
efavirenz concentrations.415 A similar investigation of differences in nevirapine exposures between 
various metaboliser groups when dosed by weight-band according to current WHO guidelines has not 
yet been conducted in children. CYP2B6 expression may be further modified by polymorphisms in 
genes coding nuclear receptors CAR (NR1|3) and PXR (NR1|2),78,81 although this has not been proved 
for nevirapine.422 
The effect of the CYP3A4 pathway on nevirapine PK is less studied. Although not confirmed for 
nevirapine, systemic exposures of CYP3A substrates have been shown to be altered by SNPs 
rs35599367 (CYP3A4*22)85,86 and rs776746 (CYP3A5*1).87,88 Additionally, CYP3A activity exhibits 
diurnal variation with clearance rates increased during the day and reduced at night.89,90 Differences 
between morning and evening nevirapine trough concentrations (Cmin) have been previously reported 
91 and may relate to diurnal variation in CYP3A-mediated effects on PK.  
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The aim of this analysis was to: (i) model the steady-state population PK of nevirapine in the largest 
cohort of African children studied so far, (ii) quantify demographic and genotypic effects on nevirapine 
disposition, (iii) characterise the effect of diurnal variation on nevirapine exposures under various 
dosing scenarios, and (iv) propose optimal dosing strategies for this population.  
6.3 Methods 
In this analysis, sparsely sampled data from the CHAPAS-3 trial (Children with HIV in Africa -
Pharmacokinetics and Adherence of Simple Antiretroviral Regimens)382 was enriched with intensive 
data from an earlier PK sub-study33 (part of CHAPAS-1).107 Both studies were conducted in African 
children from Uganda and Zambia, as briefly described below. 
6.3.1 CHAPAS-1 
The trial evaluated dosing of, and adherence to, new paediatric FDC tablets: Triomune Baby 
(nevirapine 50mg, stavudine 6mg, lamivudine 30mg) and Junior (nevirapine 100mg, stavudine 12mg, 
lamivudine 60mg) dosed twice-daily according to WHO 2006 guidelines in children <14 years.56 When 
the daily dose could not be split equally, the larger dose was given at night.  
Children in the PK sub-study were sampled on one occasion at least 4 weeks after starting treatment. 
Samples were taken immediately before the observed morning dose and 1, 2, 4, 6, 8 and 12h 
subsequently. The time of the preceding evening dose was assumed to be 12h before the morning 
dose. Samples were stored and assayed using ultra high-performance liquid chromatography with UV 
detection at the Department of Pharmacy of the Radboud University Medical Centre, Nijmegen, 
Netherlands. The method was linear over the range of 0.1-10 mg/L. The average intra-assay and inter-
assay coefficients of variation (CV) and relative error (RE) were 2.9%, 2.4%, and 97%, respectively.423  
6.3.2 CHAPAS-3 
PK, toxicity, acceptability, adherence, and virological efficacy were compared between three first-line 
antiretroviral regimens in children 13 years or younger. 382 Depending on treatment allocation, 
patients received: Triomune Baby, Triomune Junior, Duovir-N Baby (nevirapine 50mg, zidovudine 
60mg, lamivudine 30mg) or nevirapine (100mg) – all paediatric formulations; or Duovir-N (nevirapine 
200mg, zidovudine 300mg, lamivudine 200mg) or Triomune30 (nevirapine 200mg, stavudine 30mg, 
lamivudine 150mg), formulated for adults. Nevirapine-based regimens were dosed twice daily 
according to WHO 2010 guidelines.11 When the daily dose could not be split equally, the larger dose 
was given in the morning. 
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Children on nevirapine were sampled during clinic visits at weeks 6, 36, and every 24 weeks thereafter 
until the end of the study; at each visit 2 samples were taken at least 2h apart. The self-reported time 
of the morning and penultimate doses were recorded. Samples were stored and analysed by liquid 
chromatography-tandem mass spectrometry at the Division of Clinical Pharmacology, University of 
Cape Town, South Africa. The method was linear over the range of 0.0195-20 mg/L. The average intra-
assay and inter-assay CV and RE were 2.9%, 2.4% and 97%, respectively. 
6.3.3 Genotyping 
Genotyping was performed on patients from CHAPAS- 3 only, by allelic discrimination real-time PCR 
assay on a DNA Engine Chromo4 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The PCR 
protocol involved an initial denaturation step at 95°C for 15 min, followed by 50 cycles of amplification 
at 95°C for 15 s and final annealing at 60°C for 1 min. TaqMan® Genotyping Master Mix and assays for 
CYP2B6 516G>T (rs3745274; ID: C_7817765_60), CYP2B6 983T>C (rs28399499; ID: C_60732328_20), 
CYP2B6 15582C>T (rs4803419; ID: C_7817764_10), CYP3A4*22 (rs35599367, C__59013445_10), 
CYP3A5 6986G>A (rs776746, C__59013445_10), NR1I3 (rs3003596, C__16194070_10 and rs2307424, 
C__25746794_20), NR1I2 63396C>T (rs2472677, C__26079845_10), ABCC10 (rs2125739, 
C__16173668_10) were obtained from Life Technologies Ltd (Paisley, UK). Opticon Monitor® version 
3.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to obtain allelic discrimination plots and 
make allele calls. 
The distribution of the genotypes was tested for Hardy-Weinberg equilibrium using the exact test in 
the R ‘genetics’ package. 
6.3.4 Population pharmacokinetic analysis 
6.3.4.1 Model building 
The steady-state PK of nevirapine was analysed using nonlinear mixed-effects modelling with 
NONMEM 7.3408 and the first-order conditional estimation method with interaction. PsN 4.4.0, Pirana, 
and Xpose were used to facilitate modelling and for model diagnostics.379 Model building was 
conducted starting with intensive PK data from CHAPAS-1 followed by sparse from CHAPAS-3.294 The 
stepwise process was guided by differences in NONMEM objective function value (OFV; proportional 
to -2 log-likelihood), inspection of goodness-of-fit (GOF) plots and visual predictive checks (VPCs), 
biological plausibility, and clinical relevance. OFV drops >3.84 between two hierarchical models after 
adding one parameter were considered a significant improvement (P≤0.05, χ2-distribution, df=1). 
Stability and robustness of the final model, together with precision of parameter estimates, was 
evaluated using nonparametric bootstrap (n=50, due to long model run times). 
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The model-derived Empirical Bayesian Estimates for the individual parameters were used to predict 
morning (AM) and evening (PM) Cmin and AUC0-12 (area under the concentration-time between dosing 
events) at steady-state for each sampling occasion and patient. 
6.3.4.2 Structural model 
1- , 2-, and 3-compartment disposition models with first-order absorption and elimination were 
tested, as well as delayed and transit comparment410 absorption. A semi-mechanistic well-stirred 
hepatic extraction model was tested for elimination, as in Gordi et.al411. The hepatic model assumed 
nevirapine fraction unbound in plasma (fu) 40%,292 hepatic plasma flow (QH) 50 L/h,424 and liver volume 
(VH) 1L411 for a typical 70 kg individual (allometrically scaled). 
Between-subject variability (BSV) and between-occasion variability (BOV) were tested on all PK 
parameters assuming lognormal distribution. Residual unexplained variability (RUV) was described 
using a combined proportional and additive structure. We excluded from the analysis data with 
uncertain dosage history and nevirapine concentrations below-limit-of-quantification (BLQ), 
presumed to be due to non-compliance294 (confirmed by undetectable concentrations of the 
companion antiretroviral drugs). Further implausible outliers were identified using visual checks and 
excluded based on conditional weighted residuals (|CWRESI|>3).  
6.3.4.3 Covariate effects 
Allometric scaling was added to the model at an early stage (before covariate testing), as suggested 
by Holford et al.225 and applied to all clearance and volume parameters. For intrinsic clearance (CLint) 
and pre-hepatic bioavailability (FpreH) we tested the effect of age using a power- , hockey-stick- , 
exponential- or sigmoidal function with/without Hill coefficient-models225. The effect of diurnal 
variations was investigated using step or cosine functions.90 Besides weight and age, the other 
covariates tested were: study site, nucleoside reverse transcriptase inhibitor (NRTI) treatment 
backbone, sex, weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ), and formulation. 
Pharmacogenetic effects were tested as individual SNPs (rs3745274, rs28399499, rs4803419, 
rs35599367, rs776746, rs3003596, rs2307424, rs2472677, rs2125739) and as metaboliser status 
determined by SNPs 516G>T and 983T>C (extensive [EM], genotype 516GG|983TT; intermediate [IM], 
single variant allele [516GT|983TT or 516GG|983TC]; slow [SM], 2 variant alleles [516TT|983CC or 
516GT|983TC]; ultra-slow [USM], 983CC irrespective of 516G>T genotype).  
Mixture modelling with frequencies fixed to those observed in study population was used to impute 
missing genotypes (predominantly in CHAPAS-1).413 Proportionality and correction factors were 
applied on RUV to test for differences between the assays and laboratories used. 
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6.3.4.4 Simulations 
For simulation (conducted with NONMEM 7.3) demographics from the 414 patients (weight 3.5 - 29.6 
kg) from the original analysis were used and enriched with 116 records of individuals weighing 20-35 
kg from CDC Growth Charts (age and corresponding median weight used).425 The final model was used 
to simulate exposures after nevirapine administration under various dosing scenarios and assuming 
3–8 mg/L as therapeutic range for nevirapine.95 Each in silico patient was re-simulated 100 times, 
changing their metaboliser status according to the proportions in the study population, which ensured 
the same distribution in each weight-band. The effect of drug intake time (6:00, 7:00, 8:00, 9:00 
AM/PM) and dose-splitting strategies (AM/PM D1:100/50 mg, D2:75/75 mg, D3:50/100 mg) was 
studied in a single patient (0.44 years, 7.2 kg, IM) simulated 1000 times. To avoid generating 
implausibly extreme values, the maximum variability for each random effect was limited to 3 standard 
deviations. Data analysis and plots generation was performed using R380. 
 
Table 6.1 Demographic characteristics of children in CHAPAS-1 and CHAPAS-3 treated with nevirapine 
Characteristics CHAPAS-1 CHAPAS-3 Combined 
No. of children 84 336 414 
No. of samples 
included 
539 2766 3305 
No. of samples 
excluded (BLQ) 
8 (0) 238 (48) 246* 
No. of sampling 
occasions 
1 3 (1-7) 3 (1-8) 
Age [years]** 
6.2  
(0.4-15.0) 
2.6  
(0.3-12.2) 
2.92  
(0.3-15.0) 
Weight [kg] ** 
15.75  
(3.5-29.0) 
11.5  
(4.9-29.6) 
12.2  
(3.5-29.6) 
WAZ 
-1.1  
(-4.2 – 2.0) 
-1.7  
(-7.2 – 1.2) 
-1.5  
(-7.2 – 2.0) 
Sex [M/F] 52/32 177/159 80/89 
NRTI 
ABC 0 115 115 
d4T 84 107 191 
ZDV 0 114 114 
Note: Data are number of subjects or median (range); *Samples excluded from the analysis: unclear dosage 
history – 111, implausible (visual check confirmed by |CWRES|>3) – 87, BLQ confirmed by undetectable levels 
of the companion drugs – 48. **Baseline values. BLQ – below limit of quantification; WAZ - weight-for-age Z-
score,  M – male; F – female; ABC – abacavir; d4T – stavudine; ZDV – zidovudine. 
Among presented patients 6 rolled over from CHAPAS-1 to CHAPAS-3. All patients were black Africans. 
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6.4 Results 
6.4.1 Demographic characteristics and samples 
This analysis included 3305 samples (539 in intensive and 2766 in sparse PK profiles) from 414 African 
children (78 CHAPAS-1, 330 CHAPAS-3, 6 in both). Baseline demographic characteristics are presented 
in Table 6.1. Genotypes were available for 324 children (Table 6.4 in Appendix to Chapter 6); CYP2B6 
metaboliser groups were 33.1% EM, 44.6% IM, 21.7% SM, 0.6% USM (Table 6.2); the mixture-model 
allocation for remaining 96 individuals was: 41.7% EM, 49.0% IM and 9.4% SM. All tested genotypes 
were in Hardy-Weinberg equilibrium (Table 6.4 in Appendix to Chapter 6). 246 samples were excluded 
from the analysis (111 due to unclear dosage history, 87 outliers, and 48 BLQ).  
6.4.2 Population pharmacokinetics 
Nevirapine pharmacokinetics was best described using 1-compartment disposition, absorption 
through transit compartments, and elimination using the semi-physiological model with 1st-pass 
hepatic extraction (Figure 6.1 and Chapter 6.9.1 in Appendix to Chapter 6). The final model parameters 
were estimated relative to pre-hepatic bioavailability (FpreH, with typical value fixed to 1) and are 
presented in Table 6.3. All parameter estimates were found to be reasonably robust and adequate 
model fit was confirmed through VPC and GOF plots, which showed adequate fit of our model to the 
analysed data (Figure 6.2 and Figure 6.6 [in Appendix to Chapter 6]).  
Implementing the well-stirred liver model decreased OFV by 42, without adding extra parameters. The 
model was parameterised with CLint following a circadian rhythm expressed through oscillations of the 
cosine function with zenith around 12 noon and amplitude of approximately 29% (ΔOFV=-91, df=2, 
P<0.001) (Figure 6.3). The model identified distinct pre-hepatic (FpreH) and hepatic components (FH) of 
bioavailability, since changes in liver activity mechanistically affected also FH. The reference value of 
FpreH was fixed to 1, and BSV and BOV were estimated. Including the diurnal effect reduced BSV in CLin 
by 34% and BOV in FpreH by 41%. More details on the model implementation, including formulae 
explaining relationship between model parameters, are presented in the Chapter 6.9.1 in Appendix to 
Chapter 6 
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Table 6.2 Nevirapine exposures of different metabolic subgroups determined by 516GT|983TC SNP vector 
Metaboliser 
Status 
Pts CminAM [mg/L] CminPM [mg/L] 
CminPM < 3 
[mg/L]† 
3 < CminPM  <8 
[mg/L]† 
CminPM > 8  
[mg/L]† 
AUCAM 
[mg∙h/L] 
AUCPM 
[mg∙h/L] 
EM 
106 
(33.3%) 
5.01  
(3.01-7.47) 
4.58  
(2.53-7.03) 
77 
(16.6%) 
361  
(77.6%) 
27 (5.8%) 
68.51  
(39.42-104.16) 
69.34  
(38.65-104.42) 
IM 
141 
(44.2%) 
6.55  
(3.65-13.32) 
6.08  
(3.25-12.93) 
33  
(5.8%) 
378  
(66.8%) 
155 
(27.4%) 
88.93  
(50.06-173.72) 
88.60  
(50.06-173.72) 
SM 
70 
(21.9%) 
11.59  
(5.44-22.71) 
10.91  
(5.06-22.44) 
4  
(1.3%) 
78  
(25.7%) 
222 
(73.0%) 
152.07  
(72.42-270.46) 
151.27  
(71.54-287.46) 
USM 2 (0.6%) 
12.32  
(12.32-27.25) 
11.71 (11.71-
26.43) 
0  
(0%) 
1  
(12.5%) 
7 (87.5%) 
170.81 (170.81-
362.97) 
152.12  
(152.12-337.26) 
Note: Data are median (5th-95th percentile) or number (percentage). †Number of Cmin below/within/above the therapeutic range of 3 – 8 mg/L.45 EM (extensive 
metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; 
USM (ultra-slow metabolisers) - 516GG|983CC. 
Data for 319 individuals from CHAPAS-3 trial with available genotype dosed according to WHO 2010 guidelines11 corresponding to 1343 PK visits. When 
multiple PK visits were available, measurements were used to calculate the geometric mean for every patient, which were then used to calculate median and 
percentiles in each subgroup.  
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After applying allometric scaling to account for the effect of body size, and including diurnal effects 
and 1st-pass metabolism, the most significant covariate was the metaboliser status on CLint determined 
by CYP2B6 516G>T|983T>C genotype (ΔOFV=-217, df=3, P<0.001), explaining 85% of remaining BSV 
in CLint. Using six rather than four 516G>T|983T>C SNP-vector metaboliser groups415 reduced OFV by 
only 5 points (df=2, P=0.08) and was therefore not used.  
 
Note: CLH – hepatic clearance; EH – hepatic extraction; Ka – absorption rate constant; QH – hepatic plasma flow; 
VH – volume of the liver; VC – volume of the central compartment. The model parameters and presented relations 
are explained in detail in the Appendix to Chapter 6..  
Our data did not support a maturation effect on CLint, but we identified age-driven differences in FpreH, 
which were described using an exponential model (equation 7 in the Appendix in the Supplement). 
FpreH at birth was estimated as 58.3% of the value in older children (reference fixed to 100%), 90% of 
FpreH was reached by age of approximately 3.3 years and the half-life of the process was 1.55 years 
(Figure 6.4). 
The model estimated that an average child weighing 14.5 kg and aged 4.1 years would have FpreH=93% 
and their values of oral clearance (CLoral, see Chapter 6.9.1 and Figure 6.5 in Appendix to Chapter 6) 
were 1.31 L/h EM (reference), 1.09 L/h IM (17% lower), 0.66 L/h SM (50% lower) and 0.42 L/h USM 
(68% lower). A summary of the individual exposures in children from CHAPAS-3 trial dosed according 
to WHO 2010 guidelines11 is presented in Table 6.2, split by metaboliser genotype.  
  
Figure 6.1 Compartmental structure of the nevirapine pharmacokinetic model.  
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Table 6.3 Final nevirapine population parameter estimates (5th and 95th percentile)* 
Parameter Typical values Variability 
CLint 
EM [L/h] 3.27 (3.00 – 3.69) 
BSV: 21.40 (20.08 – 32.46) 
IM [L/h] 2.72 (2.27 – 2.94) 
SM [L/h] 1.65 (1.47 – 1.89) 
USM [L/h] 1.04 (0.87 – 1.38) 
AMP [%] 29.2 (27.7 – 45.2)  
SHIFT [h] -12.30 (-13.32 – -10.38)  
Vc [L] 21.92 (20.24 – 26.23)  
FpreH 
Older 
Childrenᶧ 
1 (FIXED) BSV: 18.72 (6.59 – 20.66)  
BOV: 17.02 (16.12 – 20.87) 
At Birth [%] 58.30 (50.48 – 68.24) 
t1/2 
[years] 
1.54 (1.47 – 2.58)  
MTT [h] 0.56 (0.49 – 0.70) BOV: 199.73 (177.23 – 217.70) 
KA [1/h] 0.84 (0.67 – 1.12) BOV: 44.91 (31.32 – 50.46 
NTRANS [number] 3 (FIXED)  
Increased BOV FpreH for 
unobserved intake 
1.54 (1.20 – 1.65)  
Additive error [mg/L] 0.32 (0.21 – 0.38)  
Proportional error [%] 5.26 (4.26 – 6.18)  
Increased error for sparse data 1.56 (1.49 – 1.81)  
Note: Final parameter estimates are typical population values estimated by the model. All clearance and volume 
parameters scaled allometrically to the median weight of 14.5 kg. *Estimated from nonparametric bootstrap 
(n=50) of the final model. ᶧOlder children refers to individuals where no further age-driven increase in 
bioavailability can be observed (Figure 6.4). CLint – intrinsic clearance; EM – extensive metaboliser; IM -  
intermediate metaboliser; SM – slow metaboliser; USM – ultra-slow metaboliser; AMP – amplitude of cosine 
function; SHIFT – shift in the zenith of cosine function from midnight; Vc –volume of central compartment; FpreH 
– pre-hepatic bioavailability; NTRANS – number of transit compartments (in the implementation as Savic et al.39 
this would be NN=2)  MTT – absorption mean transit time; Ka – absorption rate constant; BSVCL - between 
subject variability in clearance intrinsic; BSV – between-subject variability;  BOV – between-occasion variability 
The number of transit compartments was first estimated and then fixed during the covariate analysis in order 
to improve model stability. The number was then re-estimated in the final model and proved not to be different 
from previously fixed. 
 
Higher uncertainty related to unobserved intake time (for all sparse data and pre-dose samples in 
intensive data) was accounted for by scaling factors (proportional model) on RUV and BOV FpreH, which 
were found to be respectively 1.56 and 1.54 times larger than in PK samples after observed intake. 
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No other covariates were identified as significant. The remaining stochastic variability in clearance and 
bioavailability was low (BSV CLint 21.4%, BSV FpreH 18.7% and BOV FpreH 17%), but absorption 
parameters (where no covariates improved model fit) remained highly-variable (BOV absorption rate 
constant [KA] 44.9%, BOV absorption mean transit time [MTT] 199.7%).  
 
Figure 6.2 Visual Predictive Check of the final nevirapine population pharmacokinetic model by metabolic status 
(determined by combined effect of SNPs 516G>T and 983T>C) in semi-log scale.  
Note: Hollow dots – observed concentrations, red solid line – median of observed data, red dashed line– 5th and 
95th percentile of observed data, pink shaded area – 95% confidence interval of simulated median, blue shaded 
area - 95% confidence interval of simulated 5th and 95th percentile. For explanation of metabolic subgroups see 
Methods (Chapter 6.3.4.3). 
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6.4.3 Simulations 
Simulations were conducted to compare average CminAM and CminPM in weight-bands of African children 
divided into metaboliser groups and dosed following WHO 2010 recommendations.11 Average CminAM 
and CminPM in weight-bands >6kg were >3 mg/L for most simulated individuals regardless of 
metaboliser status (Figure 6.5a). In contrast, >25% of children in the lowest weight-band (4-6kg) had 
CminPM below the efficacy threshold (Figure 6.5b); this effect was driven mostly by EM and IM (43% and 
26% <3mg/L, respectively). 
Given the detected diurnal variation in nevirapine CLint we evaluated the effect of administration time 
(see Methods) on average morning and evening exposures. The change in median concentration 
depending on administration time and differences in systemic drug exposures are presented in Figure 
6.7 in Appendix to Chapter 6. Depending on administration time, the ratios of AM/PM exposures 
varied between 1.09–1.15 for Cmin and 1.03–1.07 for AUC0-12, differences of unlikely clinical 
significance. 
Use of some nevirapine FDCs can lead to unequal splitting of the advised daily dose between morning 
and evening intakes. Simulation results showed that ratios between simulated median Cmin AM/PM 
for tested dose-splitting strategies (see Methods) were: D1 (larger morning) 0.93, D2 (equal) 1.13, D3 
(larger evening) 1.41; and AUC0-12 0.90, 1.04, and 1.22, respectively (Figure 6.8 in Appendix to Chapter 
6). 
6.5 Discussion 
We present the largest investigation to date of nevirapine pharmacogenetics, the first report of the 
effect of 983CC homozygosity on nevirapine PK and the first study in children to quantify the combined 
effect of CYP2B6 516G>T|983T>C. Our analysis is also the first to date to characterise the diurnal 
variation in nevirapine clearance through population pharmacokinetic modelling and to evaluate the 
effect of this phenomenon on systemic drug exposures through simulations.  
The main predictor of nevirapine clearance in our cohort of African children was the combined effect 
of CYP2B6 516G>T|983T>C genotype. Oral clearance estimated by our model before adjusting for the 
CYP2B6-SNPs was 3.8 L/h, which was comparable with 3.93 L/h reported previously in children374 (both 
scaled up to 70kg) and 2.82–3.97 L/h in adults.50,66,72,73,294,295,297,298,378 Comparing the CYP2B6 
516G>T|983T>C effect with other reports is problematic, since our study is the first to use this 
categorisation with four metaboliser subgroups for nevirapine, although it has been extensively 
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applied to efavirenz.71,415 The 50% lower nevirapine clearance we detected for SM is greater than the 
30-37% drop previously reported for 516TT versus 516GG.72,73,105,278,300,305 Similar to efavirenz,198,415 the 
effect of CYP2B6 983CC (recessive homozygosity) on nevirapine PK has greater magnitude than 516TT 
(68% versus 50% drop). Unsurprisingly, nevirapine clearance is affected to lesser degree by CYP2B6-
polymorphisms than efavirenz in the same population.415 This can be explained by a different 
contribution of the CYP3A4 pathway to the metabolism of these drugs.177  
 
Figure 6.3 Diurnal variation in nevirapine intrinsic clearance detected by the model, presented over 24 h.  
Note: Shaded area refers to night (20h00 – 08h00) 
Diurnal variation has been previously documented for several CYP3A4 substrates,426,427 consistently 
revealing increased clearance rates during the day  as compared to during the night.89,322,428 Our study 
replicated those findings and detected significantly higher nevirapine clearance during the day with 
maximum at midday. The estimated amplitude of the diurnal variation is somewhat larger than 
previous reports in CYP3A4 probes.89,428 This could be due to the considerable contribution of CYP2B6 
enzymes to nevirapine clearance. Although little is known about chrono-pharmacokinetics of this 
pathway, our hypothesis is supported by the fact that CAR, which regulates expression of CYP2B6,78 
exhibits a circadian rhythm linked to a 1.7-fold magnitude induction of CYP2B mRNA.429 
Despite the 29% amplitude of diurnal variation in nevirapine clearance, the simulated difference 
between morning and evening trough exposures was less than 15%. This lack of effect is due to 
nevirapine’s relatively long half-life (25-30h at steady-state)292 in comparison to, for example, protease 
inhibitors, where the reported median difference in troughs are almost 60%.322 Simulations revealed 
only a marginal effect of intake time on exposures, but showed that the diurnal variation should be 
considered when the daily dose of nevirapine cannot be split equally, since 50% difference in the ratio 
of median Cmin AM/PM was found depending on whether the larger dose is given in the morning or 
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evening. To minimise this effect and the risk of suboptimal exposures, uneven splitting should be 
implemented with the larger dose given in the morning, which is currently not specified in the WHO 
guidelines.11  
Further novelty of our study was the use of a semi-physiological well-stirred liver model allowing the 
effect of hepatic clearance (expressed as clearance intrinsic) on both systemic clearance and 1st-pass 
hepatic extraction to be captured, so that clearance and its covariates affect bioavailability. This model 
allowed us to separate the pre-hepatic and hepatic components of bioavailability.  
 
Figure 6.4 Change in nevirapine pre-hepatic bioavailability with age. 
 
A significant degree of variability in nevirapine pharmacokinetics was explained in our model by age-
driven differences in pre-hepatic bioavailability, which possibly overshadowed the expected effect of 
maturation of the metabolic pathways. A similar effect was found for nevirapine by Foissac et al.374 
and reported for other antiretroviral drugs13 and could hypothetically be caused by reduced drug 
absorption in neonates and younger children. This may be due to more rapid gastric emptying, smaller 
gastric volume, higher gastric pH, smaller gastro-intestinal absorption area, as well as adherence and 
palatability issues.430 This phenomenon could explain sub-therapeutic concentrations seen in the 
youngest age groups in other paediatric studies.33,37,77,305,367,368,372 Our simulations show in particular 
that individuals in the <6 kg weight-band who are EM and IM are at risk of suboptimal exposures 
(observed PM Cmin <3 mg/L in 43% and 26% of individuals, respectively). 
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Figure 6.5 Model-simulated nevirapine exposures shown by dosing weight bands and metabolic subgroups 
Note: Presented plots show: (a) difference between morning and evening nevirapine Cmin when dosed according 
to current WHO recommendations;11 (b) difference in nevirapine Cmin between metabolic groups when dosed 
according to current WHO recommendations (evening Cmin is shown); (c) difference in nevirapine Cmin between 
metabolic groups when dosed according to proposed dose optimisation strategy (evening Cmin is shown). Red 
horizontal lines correspond to nevirapine therapeutic range, form 3 mg/L to 8 mg/L.95 The box in the percentile 
plots shows the 25th, median, and 75th percentile, while whiskers correspond to 5th and 95th percentile of the 
simulated data. EM (extensive metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 
516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 
516GG|983CC. 
Despite significant differences in nevirapine PK determined by CYP2B6 genotype, a genotype-driven 
dose optimisation strategy has not been previously suggested. This could be due to the fact that, 
unlike efavirenz, the relationship between high exposures and toxicity is not strongly apparent.72,234,341 
Nonetheless, suboptimal concentrations are of concern, as they could lead to virological 
failure.37,305,341,374 To prevent suboptimal exposures we suggest the dose for EM and IM in the lowest 
weight-band be increased from 100mg to 150 mg. Further harmonisation of exposures across 
metaboliser groups could be achieved by 50% reduction of nevirapine dose for SM and USM in all 
other weight-bands, as >75% of those children had PM Cmin above the 8 mg/L therapeutic upper-limit, 
although this might be of limited clinical relevance.  When daily dose cannot be split equally, larger 
doses should be given AM. The simulated Cmin based on this dose optimisation approach are presented 
on Figure 6.5c. We acknowledge however that practical implementation of such strategy in resource-
limited settings would be hindered by restricted access to genotyping and current use of FDCs. 
Our study has several limitations. The therapeutic range for nevirapine used in our analysis has not 
been previously evaluated in children or African populations. The intake time for sparse PK data was 
self-reported and might be inaccurate, given the large variability in absorption parameters, and could 
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inflate the magnitude of the detected diurnal variation. We tried to minimise this effect by excluding 
samples with uncertain dosage information and BLQ. The detected diurnal effect could hypothetically 
be further affected by food intake, which was not recorded in our study. However, food has been 
previously reported not to modify nevirapine bioavailability or clearance.420 Additionally, the analysed 
trials differed in the AM/PM dose splitting strategy (see Methods), but the model-based approach we 
employed accounts for this difference. 
6.6 Conclusions 
This is the first study quantifying the combined effect of CYP2B6 516GT|983TC on nevirapine clearance 
in children and classifying metabolisers into four metabolic groups (extensive [EM], intermediate [IM], 
slow [SM], ultra-slow [USM]). To prevent sub-therapeutic exposures EM and IM children <6kg should 
receive same the dose as those in the 6-10 kg weight-band. Further homogenisation of exposures can 
be achieved reducing the current recommended dose for SM and USM by 50% in other weight-bands. 
Additionally, we characterised the effect of diurnal variation on nevirapine pharmacokinetics, and 
found that it is of limited clinical relevance, possibly due to nevirapine long half-life. However, this 
phenomenon should be taken into consideration when daily doses cannot be split equally and larger 
doses should be given in the morning.  
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6.9 APPENDIX TO CHAPTER 6 
6.9.1 Description of the nevirapine semi-mechanistic model 
with 1st pass metabolism 
The nevirapine model presented in Figure 6.1 is explained in detail below. 
The delay between oral administration and absorption is modelled through 2 transit compartments. 
After entering the absorption compartment, nevirapine is transferred to the liver, where it undergoes 
1st-pass hepatic extraction (EH). The fraction of the drug not eliminated by 1st-pass (1-EH) is then 
transported via hepatic plasma flow (QH) to the central compartment and the systemic circulation. It 
then recirculates back to the liver, which is the site of drug clearance. In this well-stirred model, 
hepatic clearance (CLH) is determined by QH and EH as follows: 
(1)   𝐶𝐿𝐻 =  𝑄𝐻 ∙   𝐸𝐻  
EH depends on the unbound fraction of the drug (fu), liver activity (CLint), and QH and is defined as: 
(2)   𝐸𝐻 =  
𝐶𝐿𝑖𝑛𝑡∙ 𝑓𝑢
𝐶𝐿𝑖𝑛𝑡∙𝑓𝑢+𝑄𝐻
   
EH also determines the hepatic bioavailability FH 
(3)   𝐹𝐻 = 1 −  𝐸𝐻 
The total oral bioavailability (F) is determined by both the pre-hepatic (FpreH) and hepatic (FH) 
components, as follows: 
(4)   𝐹 =  𝐹𝑝𝑟𝑒𝐻 ∙ 𝐹𝐻   
After a number of transformations, oral clearance can be simplified as follows:  
(5)   𝐶𝐿𝑜𝑟𝑎𝑙 =  
𝐶𝐿
𝐹
=  
𝐶𝐿𝑖𝑛𝑡∙𝑓𝑢
𝐹𝑝𝑟𝑒𝐻
  
Due to circadian rhythm variations, CLint changes with time, thus affecting both CLH and FH, and its 
value at time (t) is defined as follows: 
(6)   𝐶𝐿𝑖𝑛𝑡(𝑡)  =  𝐶𝐿𝑖𝑛𝑡 ∙  𝑒
𝐴𝑀𝑃 ∙ 𝑐𝑜𝑠(
2𝜋
24
 ∙(𝑡− 𝑆𝐻𝐼𝐹𝑇))
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where AMP is the amplitude of the cosine oscillation and SHIFT is the phase shift of the cosine function 
relative to 00:00. In order to prevent negative values of CLint the effect of the circadian rhythm was 
modelled as exponential and can be interpreted approximately as a relative change. 
Furthermore, FpreH changes with age, as expressed by following equation: 
(7)   𝐹𝑝𝑟𝑒𝐻  =  1 – (1 −  𝐹𝑝𝑟𝑒𝐻_𝐵𝐼𝑅𝑇𝐻) ∙  𝑒
−𝐾𝐹𝑝𝑟𝑒𝐻∙ 𝐴𝐺𝐸  
where FpreH_BIRTH is the FpreH at birth, KFpreH is the rate constant for age-driven change in FpreH and AGE 
refers to age.  
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6.9.2 Supplementary tables 
Table 6.4 Observed frequencies of tested single nucleotide polymorphisms with porresponding Hardy-Weinberg P-values in 
children from CHAPAS-3 treated with nevirapine 
Gene SNP Hom-Ref† Het-LOF† Hom-LOF† MAF 
HWE 
P-value 
CYP2B6 
rs3745274 
(516G>T) 
GG GT TT 
0.36 0.18 
136 (0.43) 136 (0.43) 47 (0.15) 
rs28399499 
(983T>C) 
TT TC CC 
0.09 1 
226 (0.83) 51 (0.16) 2 (0.01) 
rs4803419 
(15582C>T) 
CC TC TT 
0.07 0.19 
227 (0.87) 39 (0.12) 3 (0.01) 
CYP3A4 
rs35599367 
(CYP3A4*22) 
GG GA AA 
0.003 1 
317 (0.99) 2 (0.01) 0 
CYP3A5 
rs776746 
(6986G>A) 
GG GA AA 
0.82 0.44 
12 (0.04) 88 (0.28) 219 (0.69) 
NR1I3 
(CAR) 
rs3003596 
AA AG GG 
0.49 1 
78 (0.24) 159 (0.50) 82 (0.26) 
rs2307424 
(540C>T) 
CC CT TT 
0.08 0.42 
272 (0.85) 44 (0.14) 3 (0.01) 
NR1I2 
(PXR) 
rs2472677 
(63396C>T) 
CC CT TT 
0.36 0.14 
124 (0.39) 160 (0.50) 35 (0.11) 
ABCC10 rs2125739 
TT CT CC 
0.23 0.27 
185 (0.58) 120 (0.38) 13 (0.04) 
Note: †number (proportion). Hom-Ref - homozygous for the functional allele; Het-LOF - heterozygous for the 
loss-of-function (LOF) allele; Hom-LOF - homozygous for the LOF allele; MAF – minor allele frequency; HWE - 
Hardy-Weinberg equilibrium. 
Information for 319 children from CHAPAS-3 study (aside from rs2125739 – data on 318 children). 
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Table 6.5 Model estimated nevirapine clearance intrinsic and corresponding hepatic clearance, hepatic extraction, hepatic 
bioavailability and oral clearance by metaboliser status. 
Metabolizer Status 
CLint 
[L/h] 
CLH 
[L/h] 
EH FH 
CLoral 
[L/h] 
Fast 3.27 1.20 7.9% 91.1% 1.29 
Intermediate 2.72 1.01 6.6% 93.4% 1.09 
Slow 1.65 0.63 4.1% 95.9% 0.68 
Very slow 1.04 0.40 2.6% 96.4% 0.43 
Note: CLint – clearance intrinsic; CLH – clearance hepatic; EH – hepatic extraction; FH – hepatic component of 
bioavailability; CLoral – oral clearance 
The relationship between parameters and how they can be derived explained in the Appendix. Presented values 
relate to an average child of 14.5 kg, 4.1 years of age and corresponding pre-hepatic bioavailability of 93% and 
hepatic plasma flow of 15.35 (L/h). 
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6.9.3 Supplementary figures 
 
 
Figure 6.6 Goodness of fit plots for the final nevirapine population pharmacokinetic model 
Note: Top left – observations vs population predictions (log scale); top right – observations vs individual 
predictions (log scale); bottom left – absolute values of individual weighted residuals vs individual predictions 
bottom right – conditional weighted residuals (CWRESI) vs time after dose. 
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Figure 6.7 Results of simulations evaluating the effect of intake time on nevirapine exposures 
Note: Plots show: (a) concentration-time curves for evaluated intake time scenarios; (b) differences between 
morning and evening Cmin depending on intake time; (c) differences between morning and evening AUC 
depending on intake time.  
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Figure 6.8 Nevirapine exposures obtained using different dose-splitting strategies 
Note: Plots show: (a) concentration-time curves for the evaluated dosing scenarios; (b) differences between 
morning and evening Cmin depending on dose-splitting strategy; (c) differences between morning and evening 
AUC depending on dose-splitting strategy.  
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6.9.4 NONMEM control stream 
; Model descr: FINAL[LIVER][COMP-$DES][MIXTURE][DIURNAL][BIO-EFF;EXP] 
; With code for AUC_TAU 
$SIZES      MAXFCN=100000000 PD=-1000 LVR=-150 LTH=-200 
$PROBLEM    PK NVP model 
;------------------------------------------------------------------------------------------------------------------------ 
$INPUT      ID TRIALNO=DROP CHAPAS EVENT WHAT=DROP WEEKNO OCC OCC_CL 
                    DAT1=DROP TIME CLOCK_START AMT DV MDV EVID BLQ NIGHT FLAG 
                    AGE WT HT SEX WAZ HAZ NRTI TB SITE DOSE_AM DOSE_PM 
                    DOSE_TOTAL TABLETS=DROP ART G516T T983C rs480349 
                    rs35599367 rs776746 rs3003596 rs2307424 rs2472677 
                    rs2125739 PGX3 MET MET2 MET3 MET4 TRAD_MED TRAD_MED_CODE 
                    TRAD_MED_TYPE=DROP COMMENTS=DROP 
;----------------------------------------------------------------------- ------------------------------------------------ 
$DATA      NVP_NONMEM_30Nov2015.csv IGNORE=@ IGNORE=(BLQ.EQ.1) 
 
;------------------------------------------------------------------------------------------------------------------------- 
$ABBREVIATED COMRES=2 
$SUBROUTINE ADVAN13 TRANS1 TOL=8 
;----------------------------------------------------------------------- ------------------------------------------------- 
$MODEL      NCOMP=4 COMP=(DEPOT DEFDOSE) COMP=(LIVER) 
            COMP=(CENTRAL DEFOBS) COMP=(AUC) 
;------------------------------------------------------------------------------------------------------------------------- 
 
;------------------------------------------------------------------------------------------------------------------------- 
;; Initial estimates Theta and Omega 
$THETA  (0,3.963850,20)    ; 1 FAST  TVCL [L/h] 
$THETA  (0,25.15930,400)  ; 2 TVV2 [L] 
$THETA  (0,0.819063,10)    ; 3 TVKA [1/h] 
$THETA  (0,0.355995,2)      ; 4 ADD error 
$THETA  (0,0.050466,1)      ; 5 PROP error [] 
$THETA  (0,0.492383,8)      ; 6 TVMTT [h] 
$THETA  2 FIX                        ; 7 NN [] 
$THETA  (0,1.609520,10)    ; 8 SPK ERROR 
$THETA  (0,2.736170,10)    ; 9 INTERM 
$THETA  (0,1.700710,10)    ; 10 SLOW 
$THETA  (0,1.083350,10)    ; 11 U-SLOW 
$THETA  (0,1.708910,10)    ; 12 NOT-OBS BOVBIO [] 
$THETA  (0,0.287272,1)      ; 13 AMP_CL 
$THETA  (-24,-12.6037,24) ; 14 SHIFT_CL 
$THETA  (0,0.592143,1)      ; 15 BIO_BIRTH [] 
$THETA  (0.05,0.4749,10)   ; 16 KBIO [] 
$OMEGA  0.037351             ; 1 BSVCL 
$OMEGA  0  FIX                    ; 2 BSVV2 
$OMEGA  0  FIX                    ; 3 BSVKA 
$OMEGA  0.041468             ; 4 BSVBIO 
$OMEGA  0  FIX                    ; 5 BSVMTT 
$OMEGA  BLOCK(1) 
 0.024070                              ; 6 BOVBIO OCC1 
$OMEGA  BLOCK(1) SAME 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.199743                          ; 14 BOVKA OCC1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 4.248400                         ; 22 BOVMTT OCC1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
;-------------------------------------------------------------------------------------------------------------------------- 
$PK                    
 
;----- Allometric Scaling --------------------------------------------------------------------------------------------- 
   TVWT = 14.5  ; Median weight in kg 
   ALLMCL=(WT/TVWT)**0.75  
   ALLMV=WT/TVWT  
    
;----- DEFINE VARIABILITY  ------------------------------------------------------------------------------------------ 
;----- BOV --------------------------------------------------------------------------------------------------------------- 
 BOVBIO =ETA(6)  ;OCC=1 lag doses and pre-dose are treated as same occasion  
 IF (OCC.GT.1.5.AND.OCC.LE.2.5)   BOVBIO = ETA(7)    ;OCC=2 (prevents NONMEM from crashing) 
 IF (OCC.GT.2.5.AND.OCC.LE.3.5)   BOVBIO = ETA(8)    ;OCC=3 
 IF (OCC.GT.3.5.AND.OCC.LE.4.5)   BOVBIO = ETA(9)    ;OCC=4 
 IF (OCC.GT.4.5.AND.OCC.LE.5.5)   BOVBIO = ETA(10)  ;OCC=5 
 IF (OCC.GT.5.5.AND.OCC.LE.6.5)   BOVBIO = ETA(11)  ;OCC=6 
 IF (OCC.GT.6.5.AND.OCC.LE.7.5)   BOVBIO = ETA(12)  ;OCC=7 
 IF (OCC.GT.7.5.AND.OCC.LE.8.5)   BOVBIO = ETA(13)  ;OCC=8 
  
; CORRECTION FACTOR FOR NOT OBSERVED INTAKE - EFFECT ON BIO 
 NOT_OBS = THETA(12) 
 IF (OCC.EQ.1.OR.CHAPAS.EQ.3) BOVBIO= NOT_OBS *BOVBIO  
  
 BOVKA =ETA(14)  ;OCC=1 lag doses and pre-dose are treated as same occasion  
 IF (OCC.GT.1.5.AND.OCC.LE.2.5)   BOVKA = ETA(15)  ;OCC=2 
 IF (OCC.GT.2.5.AND.OCC.LE.3.5)   BOVKA = ETA(16)  ;OCC=3 
 IF (OCC.GT.3.5.AND.OCC.LE.4.5)   BOVKA = ETA(17)  ;OCC=4 
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 IF (OCC.GT.4.5.AND.OCC.LE.5.5)   BOVKA = ETA(18)  ;OCC=5 
 IF (OCC.GT.5.5.AND.OCC.LE.6.5)   BOVKA = ETA(19)  ;OCC=6 
 IF (OCC.GT.6.5.AND.OCC.LE.7.5)   BOVKA = ETA(20)  ;OCC=7 
 IF (OCC.GT.7.5.AND.OCC.LE.8.5)   BOVKA = ETA(21)  ;OCC=8 
  
 BOVMTT =ETA(22)  ;OCC=1 lag doses and pre-dose are treated as same occasion  
 IF (OCC.GT.1.5.AND.OCC.LE.2.5)   BOVMTT = ETA(23)   ;OCC=2 
 IF (OCC.GT.2.5.AND.OCC.LE.3.5)   BOVMTT = ETA(24)   ;OCC=3 
 IF (OCC.GT.3.5.AND.OCC.LE.4.5)   BOVMTT = ETA(25)   ;OCC=4 
 IF (OCC.GT.4.5.AND.OCC.LE.5.5)   BOVMTT = ETA(26)   ;OCC=5 
 IF (OCC.GT.5.5.AND.OCC.LE.6.5)   BOVMTT = ETA(27)   ;OCC=6 
 IF (OCC.GT.6.5.AND.OCC.LE.7.5)   BOVMTT = ETA(28)   ;OCC=7 
 IF (OCC.GT.7.5.AND.OCC.LE.8.5)   BOVMTT = ETA(29)   ;OCC=8 
   
;-------------------  BSV -------------------------------------------------------------------------------------------------------- 
   BSVCL  =ETA(1) 
   BSVV2  =ETA(2) 
   BSVKA  =ETA(3) 
   BSVBIO =ETA(4) 
   BSVMTT =ETA(5) 
 
;----- DEFINE POPULATION PARAMETERS ------------------------------------------------------------------------------ 
;----  CL BASED ON MIXTURE MODEL ------------------------------------------------------------------------------------ 
EST=MIXEST 
 
MET_EST=MET                                                          ; patients with available genotype 
 
; for patients with missing genotype: 
IF(MET.EQ.99.AND.MIXNUM.EQ.1) MET_EST=1 ; EXT - from mixture model 
IF(MET.EQ.99.AND.MIXNUM.EQ.2) MET_EST=2 ; INTERMEDIATE - from mixture model 
IF(MET.EQ.99.AND.MIXNUM.EQ.3) MET_EST=3 ; SLOW - from mixture model 
IF(MET.EQ.99.AND.MIXNUM.EQ.4) MET_EST=4 ; ULTRA-SLOW - from mixture model 
 
IF(MET_EST.EQ.1) CLMET=THETA(1) 
IF(MET_EST.EQ.2) CLMET=THETA(9) 
IF(MET_EST.EQ.3) CLMET=THETA(10) 
IF(MET_EST.EQ.4) CLMET=THETA(11) 
 
;----------------------------------------------------------------------- ------------------------------------------------------------ 
  
   TVCL  = CLMET *ALLMCL   ; typical value of CL 
   TVV2  = THETA(2)*ALLMV ; typical value of V 
   TVKA  = THETA(3)                ; typical value of KA 
   TVMTT = THETA(6)              ; typical value of MTT 
   TVNN  = THETA(7)               ; typical value of NN 
   TVBIO = 1                              ; pre-hepatic oral bio fix to 1 
    
;----- DEFINE INDIVIDUAL PARAMETERS --------------------------------------------------------------------------------- 
  CL   = TVCL  *EXP(BSVCL)                   ; individual value of CL 
  V2   = TVV2  *EXP(BSVV2)                 ; individual value of V 
  KA   = TVKA  *EXP(BSVKA+BOVKA)  ; individual value of KA 
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  MTT  = TVMTT *EXP(BSVMTT+BOVMTT); individual value of MTT 
  NN   = TVNN                                                 ; individual value of NN 
   
;-------------  AGE effect on BIO  ------------------------------------------------------------------------------------------ 
   BIO_BIRTH =THETA(15)                                                          ; bio at birth 
   KBIO      =THETA(16)                                                                ; age effect constant 
    
; AGE EFF ON F1 AS INVERSE EXP WITH INTERCEPT 
   AGEBIO = 1 - ((1-BIO_BIRTH)*(EXP(-(AGE*KBIO))))  ; age in years from birth 
   
   BIO = TVBIO *EXP(BSVBIO+BOVBIO) *AGEBIO                  ; individual value pre-hepatic bio 
   
;------------------- ASSUMPTIONS FOR DIURNAL ------------------------------------------------------------------------ 
   AMP_CL   = THETA(13)                          ; amplitude of circadian rhythm  
   SHIFT_CL = THETA(14)                           ; shift of actophase (max) from midday 
    
;------------------- ASSUMPTIONS FOR LIVER FIRST PASS --------------------------------------------------------------- 
  CLINT=CL 
  FU = 0.4                                                     ; fraction unbound in plasma 
  QH = 50 *(WT/70)**0.75                       ; hepatic plasma flow - adult = 50L/h 
  VH = 1 *(WT/70)                                      ; volume of liver 
  
;------------------ TRANSFER RATE CONSTANTS ------------------------------------------------------------------------- 
  K32 = QH/V2                                            ; from central back to liver 
 
  ; rates from liver to central and extraction rate const defined in $DES 
    
; RESET code for Cmax Tmax 
IF (NEWIND/=2.OR.EVID>=3) THEN  
 COM(1)=0 
 COM(2)=0 
 TIMEDOSE = TIME 
 AMOUNTDOSE = AMT 
 AUC_START  = 0 
 AUC_STOP    = 0 
 AUC_TAU      = 0 
ENDIF  
 ;----------------------  TRANSIT  -------------------------------------------------------------------------------------------- 
  
F1=0 ; I need to set bioavailability in compartment 1 to 0 
 
 
KTR = (NN+1)/MTT 
  
IF (NEWIND/=2.OR.EVID>=3) THEN ; new individual, or reset event 
    ; The values read here will be stored in TDOS and PD in this very PK call 
 TNXD=TIME ; Time of the dose 
 PNXD=AMT ; Amount. If it's zero, the DE is deactivated. 
ENDIF 
 
TDOS=TNXD ; This will either save here the temporary values if it's a new individual... 
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PD=PNXD ; ...or the values which were read one record ahead during the execution of the previous 
record. 
 
IF(AMT.GT.0) THEN ; This reads one record ahead and stores the data to be used when running the 
following record 
 TNXD=TIME 
 PNXD=AMT 
ENDIF 
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
; approximation of log of gamma(n), 0.572364942 is LOG(PI)/2 
; To speed up the computation, I calculate here all the non-time-varying quantities used in $DES 
PIZZA=LOG(BIO*PD*KTR+0.00001)-LNGAM  
; without +0.00001, it won't work with ETAs in bioavailability 
 
;---------------- Initialisation for DES solver  ------------------------------------------------------------------------------ 
; SS option causes model to crash due to some low concentrations 
; Instead initialise the compartments with calculated SS Cmin 
; Based on individual parameter values  
; Followed with additional 5 days of dosing to make sure patient is at steady state 
 
  TAU_EQ=MTT+1/KA 
  KA_EQ=1/TAU_EQ                                                  ; because we’re using TRANSIT absoprtion 
   
;-------CALCULATE TEMP VALUE OF K WITH DISREGARD TO CIRCADIAN RHYTHM---- 
  EH_TEMP = (FU * CLINT) / (QH +(FU *CLINT))  ; hepatic extraction ratio 
  VTOT    = VH+V2                                                     ; approx as sum of liver and central 
  K_TEMP  =(QH*EH_TEMP)/VTOT                        ; elimination rate constant  
 
;-- dosing is every 12h, here use hf of the total dose (just approx) 
   TAU = 12 ; interdose interval 
 
   BASELINE = ((BIO*(1-EH_TEMP) * DOSE_TOTAL/2 * KA_EQ) / (VTOT * (KA_EQ - K_TEMP)))  * ( (1 / 
(1- EXP(-K_TEMP * TAU))) - (1 /( 1- EXP(-KA_EQ*TAU)))) 
    
   A_0(1)= 0.0001                        ; initialise absorption CMT 
   A_0(2)= BASELINE *VH           ; initialise liver CMT 
   A_0(3)= BASELINE *V2           ; initialise central CMT 
   
$DES                      
;------------------- First pass WITH DIURNAL VARIATION ------------------------------------------------------------ 
TIME_CLOCK=T+CLOCK_START ; calculate time progress in relation to first event (actual clock time) 
 
; diurnal oscillation with time expressed as shift from midnight 
DIURNAL_EF=EXP(AMP_CL*COS((TIME_CLOCK-SHIFT_CL)*6.283/24)) ; 2*PI=6.283 
CL_DIURNAL=CLINT *DIURNAL_EF 
 
  EH =(FU * CL_DIURNAL) / (QH +(FU *CL_DIURNAL))      ; hepatic extraction ratio 
  FH = 1 - EH                                              ; BIO after first pass metabolism  
  CLH= QH *EH                                          ; part metabolised 
  K   =(QH*EH)/VH                                    ; Metabolic rate constant from liver - ELIMINATION 
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  K23 =(QH*FH)/VH                                 ; part that goes to cent CMT 
 
;------------------------------------------------------------------------------------------------------------------------------- 
TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
KTT=0 
 
DADT(1)=0 
 
IF(PD.GT.0.AND.TEMPO.GT.0) THEN ; This happens only id PD>0, so only if a dose has been detected 
 KTT=KTR*(TEMPO) 
 DADT(1)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KA*A(1) 
ENDIF 
 
DADT(2)= KA*A(1)- K*A(2)- K23*A(2)+K32*A(3) 
DADT(3)= K23*A(2)-K32*A(3) 
DADT(4)= A(3)/V2                                   ; integral of conc for AUC 0-tau 
 
 
; For Cmax Tmax 
TIMEAFTERDOSE=T-TIMEDOSE 
CP = A(3)/V2                                            ; plasma concentration 
IF (CP.GE.COM(1)) THEN 
 COM(1) = CP                             ; CMAX 
 COM(2) = TIMEAFTERDOSE     ; time of CMAX 
ENDIF 
 
;------------------------------------- MIXTURE MODEL  ------------------------------------------------------------------- 
$MIX       NSPOP=4  
; proportions set to ones observed in the study 
P(1) = 107/323                                       ; prop of EXT 
P(2) = 144/323                                       ; prop of INTER  
P(3) = 70/323                                         ; prop of SLOW  
P(4) = 2/323                                           ; prop of U-SLOW 
;---------------------------------------------------------------------------------------------------------------------------------- 
$ERROR                     
 
  IPRED = A(3)/V2                                            ; Individual prediction in central CMT 
  IRES  = DV - IPRED                                         ; Individual residual 
 
  WA    = THETA(4)                                            ; Additive error 
  WP    = IPRED * THETA(5)                             ; Prop error 
  W     = SQRT(WA**2 + WP**2)                   ; Weighting factor for residuals 
  IF(W.LE.0.0001) W = 0.0001                        ; Protection against division with 0 
 
  IF(CHAPAS.GT.1.5) W = W*(THETA(8))      ; Additional error term for sparse data 
   
  IWRES = IRES / W 
  Y     = IPRED + W*EPS(1)   ; Model prediction of observed PK value with additive + proportional error 
   
 AA1=A(1)                 ; abs CMT 
 AA2=A(2)                 ; LIVER CMT 
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 AA3=A(3)                 ; central CMT 
CMAX = COM(1)     ; CMAX 
TMAX = COM(2)      ; time of CMAX 
 
IF(AMT.GT.0) THEN 
 TIMEDOSE = TIME 
 AMOUNTDOSE = AMT 
; Reset CMAX code when a new dose is given  
 COM(1)=0 
 COM(2)=0 
ENDIF 
 
  TAD=TIME-TIMEDOSE 
  TVPC=TIME-132               ; approx for plotting VPC 
  ; am_intake is 132h post start of dose OCC (5x pre-doses starting with pm_intake) 
  CL_ORAL =FU*CL             ; approx from Rowland and Tozer 
 
  VAR_AUC= (BSVBIO + BOVBIO) - (BSVCL)   ; for diagnostic plots 
  VAR_BIO= BSVBIO + BOVBIO                        ; for diagnostic plots 
   
;---- CALCULATE integral AUC FROM AMT IN 4TH COMP ----------------------------------------------------------- 
; due to diurnal variation AUC differs between daytime and nightime 
; needs to be calculated as exact integer of concentrations within 12h dosing interval 
 IF(EVENT.EQ.1)   AUC_START=A(4)               ; flag for dose 
 IF(EVENT.EQ.120) AUC_STOP =A(4)              ; flag for 12h post dose 
 AUC_TAU= AUC_STOP - AUC_START            ; AUC 0-12h 
  
  IF (ICALL==4.AND.Y.LE.0.1) Y=0.05               ; prevents negative simulated values for VPC 
;------------------------------------------------------------------------------------------------------------------------------------- 
$SIGMA  1  FIX  ; Scaled RUV variance - IT'S A VARIANCE SO FIXED TO "0" AND ALL ERROR IS GOING TO 
THE THETAS AND IT MAKES A SD 
$ESTIMATION MSFO=msf555 MAXEVAL=0 PRINT=1 METHOD=1 INTER MCETA=1000 
            RANMETHOD=4P ETASTYPE=1 NONINFETA=1 NOABORT NSIG=3 SIGL=9 
            ATOL=6 ; calculation method 
$ESTIMATION MSFO=msf555 MAXEVAL=9999 PRINT=1 METHOD=1 INTER MCETA=5 
            RANMETHOD=4P ETASTYPE=1 NONINFETA=1 NOABORT NSIG=3 SIGL=9 
            ATOL=6 ; calculation method 
 
$COVARIANCE PRINT=E ; standard error of estimate is calculated 
 
$TABLE      WRESCHOL ID DV OCC OCC_CL TAD TVPC TIME PRED IPRED 
            DOSE_TOTAL AA1 AA2 AA3 IWRES WRES CWRES CWRESI OBJI 
            NOPRINT ONEHEADER FILE=sdtab555 
$TABLE      ID CL CLH EH FH VH V2 KA K BIO KBIO BIO_BIRTH MTT NN 
            AUC_INF VAR_AUC VAR_BIO BSVCL BSVV2 BSVKA BSVBIO BOVBIO 
            BOVKA BOVMTT WA WP NOPRINT NOAPPEND ONEHEADER 
            FILE=patab555 
$TABLE      ID AGE AMT HT WT WAZ HAZ NOPRINT NOAPPEND ONEHEADER 
            FILE=cotab555 
$TABLE      ID CHAPAS SITE WEEKNO SEX DOSE_TOTAL DOSE_AM DOSE_PM NRTI 
            ART TB G516T T983C rs480349 rs35599367 rs776746 rs3003596 
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            rs2307424 rs2472677 rs2125739 PGX3 MET MET2 MET3 MET4 BLQ 
            NOPRINT NOAPPEND ONEHEADER FILE=catab555 
$TABLE      ID CHAPAS SITE FLAG EVENT DV OCC OCC_CL TAD TVPC WEEKNO 
            TIME AA1 AA2 AA3 AA4 CP IPRED PRED CL CL_ORAL CLH EH FH VH 
            V2 KA K BIO KBIO BIO_BIRTH MTT NN BSVCL BSVV2 BSVKA BSVBIO 
            BOVBIO NOT_OBS BOVKA BOVMTT WA WP AUC_INF AUC_START 
            AUC_STOP AUC_TAU VAR_AUC VAR_BIO CMAX TMAX AGE AMT HT WT 
            WAZ HAZ SEX DOSE_TOTAL DOSE_AM DOSE_PM NRTI ART G516T 
            T983C rs480349 rs35599367 rs776746 rs3003596 rs2307424 
            rs2472677 rs2125739 PGX3 MET MET2 MET3 MET4 MET_EST BLQ 
            OBJI NOPRINT NOAPPEND ONEHEADER FORMAT=, FILE=mytab555.csv 
; Xpose can read these tables 
 
; there must be one empty line after the last command line 
 
;-------------------------------- 
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CHAPTER 7: DETERMINANTS OF VIROLOGICAL OUTCOME AND 
ADVERSE EVENTS IN AFRICAN CHILDREN TREATED WITH 
PAEDIATRIC NEVIRAPINE FIXED-DOSE-COMBINATION TABLETS. 
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CHAPTER 7: Determinants of virological outcome and AEs in African children 
treated with nevirapine FDC tablets. 
 
Doctoral Thesis by A.M. Bienczak, March 2017 
7.1 Abstract 
Background 
Nevirapine is the only non-nucleoside reverse transcriptase inhibitor currently available as a paediatric 
fixed-dose combination tablet and is widely used in African children. Nonetheless, the number of 
investigations into pharmacokinetic determinants of virological suppression in African children is 
limited and the predictive power of the current therapeutic range was never evaluated in this 
population, thereby limiting treatment optimisation. 
Methods 
We analysed data from 322 African children (aged 0.3–13 years) treated with nevirapine, lamivudine, 
and either abacavir, stavudine, or zidovudine, and followed up to 144 weeks. Nevirapine trough 
concentration (Cmin) and other factors were tested for associations with viral load (VL)>100 copies/mL 
and transaminase increases >grade 1 using proportional hazard and logistic models in 219 initially 
antiretroviral treatment (ART)-naïve children. 
Results 
Pre-ART VL, adherence, and nevirapine Cmin were associated with VL non-suppression (hazard-ratio 
[HR]=2.08 [95% CI: 1.50-2.90, p<0.001] for 10-fold higher pre-ART VL, HR=0.78 [95% CI: 0.68–0.90, 
p<0.001] for 10% improvement in adherence and HR=0.94 [95% CI: 0.90-0.99, p=0.014] for a 1mg/L 
increase in nevirapine Cmin). There were additional effects of pre-ART CD4% and clinical site. The risk 
of virological non-suppression decreased with increasing nevirapine Cmin and there was no clear Cmin 
threshold predictive of virological non-suppression. Transient transaminase elevations >grade 1 were 
associated with high Cmin (>12.4 mg/L), HR=5.18 (95%CI 1.95–13.80, p<0.001). 
Conclusions 
Treatment initiation at lower pre-ART VL and higher pre-ART CD4%, increased adherence, and 
maintaining average Cmin higher than current target could improve virological suppression of African 
children treated with nevirapine without increasing toxicity.  
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7.2 Introduction 
Fixed-dose combination (FDC) formulations have considerably improved access to antiretroviral 
treatment (ART) through decreased cost and improved feasibility especially in Sub-Saharan Africa.33 
Currently available paediatric dispersible FDCs are limited to combinations of a non-nucleoside 
reverse transcriptase inhibitor (NNRTI), nevirapine, with two nucleoside-reverse transcriptase 
inhibitors (NRTIs), and are widely used in children in low-income countries.111  
Nevirapine pharmacokinetics (PK) exhibits high variability, attributed in part to single nucleotide 
polymorphisms (SNPs) of cytochrome P450 2B6 (CYP2B6), which encode an important metabolic 
pathway for this drug.43,72,431  In adults, low nevirapine concentrations have been associated with 
increased risk of virological failure340–342 and high exposures with increased risk of skin rashes336,346,358 
and hepatotoxicity.341,352 Based on the concentration-response relationship, a therapeutic range of 3–
8 mg/L has been suggested for nevirapine therapeutic drug monitoring (TDM).95  However, several 
studies failed to confirm these associations72,104,105 and low incidences of nevirapine-related adverse 
events (AEs) have been reported in low-income settings106 and in African children.107,108 Despite 
widespread use, few studies have investigated the pharmacokinetic determinants of efficacy of 
nevirapine-based regimens in children. The predictive power of the suggested targets has also never 
been thoroughly investigated in black Africans or in children. Whether these pharmacokinetic targets 
should be universally applied across populations was recently questioned.72   
Our aim was therefore to investigate associations between nevirapine trough concentrations (Cmin) 
and long-term virological outcomes and AEs in African children, and establish if any other factors 
predict treatment outcome after adjusting for drug exposures, allowing treatment optimisation. 
7.3 Methods 
7.3.1 Population and study design 
The CHAPAS-3 trial enrolled HIV-infected ART-naïve and ART-experienced (>2 years ART with viral load 
(VL) <50 copies/ml at screening) children aged 0.3–13 years from four sites in Uganda and Zambia,382 
treated following WHO 2010 guidelines11 with an NNRTI (nevirapine or efavirenz) and 2 NRTIs 
(lamivudine plus randomised abacavir, stavudine, or zidovudine). Nevirapine was co-formulated with 
companion NRTIs in paediatric FDCs provided by Cipla (India).382 Children on nevirapine were switched 
to efavirenz-based ART if aged >3 years and diagnosed with tuberculosis or experienced nevirapine-
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related AEs, or to boosted protease inhibitor-based (PI) ART if <3 years with these events or for clinical 
or immunological failure (or if efavirenz-intolerant). Samples for PK analysis (described previously)431 
were taken at week 6, 36, and every 24 weeks thereafter. VL was assayed retrospectively on stored 
plasma taken at enrolment and weeks 48, 96 and 132 or 144. 
7.3.2 Statistical analysis 
A previously developed model describing the steady-state population-PK of nevirapine431 was used to 
derive empirical Bayesian estimates for each child at each PK visit for: CL (clearance), Cmin (evening 
trough concentration), Cmax (maximum concentration), and AUC0-24 (area under the curve). Due to 
diurnal variability in clearance431, this analysis included measurements relating to daytime exposures 
only.  
The primary efficacy outcome was VL > 100 copies/mL (the limit of detection as many samples had to 
be diluted due to low volumes). For descriptive analysis, response was categorized as: suppressed 
(<100 copies/mL within 48 weeks of treatment initiation, maintained throughout follow-up), slow 
suppression (<100 copies/mL achieved after 48 weeks but maintained throughout subsequent follow-
up), rebounded (<100 copies/mL within 48 weeks but VL>100 copies/mL at single or multiple visits 
thereafter) and never suppressed (VL never <100 copies/mL). ART-experienced children (all VL<50 
copies/ml at enrolment) were analysed separately from ART-naïve children initiating treatment at 
enrolment. Since multiple PK exposures were available for each child, geometric means of PK 
parameters across follow-up within each individual, and inter-individual variability (expressed as 
coefficient of variation [CV]432) for Cmin and AUC0-24  were compared between groups using Kruskal-
Wallis and rank-sum tests. Categorical factors were compared between groups using Fisher’s exact 
test.  
The effect of nevirapine  Cmin on the risk of virological non-suppression (>100 copies/ml) in the subset 
of ART-naïve children only was estimated using Cox proportional hazards regression models 
(Andersen-Gill repeated outcomes framework) with Efron approximation in R (survival package).380,402–
404 VLs were matched with the model estimated Cmin from the closest sampling visit preceding each 
VL. Each time interval ran from the preceding to the current VL (classified as suppressed vs non-
suppressed “event”) and the matched Cmin was applied to the whole time interval. Non-linearity in the 
effect of Cmin was explored visually using smoothed splines, and tested using fractional polynomials 
(Stata 14.0 mfp cox).401 As Cox regression does not provide estimates of the absolute probability of 
suppression, we estimated this using a mixed-effects repeated measures logistic model (Stata 14.0 
mfp logistic).401 The best-fitting dichotomous threshold for nevirapine Cmin in the Cox model was 
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identified by profile likelihood as described previously for efavirenz.433 Following the same method, 
we conducted simulations introducing unexplained residual variability on predicted concentrations 
from the population-PK model (additive error 0.32 mg/L, proportional error 5.26%)431 to derive 95% 
confidence intervals (CI) for this threshold (2.5th and 97.5th percentile of most predictive cut-offs from 
500 simulations). The sensitivity, specificity, accuracy, and positive and negative predictive values of 
the identified threshold for VL suppression were compared to those of the 10th, 25th, and 50th 
percentiles of estimated nevirapine Cmin in this study, and cut-offs proposed in the literature.95,340,341  
Finally, we used backwards elimination (exit p=0.05, retaining all levels of categorical factors where 
any were p<0.05) to consider the additional independent effects on non-suppression of factors with 
associations (p<0.2) in univariate models. Categorical covariates included NRTI-backbone (abacavir, 
zidovudine, or stavudine), sex, clinical site, exposure to ART in children and/or mothers in prevention 
of mother to child transmission (pMTCT [regimens listed in footnotes to Tables 7.1 and 7.2]), 
metaboliser status (MET) based on CYP2B6 516G>T|983T>C single nucleotide polymorphisms (SNP) 
(extensive metabolisers [EM] - 516GG|983TT; intermediate metabolisers [IM] - 516GG|983TC or 
516GT|983TT, slow metabolisers [SM] - 516TT|983TT or 516GT|983TC; ultra-slow metabolisers [USM] 
- 516GG|983CC),431 mother as primary carer, self-reported missing any ART doses in previous 4 weeks. 
Continuous variables included baseline (pre-ART) viral load (bVL) and CD4% (bCD4%, truncated at 50% 
to avoid undue influence of outliers), and current age, weight-for-age Z-score (WAZ),416 height-for-age 
Z-score (HAZ),416 and adherence (percentage of doses taken based on MEMS-cap container openings 
in the interval between previous and current VL [truncated to a lower limit of 0.5]). The only factor 
with incomplete information was adherence; when no data was available for current interval, the 
preceding interval’s value was carried forward. If no prior MEMS data were available (n=21) we 
imputed the median value for all ART-naïve individuals. Non-linear effects in continuous variables 
were explored as described above for Cmin. Interactions between factors included in the final model 
were investigated and included if p<0.05.  
7.3.3 Adverse events (AEs) 
AEs considered to be nevirapine-related were: hypersensitivity reactions (HSR, including Stevens-
Johnson Syndrome [SJS]), raised liver enzymes (aspartate or alanine transaminase [AST or ALT] >grade 
2, i.e. >5x ULN), and acute hepatitis. The characteristics of children developing AEs were compared to 
others using Fisher’s exact or rank-sum tests. AST and ALT were measured at enrolment and weeks 6, 
12, 24, and 24-weekly throughout the study and were matched with nevirapine Cmin as described for 
VL. The association between NVP Cmin (and all covariates above plus pre-ART >grade 1 transaminase 
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elevation) and the risk of developing >grade 1 AST or ALT, i.e. >2.5x ULN (composite endpoint) were 
estimated in the ART-naïve group as for virological non-suppression. Additionally, in the same group, 
the change from baseline in transaminase levels at weeks 6, 48, and 96 was compared using Wilcoxon 
signed rank test separately for children with Cmin below and above the threshold identified most 
predictive of transaminase >1 grade elevations by likelihood profiling as explained above. Probabilities 
of AEs were similarly estimated using mixed-effects logistic regression. 
 
7.4 Results 
7.4.1 Patient characteristics 
Of 478 children in CHAPAS-3, 338 received nevirapine (99 ART-experienced) combined with a 2-NRTI 
backbone, and contributed 3340 PK samples (1566 dosing intervals, 1-6 per individual) and 718 VLs 
post enrolment (1-3 per individual). Sixteen individuals (all ART-naïve) changed ART: 9 to efavirenz 
(when tuberculosis was diagnosed) and 7 to protease-inhibitors (3 for AEs, 4 for clinical failure [2 in 
year 2 and 2 in year 3]). The demographic characteristics and model-estimated PK parameters for 
children included in this analysis are shown in Tables 7.1 and 7.2 by virological response group.  
Amongst ART-naïve children, 151 (68%) achieved and maintained VL <100 copies/mL, 125 (56%) by 
week 48. Those who took longer to suppress had almost three times higher pre-ART VL and lower 
CD4-counts. Amongst ART-naïve participants who suppressed by week 48, 27 rebounded and the 
majority of these children re-suppressed during follow-up. Pre-ART CD4% in these rebounders was 
lower than other groups, and median pre-ART VL between that for the suppressed group and for those 
taking longer to suppress or never suppressed. The remaining 45 ART-naive children (20%) never 
suppressed VL to <100 copies/mL, but only 4 showed clinical evidence of treatment failure. Individuals 
who never suppressed had significantly higher pre-ART VL than children who suppressed by week 48, 
lower adherence than the other ART-naïve children (82% vs 93%, ranksum p=0.005) and lower 
nevirapine PK exposures (p<0.05) with higher levels of intra-individual variability (p=0.02), possibly 
indicating erratic adherence patterns.
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Table 7.1 Demographic characteristics and model-derived PK parameters in different suppression groups of children in 
CHAPAS-3 treated with nevirapine (part 1) 
Treatment status at 
enrolment 
Naïve 
p* 
Experienced 
p** 
Suppression Group Suppressed 
Slow 
Suppress 
Rebound 
Never 
Suppressed 
Number of patients 
(row %) 
125 (56%) 26 (12%) 27 (12%) 45 (20%) 99 
Baseline 
Age 
[years] 
2.0 
(0.7-4.9) 
2.2 
(0.9-3.8) 
1.9 
(1.1-8.5) 
1.6 
(0.7-3.5) 
0.114 
6.1 
(5.1-10.6) 
<0.001 
Weight 
[kg] 
9.8 
(6.4-16.2) 
10.4 
(6.1-15.4) 
9.8 
(6.6-19.9) 
8.6 
(5.8-13.8) 
0.016 
19.0 
(15.3-24.5) 
<0.001 
CD4% 
[%] 
21.0 
(7.4-42.6) 
19.4 
(7.6-44.7) 
16.5 
(6.6-39.4) 
19.0 
(9.0-38.5) 
0.054 
34.5 
(21.9-48.0) 
<0.001 
CD4 
[cells/ 
mm3] 
1137 
(397-3289) 
832 
(209-1699) 
732 
(277-2061) 
1025 
(353-2453) 
0.016 
1259 
(627-2237) 
<0.001 
Viral Load 
[copies/ 
mL] 
245’250 
(6’506-1.7 mil) 
663’047 
(149’283-12.7 
mil) 
325’980 
(43’144-3.8 
mil) 
555’130 
(132’393-5.4 
mil) 
<0.001 < 50 <0.001 
Sex 
(M/F) 
68/57 15/11 8/19 28/17 0.012 49/50 0.017 
pMTCT 
(Y/N) 
22/103 5/21 5/22 6/39 0.895 8/91 0.214 
WHO Stage 
1 19 4 2 4 
0.659 
22 
0.532 
2 46 8 10 22 23 
3 53 12 13 14 38 
4 7 2 14 5 16 
Metabolic 
Subgroup 
 
EM 41 11 11 12 
0.555 
32 
0.611 
IM 59 8 11 25 41 
SM 24 7 5 7 26 
USM 1 0 0 1 0 
Note: Numbers are number or median (5th and 95th percentile). M – male, F – female. pMTCT – exposure to any 
ART in children or mothers in prevention of mother to child transmission (in ART-naïve group 29 children and 28 
mothers had any exposure to ART in pMTCT: 20 children were exposed to NVP [14 sdNVP and 6 NVP >2 days] 
and 14 children to zidovudine [5 in addition to NVP], 25 mothers were exposed to NVP [24 sdNVP and 1 NVP >2 
days] and 5 mothers to zidovudine [3 in addition to NVP]; in ART-experienced group 4 children and 8 mothers 
had any exposure to ART in pMTCT: all children were exposed to NVP [all sdNVP] and none to zidovudine, all 
mothers were exposed to NVP [all sdNVP] and none to zidovudine).  EM (CYP2B6 extensive metabolisers) - 
516GG|983TT; IM (CYPT2B6 intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (CYP2B6 slow 
metabolisers) - 516TT|983TT or 516GT|983TC; USM (CYP2B6 ultra-slow metabolisers) - 516GG|983CC.  
*Kruskal Wallis or Fisher’s Exact test comparing 4 groups of originally treatment-naïve children only. **Kruskal 
Wallis or Fisher’s Exact test comparing 5 groups including children who were treatment-experienced at 
enrolment.   
 171 
 
CHAPTER 7: Determinants of virological outcome and AEs in African children 
treated with nevirapine FDC tablets. 
 
Doctoral Thesis by A.M. Bienczak, March 2017 
Table 7.2 Demographic characteristics and model-derived PK parameters in different suppression groups of children in 
CHAPAS-3 treated with nevirapine (part 2 - continuation) 
Treatment status at 
enrolment 
Naïve 
p* Experienced p** 
Suppression Group Suppressed 
Slow 
Suppress 
Rebound 
Never 
Suppressed 
NRTI 
d4T 40 11 11 16 
0.424 
27 
0.070 ZDV 36 4 8 17 42 
ABC 49 11 8 12 30 
PK 
Cmin 
[mg/L] 
5.43 
(2.48-14.66) 
6.68 
(1.79-15.21) 
5.21 
(1.38-12.33) 
4.76 
(1.45-9.08) 
0.043 
6.57 
(3.44-16.32) 
<0.001 
AUC 
[mg*L/h] 
80.8 
(36.8-196.8) 
94.1 
(25.2-202.7) 
71.9 
(17.1-167.6) 
66.5 
(18.2-128.6) 
0.022 
92.1 
(50.1-216.9) 
<0.001 
Cmax 
[mg/L] 
7.84 
(3.61-17.84) 
9.26 
(2.66-18.27) 
6.87 
(1.68-15.39) 
6.34 
(1.76-12.02) 
0.015 
8.90 
(4.96-19.58) 
<0.001 
CL 
[L/h] 
0.91 
(0.44-1.42) 
0.99 
(0.39-1.41) 
0.91 
(0.55-1.47) 
0.85 
(0.52-1.26) 
0.68 
1.20 
(0.59-1.90) 
<0.001 
A
d
h
e
re
n
ce
 
MEMS 
Score 
[%] 
93.0 
(63.1-98.7) 
94.9 
(76.3-98.9) 
92.8 
(58.0-97.2) 
82.0 
(50.0-97.4) 
0.012 
90.2 
(59.8-99.2) 
0.017 
CV 
Cmin  
[%]† 
31.0 
(9.7-237.4) 
28.5 
(7.4-307.1) 
31.0 
(10.2-246.6) 
45.0 
(11.0-395.0) 
0.022 
21.0 
(8.0-103.2) 
<0.001 
CV  
AUC  
[%]† 
32.0 
(9.4-291.7) 
30.5 
(11.5-391.7) 
37.0 
(8.0-308.0) 
65.5 
(12.0-420.0) 
0.022 
22.0 
(8.9-124.4) 
<0.001 
Note: Numbers are number or median (5th and 95th percentile). For time-varying PK exposures and adherence, 
medians are of the geometric mean per child over all follow-up. Presented PK parameters relate to exposures 
following the morning dose. Included patients received nevirapine and had at least one PK visit. NRTI – 
nucleoside reverse transcriptase inhibitor, d4T – stavudine, ZDV – zidovudine, ABC – abacavir, CV – coefficient 
of variation432 
*Kruskal Wallis or Fisher’s Exact test comparing 4 groups of originally treatment-naïve children only. **Kruskal 
Wallis or Fisher’s Exact test comparing 5 groups including children who were treatment-experienced at 
enrolment. †Only children with >1 sampling visit.  
ART-experienced children were much older, with VL <50 copies/mL and higher CD4% at enrolment. 
The average Cmin and AUC in this group were also higher than most ART-naïve children (p<0.001). 
Despite comparable MEMS-adherence-scores, ART-experienced children had significantly lower intra-
individual variability in nevirapine PK measures than ART-naïve children (p<0.001), which might 
suggest more consistent adherence. Virological outcomes remained excellent: 88 (89%) remained 
suppressed <100 copies/mL throughout the study, 10 (10%) had a virological rebound and only 1 child 
had all VL measurements >100 copies/mL. 
 172 
 
CHAPTER 7: Determinants of virological outcome and AEs in African children 
treated with nevirapine FDC tablets. 
 
                                            Doctoral Thesis by A.M. Bienczak, March 2017 
7.4.2 Concentration-response relationship 
Cox repeated failures regression on 437 matched PK-VL measurements in 219 ART-naïve individuals 
(Table 7.3) showed that the hazard of non-suppression decreased by 7% for every 1 mg/L increase in 
nevirapine Cmin (95% CI: 2-12%). The estimated probability of non-suppression declined from 26% for 
a nevirapine Cmin of 3 mg/L to 18%, 12%, and 9% for Cmin values of 8, 12, and 16 mg/L, respectively, 
using the mixed-effects repeated measures logistic model (Figure 7.1a). Likelihood profiling identified 
a nevirapine Cmin of 10.2 mg/L (95% CI 7.9–11.8) as most predictive of decreased risk of virological 
non-suppression (Figure 7.2a in Appendix to Chapter 7). Despite the markedly decreased probability 
of non-suppression with Cmin above this threshold and improved specificity and positive predictive 
value, in comparison to the other Cmin cut-offs, the identified threshold had inferior sensitivity, 
accuracy, and negative predictive power (Table 7.4).  
 
7.4.3 Predictors of virological non-suppression 
Nevirapine Cmin, clinical site, age, WAZ, HAZ, adherence, bCD4%, and bVL were all associated with 
VL>100 copies/mL in univariate analyses (p<0.2). However, only Cmin, clinical site, adherence, bCD4% 
and bVL were independent predictors (p<0.05). After adjusting for these factors, the effect of Cmin 
dropped slightly from 7 to 6% (95% CI 1–10%) (Table 7.3).  The strongest predictors were adherence 
and bVL. Every 10% increase is MEMS-score was associated with a 22% reduction (95% CI 10–32%), 
and a 10-fold higher bVL was associated with a 2.08-fold increase (95% CI 1.50– 2.90), in the risk of 
non-suppression. Furthermore, for every 10% increase in bCD4%, the risk of viral non-suppression was 
29% (95% CI 5–46%) lower. The hazard of non-suppression was significantly greater at 2 of the 3 sites 
in Uganda, even after adjusting for other significant effects (characteristics by site in Table 7.6 in 
Appendix to Chapter 7). No significant interactions were detected between predictors in the final 
model, in particular there was no evidence that associations between NVP exposure and non-
suppression varied by centre (Site 1 – ref, Site 2 – p=0.23, Site 3 – 0.51, Site 4 - p=0.09).   
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Figure 7.1 Change in probability of non-suppression and AEs over the rage of tested neviapine concentrations 
 
Note: Plots present: (a) Probability of non-suppression (VL>100c/mL) for nevirapine Cmin, (b) probability of 
transaminase grade 2 or higher elevations for nevirapine Cmin 
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Table 7.3 Univariate and multivariate predictors of virological suppression for children in CHAPAS-3 treated with nevirapine 
Factor 
Univariate* Final Multivariate Model** 
HR (95% CI) p HR (95% CI) p 
Cmin 
[per 1mg/L higher] 
0.93 (0.88 – 0.98) 0.004 0.94 (0.90 – 0.99) 0.014 
Site 
[1 ref] 
(2) 1.65 (0.91 – 2.99) 
(3) 1.02 (0.54 – 1.93) 
(4) 1.41 (0.72 – 2.78)  
0.096 
0.943 
0.315 
(2) 1.98 (1.01 – 3.85) 
(3) 1.19 (0.64 – 2.23) 
(4) 2.58 (1.15 – 5.75) 
0.045 
0.573 
0.021 
Age 
[per 1 year older] 
0.83 (0.71 – 0.98) 0.034   
Pre-ART CD4 % 
[per 10% higher] 
0.82 (0.65 – 1.03) 0.101 0.71 (0.54 – 0.95) 0.019 
Pre-ART VL 
[per 10-fold higher] 
2.26 (1.68 – 3.02) <0.001 2.08 (1.50 – 2.90) <0.001 
WAZ 
[per unit higher] 
0.84 (0.69 – 1.01) 0.069   
HAZ 
[per unit higher] 
0.81 (0.69 – 0.95) 0.013   
MEMS-score 
[per 10% higher] 
0.87 (0.76 – 0.99) 0.037 0.78 (0.68 – 0.90) <0.001 
WHO Clinical Stage 
[1 ref] 
(2) 1.78 (0.81 – 3.91) 
(3) 1.34 (0.61 – 2.97) 
(4) 2.36 (0.87 – 6.37) 
0.154 
0.466 
0.090 
  
Note: *Showing all factors with univariate p<0.2, and hence considered for inclusion in the multivariate model. 
**Based on backwards elimination using exit p>0.05. HR –hazard ratio, Clinical sites: (1) – University Teaching 
Hospital, Lusaka, Zambia; (2) – Joint Clinical Research Centre, Kampala, Uganda; (3) – Bristol Myers Squibb 
Children’s Clinical Centre of Excellence, Baylor College of Medicine, Kampala, Uganda; (4) – Joint Clinical 
Research Centre, Gulu, Uganda. HAZ – height-for-age adjusted Z-scores. WAZ – weight-for-age adjusted Z-scores.  
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7.4.4 AEs 
 
Skin reactions were rare (four grade-2 HSR, one grade-3 HSR, and one grade-4 SJS). All occurred in 
ART-naïve patients within 2 weeks of ART initiation, and nevirapine was stopped before PK sampling. 
The mean pre-ART age and CD4% were 2.8 years and 22%, respectively, and did not differ significantly 
from other children (ranksum p>0.4); sex was also similar (2 boys, 4 girls; exact p=0.43) as was CYP2B6-
metaboliser status (3 EM, 2 IM and 1 SM, exact P=0.87).  
Transaminase measurements post-baseline were available for 335 children (2273 samples). At 
enrolment, AST was significantly higher in ART-naïve than ART-experienced children with median 43 
IU (5th-95th: 26–127) versus 32 IU (22–60), p<0.001, but ALT was similar with median 21 (9–75) versus 
23 (13–53), p=0.14. Transaminase elevations grade 3 and above were rare (15 in total) and were not 
associated with any particular characteristics (Table 7.7 in Appendix to Chapter 7), there were no cases 
of acute hepatitis. 
Of 39 >grade 1 elevations observed in 235 ART-naïve children, 24 (9 both AST and ALT, 6 AST only and 
9 ALT only) were matched with nevirapine concentrations and were included in the Cox repeated 
failures model. The model identified nevirapine Cmin (HR per unit higher [95% CI] 1.07 [1.01 – 1.13], 
p=0.032), but no other factors (including baseline transaminase elevation, sex, age and WAZ/HAZ) to 
be univariably associated with increased risk of transaminase grade 2 and above elevations. Likelihood 
profiling identified Cmin cut-off of 12.4 mg/L (95%CI 7.7-13.5) with HR (95%CI) above vs. below the 
identified threshold of 5.18 (1.95 – 13.80), p<0.01, (Figure 7.2b in Appendix to Chapter 7). All the 
observed transaminase elevations were transient and none led to change in treatment, and, although 
AST and ALT levels were higher in matched samples with nevirapine Cmin >12.4 mg/L, at most time 
points the increase from baseline was not statistically significant (Table 7.5). The probability of 
transaminase elevations by nevirapine Cmin estimated using mixed-effects repeated measures logistic 
model are presented in Figure 7.1b, and remained below 10% up to 30 mg/L.
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Table 7.4 Comparison of previously published treatment targets applied to nevirapine trough concentrations of the current data set, as well as the thresholds derived in this analysis. 
NVP target conc. 
[mg/L] 
2.57  
(10th percentile)† 
3.0341‡ 3.5340‡ 
4.04  
(25th percentile)† 
4.3342‡ 
5.82  
(50th percentile)† 
10.2† 
HR  
(95% CI)* 
2.05 
(1.28-3.30) 
1.50 
(0.95-2.36) 
1.62 
(1.08-2.41) 
1.62 
(1.08-2.41) 
1.51 
(1.04-2.23) 
1.46 
(1.02-2.11) 
3.05 
(1.59-5.86) 
P 0.003 0.078 0.017 0.017 0.032 0.043 <0.001 
Samples with 
VL>100 c/mL / 
VL<100 c/mL [n] 
< T > T < T > T < T > T < T > T < T > T < T > T < T > T 
19/17 116/285 20/28 115/274 31/41 104/261 40/55 95/247 45/68 90/234 75/132 60/170 126/241 9/61 
Percentage of 
samples with 
VL>100 c/mL 
52.7% 28.9% 41.6% 29.6% 43.0% 28.5% 42.1% 27.7% 39.8% 27.7% 36.2% 26.1% 34.3% 12.7% 
Sensitivity 14.1% 14.8% 23.0% 29.6% 33.3% 55.6% 93.3% 
Specificity 94.4% 90.7% 86.4% 81.8% 77.5% 56.3% 20.2% 
Accuracy 69.6% 67.3% 66.8% 65.7% 63.8% 56.1% 42.8% 
Positive Predictive 
Value 
52.8% 41.7% 43.1% 42.1% 39.8% 36.2% 34.3% 
Negative 
Predictive Value 
71.1% 70.4% 71.5% 72.2% 72.2% 73.9% 87.1% 
Note: < T – below target, > T – above target. *hazard ratio for concentrations below target compared to above target; †current investigation; ‡previously pub lished 
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7.5 Discussion 
We observed that virological non-suppression in a group of African children treated with nevirapine 
in combination with two NRTIs was affected by nevirapine Cmin and treatment adherence, as well as 
pre-ART viral load and CD4 cell count. Despite confirming a significant concentration-response 
relationship, we could not identify a meaningful exposure cut-off predictive of virological non-
suppression. Furthermore, other factors independent of systemic exposures were more strongly 
associated with non-suppression than nevirapine exposure. Children with lower viral load at ART 
initiation and better adherence had improved virological outcomes. Adverse events were rare, but 
high nevirapine Cmin were associated with transient grade 1 and above transaminase elevations. 
Similar to previous investigations in adults91,340,341 we confirmed that higher nevirapine concentrations 
led to superior virological suppression in children. Customarily used efficacy thresholds for nevirapine 
were derived from distributions of concentrations in adult, predominantly Caucasian, patients, even 
though nevirapine exposures are higher in African populations358 and children,305,431 bringing into 
question their universal applicability.72 We recently proposed an alternative method of selecting an 
efficacy threshold based on likelihood profiling and successfully used it for efavirenz in a similar 
population of African children.433 Interestingly, a similarly clear cut-off could not be derived for 
nevirapine, in line with findings by van Leth.234 The identified Cmin threshold of 10.2 mg/L, despite 
having superior sensitivity and negative predictive value, had substantially lower specificity and 
accuracy than other cut-offs (Table 7.4). In comparison, the threshold identified for efavirenz (Cmin of 
0.65 mg/L) was visibly superior to previously suggested and clearly predicted non-suppression, with 
only 7% of samples above it but 37% below it having VL >100 copies/mL.433 Nevirapine has lower 
potency (protein adjusted IC95 of 196.6 ng/L vs 54.7 ng/L)64 and shorter half-life than efavirenz, which 
is the most potent component of NNRTI+2NRTI ART contributing 65% of its total efficacy.240 A higher 
contribution to treatment efficacy of the two accompanying NRTIs may have obscured a clear PK 
efficacy threshold for nevirapine. The above could also explain why virological outcomes were more 
strongly related to several other factors than nevirapine exposures in children on nevirapine-based 
ART. 
The effects of pre-ART CD4% and VL on virological outcome have been well 
documented.61,145,149,150,152,434 In CHAPAS-3, ART-naïve children on nevirapine with a higher pre-ART VL 
either took much longer to achieve VL <100 copies/mL or never suppressed, consistent with the 
increased hazard of virological non-suppression with higher pre-ART VL. The pre-ART CD4% in ART-
naïve children who rebounded after achieving initial suppression by week 48 was significantly lower 
than in other groups, and it was also an independent predictor of virological non-suppression. Our 
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findings highlight the benefits of treatment initiation in early stages of disease, in children with a low 
VL and high CD4%. The recent START trial435 in adults confirmed the importance of starting ART early, 
and supported guidelines recommending initiation of ART regardless of CD4 cell count.6 
Our findings emphasize the importance of treatment adherence in achieving and maintaining 
virological suppression, consistent with other studies in African children.61,152 Children who never 
achieved VL <100 copies/mL in our study had significantly lower MEMS-scores. Adherence also 
independently predicted virological non-suppression with risk decreasing by 22% for every 10% higher 
MEMS-score. It has been hypothesised that adherence above 95% is required to achieve and maintain 
beneficial effects of ART.234,436 Interestingly, in CHAPAS-3, the median adherence in children taking 
efavirenz, an NNRTI administered once a day, was higher than for nevirapine (99% versus 91%).433 This 
could explain why the association between adherence and virological outcome was more significant 
for nevirapine than efavirenz. Meta-analyses confirm that once-daily regimens and reduced pill 
burden are associated with higher adherence to ART.437,438 Lower adherence could be a contributory 
factor to the higher proportion of ART-naïve patients on nevirapine who never achieved VL <100 
copies/mL (20% versus 6% on efavirenz) and worse virological outcomes in ART-experienced children. 
CHAPAS-3 was not designed to compare the effectiveness of nevirapine and efavirenz, but several 
other studies in children in resource-limited settings suggest better virological outcomes for the 
latter.149–154 Yet, nevirapine is currently the only NNRTI formulated as all-in-one paediatric FDC. Whilst  
developing a similar formulation containing efavirenz could improve treatment adherence and hence 
virological outcome, this is challenging due to the larger efavirenz dose and higher PK variability due 
to pharmacogenetics.415,431  
Adverse events were rare in our study, replicating other paediatric investigations.107,108,375 High 
nevirapine concentrations were associated with elevated hepatic enzymes in adults, in particular in 
those with low BMI,352,353 but several other studies including African patients showed a low risk of 
hepatotoxicity.105,106,358 In CHAPAS-3, while we detected an association between high nevirapine 
exposures and increased risk of developing >grade 1 transaminase elevations, all observed events 
were transient and did not lead to ART substitutions. Likelihood profiling identified a Cmin threshold of 
12.4 mg/L as most predictive of these transient events and, although we observed higher 
transaminase levels during the study when concentrations were above this threshold, they were not 
significantly different to baseline. Moreover, the baseline values of AST and ALT for ART-experienced 
children (on nevirapine-based ART for >2 years) were not significantly higher than in ART-naïve 
children. Together, these suggest that these findings may have limited clinical relevance. Recent 
reports hypothesise that nevirapine-related hepatotoxicity has a genetic cause.360,439,440 Similarly HSR 
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Table 7.5 Transaminase levels at 6, 48 and 96 weeks of treatment, compared to baseline liver enzymes in ART-naïve children, by nevirapine Cmin threshold most predictive of transient grade 2 
and above transaminase elevations 
Baseline 
N = 235 
Nevirapine 
Conc. 
Week 6 
N = 196 
pᶧ 
Week 48 
N = 200 
pᶧ 
Week 96 
N = 188 
pᶧ 
Median* 
Change from 
Baselineᶧ 
Median* 
Change from 
Baselineᶧ 
Median* 
Change from 
Baselineᶧ 
A
ST
 [
U
/L
] 
43.0 
(25.7 – 107.9) 
<12.4 mg/L 
36.0 
(24.2 – 95.8) 
-5.5 
(-8.5 to -3.0) 
0.001 
37.0 
(24.0 – 78.6) 
- 5.5 
(-8.5 to -2.5) 
<0.001 
35.0 
(25.0 – 71.1) 
-7.0 
(-10.0 to -4.0) 
<0.001 
>12.4 mg/L 
42.0 
(24.0 – 118) 
-7.0 
(-38.5 - 27.5) 
0.407 
51.0 
(26.8 – 268.4) 
3.8 
(-44.0 – 257.0) 
0.799 
43.0 
(31.2 – 205.0) 
8.0 
(-34.0 – 116.0) 
0.488 
A
LT
 [
U
/L
] 
21.0 
(9.0 – 95.8) 
<12.4 mg/L 
22.0 
(10.0 – 82.6) 
2.5 
(0.0 – 4.5) 
0.068 
26.5 
(13.0 – 64.6) 
5.0 
(2.5 – 8.0) 
<0.001 
24.0 
(8.6 – 67.2) 
1.5 
(-1.5 – 4.0) 
0.373 
>12.4 mg/L 
35.0 
(9.0 – 66.5) 
9.3 
(5.5 - 16.5) 
0.014 
37.5 
(18.40 – 
215.8) 
14.5 
(-16.0 – 169.0) 
0.441 
41.0 
(20.2 – 169.0) 
16.0 
(-11.0 – 186.5) 
0.343 
Note: *Median (5th and 95th percentile), ᶧ Median (95% non-parametric confidence interval) of the differences between week 6, 48 and 96 and baseline, respectively, and p-
value from Wilcoxon signed rank test 
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were rare, possibly due to dose escalation in the first 2 weeks of the study.107 Small numbers precluded 
associations with any specific patient characteristics, but they occurred early in the study, before any 
PK sampling, making it difficult to confirm speculations of their idiosyncratic etiology.72,347 
Considering nevirapine’s low genetic barrier for viral resistance,342 the risk of non-suppression 
decreasing with increasing drug concentrations, and the presented safety profile, maintaining Cmin 
higher than the current target of 3–8 mg/L could have beneficial effects on general treatment 
outcomes in African children, and nevirapine concentrations as high as 12.4 mg/L should not lead to 
increased risk of AEs. Results of recent nevirapine population-pharmacokinetic analysis in children 
from CHAPAS-3431 shows that currently recommended paediatric dosage6 provides average Cmin at the 
upper range of the 3-8 mg/L target, even though slow metabolisers determined by CYP2B6 
516G>T|983T>C genotype are at risk of exposures above 12.4 mg/L.431 
Our study has several limitations. We could not find a plausible explanation for the detected effect of 
clinical site on virological outcome, which was not due to small imbalances in other factors since these 
were either adjusted for or had no association with virological non-suppression. These centre effects 
likely reflect residual confounding from factors not captured in our study, either  differences in other 
aspects of management on ART or other local variability in the patient populations e.g. in 
socioeconomic status, distance to clinic etc. However, we found no evidence that the effect of other 
independent predictors (adherence, VL, NVP exposure) varied across centres (i.e. no 
interaction/heterogeneity) supporting generalisability of these findings to other settings. No 
genotyping was conducted at enrolment, so we were not able to assess the impact of pre-existing 
NNRTI resistance on response. However, we did not find any evidence of an association between 
pMTCT (predominantly single-dose NVP) and increased risk of non-suppression, similarly to another 
recent study,61 suggesting that the impact of pre-existing NNRTI resistance may be relatively small 
compared to the other factors assessed.  Most VLs were matched with nevirapine concentrations 
measured 12 weeks earlier and one could argue that drug concentrations measured on the same day 
as VL could be more predictive of virological outcome. However, suppression is likely related to 
maintained drug exposure above a certain threshold and a random measurement in the time period 
preceding it could be a better indicator of it. Adherence in our study was only measured in certain 
time periods and the same drug-taking pattern was assumed to persist until the next measurement. 
Most children had only 3 VLs after enrolment and our analysis assumed that no viral rebounds 
occurred in between. Lastly, our findings should not be generalised to ART based on other drugs, in 
fact, amongst children enrolled to CHAPAS-3, we found different predictors of virological outcome for 
children on efavirenz. 
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7.6 Conclusions 
Higher nevirapine concentrations were associated with significantly better virological outcomes, but 
a meaningful cut-off predictive of increased risk of non-suppression could not be identified, possibly 
due to the effects of the combined NRTIs. Lower VL at ART initiation and higher treatment adherence 
were the most predictive determinants of virological suppression. The outcome was further affected 
by pre-ART CD4% and clinical site. Adverse events were rare and, even though we detected an 
association between nevirapine Cmin >12.4 mg/L and transaminase elevations, this is of limited clinical 
relevance due to their transient character. Treatment initiation at lower VL and higher CD4%, 
increased adherence, and maintaining average Cmin higher than current target could have a positive 
effect on virological suppression of African children treated with nevirapine. 
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7.10 APPENDIX TO CHAPTER 7 
7.10.1 Supplementary tables 
Table 7.6 Demographic characteristics and model-derived PK parameters of children in CHAPAS-3 treated with nevirapine 
presented by clinical site 
Suppression Group Site 1 Site 2 Site 3 Site 4 
p 
Number of patients 49 68 59 44 
Baseline 
Age 
[years] 
2.3 
(0.8-7.9) 
1.9 
(0.7-4.4) 
1.7 
(0.5-2.9) 
2.0 
(0.8-4.3) 
0.020 
Weight 
[kg] 
9.7 
(5.9-20.7) 
9.0 
(6.1-16.3) 
9.7 
(6.4-13.9) 
10.4 
(6.4-15.3) 
0.224 
CD4% 
[%] 
13.4 
(4.5-28.6) 
21.0 
(9.0-30.5) 
18.5 
(10.8-32.6) 
30.5 
(17.0-54.8) 
<0.001 
CD4 
[cells/ 
mL] 
768 
(233-1347) 
1075 
(433-2977) 
1162 
(472-3316) 
1132 
(432-2672) 
<0.001 
Viral Load 
[copies/ 
mL] 
325’980 
(24’187-1.1 
mil) 
440’205 
(63’650-8.4 
mil) 
287’980 
(14’347-3.5 
mil) 
298’887 
(3’093-1.3 
mil) 
0.089 
Sex 
(M/F) 
30/18 34/34 32/27 22/22 0.551 
WHO Stage 
1 5 16 4 2 
0.401 
2 8 24 43 11 
3 27 24 12 27 
4 28 4 0 4 
Metabolic 
Subgroup 
 
EM 15 27 20 12 
0.533 
IM 22 27 27 26 
SM/USM 
 
11/0 14/0 11/1 5/1 
NRTI 
d4T 21 24 21 13 
0.787 ZDV 11 20 18 11 
ABC 16 24 20 20 
PK 
Cmin pm 
[mg/L] 
6.28 
(2.10-17.68) 
5.68 
(2.35-12.96) 
5.22 
(1.49-11.99) 
5.78 
(0.86-17.23) 
0.714 
AUC pm 
[mg*L/h] 
89.4 
(25.7-235.4) 
84.2 
(35.8-173.9) 
77.1 
(19.5-166.8) 
80.1 
(14.1-231.9) 
0.584 
Cmax pm 
[mg/L] 
8.65 
(2.41-21.624) 
8.19 
(3.57-15.91) 
7.54 
(1.87-15.45) 
7.75 
(1.34-21.05) 
0.454 
Adherence 
MEMS 
Score 
[%] 
87.0 
(50.0-97.0) 
94.0 
(81.0-99.9) 
86.0 
(53.6-97.0) 
86.0 
(57.3-98.0) 
<0.001 
CV  
Cmin  pm 
[%] 
20.5 
(1.0-304.4) 
15.0 
(2.0-263.4) 
15.5 
(1.7-627.0) 
31.0 
(1.3-369.6) 
0.547 
CV  
AUC  pm 
[%] 
15.5 
(1.9-327.5) 
15.0 
(2.0-334.7) 
18.0 
(2.0-760.5) 
28.0 
(1.0-463.8) 
0.499 
Note: Presented values are number or median (5th and 95th percentile). Demographic characteristics for 219 
individuals ART-naïve at enrolment with matched PK-VL measurements (included in Cox proportional hazards 
regression model). CV calculated only on individuals who had >1 matched PK visit (182 individuals)  
†EM (extensive metabolisers) ) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, 
SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 516GG|983CC 
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Table 7.7 Comparison of characteristic of children in CHAPAS-3 treated with nevirapine with > grade 2 transaminase 
elevations versus group with no > grade 2 elevations 
Transaminase 
Elevations 
> grade 2 No > grade 2 p* 
Events / children 15/14 0/321  
ART naïve/ 
experienced 
10/4 225/96 0.99 
Sex (M/F) 7/7 169/152 0.98 
Baseline 
Age 
[years] 
2.6 (0.9 – 6.6) 2.6 (0.8 – 8.5) 0.81 
Weight 
[kg] 
10.0 (6.1 – 20.0) 11.6 (6.1 – 22.1) 0.51 
WAZ -0.9 (-3.6 - 0.3) -1.6 (-4.3 – 0.1) 0.14 
HAZ -2.3 (-4.7 - 0.2) -2.4 (-4.9 - -0.6) 0.69 
Metabolic 
Status 
EM 4 107 
0.83 
IM 6 145 
SM 4 67 
USM 0 2 
NRTI 
d4T 3 103 
0.66 ZDV 6 107 
ABC 5 111 
PK 
Cmax 
[mg/L] 
7.6 (4.1 – 15.7) 8.2 (2.9 – 18.3) 0.83 
Cmin 
[mg/L] 
4.9 (2.9 – 13.0) 5.8 (2.0 – 15.5) 0.89 
Note: Presented values are number or median (5th and 95th percentile). Presented PK parameters relate to 
daytime exposures. In the > grade 2 transaminase elevations group presented value is the median of nevirapine 
concentrations measured on the same day or earliest preceding the elevated sample (10 out of 15 matched); in 
the group with no > grade 2 elevations it is the median of geometric-means of nevirapine concentrations across 
follow-up calculated within each individual. 
 *Ranksum Wilcoxon Test or Fisher’s Exact Test. M – male, F – female. EM (CYP2B6 extensive metabolisers) - 
516GG|983TT; IM (CYPT2B6 intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (CYP2B6 slow 
metabolisers) - 516TT|983TT or 516GT|983TC; USM (CYP2B6 ultra-slow metabolisers) - 516GG|983CC. NRTI – 
nucleoside reverse transcriptase inhibitor: d4T – stavudine; ZDV – zidovudine; ABC – abacavir. 
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7.10.2 Supplementary figures 
 
Figure 7.2 Profile likelihoods for virological non-suppression and transaminase elvations for the range of tested nevirapine 
concentrations 
Note: Plots show: a) association between Cmin and the risk of non-suppression, b) association between Cmin and 
the risk of grade 2 and above transient transaminase elevations. The black dots are Akaike Information Criterion 
(AIC) values for dichotomised cut-offs in tested exposure parameter based on the original data, the black line 
and shaded grey area are the mean and 95% confidence interval of AIC for cut-offs in the tested exposure 
parameter from 500 re-simulation runs. Dotted line on Figure 7.2a indicated the current efficacy threshold for 
nevirapine and on Figure 7.2b - the current safety threshold.
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The introduction of the new paediatric nevirapine and efavirenz tablets, including all-in-one fixed dose 
combination (FDC) co-formulations of nevirapine with nucleoside reverse transcriptase inhibitors 
(NRTIs), together with the WHO simplified weight band dosing significantly contributed towards 
improving antiretroviral (ARV) coverage in HIV-infected children in a resource limited setting by 
reducing its cost and increasing its feasibility.33,382,441 With growing clinical evidence new antiretroviral 
treatments (ARTs) are being introduced in a resource-rich setting, where the cost of healthcare is not 
a significant constraint. Due to high expense those options are not viable in sub-Saharan Africa, making 
optimisation of the currently available paediatric treatments a priority. Efavirenz and nevirapine based 
ARV regimens are the most widely used first line options for children in resource-limited countries. 
However, studies report high levels of pharmacokinetic (PK) variability for those drugs in children, and 
sub-optimal exposures (in particular for nevirapine) in the youngest age groups.33,34,37,40,288,374 In 
addition, the relationship between systemic exposure to efavirenz and nevirapine and the virological 
outcome in children has been little studied, and the therapeutic thresholds for nevirapine have never 
previously been evaluated in African population or children, preventing treatment optimisation. The 
presented thesis aimed to fill this gap by characterising the PK of efavirenz and nevirapine in African 
children, with particular focus on the effect of genetic polymorphisms, describing the 
PK/pharmacodynamics (PD) relationship for those drugs and identifying factors affecting both 
systemic exposures and overall treatment effect. In addition, by developing a method based on 
likelihood profiling, we identified drug concentration thresholds most predictive of virological 
suppression and suggested interventions hypothesised to provide most optimal treatment outcome. 
The sections below elaborate on the key findings, limitations, recommendations and scope for further 
work in relation to thesis objectives. 
8.1 Synthesis of findings 
8.1.1. Is the inter-individual variability in efavirenz and nevirapine 
concentrations in African children predicted by single nucleotide 
polymorphisms in CYP2B6 metabolic pathway alone, or in combination 
with selected polymorphisms in additional genes (CYP3A4, CYP3A5, 
ABCB1, NR1|2, NR1|3), or other demographic characteristics? 
 
We found that the combined effect of SNPs CYP2B6 516G>T and 983T>C on clearance was the main 
predictor of variability in efavirenz and nevirapine concentrations in African children (Tables 4.3 and 
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6.3). This confirms previous findings from adult studies (in efavirenz - Chapter 2.3.1.2.1 and nevirapine 
– Chapter - 2.3.2.2.1) and one recent investigation in efavirenz in South African children.76 Similar to 
previous studies72,176,442 we showed that despite higher prevalence 516G>T variant allele impairs the 
clearance of both drugs to smaller extent than 983T>C, and even though the latter polymorphism is 
not present among Caucasian individuals, it is of major importance for black Africans.29,198 We 
distinguished 6 separate phenotypic subpopulations in efavirenz pharmacokinetics based on CYP2B6 
516G>T|983T>C genotype (Table 4.4 and Figure 4.1 right), which could be simplified to 4 different 
metabolic subgroups as suggested by Dooley et al.71 (Tables 2.3 and 4.4). The combined effect of SNPs 
516G>T and 983T>C on nevirapine pharmacokinetics (Table 6.2 and Figure 6.5b) was not surprisingly 
of smaller magnitude than identified for efavirenz (89% drop in clearance between extensive [EM] and 
ultraslow metabolisers [USM] for efavirenz versus 68% for nevirapine), what is due to higher 
contribution of CYP3A4 to total nevirapine biotransformation (Chapter 2.3.2.1). We detected no 
significant effect of any of the other tested polymorphisms.  
The clearance of efavirenz (and hypothetically also nevirapine) has been shown to be affected by a 
number of other polymorphisms in CYP2B6 pathway but reports in regards to significance of those 
findings are inconclusive (Chapter 2.3.1.2.1). While SNP 785A>G was previously linked with both 
516G>T and 983T>C creating distinguished haplotype groups, its effect was shown to be of small 
magnitude in comparison with the other outlined polymorphisms. In our study the effect of SNP 
785A>G was investigated only in the subset of children from ARROW receiving efavirenz and did not 
prove significant. The association with SNP 15582C>T identified by Holzinger et al.176 was reproduced 
in South African patients by Sinxadi et al.,76 nonetheless it similarly was shown to be of limited 
importance and relevant only for individuals homozygous for common alleles 516G>T and 983T>C. 
Efavirenz clearance in EM was recently shown to be affected by SNPs CYP2B6 18492T>C and 
21563C>T,204–206 which were not explored in our study. Those findings were reported only in Thai 
patients and to date not reproduced in other populations.  
We hypothesised that the PK of the investigated NNRTIs could be further affected by polymorphisms 
in genes coding nuclear receptors (NR1|2 and NR1|3) but similar to majority of other studies (Chapter 
2.3.1.2.3) did not detect a significant effect of tested SNPs. A recent investigation by Swart et al.84 
showed that polymorphisms in CAR (NR1|3) start playing greater importance only in slow CYP2B6 
metabolisers (SM). Slow efavirenz clearance among patients with impaired CYP2B6 metabolism is 
further affected by polymorphisms in UGT and CYP2A6 accessory pathways (Chapter 2.3.1.2.2) leading 
to even higher drug exposures. While this effect would be limited only to a small number of patients, 
it is could explain extremely high efavirenz concentrations documented in a number of case 
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reports.177,189,286,443 The polymorphisms in the efavirenz accessory pathways were not explored in our 
analysis.  
In addition to the pharmacogenetic determinants, the PK of efavirenz and nevirapine in our studies 
(Chapters 4 and 6) was significantly affected by weight, which was accounted for in both models using 
allometric scaling of clearance parameters and volumes of distribution. The observed average 
clearance values were relatively higher in younger (and lighter) children than in the older age groups. 
Similar effect is present for the majority of other compounds and allometric scaling with body weight 
is currently a widely accepted modelling standard (Chapters 2.3.1.7.3 and 2.3.2.8.3) allowing to 
account for differences in PK between adults and children resulting from differences in body size.225,277 
The parameter estimates in both investigations were more accurate under intensive sampling scheme 
following observed drug intake than under sparse sampling following self-reported intake time. For 
both drugs this was accounted for as scaling factors on parameter uncertainty. For efavirenz the 
residual unexplained variability (RUV) in sparse data was twice larger (Table 4.3), for nevirapine we 
detected an approx. 50% larger uncertainty in RUV and between occasion variability in pre-hepatic 
bioavailability (BOV FpreH - Table 6.3) estimated in sparse data. Even though inclusion of the scaling 
factors improved the model fit, it is of limited clinical relevance. 
In addition our analysis (Chapter 6) showed that nevirapine clearance exhibits a daily rhythm 
described using a cosine oscillation with peak around 12 noon and amplitude of approximately 29% 
(Figure 6.3). The relatively large fluctuation in nevirapine clearance has little effect on the estimated 
daily exposures in terms of Cmin or AUC (Table 6.2 and Figures 6.7 and 6.8). This could be speculated 
due to long terminal half-life of nevirapine. Since the daily nevirapine dose is split between morning 
and evening administration the variability in Cmin resulting from the diurnal variability in clearance is 
much smaller than differences in exposures resulting from CYP2B6 polymorphisms. The small 
magnitude of this effect on nevirapine concentrations could explain why the diurnal oscillation in 
nevirapine clearance was never previously characterised. 
No age effect (maturation) was detected on clearance in either of the drugs but we identified age-
driven differences in nevirapine FpreH (at birth estimated as 58.3% of the value in older children 
[reference fixed to 100%], 90% of FpreH was reached by age of approximately 3.3 years and the half-
life of the process was 1.55 years [Figure 6.4]). Similar age-driven differences in nevirapine 
bioavailability were previously described by Foissac et al.374 Mechanistic hypotheses contributing to 
this effect are discussed in Chapter 6.5. Our finding does not exclude the presence of maturation in 
nevirapine clearance in younger children, nonetheless in our data this effect was overshadowed by 
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the effect on FpreH. On the contrary, the recent analysis by Salem et al.162 confirms that in children 
older than 3 years no further maturation in efavirenz clearance should be observed. 
The shringake in the presented population PK models for estimated variability parameters is outlined 
in Table 8.1. For efavirenz the values of shrinkage for BSV in CL and F1 are acceptable but not suprising 
they are much higher for the BOV parameters. The number of sampling occasions for children included 
in the analysis ranged between 2 and 8 and contributed to high shrinkage values for occasions with 
limited number of measurments. Similar trend in shrinkage can be seen for nevirapine, although the 
estimated shrinkage in BSV for pre-hepatic bioavailability was relatively high (37%). This could be 
speculated due to high complexity of the model and high number of fixed effects relating to this 
parameter.  The presented shrinkage estimates indicate that the model paramters Empirical Bayes 
Estimate were estimated with acceptable precission.  
 Virability parameter Efavirenz Nevirapine 
BSV 
Clearance 19.1 % 26.2 % 
Bioavailibility* 24.2 % 37.0 % 
BOV 
Bioavailibility* 4.7 – 28.9 % 7.7 – 44.7 % 
Mean transit time 39.7 – 67.6% 33.0 – 66.1 % 
Absorption rate constant 55.5 – 86.3 % 53.2 – 84.9 % 
Clearance 52.0 – 66.4 % ------ 
RUV 31.5 % 36.1 % 
Table 8.1 Overviewe of shrinkage in variability parameters in the population pharmacinetic models presented in Chapters 4 
and 6. *For nevirapine this relates to pre-hepatic bioavailability. 
 
8.1.2. Do average efavirenz and nevirapine exposures differ between 
WHO 2010 dosing weight bands and different metabolic subgroups, 
determined by individual CYP2B6 genotype, and could genotype based 
dose adjustment provide more balanced exposures between metabolic 
subgroups in African children?  
 
WHO 2010 weight band dosing provided adequate average efavirenz exposures across all weights 
(Figure 4.1a). Nonetheless, noticeable differences were observed between different CYP2B6 genotype 
subgroups irrespective of their weight (Figure 4.1b). CYP2B6 EM had average efavirenz exposures at 
the bottom of the current therapeutic range of 1 – 4 mg/L putting them at an increased risk of 
virological failure, whereas SM and USM had mid-dose concentrations above the target range putting 
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them at an increased risk of developing CNS AEs. Based on results of pharmacokinetic simulations we 
suggest that a dose adjustment strategy based on individual CYP2B6 516G>T|983T>C genotype (Table 
4.5), should ensure more balanced efavirenz exposures between different metabolic subgroups in all 
weight bands (Figure 4.2). The suggested dosage algorithm maximises the use of the new efavirenz 
double-scored paediatric 600 mg tablets. 
Similar genotype based dose adjustment approaches were previously suggested in adults (Chapter 
2.3.1.6) and children (Chapter 2.3.1.7.7) but were guided solely on the individual 516G>T genotype. 
We showed that such approach could lead to supratherapeutic efavirenz exposures in individuals with 
983T>C variant allele (Figure 4.3) and that despite a lower prevalence this SNP should be taken into 
consideration to guide dose adjustments in African children. This was also postulated in a recent study 
in South African children.286 Implications of the suggested dose optimisation approach are further 
discussed in Chapters 8.3 and 8.4. 
The average nevirapine exposures obtained under WHO 2010 weight band dosing was adequate in 
majority of children (Figure 6.5a) with exception of infants weighing 4 – 6 kg (where >25% of children 
had evening Cmin < 3mg/L). This effect was driven mostly by EM and intermediate metabolisers (IM) 
(43% and 26% <3 mg/L,95 respectively - Figure 6.5b). In addition, the average nevirapine Cmin differed 
significantly between metaboliser groups in all tested weight bands with majority of SM and USM 
having exposures above the current upper therapeutic target of 8 mg/L.95 To prevent suboptimal 
nevirapine concentrations we suggest the daily dose for EM and IM in the lowest weight band to be 
increased from 100 to 150 mg. Further harmonisation of nevirapine exposures could be achieved by 
50% reduction of nevirapine dose in SM and USM in all other weight-bands. Implications and feasibility 
of genotype guided treatment optimisation for nevirapine are discussed in Chapter 8.3. 
 
8.1.3. Are efavirenz and nevirapine concentrations predictive of 
virological response and adverse events in African children treaded 
with paediatric solid FDC formulations, and what is the contribution of 
other variables to the observed treatment effects? 
 
The results of the conducted PK/PD analysis (Chapter 5) suggest that efavirenz exposures are the main 
predictor of the virological outcome in African children on efavirenz based ART. There was a strong 
association (P<0.0001) between the systemic exposure to efavirenz (measured as C12h, C24h or AUC) 
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and the risk of non-suppression (lower risk of VL > 100 copies/mL for higher exposures), which was 
best described using a log-linear model (Table 5.2). After adjusting for the effect of all significant 
covariates in the multivariate analysis we identified that sex, age and site as additional independent 
predictors of virological outcome (with an interaction in the effect of the first two variables, Table 5.3). 
The risk of virological non-suppression for boys <8 years was 5 times greater than that for girls of 
similar age. Older children had increased risk of virological non-suppression compared with younger 
children, but there was no evidence of a difference between boys and girls >8 years. The hazard of 
virological non-suppression was significantly higher in the smallest site, which contributed only 5 
children and is of little clinical relevance. There was marginal evidence that poorer adherence 
independently increased the hazard of virological non-suppression (P = 0.065 after including in the 
final multivariate model in addition to significant differences between suppression groups presented 
in Table 5.1). The AEs in children in efavirenz arm were rare and could not be associated with any 
particular characteristics. 
The association between plasma nevirapine exposure and the virological outcome (explored in 
Chapter 7) was considerably weaker than for efavirenz (also inversely correlated), and in the 
multivariate analysis pre-ART VL (2.08-fold increase in risk for 10-fold higher bVL, P<0.001) and 
adherence (22% reduction in risk for every 10% increase is MEMS score, P<0.001) were the strongest 
independent predictors of non-suppression (Table 7.3). The risk of non-suppression was in addition 
higher for children with lower baseline CD4% (every 10% increase in bCD4% was associated with a 
29% drop in the hazard). Similar to efavirenz there was a significant effect of treatment site, but after 
accounting for all independent predictors there was no association with age or sex. The 
hypersensitivity reactions to nevirapine were rare and could not be attributed to any characteristics, 
but transient transaminase grade 2 and above elevations were associated with high nevirapine 
concentrations (7% increase in risk for every unit increase in nevirapine Cmin, P=0.032).  
The associations between drug exposures and treatment outcome for efavirenz in children have been 
little studied and for nevirapine never been previously characterised. Most previous paediatric 
investigations focused on predictors of treatment efficacy other than drug exposures (Chapter 
2.3.1.7.5 and 2.3.2.8.5) and the majority of them were comparative studies including 2 or more 
different treatments (Table 2.6 and 2.7). Interestingly our analyses, in addition to systemic exposures, 
found different predictors of virological outcome for both of the investigated drugs (Tables 5.3 and 
7.3). Nonetheless, it could be speculated that sex and age effects detected for efavirenz could be 
linked to differences in treatment adherence between age groups and genders (and hence the effect 
of adherence itself for efavirenz proved not significant). Literature shows inconclusive information on 
the effect of gender and age on treatment outcome with some studies reporting increased risk of 
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treatment failure for younger children,280,444,445  some for older age groups149,153 and some a non-linear 
effect.154  Conversely, the reports consistently show that treatment failure is linked to 
malcompliance,61,149,152 and it has been speculated that adherence above 95% is required to achieve 
and maintain virological suppression.234,436 Considering that a large proportion of children in the 
efavirenz arm took > 95% of the prescribed doses, it could provide a plausible explanation why the 
effect of adherence for that drug was not picked up in our analysis. Differences in treatment 
compliance could also explain better virological outcome observed among children on efavirenz than 
nevirapine in CHAPAS-3 (the average MEMS scores higher [Tables 5.1] and lower [Tables 7.1 and 7.2], 
respectively).  
Even though CHAPAS-3 was not designed to compare the effectiveness of nevirapine versus efavirenz, 
a number of other studies suggest a better virological outcome for the former (Table 2.6). Meta-
analyses report that once-daily regimens and reduced pill burden are associated with higher 
adherence to ART.437,438 Interestingly, in CHAPAS-3 the median adherence in children taking efavirenz, 
an NNRTI administered once a day, was higher than for nevirapine (99% versus 91%). Lower adherence 
could be a contributory factor to the higher proportion of ART-naïve patients on nevirapine who never 
achieved VL <100 copies/mL (20% versus 6% on efavirenz), as well as worse virological outcomes in 
ART-experienced children. Taking presented arguments into consideration one could speculate that 
once-daily regimens could be associated with superior virological suppression than twice-daily 
(although it cannot be excluded that differences in suppression levels seen in our study were related 
to differences in baseline CD4%, VL and age between the treatment arms). 
We found that children treated with nevirapine with higher baseline CD4% and lower baseline VL had 
a better virological outcome but surprisingly a similar effect was not detected for efavirenz. We 
hypothesise that this could be resulting from differences in baseline characteristics and smaller sample 
size in the efavirenz arm. According to WHO 2010 guidelines11 (followed in CHAPAS-3) nevirapine is 
licensed for use from 3 months of age, while efavirenz from 3 years, which contributed to a higher 
average age in the efavirenz arm. In CHAPAS-3 children in the efavirenz arm were older with lower 
baseline VL and marginally higher CD4%. Those factors together with a smaller number of children in 
efavirenz group could have precluded us from detecting similar predictors of virological suppression 
as for nevirapine. Nonetheless, better treatment outcomes in children initiated on NNRTIs at higher 
baseline CD4% and lower baseline VL have been previously highlighted in a number of investigations 
(Tables 2.6 and 2.7) as well as additional trials including other treatment options.12,444–446 Recently, 
studies START435 and TEMPRANO447 reported benefits of early ART initialisation in HIV infected 
asymptomatic adults in line with our findings in children, which are consistent with results of 
paediatric study CHER.446  
 194 
 
CHAPTER 8: Conclusions 
                                            Doctoral Thesis by A.M. Bienczak, March 2017 
Lastly, one could deliberate on the selection of trough concentrations as the PK predictor of treatment 
effect in presented analyses. Our main criterion was applicability of research to the clinical settting. 
Even though efficacy and/or safety could be correlated which various other PK parmaters such as: CL, 
AUC, and Cmax, only trough (or mid-dose) drug concentrations are routinely measured in clinical 
practice (TDM), wherea the other paramters need to be derrived limiting their application. It has been 
speculated that AUC is a better descriptive measure because it captures drug exposure within a certain 
time frame (dosing interval), nonetheless taking into consideration the mechanism of action of ARVs 
virological non-suppression is caused by drug concentrations below a defined threshold (required for 
maintaining inhibition of viral replication) and Cmin might be better indicator for it. Pfister et al.172 
correlated apparent clearance (CL/F) with probability of virological failure, and even though this 
measure is more sensitive to temporal changes in adherence patterns than clearance, physiologically 
it is not expected to change much between sampling occasions. Cmin is a measure more sensitive to 
suboptimal treatment adherence. In contrast AEs are customarily associated with Cmax, and even 
though from mechanistical point of view this parameter might be more appropriate, nonetheless it is 
not observed routinely in clinical practice. Additionally, the parameters used in our analyses were 
model derived and we observed very high correlation between them (Chapter 5.4). All analyses were 
repeted using different PK predictors and interpretation of the results was the same (not shown). 
 
8.1.4. What thresholds in efavirenz and nevirapine concentrations are 
most predictive of virological suppression and adverse events in African 
children?  
 
The developed method for selection of drug exposure cut-off most predictive of increased risk of 
clinical effect (here virological non-suppression or AE) based on likelihood profiling and Cox 
proportional hazards model identified mid-dose concentration (C12h) of 1.12 mg/L, trough 
concentration (C24h) of 0.65 mg/L and AUC of 28 mg•h/L as efficacy thresholds for efavirenz in African 
children (Table 5.2 and Figure 5.1). While the new C12h cut-off did not differ markedly in sensitivity, 
specificity, or negative predictive power from the 1.0 mg/L value proposed by Marzolini et al.,94 the 
proposed cut-offs for C24h and AUC substantially improved specificity, accuracy and positive 
predictive power, while maintaining a negative predictive power comparable with previously 
suggested therapeutic thresholds (Table 5.4). 
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The low frequency of CNS AEs in our study prevented identification of the upper therapeutic threshold 
for efavirenz. We suggest the efavirenz C12h efficacy threshold in children should remain 1 mg/L, but 
based on the results of our investigation we suggest that the targets for C24h and AUC could be 
lowered to 0.65 mg/L and 28 mg•h/L, respectively. Due to the insufficient evidence in our study we 
suggest that the upper therapeutic threshold should remain 4 mg/L as previously suggested.94,95 
Even though the risk of virological non-suppression decreased with increasing nevirapine Cmin, there 
was no clear Cmin threshold predictive of virological outcome. Likelihood profiling identified a 
nevirapine Cmin of 10.2 mg/L as most predictive of decreased risk of virological non-suppression (Figure 
7.2a) and while it had superior sensitivity and negative predictive value, the specificity and accuracy 
of this cut-off was substantially lower than for previously suggested alternatives (Table 7.3). In fact, 
none of the nevirapine Cmin thresholds presented in Table 7.3 provided a meaningfully better 
predictive power.  This could be explained by the lower potency of nevirapine than efavirenz, and as 
a consequence lower relative contribution to the total antiretroviral effect, which is to greater extend 
affected by the concentrations of companion drugs.  
Likelihood profiling applied to the Cox model describing the association between nevirapine 
concentrations and the risk of developing grade 2 and above transaminase elevations identified Cmin 
of 12.4 mg/L as threshold most predictive of those events (Figure 7.2b). Nonetheless, the probability 
of transaminase elevations estimated using mixed-effects repeated measures logistic model showed 
that the risk remained below 10% for nevirapine concentrations up to 30 mg/L (Figure 7.1b). 
Additionally, the vast majority of the transaminase elevations in our study were transient and resolved 
without any intervention (including all but one of the 15 grade 3 and above elevations). The observed 
transaminase elevations for individuals with nevirapine concentrations > 12.4 mg/L were small (Table 
7.5) and of limited clinical importance. Based on those findings we suggest that maintaining average 
nevirapine Cmin at the upper range or above of the current target could have a positive effect on 
virological suppression in African children without increasing toxicity. 
PK/PD evaluation in further clinical cohorts including different populations should be done to validate 
our findings.  
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8.2 Significant contributions to the field of HIV research  
In the first study (Chapter 4) we confirmed that SNPs CYP2B6 516G>T and 983T>C are the main 
predictors of variability in efavirenz concentrations and were the first to quantify their effect on 
clearance in children and average efavirenz exposures in dosing weight bands suggested by WHO. We 
showed that dose adjustment based solely on SNP 516G>T could lead to significant overexposure in 
approximately 14% of African patients with 983TC or 983CC genotypes proving that dosing guidelines 
in African children should take into consideration the effect of both of those polymorphisms.  
In our second investigation (Chapter 5) we described the log-linear relationship between efavirenz 
concentrations and risk of non-suppression and hypothesised that some of the previous studies were 
unable to identify this effect because they were underpowered, limited to a single measurement per 
patient, or utilised inadequate statistical methods. In addition, we suggested a new approach based 
on likelihood profiling and Cox repeated failures model to define concentrations thresholds associated 
with increased risk of virological non-suppression for efavirenz in African children. We derived new 
efficacy cut-offs for efavirenz trough concentrations and AUC (which in our study proved superior in 
predicting treatment outcome than previously suggested thresholds) and propose they should be 
utilised for optimisation of HIV treatment in African children.  
The third study (Chapter 6) is the first report of the effect of 983CC homozygosity on nevirapine 
pharmacokinetics, the first paediatric investigation describing the effect of SNP 983T>C on nevirapine 
concentrations, and the first study in nevirapine describing combined effect of SNPs 516G>T and 
983T>C using metabolic subgroups. Our analysis is also the first to date to characterize the diurnal 
oscillation in nevirapine clearance and to evaluate the effect of this phenomenon on systemic drug 
exposures through simulations. Additional novelty is implementation of the hepatic first pass model 
allowing to distinguish between pre-hepatic and hepatic sources of variability in bioavailability, which 
was never previously used in this drug. Even though our findings have limited clinical relevance they 
increase the knowledge of nevirapine pharmacokinetics. 
Our fourth study (Chapter 7) is the first study characterising the relationship between nevirapine 
concentrations and virological suppression and transaminase elevations in children. In addition our 
analysis suggests beneficial effect of ART initiation at lower VL and higher CD4%, and higher ART 
adherence on the virological suppression.  
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8.3 Implications for the current HIV treatment guidelines 
We suggest that CYP2B6 genotype guided efavirenz dose adjustment should provide a more optimal 
treatment outcome in African children. We base this recommendation on the strong link between 
efavirenz exposures and the virological outcome detected in our study (Chapter 5) and in previous 
investigations (Chapters 2.3.1.4, 2.3.1.5, 2.3.1.7.5 and 2.3.1.7.6). In addition, our analysis (Chapter 4) 
shows that the combined effect of SNPs 516G>T and 983T>C is the main predictor of variability in 
efavirenz PK, which confirms the previous studies (Chapters 2.3.1.2, 2.3.1.7.3, 2.3.1.7.4). Our findings 
(Chapter 4) indicate that under current dosing schedule6 African children EM for CYP2B6 are under 
increased risk of developing suboptimal drug exposures, which could hypothetically lead to treatment 
failure. In contrast, children SM and USM for CYP2B6 exhibit high efavirenz exposures, which can 
contribute towards CNS adverse events and have been associated with treatment discontinuation in 
adults (Chapter 2.3.1.5) and case reports of severe behavioural changes and CNS manifestations in 
children.286  
Our recommendations contradict conclusions drawn from the population pharmacokinetic modelling 
and simulations conducted by Bristol-Myers Squib291 supporting Sustiva (efavirenz originator drug) 
label extension to children < 3 years old granted by FDA in 2013268 and EMA in 2015.269 The analysis 
by Luo et al.291 presented some conflicting findings – despite detecting a significant reduction in 
efavirenz clearance determined by the individual CYP2B6 516G>T genotype authors concluded that 
CYP2B6 genetic status was not informative in guiding paediatric dosing due to large variability in 
clearance within the genotypic subgroups leading to disregard of CYP2B6 effect in approved Sustiva 
dosing recommendations. We would like speculate that those findings were confounded by the 
inherent flaws in the analysis and the model and would like to discuss them further. 
The aforementioned investigation inadequately characterised sources of variability in efavirenz PK. 
The authors stressed the importance of developmental changes in youngest children, nonetheless the 
age effect was not accounted for in their model. Additionally, the differences in clearance values 
between metaboliser subgroups were presented with disregard to children’s age (each subgroup 
included children ranging between 3 months to 18 years old). Recent analysis by Salem et al.162 
(Chapter 2.3.1.7.3) reported significant differences in efavirenz PK driven by age (maturation of 
efavirenz clearance and age-driven differences in bioavailability of liquid formulation). To avoid the 
confounding effect of age Luo et al. should have compared the differences in clearance between 
metaboliser subpopulations by weight (or age) bands, or alternatively based the comparison on 
systemic exposures to efavirenz. Furthermore, in our analysis we showed that SNP CYP2B6 516G>T 
alone was not sufficient to determine metaboliser phenotype for black African children, and that SNP 
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983T>C despite lower prevalence affects efavirenz clearance to greater extend. The latter SNP was 
not taken into account in the analysis by Luo et al., even though over 50% of children in that study 
were black African.  
Additionally, the clearance estimated in the discussed study was expressed as apparent clearance 
(CL/F), which by definition is affected by the bioavailability. If the variability in the bioavailability is not 
accounted for in the model, it will inflate the variability in CL/F. It is unclear, if authors explored any 
covariates other than formulation on bioavailability, and did not include any between subject 
variability (BSV) or between occasion variability (BOV) on this parameter (despite analysing 
longitudinal data with repeated sampling).  Karlsson et al.390 showed that ignoring BOV might lead to 
biased parameter estimates and high incidence of spurious findings. It can be speculated that the 
variability in the data was further inflated by lack of accurate dosage history. The overall poor 
performance of Luo’s model is apparent by extremely high values of residual unexplained error 
(proportional error of 45% for capsules and 78% for solution), as opposed to 6.7% proportional and 
0.1 mg/L additive residual error in our model.  
We argue that the aforementioned shortcomings of the outlined analysis contributed to confounded 
conclusion and the current treatment guidelines in African children should be re-evaluated and 
optimised between the metabolic groups determined by individual CYP2B6 516G>T|983T>C 
genotype. Our recommendations are in line with the recent guidelines for efavirenz dosage in children 
< 3 years developed by the Panel on Antiretroviral Therapy and Medical Management of HIV-Infected 
Children at the United States Department of Health and Human Services (DHHS) (Chapter 2.3.1.7.7 
Table 2.8)  currently tested in study P1070289 (discussed in more detail in Chapter 8.5). 
Despite a similar strong link between pharmacogenetics and variability in nevirapine exposures 
(Chapters 2.3.2.2.1 and 6), our findings indicate that interventions other than dosage modification 
could ensure a more beneficial virological outcome. Our analysis showed that CYP2B6 EM and IM in 
the lowest weight band had exposures below the current therapeutic range, whereas SM and USM in 
all other weight-bands had concentrations above it. Even though the literature highlights that 
suboptimal nevirapine concentrations might lead to emergence of drug resistance and increased risk 
of virological failure,30,33 in our analysis no clear efficacy cut-off could be defined (Chapter 7). While 
dose increases in CYP2B6 EM and IM in the lowest weight band could hypothetically improve 
virological outcome, implementation of this strategy would require addition of nevirapine liquid to 
the current formulation, increasing the cost of treatment and limiting its feasibility. Additionally, given 
the fast growth rates in infants after starting ART they would spend only a short time within that 
weight band what would limit the effect of suboptimal exposures.37 Conversely, the dose reductions 
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in CYP2B6 SM and USM would not be possible while treating with all-in-one paediatric FDCs and would 
impose children to receive two separate tablets. This would not only increase the cost of ART but also 
hypothetically could affect adherence by increasing the pill burden. Furthermore, the results of our 
study showed a benefit of maintaining nevirapine exposures in children at the top or above the current 
upper therapeutic limit of 8 mg/L95 without increasing toxicity (Chapter 7).  
The detected diurnal variability in nevirapine clearance had little effect on the average drug exposures 
and does not require modifications of the current dosing schedule, but the results of the PK 
simulations indicate that when the daily nevirapine dose cannot be split equally, larger doses should 
be given in the morning (Figure 6.7 and Figure 6.8).  
In addition, even though we detected a concentration-response relationship for nevirapine this 
correlation was not as strong as for efavirenz (Chapter 7). In fact, our analysis showed that other 
factors (in particular treatment adherence and baseline VL) were stronger correlated with virological 
outcome than nevirapine concentrations (Chapter 7). Based on our findings we hypothesise that 
interventions improving treatment compliance and ART initialisation at a lower baseline VL and CD4% 
could provide a more beneficial effect on warranting the most optimal outcome of treatment with 
nevirapine than modification of the current dosage guidelines. Such interventions should similarly 
provide further improvements of treatment outcome for efavirenz in addition to genotype guided 
dose adjustment. 
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8.4 Implications for HIV research and clinical practice 
Few studies evaluated genotype based dosage adjustment strategies in clinical practice. Efavirenz 
dose reductions guided by individual genotype or phenotype proved to limit drug toxicities without 
compromising treatment efficacy in adults (Chapter 2.3.1.6) but to date only scarce information is 
available in children (Chapter 2.3.1.7.7). Paediatric data is currently limited to preliminary results of 
study P1070.289 We showed that efavirenz dose optimisation based solely on SNP 516G>T, investigated 
previously in adults and currently in children in study P1070,290 would not be appropriate in African 
children, as it would lead to overdosing in individuals with 983T>C variant allele. No prior study 
evaluated the effects of efavirenz dose adjustment based on the allocation to metabolic CYP2B6 
subgroups guided by combined 516G>T|983T>C genotype and we identify this to be the area of the 
greatest clinical need. One could envisage that implementation of such strategy in a recourse-limited 
setting would be hindered by access to genotyping and its cost. In order to facilitate such “apriori” 
dose adjustments a “point of care” genotype testing system would need to be developed. Implications 
of efavirenz “apriori” genotype-guided dosage (based on combined effect of SNPs 516G>T and 
983T>C) for treatment efficacy, safety, feasibility and cost should assessed though a well-powered 
clinical study in African patients. Hopefully some of those questions will be answered by the results of 
the ongoing study P1070.290 
The results of our study additionally put in question the universal efavirenz dose reduction strategy 
(from 600mg to 400mg) in adults postulated by ENCORE-1 study team and recently incorporated into 
WHO guidelines.6 The universal dose reduction was previously challenged by Maartens and 
Meintjes,266 who highlighted possible alterations to efavirenz pharmacokinetics in pregnancy, in 
patients on rifampicin-based treatment for tuberculosis, and in different metabolic subgroups. Recent 
study by Dooley et al.71 confirmed that pregnancy indeed increases the efavirenz clearance by on 
average 19%. Our study, similar to Lam et al.267 and Hui et al.223 argues that dose reduction based on 
genotype may be a more practical approach for optimizing therapy. The simulation study by Lam et 
al.267 reported that individuals 516GG would be at an increased risk of suboptimal concentrations on 
the new dose of 400 mg comparing to standard 600 mg and suggested that 500mg would be more 
optimal for those patients. The main predicament of ENCORE-1 study was that efavirenz dose 
reduction from 600mg to 400mg would reduce the cost and improve safety of treatment without 
compromising the efficacy. Lungren et al.131 hypothesised that a universal dose reduction to 400mg 
could provide a cost saving of $14 per year for patients on FDC tablets, but a cost-effectiveness study 
by Schackman et al.263 suggests that “apriori” CYP2B6 genotyping to guide efavirenz dosing would also 
provide similar cost savings.  
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A lot of controversy surrounds the current efavirenz efficacy threshold of 1 mg/L94,95 and a number of 
studies hypothesise that the actual cut-off should be lower. In addition the 1 mg/L cut-off was derived 
based on random efavirenz mid-dose concentrations from therapeutic drug monitoring (TDM), 
nonetheless they are customarily applied also to trough concentrations. Our study derived new, 
alternative trough concentration and AUC efficacy thresholds for African children but there is a need 
for similar investigations in adults. Recently we applied our method to adult data from a small South 
African study and showed that a TDM efavirenz concentration of 0.7 mg/L was most predictive of 
increased risk of non-suppression.236 The results should be interpreted with caution due to a small 
sample size and our findings should be confirmed in a larger, longitudinal trial with repeated 
measurements. The derived paediatric and adult target thresholds should be verified in a prospective 
clinical study. 
The CNS AEs in our study for efavirenz were very rare, similar to other paediatric investigations, and 
we hypothesise that is due to underreporting and lack of appropriate tools facilitating their detection. 
Systemic reviews suggest that the scale of neurological and neuropsychiatric impairment caused by 
efavirenz treatment might be underestimated.245,251 In addition patients develop tolerance to 
experienced CNS AEs soon after start of efavirenz treatment.69,186 A study by Ciccarelli et al.250 reported 
that almost 50% of otherwise asymptomatic patients on efavirenz had some form of cognitive 
disorders or impairment. Such neurocognitive complications of treatment have been little studied in 
children and should be of great concern, as they could affect not only their well-being but also their 
neuropsychological and behavioural development as well as future educational achievements. It could 
be speculated is that in the majority of children, due to development of tolerance to the common CNS 
AEs, such behavioural and cognitive changes might remain unnoticed. Alarming are also the recent 
reports of severe CNS manifestations, such as cerebellar dysfunction, seizures, aggressive and anti-
social behaviour in South African children treated with efavirenz, which were all associated with 
impaired CYP2B6 metabolism (caused by 516G>T and 983T>C variant alleles).286 Those reports 
strengthen the importance of interventions aiming to reduce prevalence of persistently high efavirenz 
exposures in African children and their authors, similar to us, postulated that such dose adjustments 
should be guided by the individual 516G>T|983T>C genotype. Nonetheless, more research is required 
to establish the extent of cognitive impairment in children treated with efavirenz and underreporting 
related to lack of appropriate measurement tools.  
Recently, following a WHO initiative, a discussion started on development of efavirenz based all-in-
one paediatric FDC tablet.448 It is expected that similar to currently available paediatric nevirapine FDC 
tablets such formulation would provide not only cost savings, improve the feasibility and coverage of 
antiretroviral treatment in children in resource limited setting, but also reduce pill burden related ART. 
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Efavirenz PK data from ARROW and CHAPAS-3 (analysed in this thesis), with addition of PK data from 
other paediatric studies, were used to create a paediatric efavirenz mega-model and simulate 
exposures of various dosage scenarios across WHO weight bands.448 While we acknowledge the 
advantages of such formulation, taking into consideration the results of our analysis we question its 
universal roll without prior genotyping. Furthermore, we emphasize that the currently available 
paediatric formulations (ABC/3TC FDC and double scored efavirenz tablet) give more flexibility in 
adjustment of efavirenz dose based on individual CYP2B6 genotype preventing exposure to excessive 
concentrations. In addition, if efavirenz is administered with abacavir containing NRTI-backbone this 
already reduces the frequency of drug intake from twice a day (BD), required for nevirapine based 
regimen or other NRTI-backbones, to once a day (QD). Substitution of a BD with a QD regimen has 
been shown to have a positive effect on treatment compliance,437,438 which is also observed in 
CHAPAS-3 as higher adherence scores for efavirenz (despite a 2-pill regimen). We hypothesise that an 
efavirenz-based QD 1-pill regimen would have little advantage over a QD 2-pill regimen, but the latter 
could allow dosage personalisation. Until more conclusive data on the effect of sustained high 
efavirenz concentrations on behavioural and cognitive impairment in children is generated, our 
priority should be safeguarding this vulnerable population from possible but omittable risks. The 
modification of current guidelines cannot be however implemented based on the results of our 
analysis alone and should be supported by the results of a prospective study. 
The results of such randomised prospective study led to the recent changes in the recommended first 
line regimen for children <3 years of age.6,111 Study P1060145,146 showed significantly lower mortality 
and higher suppression in children <3 years old on a lopinavir boosted with ritonavir (LPV/r) rather 
than nevirapine based ART. Nonetheless, the use of nevirapine in this age group still has some 
advantages comparing to other available treatment options. It is the main drug used for pMTCT 
worldwide and it can be hypothesised that a continuous treatment with nevirapine following the 
single dose at birth could help prevent the establishing of HIV latent reservoirs in neonates449 and 
possibly recreate phenomenon observed in the case of Mississippi baby.450  With a rapid progress of 
work on HIV cure HIV-infected children with virtually undetectable viral load and limited viral 
reservoirs would stand the best chance to have the virus eradicated from their bodies. Even though 
more studies are required this is currently the fastest evolving branch of HIV research.451 Much 
controversy surrounds early treatment start in children due to lifelong exposure and concerns about 
the toxicity but recent results of study CHER446 proved the benefit of such ART initiation approach. 
Furthermore, if the treatment start at birth could facilitate eradication of the virus in the future life, 
when this happens those children would require no further antiretroviral treatment. Currently this is 
a hypothetical scenario but due to low cost and availability of age appropriate formulations treatment 
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with nevirapine from birth could help facilitate it in the future. Additionally, in terms of older children 
a number of studies showed that nevirapine re-use in patients who achieved and maintained 
virological suppression on LPV/r based regimen is a safe option maintaining the virological outcome 
and hypothetically preventing the long term toxicities related to LPV/r. 58,59 The pharmacokinetic 
simulations we conducted showed that (with minor modifications) the current simplified weight-band 
dosing provides optimal nevirapine exposures in children weighing >4kg justifying further use of the 
current paediatric FDC formulation, which showed high acceptability among children and the 
caregivers.158 
8.3 Limitations of the studies 
The main limitation of the efavirenz pharmacokinetic study (Chapter 4) is that it was restricted only to 
a selection of SNPs which didn’t include polymorphisms in the accessory metabolic pathways. Recent 
reports show that polymorphisms in the accessory pathways become particularly important when 
primary metabolic route is affected103,177,452 and could help predict individuals with exceptionally high 
efavirenz concentrations. In addition literature shows that absorption of efavirenz is increased by food 
co-administration, which was not recorded in our study, which potentially increased the levels of 
between occasion variability in the absorption parameters and bioavailability. Small number of TB co-
infected children in our study hindered drawing significant conclusions to the effect of TB treatment 
on efavirenz pharmacokinetics. 
The majority of the data included in the nevirapine pharmacokinetic analysis (Chapter 6) was sparse 
with a self-reported intake time, which might not be accurate. This could have inflated the variability 
in the absorption parameters and the detected diurnal effect what we tried to minimise by exclusion 
of outlying samples, ones with uncertain dosage history and below level of quantification (BLQ). It 
could addtionaly be speculated that the unequal interval between morning and evening drug intake 
could have inflated the characterised diurnal variation. The applied non-linear mixed effects modelling 
should account for differences in the dosing intervals but only, if those were recorded correctly. 
Furthermore, there could be alternative explanations to the detected diurnal effect. In some drugs it 
was contributed to differences in hepatic blood flow,322,323 which could be affected by food intake (not 
recorded in our study). Nonetheless, during the model building diurnal effect provided better fit when 
included on clearance rather than bioavailability (based on the changes in OFV and diagnostic plots). 
An additional confounding factor might be that both analysed studies had a different procedure for 
splitting of unequal daily doses (higher dose in the evening in CHAPAS-1 and in the morning in CHAPAS-
3), but the model-based approach we employed should have account for this difference. Lastly, we 
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did not have genotype information for children from CHAPAS-1 study and used mixture modelling to 
allocate those individuals to different metabolic subgroups. 
The limitation of the method developed for estimation of a dichotomized efficacy threshold in the 
second and fourth studies (Chapters 5 and 7) is that it might lead to over fitting and low external 
generalizability (which we were unable to test in a validation data set). In addition the CIs for the 
identified thresholds were relatively large which could be contributed to a small data set. Larger 
studies are required to facilitate a more precise estimation of the efficacy cut-off and a prospective 
study is needed to confirm it. While our findings should also be interpreted in terms of treatment 
effectiveness and a true efficacy threshold in a setting of ideal adherence might be lower, treatment 
effectiveness measure is more relevant to a clinical setting. Adherence in our studies was measured 
only in certain time periods and MEMS scores were extrapolated to periods when patients did not 
have devices assuming no changes in drug taking patters which could have affected our findings for 
this variable. VLs in our studies were not measured between baseline and week 36 what prevented us 
from characterising the initial VL decline after treatment initialisation. Furthermore, VL was measured 
on average only up to every 24 weeks, so our analysis assumes that no viral rebounds occurred 
between scheduled measurements. We could not find a plausible rationale for the detected effect of 
clinical site on the virological outcome and possible explanations were listed in Chapter 7.5. Moreover, 
no genotyping was conducted at enrolment, so we were not able to assess the impact of pre-existing 
NNRTI resistance on response. Lastly, antiretroviral therapy consists of a combination of drugs and its 
efficacy depends on all the components of the tested regimen and our findings might not be 
generalizable to efavirenz or nevirapine-based treatment accompanied by drugs different to the ones 
studied in CHAPAS-3. 
Furthermore, in the second study (efavirenz PK/PD – Chapter 5) due to a low frequency of CNS AEs we 
were not able to confirm their association with high efavirenz exposures. Recent studies in adults 
indicate that CNS AEs might be underreported and in particular in children more sophisticated 
methods based on cognitive investigations are required.250,251  
In addition in the fourth study (nevirapine PK/PD – Chapter 7) most viral loads were matched with 
nevirapine concentrations measured 12 weeks earlier, and one could argue that drug concentrations 
measured on the same day as viral load could be more predictive of virological outcome. However, 
suppression is likely related to maintained drug exposure above a certain threshold, and a random 
measurement in the time period preceding it could be an adequate indicator of it. 
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8.6 Conclusions to stated hypothesis  
In conclusion SNPs 516G>T and 983T>C in CYP2B6 are the main predictors of variability in efavirenz 
and nevirapine concentrations in HIV-infected African children treated with paediatric solid FDC 
tablets under the WHO simplified weight band dosing, but the variability in drug concentrations is not 
the sole predictor of treatment outcome. While the genotype guided dose adjustments for efavirenz 
could significantly contribute towards treatment optimisation by preventing suboptimal drug 
exposures in extensive metabolisers (leading to increased risk of virological failure) and excessive 
concentrations in (ultra)slow metabolisers (hypothesised to increased risk of CNS side effects), its 
application would provide limited benefits for nevirapine. Even though the increase of nevirapine dose 
in extensive and intermediate metabolisers in the lowest weight band could help prevent sub-optimal 
drug exposures, the conducted analyses suggest that other interventions could ensure a more 
beneficial virological outcome. Virological suppression in children treated with nevirapine could be 
improved if the treatment is started at a lower pre-ART VL and higher pre-ART CD4%. In addition we 
speculate that virological outcome for both drugs could be improved through interventions enhancing 
treatment adherence. Based on this reasoning “apriory” 516G>T|983T>C genotype adjusted once 
daily efavirenz treatment with in combination with abacavir and lamivudine could provide the most 
optimal virological outcome while minimising CNS side effects in African children >3 years of age. 
Before the official guidelines can be modified a “point of care” genotype testing system needs to be 
developed and the suggested “apriori” dose adjustment should be tested in a prospective study. In 
addition, more research is required to evaluate efficacy and safety of efavirenz treatment in children 
<3 years old before this approach could be extrapolated to this age group.
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